U.S. patent application number 17/118064 was filed with the patent office on 2021-06-24 for non-meiotic allele introgression.
The applicant listed for this patent is Recombinetics, Inc.. Invention is credited to Daniel F. Carlson, Scott C. Fahrenkrug.
Application Number | 20210185990 17/118064 |
Document ID | / |
Family ID | 1000005436145 |
Filed Date | 2021-06-24 |
United States Patent
Application |
20210185990 |
Kind Code |
A1 |
Fahrenkrug; Scott C. ; et
al. |
June 24, 2021 |
NON-MEIOTIC ALLELE INTROGRESSION
Abstract
Methods, uses, and compositions for manipulating genomic DNA.
Some of the embodiments of the invention provide for making a
founder animal that is completely free of all unplanned genetic
modifications. Some embodiments are directed to removing genetic
faults in established breeds without making other alterations to
the genome. Other embodiments are directed to particular tools or
processes such as TALENs or CRISPR with a preferred truncation. One
embodiment involves introducing a targeted targeting endonuclease
system and a HDR template into a cell (optionally with a mismatch
in the binding of the targeting endonuclease and the targeted
site). Another embodiment includes processes of making a
genetically modified livestock animal comprising a genome that
comprises inactivation of a neuroendocrine gene selective for
sexual maturation, with the inactivation of the gene preventing the
animal from becoming sexually mature. One embodiment includes
compositions and methods for making livestock with a polled allele,
including migrating a polled allele into a bovine species without
changing other genes or chromosomal portions.
Inventors: |
Fahrenkrug; Scott C.;
(Minneapolis, MN) ; Carlson; Daniel F.; (Woodbury,
MN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Recombinetics, Inc. |
Eagan |
MN |
US |
|
|
Family ID: |
1000005436145 |
Appl. No.: |
17/118064 |
Filed: |
December 10, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16424356 |
May 28, 2019 |
10920242 |
|
|
17118064 |
|
|
|
|
15802272 |
Nov 2, 2017 |
10959414 |
|
|
16424356 |
|
|
|
|
14625797 |
Feb 19, 2015 |
|
|
|
15802272 |
|
|
|
|
14263446 |
Apr 28, 2014 |
9528124 |
|
|
14625797 |
|
|
|
|
13404662 |
Feb 24, 2012 |
|
|
|
16424356 |
|
|
|
|
13594694 |
Aug 24, 2012 |
|
|
|
16424356 |
|
|
|
|
13404662 |
Feb 24, 2012 |
|
|
|
13594694 |
|
|
|
|
14067634 |
Oct 30, 2013 |
|
|
|
16424356 |
|
|
|
|
14154906 |
Jan 14, 2014 |
|
|
|
16424356 |
|
|
|
|
61870401 |
Aug 27, 2013 |
|
|
|
61446651 |
Feb 25, 2011 |
|
|
|
61446651 |
Feb 25, 2011 |
|
|
|
61662767 |
Jun 21, 2012 |
|
|
|
61870510 |
Aug 27, 2013 |
|
|
|
61720187 |
Oct 30, 2012 |
|
|
|
61752232 |
Jan 14, 2013 |
|
|
|
61870570 |
Aug 27, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 2800/30 20130101;
A01K 2227/108 20130101; C12N 15/902 20130101; C12N 15/8771
20130101; C12N 15/8509 20130101; A01K 67/0276 20130101; A01K
67/0275 20130101; C12N 15/8778 20130101; C12N 15/85 20130101; A01K
2227/107 20130101; C07K 14/715 20130101; C12N 15/907 20130101; C12N
15/90 20130101; A01K 2227/40 20130101; C12N 2800/90 20130101; A01K
2227/101 20130101; C12N 2750/14143 20130101; C07K 14/47 20130101;
A01K 2227/102 20130101; A01K 2227/103 20130101 |
International
Class: |
A01K 67/027 20060101
A01K067/027; C12N 15/85 20060101 C12N015/85; C12N 15/90 20060101
C12N015/90; C07K 14/715 20060101 C07K014/715; C07K 14/47 20060101
C07K014/47; C12N 15/877 20060101 C12N015/877 |
Goverment Interests
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under Grant
number 1R41HL108440-01 awarded by the National Institutes of
Health, Grant number 1R43RR033149-01A1 awarded by the National
Institutes of Health and Biotechnology Risk Assessment Program, and
competitive Grant number 2012-33522-19766 awarded by the
USDA--National Institute of Food and Agriculture. The government
has certain rights in the invention.
Claims
1. A method for altering the genome of an animal cell, the method
comprising: identifying a target DNA region within the animal cell,
the target region comprising a target cleavage site; contacting the
animal cell with a targeted nuclease such that the nuclease cleaves
the target DNA region at the target cleavage site, wherein the
targeted nuclease comprises one or more binding domains that
specifically bind to one or more sequences within the target DNA
region.
2. The method of claim 1, wherein the targeted nuclease is selected
from the group consisting of a transcription-activator-like
effector nuclease (TALEN), a CRISPR-based nuclease (e.g.,
CRISPR/Cas9), and a zinc finger nuclease.
3.-11. (canceled)
12. The method claim 1, wherein the method is performed without
introducing into the animal cell (1) a fluorescent marker gene or
(2) a reporter gene that, when incorporated into chromosomal DNA of
the cell, confers a trait on the cell that permits isolation by one
or more survival selection criteria (e.g., survival in the presence
of a small molecule).
13.-18. (canceled)
19. The method of claim 1, wherein the animal cell is a primary
somatic cell.
20. The method of claim 19, further comprising: cloning the primary
somatic cell to produce one or more embryos; and implanting the one
or more embryos into a surrogate mother.
21. The method of claim 20, wherein cloning the primary somatic
cell comprises somatic cell nuclear transfer or chromatin
transfer.
22. The method of claim 21, further comprising producing a
gene-edited animal from the implanted embryo.
23. The method of claim 1, wherein the animal cell is a totipotent
or pluripotent cell.
24. (canceled)
25. The method of claim 23, further comprising implanting the
embryo into a surrogate mother.
26. The method of claim 25, further comprising producing a
gene-edited animal from the implanted embryo.
27. The method of claim 1, wherein the targeted nuclease cleaves
the target DNA region at or adjacent to a neuroendocrine gene
involved in sexual maturation.
28. The method of claim 27, wherein the neuroendocrine gene is
selected from the group consisting of gpr54, kiss1, and gnrh11.
29. The method of claim 28, wherein the neuroendocrine gene of the
resulting animal cell is inactivated.
30. (canceled)
31. The method of claim 29, wherein inactivation of the
neuroendocrine gene involves insertion of a stop codon in a
sequence of the neuroendocrine gene.
32. The method of claim 31, further comprising administering a
rescue agent to an animal that comprises or is derived from the
animal cell such that the animal proceeds to sexual maturity.
33.-55. (canceled)
56. A method of modifying a bovine cell, the method comprising:
contacting the bovine cell with a targeted endonuclease that
targets and cuts a gene encoding the prolactin receptor; contacting
the bovine cell with a homology-dependent repair template such that
the template integrates into the genome of the bovine cell to
encode a truncated prolactin receptor protein.
57. The method of claim 56, wherein the truncated prolactin
receptor protein is 461 amino acids in length.
58. The method of claim 56, wherein the targeted endonuclease is
selected from a zinc finger nuclease, a TAL effector nuclease
(TALEN) and a CRISPR/Cas 9 nuclease.
59.-91. (canceled)
Description
CROSS-REFERENCE
[0001] This application is a continuation of U.S. application Ser.
No. 16/424,356 "Efficient Non-Meiotic Allele Introgression" filed
May 28, 2019, which is a continuation-in-part of U.S. application
Ser. No. 15/802,272, filed Nov. 2, 2017, which is a divisional of
U.S. application Ser. No. 14/625,797 filed Feb. 19, 2015, which is
a continuation of U.S. application Ser. No. 14/263,446 filed on
Apr. 28, 2014, which claims priority to U.S. Provisional Appl. No.
61/870,401 filed on Aug. 27, 2013. This application is a
continuation-in-part of U.S. application Ser. No. 13/404,662,
"Genetically Modified Animals and Methods for Making the Same"
filed Feb. 24, 2012, which claims priority to U.S. Provisional
Appl. No. 61/446,651 filed on Feb. 25, 2011. This application is a
continuation-in-part of U.S. application Ser. No. 13/594,694,
"Genetically Modified Animals and Methods for Making the Same"
filed on Aug. 24, 2012, which claims priority to U.S. Provisional
Appl. No. 61/662,767 filed on Jun. 21, 2012 and is a
continuation-in-part of U.S. application Ser. No. 13/404,662,
"Genetically Modified Animals and Methods for Making the Same",
filed Feb. 24, 2012 which claims priority to U.S. Provisional Appl.
No. 61/446,651 filed Feb. 25, 2011. This application is a
continuation-in-part of U.S. application Ser. No. 14/067,634,
"Control of Sexual Maturation in Animals" filed on Oct. 30, 2013,
which claims priority to U.S. Provisional Appl. No. 61/870,510
filed on Aug. 27, 2013 and claims priority to U.S. Provisional
Appl. No. 61/720,187 filed on Oct. 30, 2012. This application is a
continuation-in-part of U.S. application Ser. No. 14/154,906,
"Hornless Livestock" filed on Jan. 14, 2014 which claims priority
to U.S. Provisional Appl. No. 61/752,232 filed Jan. 14, 2013 and
claims priority to U.S. provisional Appl. No. 61/870,570 filed Aug.
27, 2013. Each of these applications is hereby incorporated by
reference in its entirety.
SEQUENCE LISTING
[0003] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Dec. 9, 2020, is named 53545 746 303 SL.txt and is 864,111 bytes
in size
BACKGROUND OF THE INVENTION
[0004] Animal genetic engineering has traditionally been
accomplished by random insertion of expression cassettes, which
suffered from low efficiency, unpredictable expression, and/or the
requirement of linked selection markers. In addition, there are
numerous challenges in the livestock industry, such as the risks
posed to humans by horned cattle, limited ability to control the
size, weight or build of the livestock, limited thermoregulation,
etc.
SUMMARY OF THE INVENTION
[0005] Disclosed herein is a method for altering the genome of an
animal cell, the method comprising: identifying a target DNA region
within the animal cell, the target region comprising a target
cleavage site; contacting the animal cell with a targeted nuclease
such that the nuclease cleaves the target DNA region at the target
cleavage site, wherein the targeted nuclease comprises one or more
binding domains that specifically bind to one or more sequences
within the target DNA region. In some embodiments, the target
region is from 10 nucleotides to 200 nucleotides in length, such as
from 10 nucleotides to 100 nucleotides, from 10 nucleotides and 75
nucleotides, from 10 to 60 nucleotides, from 10 nucleotides to 50
nucleotides, from 10 to 30 nucleotides, from 30 nucleotides to 70
nucleotides, from 40 nucleotides to 60 nucleotides, or from 45
nucleotides to 55 nucleotides in length. The targeted nuclease can
be selected from the group consisting of a
transcription-activator-like effector nuclease (TALEN), a
CRISPR-based nuclease (e.g., CRISPR/Cas9), and a zinc finger
nuclease. The targeted nuclease can be a
transcription-activator-like effector nuclease (TALEN). The TALEN
can comprise a first peptide and a second peptide, wherein the
first peptide and the second peptide are configured to bind to one
another in a non-covalent fashion, and wherein the first peptide
comprises a first binding domain fused to a first portion of a
bipartite nuclease, and the second peptide comprises a second
binding domain fused to a second portion of a bipartite nuclease.
The bipartite nuclease can be a bipartite FokI nuclease. In some
embodiments, contacting the animal cell with the targeted nuclease
comprises delivering mRNA encoding the TALEN into the animal cell
such that the mRNA is expressed to produce the TALEN within the
cell. A nuclear localization signal can be coupled to the
TALEN.
[0006] In some embodiments, mRNA is delivered into the animal cell
by any one of: electroporation, transfection, lipofection,
liposome, nucleofection, biolistic particle delivery, nanoparticle
delivery, lipid transfection, electrofusion, or direct
injection.
[0007] Contacting the animal cell with the targeted nuclease can
comprise expressing the targeted nuclease from plasmid DNA inside
the animal cell. The targeted nuclease can be a CRISPR-based
nuclease. The targeted nuclease can be a zinc finger nuclease.
[0008] The method can be performed without introducing into the
animal cell (1) a fluorescent marker gene or (2) a reporter gene
that, when incorporated into chromosomal DNA of the cell, confers a
trait on the cell that permits isolation by one or more survival
selection criteria (e.g., survival in the presence of a small
molecule). The animal cell can be an artiodactyl cell. The animal
cell can be a cell of a livestock animal. The livestock animal can
be selected from the group consisting of swine, cows, sheep, and
goats. The animal cell can be an animal cell selected from the
group consisting of cattle, swine, sheep, chicken, goats, rabbit,
and fish. The animal cell can be a bovine cell or a porcine cell.
The animal cell can be a primary somatic cell.
[0009] The method can further comprise cloning the primary somatic
cell to produce one or more embryos; and implanting the one or more
embryos into a surrogate mother. Cloning the primary somatic cell
can comprise somatic cell nuclear transfer or chromatin transfer.
The method can further comprise producing a gene-edited animal from
the implanted embryo.
[0010] The animal cell can be a totipotent or pluripotent cell. The
animal cell can be a cell from an embryo.
[0011] The method can further comprise implanting the embryo into a
surrogate mother. The method can further comprise producing a
gene-edited animal from the implanted embryo.
[0012] The targeted nuclease can cleave the target DNA region at or
adjacent to a neuroendocrine gene involved in sexual maturation.
The neuroendocrine gene can be selected from the group consisting
of GPR54, KISS1, and GnRH11. The neuroendocrine gene of the
resulting animal cell can be inactivated. Inactivation of the
neuroendocrine gene can prevent natural sexual maturation.
Inactivation of the neuroendocrine gene can involve insertion of a
stop codon in a sequence of the neuroendocrine gene.
[0013] The method can further comprise administering a rescue agent
to an animal that comprises or is derived from the animal cell such
that the animal proceeds to sexual maturity. The rescue agent can
comprise a gonadotropin or a gonadotropin analogue. The rescue
agent can comprise kisspeptin.
[0014] The method can further comprise contacting the animal cell
with a homology-dependent repair (HDR) template such that the HDR
template is incorporated into genomic DNA of the animal cell,
thereby altering the genome of the animal cell. Incorporation of
the HDR template into the genomic DNA of the animal cell can result
in an animal cell with an allele that is not present (or differs
from the corresponding allele) in the animal cell prior to
contacting the animal cell with the HDR template. Contacting the
animal cell with an HDR template can comprise expressing a vector
that encodes the HDR template within the animal cell. The
incorporated allele can be identical to an allele from a first
breed that differs from a corresponding allele of a second breed
from which the animal cell was originally derived. The first breed
can be Belgian Blue cattle and the second breed can be Wagyu cattle
or Nelore cattle. The incorporated allele can be a myostatin allele
that causes a double-muscling phenotype. The animal cell, after
incorporation of the HDR template, can be homozygous for the
allele. The animal cell, after incorporation of the HDR template,
can be heterozygous for the allele. The allele can have an
insertion or a deletion relative to a corresponding allele in the
animal cell prior to contact with the targeted nuclease and
incorporation of the HDR template. The allele can have a single
nucleotide polymorphism relative to the corresponding allele in the
animal cell prior to contact with the targeted nuclease and
incorporation of the HDR template. The HDR template can comprise a
first arm and a second arm, wherein the first arm is homologous to
DNA on a first side of the target cleavage site and the second arm
is homologous to DNA on a second side of the target cleavage site.
The sequence of the homology-dependent repair template can be
incorporated into the genomic DNA of the animal cell at a success
rate of greater than 1%. The HDR template can be single-stranded
DNA. The allele can be the polled allele. Incorporation of the HDR
template into the animal cell can result in a cell that comprises a
natural allele that differs from a corresponding native allele,
wherein the natural allele is selected from CWC15, ApaF1, GDF8,
IGF2, SOCS2, DGAT1, GHRHR, TP53, DAZL, APC, PTEN, RB1, Smad4,
BUB1B, BRCA1, BRCA2, ST14, AKT1, EGF, EGFR, KRAS, PDGFRA/B, LDLR,
ApoE, ApoB, NOD2, VANGL1, VANGL2, miR-145, BMP10, SOS1, PTPN11,
Nrg1, Kir6.2, GATA4, Hand2, and HLA-DQA. The targeted nuclease can
induce a double-strand break at the cleavage site.
[0015] The method can further comprise delivering a recombinase to
the animal cell. The method can produce a cell. The method can
produce an animal. The method can produce a descendant of the
animal.
[0016] Disclosed herein is a method of modifying a bovine cell, the
method comprising: contacting the bovine cell with a targeted
endonuclease that targets and cuts a gene encoding the prolactin
receptor; contacting the bovine cell with a homology-dependent
repair template such that the template integrates into the genome
of the bovine cell to encode a truncated prolactin receptor
protein. The truncated prolactin receptor protein can be 461 amino
acids in length. The targeted endonuclease can be selected from a
zinc finger nuclease, a TAL effector nuclease (TALEN) and a
CRISPR/Cas 9 nuclease. The targeted endonuclease can be a TAL
effector nuclease (TALEN).
[0017] In one aspect, the TALEN has zero mismatches to a targeted
region of the gene encoding the prolactin receptor. The method can
further comprise contacting the bovine cell with a targeted
endonuclease comprises expressing exogenous mRNA encoding a TAL
effector nuclease (TALEN).
[0018] Disclosed herein is a method of genetically modifying a
bovine cell, the method comprising: obtaining a bovine cell; and
editing a horned gene of the bovine cell such that the horned gene
is edited to a polled gene. The horned gene of the bovine cell can
comprise a nucleotide sequence according to SEQ ID NO: 385 or a
nucleotide sequence that has at least 95% sequence identity to SEQ
ID NO: 385.
[0019] The polled gene can comprise the nucleotide sequence
according to SEQ ID NO: 386 or a nucleotide sequence that has at
least 95% sequence identity to SEQ ID NO: 386. The horned gene can
comprise the nucleotide sequence of SEQ ID NO: 385 and the polled
gene comprises the nucleotide sequence of SEQ ID NO: 386.
[0020] In another aspect, editing the horned gene does not involve
meiotic introgression.
[0021] Editing the horned gene can comprise implementing CRISPR,
zinc finger nuclease, meganuclease, or TALEN technology. Editing
the horned gene can comprise contacting the bovine cell with a
TALEN that targets the horned gene. Editing the horned gene can
comprise introducing into the bovine cell a homology directed
repair (HDR) template homologous to a portion of the horned gene.
The TALEN can target the horned gene at a DNA target sequence
according to any of SEQ ID NOs: 240, 347, 348, 149, 150, 151, 152
and 153.
[0022] In some embodiments, editing a horned gene of the bovine
cell such that the horned gene is edited to a polled gene comprises
a 202 bp insertion-deletion event.
[0023] The HDR template can comprise a nucleotide sequence of SEQ
ID NO: 381. The TALEN can comprise an amino acid sequence according
to SEQ ID NOS: 460-467. Editing the horned gene can comprise
implementing CRISPR technology using guide RNA.
[0024] In one aspect the bovine cell, after editing, is
heterozygous for the polled gene. Alternatively, the bovine cell,
after editing, can be homozygous for the polled gene. The bovine
cell can be a somatic bovine cell. The method can further comprise
transferring a nucleus of the somatic bovine cell to an enucleated
egg of the same species.
[0025] The method can further comprise producing an animal that is
derived from the cell. The method can be used to produce a cell.
The method can be used to produce an animal. The animal can
comprise a polled phenotype. The method can be used to produce an
animal and a descendant of the animal.
[0026] Described herein is a non-human animal made by a method of
introgressing an allele or gene into chromosomal DNA of a non-human
animal cell comprising introducing into a cell isolated from a
non-human animal line: (i) a CRISPR/Cas endonuclease; (ii) a guide
RNA (gRNA) comprising a spacer RNA sequence that interacts with a
target sequence in the chromosomal DNA of the cell; (iii) a
homology-directed repair (HDR) template DNA sequence encoding an
allele or a gene flanked by sequences homologous to the target
sequence in a chromosomal DNA of the cell; and (iv) cloning the
cell; wherein said introducing alters the chromosomal DNA of the
cell to have identity with the HDR template DNA sequence at the
target sequence in the chromosomal DNA, thereby introgressing the
allele or the gene into the chromosomal DNA of the cell, wherein
the HDR template DNA sequence also comprises a DNA sequence
encoding a mismatch in the target sequence that alters the
interaction with the RNA spacer sequence of the gRNA, and wherein
the mismatch is introduced into the chromosomal DNA of the cell and
creates a sequence in the chromosomal DNA of the animal that is not
found in the non-human animal line.
[0027] In one aspect, the mismatch creates a sequence in the
chromosomal DNA of the animal that is not found in the same breed
as the animal line. The mismatch can create a sequence that is not
found in nature. The mismatch can comprise a substitution of a DNA
base for a base that does not promote binding to the gRNA of a
CRISPR/Cas. The substitution can comprise a 1 to 5 base pair
substitution. The mismatch can comprise an insertion or a deletion
of a DNA base. The mismatch can comprise an insertion of 1-5 DNA
bases. The mismatch can comprise a deletion of 1-5 DNA bases.
[0028] In another aspect, the target sequence can encode at least a
part of an endogenous allele, wherein the HDR template DNA sequence
encodes a natural allele that is homologous to the endogenous
allele flanked by sequences homologous to the target sequence in
the chromosomal DNA of the animal, and wherein the natural allele
replaces the endogenous allele. The target sequence can encode at
least part of an endogenous allele that encodes a protein or is
part of a locus associated with a trait, wherein the HDR template
DNA sequence encodes a different allele that is homologous to the
endogenous allele. In some embodiments, the HDR template can encode
a locus (or a part thereof) that is associated with an enhancement
of the trait flanked by sequences homologous to the target sequence
in the chromosomal DNA of the cell, wherein the different allele
replaces the endogenous allele, and wherein the trait is selected
from the group consisting of: a horn growth trait, a meat trait, a
meat production trait, a milk production trait, a dairy trait, and
a disease resistance trait. The disease resistance trait can be
selected from: a gene for resistance to African swine fever
(P65/RELA): (a) genes that potential tumor growth (e.g., TP53, APC,
PTEN, RB1, Smad4, BUB1B, BRCA1, BRCA2, ST14 or a combination
thereof); (b) human oncogenes for animal models of cancer (e.g.,
AKT1, EGF, EGFR, KRAS, PDGFRA/B or a combination thereof); (c)
genes in animal models for hypercholesterolemia (to induce
atherosclerosis, stroke, and Alzheimer's disease models), e.g.,
LDLR, ApoE, ApoB or a combination thereof; (d) Inflammatory Bowel
disease, e.g., NOD2; (e) spina bifida, e.g., VANGL1 and/or VANGL2;
(f) pulmonary hypertension, e.g., miR-145; (g) genes for cardiac
defects, e.g., BMP10, SOS1, PTPN11, Nrg1, Kir6.2, GATA4, Hand2, or
a combination thereof and (h) celiac disease genes, e.g.,
HLA-DQA1.
[0029] The target sequence can encode at least part of an
endogenous allele, wherein the HDR template DNA sequence encodes an
allele that is homologous to the endogenous allele flanked by
sequences homologous to the target sequence in the chromosomal DNA
of the cell, and wherein the allele that is homologous to the
allele replaces the endogenous allele, and wherein the allele that
is homologous to the endogenous allele is from the same species of
animal as the non-human animal line. The target sequence can encode
at least part of an endogenous allele, wherein the HDR template DNA
sequence encodes an allele that is homologous to the endogenous
allele flanked by sequences homologous to the target sequence in
the chromosomal DNA of the cell, and wherein the allele that is
homologous to the endogenous allele replaces the endogenous allele,
and wherein the allele that is homologous to the endogenous allele
is not from the same breed of animal as the non-human animal
line.
[0030] In one aspect, the cell is selected from the group
consisting of a primary cell, a primary somatic cell, a zygote, a
germ cell, a stem cell, an oocyte, and a sperm. CRISPR/Cas
endonuclease can be introduced into the cell as mRNA. The cell can
be homozygous for the allele or the gene introgression into the
chromosomal DNA of the cell.
[0031] The non-human animal line can be selected from the group
consisting of: a non-human vertebrate line, a non-human primate
line, a swine line, a cattle line, horse line, sheep line, a goat
line, an avian line, a chicken line, a rabbit line, a fish line, a
dog line, and a cat line.
[0032] In another aspect, the target sequence encodes at least part
of an endogenous allele, wherein the HDR template DNA sequence
encodes an allele that is homologous to the endogenous allele
flanked by sequences homologous to the target sequence in the
chromosomal DNA of the cell, wherein the allele that is homologous
to the endogenous allele replaces the endogenous allele, and
wherein the mismatch comprises a single nucleotide polymorphism
(SNP) that is located within the allele that is homologous to the
endogenous allele. In another aspect, the target sequence encodes
at least part of an endogenous allele, wherein the HDR template DNA
sequence encodes an allele that is homologous to the endogenous
allele flanked by sequences homologous to the target sequence in
the chromosomal DNA of the cell, wherein the allele that is
homologous to the endogenous allele replaces the endogenous allele,
and wherein the mismatch consists of a SNP, that is located within
the allele that is homologous to the endogenous allele. In yet
another aspect, the target sequence encodes at least part of an
endogenous allele, wherein the HDR template DNA sequence encodes an
allele that is homologous to the endogenous allele flanked by
sequences homologous to the target sequence in the chromosomal DNA
of the cell, wherein the allele that is homologous to the
endogenous allele replaces the endogenous allele, and wherein the
mismatch comprises a plurality of SNPs that is located within the
allele that is homologous to the endogenous allele. Alternatively,
the target sequence can encode at least part of an endogenous
allele, wherein the HDR template DNA sequence encodes an allele
that is homologous to the endogenous allele flanked by sequences
homologous to the target sequence in the chromosomal DNA of the
cell, wherein the allele that is homologous to the endogenous
allele replaces the endogenous allele, and wherein the mismatch
consists of a plurality of SNPs that are located within the allele
that is homologous to the endogenous allele. The allele can be a
SNP.
[0033] Disclosed herein is a method of making a genetically
modified animal, said method comprising: (i) exposing embryos or
cells to an mRNA encoding a TALEN, with the TALEN specifically
binding to a target chromosomal site in the embryos or cells, (ii)
cloning the cells in a surrogate mother or implanting the embryos
in a surrogate mother, with the surrogate mother thereby gestating
an animal that is genetically modified without a reporter gene and
only at the TALEN targeted chromosomal site. In one aspect, the
method includes exposing the embryos to the TALEN without a
reporter gene, with more than about 1% of the embryos incorporating
the modification at the targeted chromosomal site. Alternatively,
exposing the cells to the TALEN without a reporter gene, and
cloning the cells, with more than 1% of the cloned cells providing
animals incorporating the modification at the targeted chromosomal
site. The cells can be primary somatic cells or stem cells. The
cells can be cloned by somatic cell nuclear transfer or chromatin
transfer. The gestated animal can be homozygous for the
modification. The gestated animal can be a founder animal.
[0034] The above method can be used to prepare a genetically
modified animal. The animal can be a founder animal.
[0035] The genetic modification can be chosen from the group
consisting of an insertion, deletion, inversion or translocation.
The TALEN can be a first TALEN and the targeted chromosomal site is
a first site, with the method further comprising a second TALEN
directed to a second targeted chromosomal site. The TALEN can be a
right TALEN and further comprise a left TALEN that is introduced
with the right TALEN.
[0036] In another aspect, the method comprises providing embryos
having genetics known to be capable of expressing a set of traits
and exposing the embryos to the TALEN without a reporter gene and
screening the gestated animal for the modification and for
expression of the set of traits. Alternatively, the method
comprises exposing the cells to the TALEN without a reporter gene,
creating colonies of clonal cells, and testing a subset of members
of the colonies to identify colonies incorporating the modification
at the targeted chromosomal site. Testing the subset of members of
the colonies can be a destructive process. The testing process can
be chosen from the group consisting of a nucleolytic assay,
sequencing, PAGE, PCR, primer extension, or hybridization.
[0037] Alternatively, the method comprises exposing the embryos or
cells to single stranded DNA (ssDNA) that contains an exogenous
sequence, with the genetic modification comprising the exogenous
sequence. The ssDNA can be introduced into the cell after a vector
encoding a TALEN is introduced into the cell. The ssDNA can be
introduced into the cell between about 8 hours and about 3 days
after the vector expressing a TALEN is introduced into the cell.
TALEN mRNA can be directly introduced into the cell at about the
same time as the ssDNA.
[0038] The exogenous sequence can comprise an alternative allele
for the TALEN targeted chromosomal site. The alternative allele can
be linked to a quantitative trait or qualitative trait.
Alternatively, the alternative allele can comprise a myostatin
allele present in Belgian Blue cattle. The cell or embryo can
belong to a first breed and the allele can belong to a second breed
of the animal. The first breed can be Wagyu or Nelore cattle and
the second breed can be Belgian Blue cattle, with the offspring
being a Wagyu or Nelore calf. The allele can be chosen from the
group consisting of an insertion, a deletion, a polymorphism, and a
single nucleotide polymorphism.
[0039] The alternative allele can provide for an enhanced livestock
trait, and is chosen from the group consisting of a horn polled
locus, a gene recessive for fertility defects, a gene for enhancing
meat production, a gene for enhancing dairy production, a gene for
resistance to African swine fever, and combinations thereof; or can
provide for an animal model, and is chosen from the group
consisting of a gene for reduction of animal size, a gene that
potentiate tumor growth, an oncogene, hypercholesterolemia genes,
an inflammatory bowel disease gene, a spina bifida gene, a
pulmonary hypertension gene, a gene causing a cardiac defects, and
a celiac disease gene.
[0040] The targeted chromosomal site can be chosen for a disruption
of a gene, wherein the disruption of the gene comprises an
insertion, deletion, or substitution of one or more bases in a
sequence encoding the gene and/or a cis-regulatory element
thereof.
[0041] The genetic modification can be chosen from the group
consisting of an insertion, a deletion, a change to an exogenous
nucleic acid sequence, an inversion, a translocation, a gene
conversion to natural allele, a gene conversion to a synthetic
allele, interspecies allele migration, intraspecies allele
migration, and a gene conversion to a novel allele.
[0042] The method can further comprise delivering a recombinase to
the cell or embryo. The TALEN mRNA can be directly introduced into
the cell as mRNA. The direct introduction into the cell can
comprise a method chosen from the group consisting of
electroporation, transfection, lipofection, liposome,
nucleofection, biolistic particles, nanoparticles, lipid
transfection, electrofusion, and direct injection. The TALEN mRNA
can be introduced into the cell as a plasmid that encodes the
mRNA.
[0043] In another aspect the method comprises a cell, wherein the
cell is a primary cell or stem cell and the method is performed
without a selection step that requires either a positive or a
negative survival selection criterion. The cell can be chosen from
the group consisting of a livestock cell, an artiodactyl cell, a
cultured cell, a primary cell, a primary somatic cell, a zygote, a
primordial germ cell, a stem cell, and a zygote, or wherein the
embryo is a blastocyst.
[0044] The gestated animal can be chosen from the group consisting
of swine, cows, sheep, goats, chickens, rabbits, fish, zebrafish,
dog, mouse, cat, mouse, rat, and laboratory animal.
[0045] Disclosed herein is a method of making a genetically
modified non-human animal cell or embryo comprising exposing
embryos or cells of the animal in vitro to an mRNA encoding a
TALEN, with the TALEN specifically binding to a targeted
chromosomal site in the embryos or cells, with the cells or embryos
being genetically modified only at the targeted chromosomal site
and with the method being performed without a reporter gene. The
method can further comprise culturing the cells and isolating
colonies of the cells. The method can be performed without
additives that create a positive or a negative selection pressure
to select genetically modified cells. The method can comprise
exposing the embryos or cells of the animal in vitro to a single
stranded DNA that contains an exogenous sequence. The method can
result in the production of a cell.
[0046] Disclosed herein is a genetically modified animal, the
animal being a founder comprising an exogenous nucleic acid
sequence at an intended site and being free of all other genetic
modifications. The exogenous nucleic acid sequence can be an allele
and the intended site is a homologue of the allele. The animal can
be homozygous for the allele.
[0047] Disclosed herein is a method of creating a genetic
modification comprising exposing a non-human primary cell in an in
vitro culture or a non-human embryo to a nucleic acid encoding a
TALEN, wherein the nucleic acid encodes an N-terminal leader
portion having at least 80% homology to SEQ ID NO:132. The
N-terminal leader portion can have 80% homology to the 22-residue
sequence portion of SEQ ID NO:132 and a total of no more than about
30 residues. The nucleic acid can have at least 90% homology to SEQ
ID NO: 131.
[0048] Certain embodiments are directed to hypothermic conditions
for use of targeting endonucleases. One aspect encompasses a
hypothermic method of template-directed repair to change a
chromosomal DNA of a cell, comprising introducing into a living
cell a targeted nuclease system and a nucleic acid template,
wherein the targeted nuclease system and the template operate to
alter the chromosomal DNA to have identity to the template sequence
wherein the living cell is maintained at a hypothermic culturing
temperature below a physiological temperature for a time period of
more than three days measured from the time of the introduction. A
method of hypothermic template-directed repair may involve the
hypothermic culturing increasing a stable incorporation of the
template sequence into the chromosomal DNA. A method of hypothermic
template-directed repair may further involve a culturing
temperature kept within a range from 20 to 34.degree. C. A method
of hypothermic template-directed repair may further involve a time
period of more than three days. The time period may range from more
than three days to about two weeks. A method of hypothermic
template-directed repair may further involve testing a cell for the
template sequence. A method of hypothermic template-directed repair
may further involve a targeted nuclease system comprising Cas9 and
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
or a plurality of TAL effector repeat sequences that are fused to
the nuclease (TALEN). The targeted nuclease system may comprise
Cas9 and Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) or a plurality of TAL effector repeat sequences that are
fused to the nuclease (TALEN), wherein the nucleic acid guide is an
ssDNA. A method of hypothermic template-directed repair may further
involve one or more of a nuclease, a nucleic acid guide, and a
nucleic acid template introduced into the cell as an mRNA. A method
of hypothermic template-directed repair may further involve a cell
selected from the group consisting of a primary cell, a primary
somatic cell, an egg, a sperm, a zygote, a germ cell, a stem cell,
an oocyte, a sperm, and an embryo. A method of hypothermic
template-directed repair may further involve an animal homozygous
for the template sequence.
[0049] Another aspect encompasses a method of template-directed
repair to change a chromosomal DNA of a cell, comprising
introducing into a living cell a targeted nuclease system, a
nucleic acid template, and a cold-factor for inhibiting cell
growth, wherein the targeted nuclease system and the template
operate to alter the chromosomal DNA to have identity to the
template sequence. The method of template-directed repair to change
a chromosomal DNA of a cell may comprise a cold-factor for
inhibiting cell growth, such as Cold-inducible RNA-binding protein
(CIRP). See Nishiyama et al., J. Cell Biol., (1997):137(4):899-908.
The method of template-directed repair to change a chromosomal DNA
of a cell may comprise a cell-cycle inhibitor introduced by
placement into a culture that comprises the cell. The cell-cycle
inhibitor may be introduced as a protein, as RNA, as an mRNA, or
through a vector encoding the cell-cycle inhibitor. The cell-cycle
inhibitor may be introduced as a protein, as RNA, as an mRNA, or
through a vector encoding the cell-cycle inhibitor wherein the
template is a HDR template. The template may be ssDNA. One or more
of the nuclease system and the nucleic acid template may be
introduced into the cell as an mRNA. The cell may be selected from
the group consisting of a primary cell, a primary somatic cell, a
zygote, a germ cell, a stem cell, and an embryo. A genetically
modified animal may be prepared according to the method of any of
the above. A founder animal may be made by the method of any of the
above. A cell may be made by the method of any of any of the
above.
[0050] In another aspect, various allelic and genetic modifications
are contemplated. For example, a modification comprises a nonhuman
animal comprising a heritable exogenous allele that provides
elevated fecundity and/or a heritable exogenous allele that
provides parent-of-origin dependent muscle hypertrophy. The animal
of may be a goat. The animal may be chosen from the group
consisting of livestock, primate, swine, cattle, horse, sheep,
goat, chicken, rabbit, fish, dog, mouse, cat, rat, and laboratory
animal. The animal may be free of fluorescent markers, selectable
markers, and expressible markers. The elevated fecundity allele of
the animal may be FecB; BMPR-IB. The muscle hypertrophy allele of
the animal may be Callipyge. The animal may be homozygous for the
exogenous allele.
[0051] The animal may be a non-human animal comprising an exogenous
allele for APC. The animal may comprise an allele directed to a
cancerous phenotype. The exogenous allele may be a human allele.
The animal may be a laboratory animal model. The animal may be
selected from the group consisting of pig, miniature pig, Ossabow
pig, rabbit, dog, sheep, and goat. The animal may be a founder. The
animal may be free of chromosomal changes other than introgression
of the exogenous allele. Disclosed herein is a method of making the
animal of comprising an HDR templated introgression of the
exogenous allele with a targeted nuclease system. The method of
making the animal may comprise an HDR templated introgression of
the exogenous allele with a targeted nuclease system wherein the
exogenous allele is chosen to be a human allele that is associated
with a cancerous phenotype.
[0052] Another aspect is an animal comprising an exogenous allele
selected from Table 7 entitled "Frequencies for recovery of
colonies with HDR alleles". Also disclosed is a method for creating
the animal comprising introgressing an allele into an animal, the
allele being chosen from the group listed on said Table 7 or as
follows. The allele may be LDLR, e.g., for cholesterol modeling.
The allele may be DAZL, e.g., for sterility. The allele may be APC,
e.g., for cancer modeling. The allele may be p53. The allele may be
RAG2, e.g., knocked-out for immunosuppression. The allele may be
IL-2, e.g., knocked-out for immunosuppression (not in Table). The
allele may be a double knock-out of RAG2 and 11-2 for
immunosuppression (not in Table). The allele may be ROSA, e.g., for
a safe harbor. The allele may be SRY, e.g., for modifications to a
Y chromosome, for sex selection; -- is KISS OR KISSR, e.g., for
maturation or prevention thereof, e.g., knockout. The allele may
beGDF8, e.g., for increasing muscling in animals. The allele may be
EIF4G, e.g., for resistance to foot and mouth diseases (FMDV). The
allele may be p65 for resistance to African Swine Fever. The allele
may becaFecB for twinning, including interspecies introgression.
The allele may be Diglyceride acyltransferase (DGAT) knockout for
increased dairy merit. The allele may be ATP-binding cassette
sub-family G member 2 (ABCG2) for increased dairy merit. The allele
may bepleiomorphic adenoma gene 1 (PLAG1) for influencing age at
puberty, stature and body weight. The allele may be Beta
lactoglobulin for reducing allergenicity of milk, is ovomucoid,
ovalbumin, ovotransferrin, or lysozyme for reducing allergenicity
of avian eggs. The animal may be a pig, sheep, goat, or cow with an
introgressed allele. Disclosed herein is a cell or an animal
comprising any of the above modifications. The cell or animal may
be a vertebrate, livestock, primate, swine, cattle, horse, sheep,
goat, chicken, rabbit, fish, dog, mouse, cat, rat, or laboratory
animal.
[0053] Another aspect is a method of creating a single nucleotide
polymorphism (SNP) in a chromosomal DNA of a cell, comprising
introducing a targeted nuclease system and a HDR template into the
cell, with the targeted nuclease system comprising a DNA-binding
member for specifically binding an endogenous cognate sequence in
the chromosomal DNA, wherein the targeted nuclease system and the
HDR template operate to alter the chromosomal DNA to have identity
to the HDR template sequence, wherein the HDR template sequence
comprises a SNP. The HDR template sequence may comprise a plurality
of SNPs. The HDR template sequence may comprise an exogenous allele
that replaces an endogenous allele, with the exogenous allele
comprising an SNP in a sequence alignment with the endogenous
allele. The HDR template sequence may comprise a plurality of SNPs
wherein the HDR template sequence comprises an exogenous allele
that replaces an endogenous allele, with the exogenous allele
comprising an SNP in a sequence alignment with the endogenous
allele. The method may produce a modification wherein the
chromosomal DNA is free of SNPs outside of the exogenous allele.
The method of any of the above being free of SNPs outside of the
exogenous allele with the HDR template sequence being identical to
the chromosomal DNA except for one or more SNPs in the exogenous
allele. The method of any of the above being free of SNPs outside
of the exogenous allele with the HDR template sequence being
identical to the chromosomal DNA except for one or more SNPs in the
exogenous allele wherein there is only one SNP. The method of any
of the above wherein the HDR template is designed to reduce
specific binding of the DNA-binding member to the HDR template
sequence and the HDR template sequence comprises a SNP, as aligned
with the chromosomal DNA.
[0054] Further disclosed herein is a genetically modified animal
from a first breed comprising an allele of a gene selected from
another species or another breed; wherein the animal of the first
breed is free of genetic changes other than the allele; methods of
making the animal as set forth herein.
[0055] Another aspect of the present invention is a method of
homology-directed repair (HDR) to introgress an exogenous allele
into chromosomal DNA of a cell, comprising introducing a targeted
endonuclease system and a HDR template that comprises the exogenous
allele into the cell, with the targeted nuclease system comprising
a DNA-binding member for specifically binding an endogenous cognate
sequence in the chromosomal DNA, wherein the targeted nuclease
system and the HDR template operate to alter the chromosomal DNA to
have identity to the HDR template sequence to introgress the
exogenous allele into the chromosomal DNA in place of an endogenous
allele, with the targeting endonuclease system and/or HDR template
comprising a feature to reduce specific binding of the targeting
endonuclease system to DNA. The method of may comprise a feature to
reduce specific binding comprising a mismatch in the DNA-binding
member sequence relative to the endogenous cognate sequence and/or
a mismatch in the DNA-binding member sequence relative to the HDR
template sequence. The targeted endonuclease system may comprise a
plurality of TAL effector repeat sequences that are fused to a
nuclease (TALEN), with the TALEN comprising a sequence of Repeat
Variable Diresidues (RVDs) and the mismatch is in the sequence of
RVDs relative to the endogenous cognate sequence. The the targeted
nuclease system may comprise a Cas9 nuclease and a guide RNA, with
the mismatch being in the gRNA sequence relative to the endogenous
cognate sequence. The targeted endonuclease system may comprise a
plurality of TAL effector repeat sequences that are fused to a
nuclease (TALEN), with the TALEN comprising a sequence of Repeat
Variable Diresidues (RVDs) and the mismatch is in the sequence of
RVDs relative to the HDR template sequence. The targeted nuclease
system may comprise a Cas9 nuclease and a guide RNA, with the
mismatch being in the gRNA relative to the HDR template sequence.
The exogenous allele may be a natural allele and the HDR template
may comprise the mismatch, with the mismatch creating a sequence
that is not found in nature. The exogenous allele may be free of
mismatches and comprise DNA expressed by the cell. The exogenous
allele may comprise the mismatch and DNA expressed by the cell. The
method may further comprise selecting the DNA-binding member
sequence and the endogenous cognate sequence so that altering the
chromosomal DNA to have identity to the HDR template sequence
creates the mismatch in the DNA-binding member sequence relative to
the altered chromosomal DNA sequence. The exogenous allele may be a
natural allele and the HDR template consists of the natural allele
and DNA that has an identity with the chromosomal DNA sequence.
Selecting the DNA-binding member sequence and the endogenous
cognate sequence may further comprise placing a second mismatch in
the endogenous cognate sequence that is not changed when the
chromosomal DNA is altered to have identity to the HDR template.
The method may further comprise selecting the DNA-binding member
sequence and the endogenous cognate sequence to place the mismatch
in the endogenous cognate sequence relative to the DNA-binding
sequence, and altering the chromosomal DNA to have identity to the
HDR template sequence does not remove the mismatch. The mismatch
may comprise an insertion, a deletion, or a substitution. The
insertion, deletion, or substitution may have a length from 1 to 20
residues. The insertion, deletion, or substitution may have a
length from 1 to 20 residues. The mismatch may be one SNP. The
method may comprise a plurality of mismatches. The targeting
endonuclease system may comprise a pair of TALENs that localize to
the chromosomal DNA with a spacer sequence between the pair,
wherein the feature comprises selecting the HDR template to create
a change in a length of the spacer sequence to block cleavage of
the DNA by the TALENs pair. The spacer length may be decreased by a
deletion or increased by an insertion. The spacer length may be
increased or decreased by a number of residues in a range from 1 to
60. The cell may be selected from the group consisting of a primary
cell, a primary somatic cell, a zygote, a germ cell, a stem cell,
an oocyte, a sperm, and an embryo. The HDR template may be a ssDNA.
The nuclease system may be introduced into the cell as an mRNA. The
targeted nuclease system may specifically bind the endogenous
cognate sequence with a binding protein. The exogenous allele may
comprise an APC allele. The method of any of the above may be free
of reporters, fluorescent markers, selectable markers, and
expressible markers. The cell may be a livestock cell. The cell may
be from vertebrate, livestock, primate, swine, cattle, horse,
sheep, goat, chicken, rabbit, fish, dog, mouse, cat, rat, and
laboratory animal. The animal may be homozygous for the exogenous
allele. Disclosed herein is a method of making a genetically
modified animal comprising cloning a cell modified by the method of
any of the above. The animal may be a founder. Disclosed herein is
a genetically modified animal prepared according to the method of
any of the above. The genetically modified animal may be a founder
animal. Disclosed herein is a cell made by the method of any of the
above. Disclosed here in is a kit comprising the targeted nuclease
system and the HDR template of any of the above. Disclosed herein
is a use of any of the above comprising preparing a cell for
research in vitro, or preparing a cell for use in making an
animal.
[0056] Another aspect comprises a genetically modified animal, the
animal belonging to a breed having an endogenous allele in the
chromosomal DNA of the animal, the animal comprising a change at an
SNP, the SNP being in the endogenous allele relative to an
exogenous allele found in another species or another breed of
animal. The genetically modified animal may belong to a breed
having an endogenous allele in the chromosomal DNA of the animal,
the animal comprising an exogenous allele found in another species
or another breed of animal, with the exogenous allele having a
change at an SNP relative to the endogenous allele. In other words,
the modified animal has an SNP so that it now has an allele that is
not normally found in its breed, with that allele being from some
other breed or species. The change could be only that SNP or there
could be other changes, with the SNP being necessary to mirror the
desired allele. The SNP is not a result of random processes, but is
an intended result. The animal may comprise a plurality of the
SNPs. The animal may comprise further changes in the chromosomal
DNA of the animal relative to the exogenous allele. The animal of
any of the above being free or reporters. The animal of any of the
above being homozygous for the SNP and/or the SNPs. The animal of
any of the above being from vertebrate, livestock, primate, swine,
cattle, horse, sheep, goat, chicken, rabbit, fish, dog, mouse, cat,
rat, and laboratory animal.
[0057] Another aspect comprises a method of creating a landing pad
in a chromosomal DNA of a cell, comprising introducing a targeted
nuclease system and a HDR template into the cell, with the targeted
nuclease system comprising a DNA-binding member for specifically
binding an endogenous cognate sequence in the chromosomal DNA,
wherein the targeted nuclease system and the HDR template operate
to alter the chromosomal DNA to have identity to the HDR template
sequence, wherein the HDR template sequence comprises a landing
pad.
[0058] Also disclosed herein is a genetically modified livestock
animal comprising a genome that comprises inactivation of a
neuroendocrine gene selective for sexual maturation, with the
inactivation of the gene preventing the animal from becoming
sexually mature. Inactivation of the gene may comprise an
insertion, deletion, or substitution of one or more bases in a
sequence encoding the sexual maturation gene and/or a
cis-regulatory element thereof. The inactivated gene may be
inactivated by: removal of at least a portion of the gene from a
genome of the animal, alteration of the gene to prevent expression
of a functional factor encoded by the gene, or a trans-acting
factor. The gene may be inactivated by the trans-acting factor,
said trans-acting factor being chosen from the group consisting of
interfering RNA and a dominant negative factor, with said
trans-acting factor being expressed by an exogenous gene or an
endogenous gene. The trans-acting factor may comprise a dominant
negative for GPR54. Inactivation of the gene may be under control
of an inducible system. The inducible system may comprise a member
of the group consisting of Tet-On, Tet-Off, Cre-lox, and Hiflalpha.
The animal may bechosen from the group consisting of cattle, swine,
sheep, chicken, goats, and fish. Further disclosed is a livestock
animal of any of the above wherein the sexual maturation gene is
chosen from the group consisting of Gpr54, Kiss1, and GnRH11. The
livestock animal may further express a trait as a result of
expression of a recombinant protein. The livestock animal may
express an exogenous recombinant protein. The trait may be chosen
from the group consisting of production traits, type traits, and
workability traits. The livestock animal of any of the above may be
sexually immature at an age that a wild type animal of the same
species is sexually mature. The livestock animal of any of the
above may be genetically unable to mature without a treatment.
[0059] Further disclosed herein is a genetically modified livestock
animal comprising a genome that is heterozygous for an inactivation
of a neuroendocrine gene selective for sexual maturation, wherein
progeny homozygous for the inactivated gene are thereby prevented
from becoming sexually mature. The sexual maturation gene may be
chosen from the group consisting of Gpr54, Kiss1, and GnRH11.
[0060] Another aspect comprises an in vitro organism chosen from
the group consisting of a cell or an embryo, the in vitro organism
comprising a genome that comprises an inactivation of a sexual
maturation gene. The organism may be a cell or embryo chosen from
the group consisting of cattle, swine, sheep, chicken, goats,
rabbit, and fish. The inactivation may be in a gene chosen from the
group consisting of Gpr54, KiSS1, and GnRH11.
[0061] Another aspect comprises a process of making a livestock
animal comprising introducing, into an organism chosen from the
group consisting of a livestock cell and a livestock embryo, an
agent that specifically binds to a chromosomal target site of the
cell and causes a double-stranded DNA break to inactivate a
neuroendocrine gene selective for sexual maturation, with the agent
being chosen from the group consisting of a TALEN, a zinc finger
nuclease, Cas9/CRISPR and a recombinase fusion protein. The agent
may be a TALEN of a TALEN pair that comprises a sequence to
specifically bind the chromosomal target site, and creates the
double stranded break in the gene or creates the double stranded
break in the chromosome in combination with a further TALEN that
creates a second double stranded break with at least a portion of
the gene being disposed between the first break and the second
break. The process may further comprise co-introducing a
recombinase into the organism with the TALEN or TALENs. A transgene
expressing the agent may be placed in a genome of the organism
Introducing the agent into an organism may comprise a method chosen
from the group consisting of direct injection of the agent as
peptides, injection of mRNA encoding the agent, exposing the
organism to a vector encoding the agent, and introducing a plasmid
encoding the agent into the organism. Further disclosed is the
process of any of the above wherein the agent is the recombinase
fusion protein, with the process comprising introducing a targeting
nucleic acid sequence with the fusion protein, with the targeting
nucleic acid sequence forming a filament with the recombinase for
specific binding to the chromosomal site. The recombinase fusion
protein may comprise a recombinase and Gal4. The process of any of
the above may further comprise introducing a nucleic acid into the
organism, wherein the nucleic acid is inserted into the genome of
the organism at a site of the double-stranded break or between the
first break and second break. The process of any of the above may
further comprise introducing an exogenous nucleic acid template
having a sequence into the organism, with the genome of the
organism at a site of the double-stranded break receiving the
sequence. The exogenous template can be copied or actually inserted
into the genome, with the result being the same, regardless of the
theories about it being one or the other mechanism. The result may
be that the genome has the sequence of the template. The nucleic
acid may comprise a member of the group consisting of a stop codon,
a reporter gene, and a reporter gene cassette. The process of any
of the above may further comprise cloning the animal from the
organism. The animal may be chosen from the group consisting of
cattle, swine, sheep, chicken, goats, rabbit, and fish. The sexual
maturation gene may be chosen from the group consisting of Gpr54,
Kiss1, and GnRH11. Inactivation of the gene may be under control of
an inducible system.
[0062] Disclosed herein is a process of raising a livestock animal
comprising administering an agent to an animal for sexual
maturation of the animal, with the agent compensating for a genetic
inability of the animal to sexually mature. The agent may comprise
a gonadotropin or a gonadotropin analogue. The process may further
comprise breeding the sexually mature animal to produce progeny.
The genetic inability of the animal to mature may be a result of a
genetically inactivated neuroendocrine gene selective for sexual
maturation, hereafter variation 1. The inactivated gene may be
chosen from the group consisting of Gpr54, Kiss1, and GnRH11. The
inactivated gene may be inactivated by: removal of at least a
portion of the gene from a genome of the animal, alteration of the
gene to prevent expression of a functional factor encoded by the
gene, or a trans-acting factor. The animal may be chosen from the
group consisting of cattle, swine, chicken, sheep, fish, rabbit,
and goats. The administration of the agent to the animals may take
place in a treatment facility. The progeny may be distributed from
the treatment facility to a plurality of locations to be
raised.
INCORPORATION BY REFERENCE
[0063] All publications, patents, and patent applications mentioned
in this specification are herein incorporated by reference to the
same extent as if each individual publication, patent, or patent
application was specifically and individually indicated to be
incorporated by reference, including U.S. application Ser. No.
14/154,906 "Hornless Livestock," U.S. Prov. Appl. No. 61/870,570
"Hornless Livestock", U.S. Prov. Appl. No. 61/752,232 "Hornless
Livestock", U.S. application Ser. No. 13/594,694 "Genetically
Modified Animals and Methods for Making the Same," U.S. Prov. Appl.
No. 61/662,767, U.S. Prov. Appl. No. 61/446,651, U.S. application
Ser. No. 13/404,662, U.S. Prov. Appl. No. 61/870,510, U.S. Prov.
Appl. No. 61/720,187, and Ser. No. 14/067,634 "Cells with Modified
Neuroendocrine Genes."
BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Various features of the disclosure are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be obtained
by reference to the following detailed description that sets forth
illustrative embodiments, in which principles of the invention are
utilized, and the accompanying drawings of which:
[0065] FIG. 1: An illustration of a TALEN and genetic modifications
caused by the same.
[0066] FIG. 2: An illustration of TALENs operating at a plurality
of DNA loci.
[0067] FIG. 3A: TALEN activity in bovine embryos. An experimental
overview is given.
[0068] TALENs are designed to opposing strands of the DNA target
such that the FokI nuclease homodimeric monomers are able to
dimerize and cleave DNA between the two monomers. Bovine in
vitro-produced zygotes are injected with TALEN mRNA on day 1 (D1)
and cultured in vitro to blastocyst formation. Individual
blastocysts (blasts) are collected on day 8, subjected to whole
genome amplification (WGA) and analyzed for indels by PCR
amplification and Cel-I (SURVEYOR Nuclease, Transgenomics)
treatment.
[0069] FIG. 3B: TALEN activity in bovine embryos. SURVEYOR Nuclease
treatment for analysis of indels in bovine embryos mediated by
ACAN12 TALENs. The amplicon length and predicted SURVEYOR cleavage
products that are indicative of indels, is shown above.
[0070] FIG. 4: Deletions and insertions sequenced from bovine
embryos treated with ACAN12 TALENs. The wild-type sequence is shown
with TALEN binding sites underlined. Both deletion and insertion
events are identified.
[0071] FIG. 5: Comparison of TALEN scaffold for gene editing in
livestock fibroblasts. Panel a) A diagram of TALEN scaffolds tested
in this experiment. Each scaffold (+231, Christian et. al. 2010 and
Carlson +63, (compare to: Miller et. al. 2011)) contains a SV40
nuclear localization signal (NLS) and has a C-terminal fusion of
the FokI homodimer domain. Numbering is relative to the DNA binding
domain. The amino acid prior to the first repeat variable diresidue
repeat (RVD) is labeled "-1" and the amino acid following the last
RVD repeat is labeled "+1". Panel b) The SURVEYOR assay was
conducted on fibroblasts transfected with either DMDE7.1 or ACAN12
TALEN pairs. Scaffold and temperature treatment is indicated above
the gel and percent NHEJ is indicated below. Abbreviations, NT=not
treated. Panel c) Activity of four additional TALEN pairs with
either the +231 or Carlson +63 scaffold.
[0072] FIG. 6: Deletions and insertions sequenced from cells
treated with ACAN12 TALENs are shown in SEQ ID NO: 27-38. The
wild-type ACAN12 sequence (SEQ ID NO. 26) is displayed in italics
and the left and right (complimentary) TALEN-recognition sequences
are underlined. Inserted nucleotides are highlighted in boxes and
mismatch nucleotides are denoted by lower-case text.
[0073] FIG. 7: Transposon co-selection for indel enrichment. An
experimental timeline is shown in panel (a). Day zero (D0), cells
are transfected with a mixture of plasmids including an expression
cassette for each TALEN, a transposon encoding a selection marker,
and a transposase-expression cassette. The TALEN plasmid is the
major component (4-fold excess by mass) of each transfection.
Fibroblasts were cultured in DMEM (high glucose) supplemented to
10% FBS, 20 mm GlutaMAX and 1.times. Penn/Strep solution (all from
Invitrogen) and transfected by using the Basic Fibroblast
Nuclofection Kit (Amaxa Biosystems/Lonza) or Minis LT1 reagent
(Mirus) as previously described (Carlson 2011). Briefly, each
transfection included 500,000-1,000,000 fibroblasts, 2 ug each
TALEN plasmid and 750 ng of transposon components (500 ng
pKT2P-PTK; 200 ng pKC-SB100.times.; 50 ng pMAX-EGFP (Lonza)).
Transfected cells are cultured for 3 days at either 30 or 37
degrees Celsius prior to splitting, collection of a sample for
SURVEYOR assay and re-plating for extended culture+/-selection for
transposon integration. All cells are cultured at 37 degrees
Celsius after day 3. Cells cultured for 14+ days are collected for
SURVEYOR assay and cryopreserved for downstream applications, e.g.,
single-cell nuclear transfer. Panel b) Fibroblasts were transfected
using cationic-lipids. No activity was observed at day 3 (due to
low transfection efficiency) so only data for day 14+ populations
is provided. Temperature treatment, selection, and TALEN id
(identified by letters A-C as indicated in panel (c)) are shown
above the gel. Panel c) Fibroblasts were transfected by
Nucleofection and percent NHEJ was measured at day 3, and in day
14+ non-selected (NS) and selected (S) populations. Temperature
treatment is indicated above each matrix. Abbreviations: nd=not
detected; wt=wild type amplicon, SURVEYOR treated.
[0074] FIG. 8A: Direct PCR sequencing for identification of indels.
PCR amplicons from individual fibroblast colonies were purified,
sequenced and compared to the wild-type sequence SEQ ID NO: 68.
Mutation of one allele or non-overlapping mutations of both alleles
will result in double sequence near the TALEN recognition sites
(top). Overlapping bi-allelic mutations can be identified where
differences between each allele can be identified by double peaks
flanking the mutation site. Colonies with homozygous mutations do
not display double peaks near the indel site.
[0075] FIG. 8B: Sequence comparisons of wild-type and bi-allelic
clones with homozygous indels, as in FIG. 8A.
[0076] FIG. 9A: DMD (Duchenne's Muscular Dystrophy) Bi-allelic
modification alleles. Colonies with either homozygous modification
alleles (i.e., both alleles harbor the same mutation) or bi-allelic
mutation with different mutations on each allele are displayed. For
colonies with two indels, the number of times each allele was
sequenced is displayed on the right. In some cases, a third
mutation or single wild-type allele was sequenced, indicating that
not all colonies are 100% clonal. Frame-shift alleles are indicated
and mismatch nucleotides are denoted by lower-case text.
[0077] FIG. 9B: LDLR bi-allelic modification alleles, with
notations as in FIG. 9A.
[0078] FIG. 10: TALEN-induced deletions and inversions. A schematic
of the DMD locus is shown in panel (a). DNA orientation is denoted
by black chevrons. TALENs targeted to exons 6 and 7 (black
arrowheads) co-transfected into male pig fibroblasts could result
in a NHEJ fusion event between exons 6 and 7. This could be
identified using primers (black arrows) resulting in .about.500 bp
amplicon. Panel b) SURVEYOR assay of cells transfected
simultaneously with TALENs targeted to exons 6 and 7 reveal NHEJ
indels at both sites. Percent NHEJ is displayed below. Panel c) PCR
with primers flanking the presumptive deletion site yield a
.about.500 basepair product when both exon-6 and exon-7 TALENs are
introduced simultaneously, but not when transfected singly. Panel
d) The predicted outcome of an inversion event of the sequence
between the TALEN target sites is shown. DNA orientation is denoted
by black chevrons. Primers outside the presumptive flanking sites
at the 5' and 3' end of the inversion locus are shown (black
arrows) along with predicted product size. PCR products were
observed at both 5' and 3' junctions only when both exon-6 and
exon-7 TALENs are introduced simultaneously.
[0079] FIG. 11: DMD deletion sequences. DMD deletion junctions from
replicate transfections are displayed. Above, exons 6 and 7
sequences are shaded, and TALEN-recognition sites are underlined.
Inserted nucleotides are shaded.
[0080] FIG. 12: DMD inversion sequences. A schematic of the DMD
inversion allele is shown with the 5' and 3' junctions (boxed) that
were analyzed by sequencing. Below, the predicted sequence for each
fusion is shown corresponding fusion at the center of each spacer
for the TALEN pairs. TALEN-recognition sites are underlined.
Sequenced inversion alleles from a transfected population are
shown. The number of times each allele was sequenced is indicated
at the right and inserted nucleotides are underlined. Mismatched
nucleotides are denoted as lower-case text.
[0081] FIG. 13: HDR induction in bovine fibroblasts. Panel a)
TALENs (btGDF83.1, arrow) and a dsDNA template (BB-HDR) were
designed to introduce an 11-basepair deletion into exon-3 of bovine
GDF8 (Belgium Blue mutation) by Double-Strand Break-induced
homologous recombination. Half of the binding site for the left
TALEN is missing in the BB-HDR template and thus should be
resistant to TALEN cleavage. Panel b) SURVEYOR assay demonstrates
activity of btGDF83.1 TALENs at both 37 and 30.degree. Celsius. The
PCR product used for this assay was generated using primers b and
b' (shown in panel a). The BB-HDR template was not included in
these replicates since it would confound estimates of btGDF83.1
activity. Panel c) Allele-specific PCR demonstrates that HDR
induction is dependent on co-transfection of TALENs and the BB-HDR
template. The PCR assay was developed to specifically detect HDR
modified GDF8 alleles using primers c and c' (shown panel a). The
3' end of primer c' spans the 11-basepair deletion, and cannot
amplify the wild type allele (wt). Five hundred cell equivalents
were included in each PCR reaction including the positive control
"C". Percent HDR was determined by comparative densitometry between
experimental and control reactions.
[0082] FIG. 14: Confirmation of Belgian Blue introgression by
sequencing. The schematics of Wagyu wild-type GDF8 (HDR Templates
for GDF8 are SEQ ID NOs. 351-353) and the Belgian Blue template
(BB-HDR) are shown. PCR was conducted using primers located outside
of the homology arms (c and d) on five PCR positive colonies
followed by cloning and sequencing with primer b'. Comparison to
the wild-type sequence reveals the expected 11-basepair deletion
characteristic the Belgian Blue allele (heterozygous) in 4 of 5
colonies.
[0083] FIG. 15: Schematic and gel for TALEN-mediated HDR. A TALEN
pair (LDLR2.1) targeted to the fourth exon of the swine low density
lipoprotein receptor (LDLR) gene was co-transfected with the
supercoiled plasmid Ldlr-E4N-stop, which contains homology arms
corresponding to the swine LDLR gene and a gene-trap enabling
expression of Neomycin phosphotransferase upon HDR.
[0084] FIG. 16: Detailed sequence information for the Carlson +63
scaffold of FIG. 5 and comparison to an alternative scaffold used
by Sangamo Biosciences.
[0085] FIG. 17-1 and FIG. 17-2: Detailed nucleic acid sequence for
the vector used to make the Carlson +63 scaffold of FIG. 5,
including non-translated portions.
[0086] FIG. 18: Use of an AAV-delivered single stranded DNA
template emplate for homologous recombination at the bovine GDF8
locus. a) TALENs (btGDF83.1, blue arrow) and a rAAV homologous
recombination template (AAV-BB-HDR) were designed to introduce an
11 bp deletion into exon-3 of the bovine GDF8 gene (Belgium Blue
mutation) by homologous recombination. b) Allele-specific PCR
demonstrates that HR induction is dependent on transfection
btGDF83.1 TALENs and infection with defective AAV containing the
AAV-BB-HDR template. The PCR assay was developed to specifically
detect HDR modified GDF8 alleles using primers c and c' (shown
panel a). The 3' end of primer c' spans the 11 bp deletion, and
cannot amplify the wild type allele "WT". 1,000 cell equivalents
were included in each PCR reaction and positive control reactions
with the indicated copy number of a control template were used for
comparative quantification of homologous recombination.
[0087] FIG. 19: Use of single stranded oligonucleotides (ssOligos)
as a template for homologous recombination at the bovine GDF8
locus. TALENs (btGDF83.1, arrow) and two ssODNs were designed to
introduce an 11 bp deletion into exon-3 of the bovine GDF8 gene
(Belgium Blue mutation) by homologous recombination. Each ssODN was
76 base pairs in length and were sense and antisense strands of the
same target site Allele-specific PCR demonstrates that HDR
induction is dependent on transfection btGDF83.1 TALENs and
subsequent transfection of ssODNs using Lipofectamine LTX 24 hours
later. The PCR assay was developed to specifically detect HDR
modified GDF8 alleles using primers c and c' (shown panel a). The
3' end of primer c' spans the 11 bp deletion, and cannot amplify
the wild type allele "WT". 1,000 cell equivalents were included in
each PCR reaction and positive control reactions with the indicated
copy number of a control template were used for comparative
quantification of homologous recombination. BB-HDR Sense (S) has
SEQ ID NO:133 and BB-HDR Anti (AS) has SEQ ID NO:134.
[0088] FIG. 20: Transfection of TALEN encoding mRNAs into livestock
cells results in efficient target cleavage. Panel a: The indicated
quantity of mRNA was transfected into pig fibroblasts and
transfected cells were cultured at either 30 or 37 degrees Celsius
for three days prior to indel analysis. Panel b: Percent NHEJ was
determined. The average percent NHEJ for by transfection of 4
micrograms of plasmid DNA encoding the DMD7.1 TALENs is displayed
by dashed lines for cells cultured at 30 or 37 degrees Celsius.
[0089] FIG. 21: Transfection of mRNA encoded TALENs enhances ssODN
HDR. btGDF83.1 TALEN mRNA and BB-HDR sense ssODN (SEQ ID NO:133)
were introduced into Wagyu cells by the specified mechanism and HDR
was measured by PCR assay described above. Colonies were isolated
from the population of cells where both TALEN mRNA and the ssODNs
were delivered simultaneously by nucleofection.
[0090] FIG. 22: Introgression of naturally occurring alleles within
a species using mRNA encoded TALENs and ssODNs. The Piedmontese
Myostatin allele C313Y was introgressed into Waygu fibroblasts by
the methods of FIG. 21 using btGF83.6-G (SEQ ID NO: 351). The
sequence labeled "oligo" is has SEQ ID NO:503.
[0091] FIG. 23: The process of FIG. 22 was repeated at a different
temperature (37.degree. C.) using btGF83.6-G (SEQ ID NO: 351).
[0092] FIG. 24: Introgression of naturally occurring alleles from
one species to another using mRNA encoded TALENs and ssODNs. The
Piedmontese Myostatin allele C313Y was introgressed into Ossabaw
fibroblasts by the methods of FIG. 25. The following ssODN was used
ggccaattactgctctggagagtatgaattcgtatttttacaaaaataccctcacactcatcttg
(SEQ ID NO:146)
[0093] FIG. 25: Introduction of a particular frameshift allele into
porcine LDLR using mRNA encoded TALENs and ssODNs. A 90-bp oligo
was created to introduce a 4 base pair insertion into exon 2 of the
porcine LDLR gene. The insertion creates a novel BamH1 site and is
predicted to cause a frameshift allele. After co-transfection of
ssLDLR2.1 TALEN mRNA (at indicated dosage in micrograms) and 0.3
nMol of ssODN cells were cultured at 30.0 for 3 days, followed by
an additional day at 37.degree. C. NHEJ was measured by SURVEYOR
assay at days 4 and 20. Percent HDR was determined by BamH1 digest
of PCR products that include exon 2 of porcine LDLR and
quantification of restriction fragments (indicative of HDR) and
comparison to wild type products (top product, no HDR) by
densitometry. Colonies were isolated from each treatment and
analyzed by PCR and BamH1 digest. The sequence labeled "Wt" has SEQ
ID NO:523 and the sequence labeled "Sense" has SEQ ID NO:524.
[0094] FIG. 26: DNA and mRNA encoded TALENs are active in stem
cells. The top panel shows percent NHEJ of DMD7.1 TALENs
transfected as plasmid DNA into porcine male germ-line stem cells
(GSCs). Nucleofection solutions L, V or B were evaluated. The lower
panel shows SURVEYOR assay results of porcine GSCs transfected with
mRNA encoding DMD7.1 TALENs. The quantity of mRNA (micrograms) is
indicated.
[0095] FIG. 27: TALENs mediate DSB in chicken cells and can
stimulate homologous recombination in chicken primordial germ cells
(PGCs). Panel a) TALEN activity was first determined in DF1
immortalized chicken cells line transfection and SURVEYOR assay.
Panel b) Schematic depiction of the targeting strategy of the
chicken ddx4 locus. The GFP/Puromycin reporter gene will replace
the endogenous coding sequence in the second exon of targeted
cells. Penal c) PGCs were transfected with the homologous
recombination construct, TALENs (either Tal 1.1 or Tal 7.1, empty
vector) and a puromycin selection transposon. After selection in
puromycin, GFP+ cells could be isolated when Tal 1.1 TALENs were
used (right picture, left is bright field) but not with Tal7.1
TALENs or empty vector transfections.
[0096] FIG. 28: Schematic and gel for the TALEN-mediated HDR of
FIG. 27.
[0097] FIG. 29: Transgenic swine created by the processes of FIGS.
27 and 28.
[0098] FIG. 30: Illustrates a general process of using a
TAL-effector endonuclease (TALEN).
[0099] FIG. 31: Illustrates a general process of using a
Cas9/CRISPR endonuclease (an RNA-guided endonuclease).
[0100] FIG. 32: Illustrates the theory of operation for TALENs that
explains why they are generally ineffective for making SNP changes;
similar processes apply to other targeted endonucleases.
[0101] FIG. 33: Illustrates a general method of making and using
targeting endonucleases that is effective to make an SNP edit.
[0102] FIG. 34: Illustrates another general method of making and
using targeting endonucleases that is effective to make an SNP
edit.
[0103] FIG. 35: TALEN-mediated introgression of POLLED. Panel a) A
schematic of the strategy to introgress the Polled allele into
Holstein (HORNED) cells. The POLLED allele, bottom, is a tandem
repeat of 212 bp (horizontal arrow) with a 10 bp deletion (not
shown). TALENs were developed to specifically target the HORNED
allele (vertical arrow) which could be repaired by homologous
recombination using the POLLED HDR plasmid. Panel b) Representative
images of colonies with homozygous or heterozygous introgression of
POLLED. Three primer sets were used for positive classification of
candidate colonies: F1+R1, F2+R2 and F, 1+P (POLLED specific).
Identity of the PCR products was confirmed by sequencing F1+R1
amplicons.
[0104] FIG. 36: A plot of experimental data generated for
evaluation of transfected mRNA as a source of TALENs. TALENs were
introduced into fibroblasts encoded by either unmodified mRNA,
modified mRNA (mod mRNA) or plasmid DNA (pDNA). Two quantities of
each TALEN preparation were transfected into cells subsequently
cultured 3 days at 30.degree. C. or 37.degree. C. prior to analysis
of indels, reported as % NHEJ.
[0105] FIG. 37A: A plot showing that an mRNA source of TALENs
stimulated efficient and consistent HDR using an oligo donor. Each
chart displays results of targeting a specific locus in fibroblasts
(e.g., ssIL2RG; "ss" for Sus scrofa and "bt" for Bos taurus) using
oligo donor templates and TALENs delivered as plasmid DNA or mRNA.
(Insets) Diagrams of the oligo templates, in which the shaded boxes
represent the TALEN-binding site and the spacers are shown in
white. Each oligo contains either a 4-bp insertion (ins4) or
deletion (del4) that introduces a novel restriction site for RFLP
analysis. Presumptive BMs replace the conserved -1 thymidine
(relative to the TALEN-binding site) with the indicated nucleotide.
Fibroblasts were transfected with either TALEN-encoding plasmids (3
.mu.g) or mRNA (1 .mu.g) along with 3 .mu.M of their cognate
oligo-homologous template. Cells were then incubated at 37.degree.
C. or 30.degree. C. for 3 d before expansion at 37.degree. C. until
day 10. TALEN activity was measured by the Surveyor assay at day 3
(Day3 Surveyor), and HDR was measured at days 3 and 10 by RFLP
analysis (Day3% HDR and Day10% HDR). Each bar displays the average
and SEM from three replicates.
[0106] FIG. 37B: A plot of experimental data generated to evaluate
kinetics of TALEN induced HDR with oligonucleotide templates. Cells
were transfected with either TALEN-encoding mRNA or plasmid DNA and
oligos with 4 base pair insertions targeting LDLR or APC genes.
Panel a) RFLP analysis on cell populations at indicated time
points. Panel b) Results from panel a, were quantified by
densitometry and the averages were plotted as a function of time
with SEM (n=3). HDR signal first appears 12 hours post-transfection
and accumulates over time.
[0107] FIG. 38: A plot of experimental data generated to evaluate
influence of mutation type on the frequency of HDR. Panel a) The
wildtype ssLDR (SEQ ID NO:241) and sequence of five oligos used to
target ssLDLR: (from top to bottom: SEQ ID NOS: 242, 243, 244, 245,
and 246). TALEN binding sites are indicated in boxed text and the
novel BamHI site is underlined. SNPs including BMs and insertions
are circled. Panel b) Cells were transfected with LDLR2.1 TALEN
mRNA (1 .mu.g) and oligos (2 .mu.M final). HDR at day 3 was
determined by RFLP analysis and the average with SEM (n=3) was
plotted. Panel c) Cattle cells were transfected with btRosa1.2
TALEN mRNA and either 41_mloxP or 60_loxP oligos (2 .mu.M final).
The numbers 41 and 60 refer to the number of homologous bases. Each
oligo contains a 34 bp loxP site, either a modified (mloxP) or wild
type (loxP) version, in the center of the spacer.
[0108] FIG. 39: CRISPR/Cas9 mediated HDR to introgress the p65
S531P mutation from warthogs into conventional swine. Panel a) The
S531P missense mutation is caused by a T-C transition at nucleotide
1591 of porcine p65. The S-P HDR template includes the causative TC
transition mutation (oversized text) which introduces a novel XmaI
site and enables RFLP screening. Panel b) Cells were transfected
with S-P-HDR oligos (2 .mu.M), two quantities of plasmid encoding
hCas9 (0.5 g or 2.0 .mu.g); and five quantities of the G2A
transcription plasmid (0.05 to 1.0 .mu.g). Cells from each
transfection were split 60:40 for culture at 30 and 37.degree. C.
respectively for 3 days before prolonged culture at 37.degree. C.
until day 10. Surveyor assay revealed activity ranging from 16-30%.
Panels c and d) RFLP analysis of cells sampled at days 3 and 10.
Expected cleavage products of 191 and 118 bp are indicated by black
arrows. The two gRNA sequences are P65_G1S (SEQ ID NO:247) and
P65_G2A (SEQ ID NO:248). The wild type porcine p65 is SEQ ID
NO:249, shown in alignment with the homology directed repair (HDR)
template S-P-HDR (SEQ ID NO:250). The left TALEN sequence and right
TALEN sequence to bind p65 DNA are SEQ ID NOs: 251 and 252,
respectively.
[0109] FIG. 40: Experimental data for comparison of TALENs and
CRISPR/Cas9 mediated HDR. Panel a) APC14.2 TALENs (SEQ ID NOS:253
and 254) and the gRNA sequence APC14.2 G1a (SEQ ID NO:255) are
shown relative to the wild type APC sequence (SEQ ID NO:256).
Below, the HDR oligo (SEQ ID NO:257) is shown which delivers a 4 bp
insertion (boxed text) resulting in a novel HindIII site. Cells
were transfected with HDR template, and TALEN mRNA, plasmid DNA
encoding hCas9 and the gRNA expression plasmid; or mRNA encoding
hCas9 plus the gRNA expression plasmid, cultured at either 30 or
37.degree. C. for 3 days before expansion at 37.degree. C. until
day 10. Panel b) Charts displaying RFLP and Surveyor assay
results
[0110] FIG. 41: Experimental data for SNP introgression using oligo
donors. Panel a) is a plot of maintenance of HDR alleles with or
without blocking mutations (BMs) for pig LDLR and GDF8. Each oligo
had the same SNPs/restriction 313 site plus or minus BMs. Average
homologous recombination and SEM (n=3) is shown. Panel b) shows
results for introgression of myostatin C313Y into Wagyu
fibroblasts. The C313Y missense mutation is caused by a G-A
transition (indicated by oversized text) at nucleotide 938 of
bovine myostatin. The HDR template (labeled donor, SEQ ID NO:258),
also includes a T to C transition (circled) to introduce a novel
EcoRI site for RFLP screening. Two left TALENs were designed
against the locus, btGDF83.6-G (SEQ ID NO:259), targeting the wild
type alelle (Wt) (SEQ ID NO:260), and btGDF83.6-A (SEQ ID NO:261),
targeting the mutant allele (C313Y); both share a common right
TALEN (SEQ ID NO:262). Transfection, culture and measurement were
conducted as above. The average and SEM for btGDF83.6-G (n=30) and
btGDF83.6-A (n=5) represent twelve and three biological replicates,
respectively. A two-sided student's t-test was used to compare
averages between groups; the p values are indicated.
[0111] FIG. 42: A plot that shows results for sequence analysis of
TALEN stimulated HDR alleles. The count of perfect, intended HR
reads versus the wild type reads is plotted for insertion (panel a)
and SNP alleles (panel b). The target locus, time point and whether
or not BMs were included in the oligo are indicated. Panel c).
Reads from btGDF8 and p65 sorted for incorporation of the target
SNP and classified as intended (iSNP) versus those with an
additional mutation (iSNP+Mut) and plotted against the total number
of reads.
[0112] FIG. 43: Results of sequence analysis of HDR alleles.
Sequencing reads containing the correct insertion (Panel a) or SNP
allele (Panel b) were analyzed for incorporation of BM. The target
locus, time point and whether or not BMs were included in the oligo
are indicated below each graph. Panel c). The data of FIG. 13 panel
c was further classified by mutation type and compared. Some reads
contained only the iSNP, others had a concomitant indel
(iSNP+indel), or a concomitant unintended SNP (iSNP+uSNP).
[0113] FIG. 44: Experimental data for multiple SNPs placed in the
TALEN DNA-binding site to stabilize HDR alleles in the EIF4GI gene.
Panel a) shows a portion of wild type EIF4GI Wt-NL (SEQ ID NO:263)
and a pair of TALENs (SEQ ID NOS: 264 and 265) designed to cut the
wild type EIF4GI to stimulate homologous recombination. Also
aligned to the Wt sequence is the core sequence (SEQ ID NO:266) of
the donor oligo, DF-HDR, used to introduce three SNPs (underlined
oversized letters) into the genome. The third SNP creates a novel
EagI restriction site that was used for RFLP analysis. Pig
fibroblasts were transfected with EIF4GI14.1 TALEN mRNA (2 g) and
DF-HDR (2.mu.M) and then cultured at 30.degree. C. for 3 days prior
to analysis and colony propagation. Panel b) shows RFLP analysis on
population three days post transfection. Expected product sizes of
344, 177 and 167 bp are indicated by filled triangles. Panel c)
shows RFLP assay on isolated cellular clones. Day 3 cells were used
to derive monoclonal colonies through dilution cloning. An example
of colonies with heterozygous (open triangles) or homozygous
(filled triangles) HDR alleles are indicated.
[0114] FIG. 45: A plot of data for hypothermic treatment
maintenance of SNP HDR alleles. Pig fibroblasts were transfected
with TALEN mRNA (1 g) and oligos (3.mu.M). Cells from two
independent transfections were pooled for each replicate and evenly
distributed into six wells of a 6-well plate and cultured at
30.degree. C. Samples were collected from these populations for
RFLP analysis on days 1-7 (minus day 6, 1D to 7D along X-axis)
post-transfection and the remaining cells were transferred to
37.degree. C. Samples for each condition were collected again at
day 12 for RFLP analysis. The average HDR and SEM (n=3) is shown at
the initial collection and once again at day 12.
[0115] FIG. 46: Experimental results for TALENs made with
intentional RVD mismatches to improve frequency of correct alleles
when introducing a SNP. Panel a) shows a TALEN pair (caCLPG 1.1,
SEQ ID NOs: 267-270, top to bottom, left to right) designed to
target the caCLPG region. Oligo driven HDR was utilized to
introduce the desired Adenine to Guanine SNP (the targeted Adenine
is boxed). The desired SNP allowed genotyping by a loss of an AvaII
restriction site. Each TALEN monomer is indicated in shading above
their respective binding locations. Panel b) A caCLPG wildtpe
sequence is shown (SEQ ID NO:271). Each allele of single-cell
derived colonies that were resistant to AvaII were sequenced
(fourteen sequences with SEQ ID NOS: 272-277, 279, 278 and 280-285,
from top to bottom). All of the alleles that contained the SNP of
interest (boxed) also contained deletions (marked with dashes in
the AvaII Resistant Allele sequences) or insertions (marked with
dashes in the WT sequence). In panel c), intentional mismatches
(italicized circled text) were introduced into the RVD sequence.
The desired SNP (boxed) was in the right monomer of the TALEN.
Panel d) shows TALEN activity as measured via a Cell assay. The
percent of non-homologous end joining (% NHEJ) is indicated for
each was measured. Panel e) shows both an alignment of a caCLPG
wildtpe sequence is shown (SEQ ID NO:294) with sequenced alleles of
AvaII-resistant single-cell derived colonies produced with caCLPG
1.1c (six sequences, with SEQ ID NOS: 295, 298 and 297-300, top to
bottom). The desired SNP is boxed. Colony 37 and 78 were
heterozygous for the desired SNP and showed no additional indels.
Colony 142 was homozygous for the desired SNP, but contained a 4 bp
insertion on one allele.
[0116] FIG. 47: Results for experiments to introgress a SNP with
and without a mismatch in the targeting endonuclease. Panel a)
shows a schematic of the bovine DGAT sequence around K323A (SEQ ID
NOs: 301 and 302). The grey arrows represent the TALEN monomers
where they bind to the DGAT sequence. The left arm consists of 16
RVDs, the right arm consists of 15 RVDs, and the spacer is 16 base
pairs long. The GC and gga gct, boxed, are the targeted base pairs.
The DGAT oligo converts the GC to an AA to create the desired DGAT
mutant. As a marker for HDR, the boxed GGGAGC is converted to
AAGCTT that creates a novel HindIII restriction site. Since this
change is in the spacer, it should not affect TALEN binding as to
not interfere with the intentional mismatch results. Panel b) DGAT
TALEN RVD sequences. btDGAT 14.2 contains no intentional mismatches
in the RVDs. btDGAT 14.4, 14.5, and 14.6 each contain one
intentional RVD mismatch at either position 1, 3, or 5 of the left
TALEN monomer (circled). Panel c) Bovine fibroblasts were
transfected with 1 ug of talen and 0.4 nmoles of oligo. Three days
after transfection cells were lysed, the DGAT sequence was
amplified by PCR, digested with HindIII and ran on an acrylamide
gel. The percent efficiency of HDR was determined by densitometry
(HR). Panel d) Sequence analysis of colonies produce with the
original 14.2 TALENs. Of twelve colonies, none that were positive
for the HindIII RFLP contained the desired mutation due to indels
overlapping the site. (From top to bottom, SEQ ID NOs: 311 to 319,
321). Panel e) Colonies derived from TALENs 14.5 and 14.6 produced
the correct DGAT mutation and HindIII restriction site. These two
TALEN pairs produced a total of two homozygous (HH) and three
heterozygous (Hh) colonies. TALEN 14.4 did not produce any colonies
with the correct DGAT mutation (data not shown), from top to
bottom, SEQ ID NOs: 322 to 327.
[0117] FIG. 48: Sets forth the process of TALEN-HDR/RMCE. The
floxed cassette is transfected along with TALENs compatible with
the oligo, the loxP oligo and a source of Cre recombinase. The bar
graph shows the number of puromycin resistant colonies produced by
this method when YFC-Cre versus mCherry was included in the
transfection. To confirm targeting to the SRY locus, PCR was
conducted across the predicted junction (shown) will result in a
370 bp product. This product is apparent only when Cre is
included.
[0118] FIG. 49: An illustration of a process of making and using
animals genetically modified for control of maturation.
[0119] FIG. 50: Confirmation of Belgian Blue introgression by
sequencing. The schematics of Wagyu wild-type GDF8 and the Belgian
Blue template (BB-HDR) are shown. PCR was conducted using primers
located outside of the homology arms (c and d) on five PCR positive
colonies followed by cloning and sequencing with primer b'.
Comparison to the wild-type sequence revealed the expected
11-basepair deletion characteristic the Belgian Blue allele
(heterozygous) in 4 of 5 colonies.
[0120] FIG. 51: Introgression of naturally occurring alleles from
one species to another using mRNA encoded TALENs and ssODNs. The
Piedmontese Myostatin allele C313Y was introgressed into
Ossabaw.
[0121] FIG. 52: Modification of targeted genes. Each chart displays
results of targeting a specific locus in fibroblasts (e.g.,
ssIL2RG; "ss" for Sus scrofa and "bt" for Bos taurus). (Insets)
Diagrams of the oligo templates, in which the shaded boxes
represent the TALEN-binding site and the spacers are shown in
white. HDR was measured at days 3 and 10 by RFLP analysis (Day3%
HDR and Day10% HDR). Each bar displays the average and SEM from
three replicates.
[0122] FIG. 53: Sequence analysis of TALEN stimulated HDR alleles.
PCR amplicons flanking the target site (200-250 bp total) derived
from TALEN mRNA and oligo transfected cell populations were
sequenced by ILLUMINA sequencing. Total read count ranged from
10,000 to 400,000 per sample. The count of perfect, intended HR
reads versus the wild type reads is plotted for insertion (panel a)
and SNP alleles (panel b). The target locus, time point and whether
or not BMs were included in the oligo are indicated below. Panel
c). Reads from btGDF8 and p65 were sorted for incorporation of the
target SNP and then classified intended (iSNP) versus those with an
additional mutation (iSNP+Mut) and plotted against the total number
of reads.
[0123] FIG. 54: Cloned pigs with HDR alleles of DAZL and APC. (A)
RFLP analysis of cloned piglets derived from DAZL- and APC-modified
landrace and Ossabaw fibroblasts, respectively. Expected RFLP
products for DAZL founders are 312, 242, and 70 bp (open
triangles), and those for APC are 310, 221, and 89 bp (filled
triangles). The difference in size of the 312-bp band between WT
and DAZL founders reflects the expected deletion alleles. (B)
Sequence analysis confirming the presence of the HDR allele in
three of eight DAZL founders, and in six of six APC founders. BMs
in the donor templates (HDR) are indicated with arrows, and
inserted bases are enclosed in blocks. The bold text in the top WT
sequence indicates the TALEN-binding sites. FIG. 54 panel (B)
discloses SEQ ID NOS 182-195, respectively, in order of
appearance.
[0124] FIG. 55: A schematic of porcine GPR54 and the gene targeting
strategy for knockout is depicted in panel a. TALENs designed to
bind exon 3 (underlined text) were co-transfected with an
oligonucleotide homology template (HDR) designed to introduce a
premature stop codon and a HindIII restriction site. FIG. 55 panel
a discloses SEQ ID NOS 196 and 519, respectively, in order of
appearance. Panel b: 2 micrograms of TALENs encoding mRNA plus 0.2
nMol of the HDR template were transfected into pig fibroblasts that
were grown as colonies and analyzed for homology dependent repair
by HindIII RFLP assay. PCR results are shown; each lane represents
one colony. Cleavage products of 231 and 158 bp are indicative of
homology dependent repair. Colonies with the parent band of 389 bp
are classified as heterozygous (open triangle) and those without
are classified as homozygous (filled triangle) for the HDR,
knockout allele.
[0125] FIG. 56: Panel a: Nucleotide and deduced translated amino
acid sequence of mRNA encoding tilapia kisspeptin. The structural
organization of the kiss gene is conserved and contains two coding
exons, one encoding both the signal peptide and part of the
kisspeptin precursor, the other encoding the remainder of the
precursor including the kisspeptin-10 sequence. The position of the
intron is indicated by a triangle glyph. The location of the
forward and reverse primers for PCR amplification of the target
region (442 bp) are shown. The binding sites for the two engineered
pairs of TALENs, Kiss1.1a and Kiss1.1b are indicated in black and
gray boxes. FIG. 56 panel a discloses SEQ ID NOS 198 and 564-565,
respectively, in order of appearance. Panel b shows a schematic
representation of the targeted kiss genomic region showing the
location of the kisspeptin-10 biologically active peptide and each
kiss1.1a and 1b TALENs recognition sites. PCR (442 bp) and qPCR
primer pairs (138 bp amplicon) used for analysis of indels are
shown as well.
[0126] FIG. 57: Panel a: Nucleotide and deduced translated amino
acid sequence of mRNA encoding tilapia GPR-24 mRNA. The structural
organization of the kissr gene is conserved and contains five
coding exons. The positions of all four introns are indicated by a
triangle glyph. The KissRE2 and KissRE3 TALENs targeted loci are
located in the coding exon 2 (white boxes) and 3 (gray boxes)
respectively. The location of the sense Left and antisense Right
TALENs recognition sites are shown in boxes. FIG. 57 panel a
discloses SEQ ID NOS 528-529 and 566, respectively, in order of
appearance. Panel b shows a schematic representation of the tilapia
GPR-24 genomic region showing the location of the introns (Stroked
goalpost), the coding exons 2 and 3 (black arrows) containing the
kissRE2 and RE3 loci (white boxes). The location primers used for
PCR and qPCR analysis and the size of the corresponding amplicons
are shown as well.
[0127] FIG. 58: Melt analysis of 100-120 bp qPCR product containing
the kiss and kissRE3 loci. Panels a and b show melting curves of
amplicons generated from the gDNA extracted from the fin of fish
treated kiss1.1a and kissRE3 TALENs pairs. The plain arrows point
to melting profiles (panel a) or (panel b) that were significantly
different than those obtained from untreated fish (dotted arrows)
and correspond to candidate mutant fish kiss #41, RE3 #1, 4, 6 and
11. Panel c: A 442 bp genomic segment containing the targeted Kiss
loci was PCR amplified from--TALEN treated fish #41. The PCR
product was cloned into TOPO 2.1 TA vector, and transformant
colonies were hand-picked for direct QPCR analysis. The plain
arrows point to selected melt profiles obtained from colonies
containing different deletions at the kiss loci. Panel d: To better
visualized the varied mutations cloned, we graphed our QPCR colony
screen on a scatter plot of Cts versus melt temperature, where each
clone is represented by a data plot (x, y) with x representing its
Ct and y representing its melt temperature. The graph represent
colonies containing the 702 bp PCR fragment amplified from Fish RE3
#4. Melt temperature below that of a wild type sequence all
contained the kissRE3 amplicon with varied deletions at the target
site. Cts: Cycle thresholds.
[0128] FIG. 59: Description of somatic mutations induced by
engineered TALENs at the kiss gene (site kiss1.1a) (panel a) and
kissR gene site (KissRE3) (panel b). The wild-type sequences are
shown at the top of each panel with the sense left and antisense
right TALEN recognition element sites shown in bold highlighted in
dark gray and the sense spacer highlighted as underlined text.
Deletions are shown as dashes and insertions as lower case letters
highlighted in light gray. The net change in length caused by each
indel mutation is to the right of each sequence (+, insertion; -,
deletion). A few alterations have both a deletion and an insertion
of sequence. The number of times each mutant allele was isolated is
shown in brackets. FIG. 59 panel a discloses SEQ ID NOS 202,
530-532 and 206-211 and FIG. 59 panel b discloses SEQ ID NOS 212,
533, 214-216 and 534-535, all respectively, in order of
appearance.
[0129] FIG. 60: Panel a: Selected sequencing chromatography of PCR
products from two sibling progeny in line KissRE3 #11. These graphs
indicate the presence of mutation reading simultaneously a kissRE3
mutant and a WT allele. Boxes indicate matching nucleotides on the
mutant and WT alleles and arrow points to the location where
sequences become divergent and thus where these deletion begin. To
characterize the mutation we analyzed the pattern of unique
nucleotide reads in the sequence (where the chromatograph show
above background non duplicate nucleotide reads). By shifting the
WT sequence and increased size deletion sequences, we found that a
7 pb and 5 bp deletions reproduce the pattern of single nucleotide
reads on these chromatograph. FIG. 60 panel a discloses SEQ ID NOS
219, 222, 220, 536 and 537, respectively, in order of appearance.
Panel b: Description of all inherited indel mutations induced by
engineered TALENs at the kiss gene (kiss1.aa site, top) and kissr
gene (KissRE3 site, bottom). The wild-type sequences are shown at
the top with the sense left and antisense right TALEN recognition
elements shown in bold letter highlighted in dark gray and the
sense spacer highlighted as underlined text. Deletions are shown as
dashes. The net change in length caused by each indel mutation is
to the right of each sequence (-, deletion). The number of times
each mutant allele was isolated is shown in brackets. FIG. 60 panel
b discloses SEQ ID NOS 202, 208, 226, 212, 228, 214, 230-232 and
538, respectively, in order of appearance. Panel c: Description of
the most severe lesions found at the kiss and kissRE3 sites. The 18
nt deletion at the kiss1.1a loci result in the loss of 6AA
(underlined) 3 of which are from the core sequence of the
kisspeptin-10 active peptide (highlighted in gray). The 7 nt
deletion at the kissRE3 loci (underlined text) result in
significant alteration of the gene product with two AA substitution
immediately followed by a stop codon. The resulting protein is
C-terminally truncated by 215 AA. FIG. 60 panel c discloses SEQ ID
NOS 234-237, 539 and 239, respectively, in order of appearance.
[0130] FIG. 61: Panel a) Schematic of the bovine horned/polled
locus. TALENs were designed to cut the horned variant where
indicated by arrowheads. Panel b) The sense strand sequence of four
TALENs. Panel c) Surveyor assay of horned Holstein fibroblasts
cells three days post transfection with mRNA encoding each TALEN
pair. TALEN ID and incubation temperature post transfection are
indicated above the gel. Sequence identifiers as follows: HP1.1
left and right (SEQ ID NOs: 240 and 347); HP1.2 left and right (SEQ
ID NOS: 348 and 149); HP1.3 left and right (SEQ ID NOS: 150 and
151); HP1.4 left and right (SEQ ID NOS: 152 and 153).
[0131] FIG. 62: TALEN-mediated introgression of POLLED. Panel A) A
schematic of the strategy to introgress the Polled allele into
Holstein (HORNED) cells. The POLLED allele, bottom, is a tandem
repeat of 212 bp (red arrow) with a 10 bp deletion (not shown).
TALENs were developed to specifically target the HORNED allele
(green vertical arrow) which could be repaired by homologous
recombination using the POLLED HDR plasmid. Panel B) Representative
images of colonies with homozygous or heterozygous introgression of
POLLED. Three primer sets were used for positive classification of
candidate colonies: F1+R1, F2+R2 and F1+P (POLLED specific).
Identity of the PCR products was confirmed by sequencing F1+R1
amplicons.
[0132] FIG. 63: Example of polled conversion in an isolated colony.
Individual colonies were propagated from cell populations described
in FIG. 2. Each colony was analyzed by the PCR method described in
FIG. 2. Clone 3 has a product at both 389 and 591 bp (arrow)
indicative of a heterozygous conversion to the polled allele. The
Repair Template used was 591 residues in length.
[0133] FIG. 64: Panel a) Schematic to convert a horned allele to a
polled allele. HP1.3 TALENs plus a short repair template are
introduced into horned cells. The repair template was generated by
PCR from polled Angus genomic DNA; homology lengths are indicated.
Panel b) PCR assessment of polled conversion in horned Holstein
fibroblasts transfected with 2 .mu.g of TALEN mRNA+500 ng of ssDNA
coated with Gal4:RecA. Each lane/PCR reaction consists of .about.3
cell equivalents diluted from a transfected population. PCR using
primers btHP-F1 and btHP-R1 from horned cells results in a product
of 389 bp. Conversion to polled results in a net insertion of 202
base pairs; thus the PCR product of the same primers results in a
591 bp product (arrow in left margin). The number of reactions with
products indicative of polled conversion is shown in the upper
right corner. Panel c) PCR assessment of polled conversion in
horned Holstein fibroblasts transfected with 2 ug of TALEN
mRNA+1,500 ng of ssDNA. The number of reactions with products
indicative of polled conversion is shown in the upper right
corner.
[0134] FIG. 65: Comparison of TALENs and CRISPR/Cas9 mediated HDR
at porcine APC. Panel a) APC14.2 TALENs (SEQ ID NOS: 154 and 155)
and the gRNA sequence APC14.2 G1a (SEQ ID NO: 157) are shown
relative to the wild type APC sequence (SEQ ID NO: 156). Below, the
HDR oligo (SEQ ID NO: 158) is shown which delivers a 4 bp insertion
resulting in a novel HindIII site. Pig fibroblasts transfected with
2 .mu.M of oligo HDR template, and either 1 .mu.g TALEN mRNA, 1
.mu.g each plasmid DNA encoding hCas9 and the gRNA expression
plasmid; or 1 .mu.g mRNA encoding hCas9 and 0.5 .mu.g of gRNA
expression plasmid, were then split and cultured at either 30 or
37.degree. C. for 3 days before expansion at 37.degree. C. until
day 10. Panel b) Charts displaying RFLP and Surveyor assay
results.
[0135] FIG. 66: Schematic of the bovine PRLR gene (SEQ ID NO: 525)
and position within the genome. A mutation that leads to truncation
of the PRLR gene is cretaed, which corresponds to the SLICK 1
allele. The CG.fwdarw.G mutation causes a frame shift and
termination at amino acid 461 (Trunc461). The Xba1 site was
included in one of the HDR template designs to enable RFLP (SEQ ID
NOS: 383 and 384).
[0136] FIG. 67: Schematic of the bovine PRLR gene (SEQ ID NO: 525).
Holstein cells were transfected with 1 .mu.g PRLR9.1 TALENs along
with 0.4 nmol of the HDR template, PRLR9.1 (SLICK1) Xba1 RE site
(SEQ ID NO: 383). Three days after transfection, the population of
cells was screened for TALEN activity by Cell and RFLP assay (left
gel). Remaining cells were re-plated for derivation of individual
colonies and screened by RFLP assay (right gel). Many candidates
were identified, and sequence analysis revealed that clones 11 and
93 were positive for precise introgression of SLICK1.
[0137] FIG. 68: Pictures of live POLLED Holstein calves.
[0138] FIG. 69: Pictures of a POLLED Holstein calf eye showing an
extended eyelash length indicative of a homozygous POLLED
phenotype.
[0139] FIG. 70: Comparison of the eyelashes of a horned bull (A) as
compared to POLLED cattle (B-E) with the same allele introgressed
into the POLLED Holstein seen in FIGS. 68 and 69 (Allais-Bonnet et
al., (2013) Novel Insights into the Bovine POLLED Phenotype and
Horn Ontogenesis in Bovidae. PLoS ONE 8(5):
e63512.doi:10.1371/journal.pone.0063512).
[0140] FIG. 71: Picture of an Angus/Holstein crossbreed (see
http://albertachickensetc.punbb-hosting.com/viewtopic.php?id=15272).
[0141] FIG. 72: Chromosome 1: Celtic POLLED allele homology
template. 202 bp POLLED allele present in Celtic Allele double
underlined, 212 bp Horned allele (SEQ. ID NO: 526) includes
underlined and double underlined sequence. The double underlined
region is deleted to create POLLED allele. The 5' homology arm
(before the double underlined sequence) is indicated by the box, 3'
homology arm (after the double underlined sequence) is indicated by
the box.
[0142] FIG. 73: CRISPR/Cas9 target sequence, ssKiss1 Exon 2 and the
repair template ssKiss1 Ex2.9 for porcine fibroblast Kiss knockout
experiment. FIG. 73 discloses SEQ ID NOS 540-541, 394 and 542-547,
respectively in order of appearance.
[0143] FIG. 74: CRISPR/Cas9 target sequence, ssKiss1 Exon 2, and
the repair template ssKiss1c.2.9 Blocking HDR designed to be
inserted by HDR within ssKiss1 Exon 2 for porcine fibroblast Kiss
knockout experiment. FIG. 74 discloses SEQ ID NOS 540-541 and
548-553, respectively, in order of appearance.
[0144] FIG. 75: Efficiency of blocking HDR oligo in fibroblast
population. The blocking oligo changes the CGG PAM to CAG and
introduces a silent mutation to generate an AcuI restriction site.
The gel shows the results of RFLP analysis, indicating the
inclusion of the AcuI restriction site. FIG. 75 discloses SEQ ID
NOS 540-541 and 554-557, respectively, in order of appearance.
[0145] FIG. 76: Kiss swine fibroblast transfection population data
without the Blocking HDR oligo. Panel A shows the RFLP analysis of
male pig fibroblasts next to transfected (+) or non-transfected (C)
controls. Cells were transfected with a combination of IDT Alt-R
crRNA:Tracer RNA complex, Cas9=Alt-R HiFi Cas9 nuclease (protein)
and ssKiss1 c.2.9 HD3 HDR. Results show RFLP analysis 3 days after
transfection. Panel B shows RFLP analysis of Female pig fibroblasts
transfected with IDT Alt-R crRNA:Tracer RNA complex, Cas9=Alt-R
HiFi Cas9 nuclease (protein) with and without the ssKiss1 c.2.9 HD3
HDR template. Results show RFLP analysis 3 days after transfection.
Cells from these populations were plated at low density for
isolation of single cell derived colonies and evaluated for
editing. Select homozygous HDR clones were confirmed by Sanger
Sequencing and used for cloning founder animals.
[0146] FIG. 77: Kiss Colony RFLP Image. Individual colonies were
propagated from the transfected population above and subjected to
RFLP analysis for identification of mutant colonies. Three outcomes
were apparent: (1) Wild Type (WT) RFLP result, (2) Mutant RFLP
result (this population was sequenced and used in bi-allelic mutant
animals), (3) Heterozygous RFLP result. The letter A indicates
another example mutant result which was not used in cloning.
[0147] FIG. 78: Confirmation of HDR in RFLP positive colonies by
Sanger Sequencing. Row 1 shows the consensus sequence from the
alignment. Row 2 shows the predicted sequence from Ensembl. Row 3
shows sequence of untransfected kiss1 cells. Rows 4-6 show sequence
of from colonies isolated after transfection with the gene editing
reagetents. These are examples of colonies with homozygous HDR with
the ssKiss1 c.2.9 HD3 HDR as indicated by the 8 bp insertion. The
colony represented in row 5 was used for production of founder
animals by cloning. FIG. 78 discloses SEQ ID NOS 393, 389 and
558-561, respectively, in order of appearance.
[0148] FIG. 79: Confirmation of Kiss1 knockout by HDR in pig
zygotes. 25 ng/.mu.l gRNA; 50 ng/.mu.l Cas9; 33.3 ng/.mu.l HD3 HDR;
66.7 ng/.mu.l Blocking HDR Microinjection: n=18. The injected
zygotes were cultured to blastocyst stage prior to whole genome
amplification, PCR over the target site, and Sanger Sequencing.
Amplicons were sequenced using Sanger Sequencing followed by
analysis using ICE software (Synthego). Results indicate that about
22% of injected zygotes were heterozygous (31-60% mutant). Guide
RNA is IDT Alt-R crRNA: Tracer RNA complex, Cas9=Alt-R HiFi Cas9
nuclease (protein). HDR templates are IDT ssDNA
oligonucleotides.
[0149] FIG. 80: Confirmation of Kiss1 knockout by HDR in pig
zygotes. 25 ng/.mu.l gRNA; 25 ng/.mu.l Cas9; 26.7 ng/.mu.l HD3 HDR;
53.3 ng/.mu.l Blocking HDR Microinjection: n=11. The injected
zygotes were cultured to blastocyst stage prior to whole genome
amplification, PCR over the target site, and Sanger Sequencing.
Amplicons were sequenced using Sanger Sequencing followed by
analysis using ICE software (Synthego). Results indicate that about
9% of injected zygotes were heterozygous (31-60% mutant). Guide RNA
is IDT Alt-R crRNA: Tracer RNA complex, Cas9=Alt-R HiFi Cas9
nuclease (protein). HDR templates are IDT ssDNA
oligonucleotides.
[0150] FIG. 81: Development of a gene edit cell line of GPR54 knock
out pig fibroblasts. A PCR-RFLP assay was run to confirm that a
frame shift and premature stop codon were successfully integrated
into Exon 3 of the GPR54 gene using TALENS. FIG. 81 discloses SEQ
ID NOS 196 and 562-563, respectively, in order of appearance.
[0151] FIG. 82: Confirmation of the GPR54 knockout from FIG. 81 in
pig embryos produced by somatic cell transfer and grown to piglets
after impregnanton within sows.
DETAILED DESCRIPTION OF THE INVENTION
[0152] The inventors have developed precise, high frequency editing
of a variety of genes in various cells and/or animals that are
useful for agriculture, for research tools, or for biomedical
purposes. These livestock gene-editing processes include TALEN- and
CRISPR/Cas-stimulated homology-directed repair (HDR) using plasmid,
rAAV and oligonucleotide templates. Nucleases such as CRISPR/Cas,
TALENs, and zinc finger nucleases are used to target specific
nucleic acid sequences. Transcription activator-like (TAL) effector
sequences can be assembled to specifically bind DNA targets by
assembling sequences of repeat variable diresidues (RVDs). Fusion
proteins of TAL effectors with a nuclease can make targeted
double-stranded breaks in cellular DNA that can be used to make
specific genetic modifications to cells.
[0153] Traditional breeding programs based on animal mating or
artificial reproductive techniques involve mixing many genes in the
hope of ultimately producing a good combination of genes that
create or combine desirable traits. Transgenic techniques can
accelerate traditional breeding processes. In some instances,
however, transgenic processes while perhaps an overall improvement,
are nonetheless slow, costly, and/or labor-intensive. Low
efficiencies and unpredictability in results have slowed some
efforts in the field. Further, in traditional breeding programs,
processes that make a change only at a single intended genomic site
are not available.
[0154] Gene editing tools such as targeting endonucleases are
useful for making genetically modified animals. Using these tools
to change a native allele at only one base is difficult or
impossible using conventional processes. New techniques are
described herein for making these edits at a single base, or a
plurality of single-base edits. These processes are useful for
introgression of an allele that differs only by a single nucleotide
polymorphism (SNP) or a plurality of SNPs. The ability to
introgress SNPs from one breed or species into another is believed
to create important new opportunities. The term SNP refers to a
difference of one base at the same relative site when two alleles
are aligned and compared; herein, the term is also used in some
contexts to mean a single base change.
[0155] Disclosed herein are processes to make transgenic animals
that have changes only at an intended site. Additionally, the
processes can make specifically intended changes at the intended
site. In some instances, it is not necessary to remove other
changes resulting from problems like the use of linked-reporter
genes, or linked positive and negative selection genes, or random
transgene integration, as the inclusion of such features are
bypassed. Moreover, the processes can be used in the founder
generation to make genetically modified animals that have only the
intended change at the intended site. Other processes are also
disclosed that involve unlinked marker genes and the like. Some
embodiments use TALENs.
[0156] Compositions and methods of making higher animals, such as
swine or cows, with genetic modifications are set forth herein.
Some of these methods involve cloning from primary artiodactyl or
other livestock cells. Further, methods for identifying cells or
embryos that have been modified with TALENs are presented, as well
as processes for enriching the percentage of TALEN-treated cells or
embryos. Unexpectedly, it was observed that a genetic modification
of one chromosome by a TALEN often caused the complementary locus
of the other chromosome to also be modified by cellular
machinery.
[0157] Further, it was also discovered that TALENs could be used to
make gross chromosomal deletions (GCDs) at a plurality of sites.
FIG. 2 illustrates this approach, which involves a first TALEN pair
directed to a first locus and a second TALEN pair directed to a
second locus. It was also surprisingly discovered that inversions
of large chromosomal sequences could be created using pairs of
TALENs. One use of the inversions is the creation of artiodactyls
or other founder animals with fixed genetic traits, or the creation
of deletion strains.
[0158] Targeted endonuclease technologies, such as zinc finger
nucleases (ZFNs), TAL effector nucleases (TALENs) and clustered
regularly interspaced short palindromic repeats/CRISPR associated
endonuclease cas9 (CRISPR/Cas9) can be utilized to disrupt
gene-function by introducing insertions and/or deletions (indels)
into genomes of species, such as by non-homologous end-joining
(NHEJ). However, indels introduced by NHEJ are variable in size and
sequence which makes screening for functionally disrupted clones
arduous and does not enable precise alterations. TALEN or
CRISPR/Cas9 mediated homology-directed repair (HDR) supports the
introduction of defined nucleotide changes in lower eukaryotic
models including yeast, zebrafish and, very recently, mice. These
are models that allow for long-passage cells or primordial germ
cells to be modified to make transgenic animals.
[0159] Demonstrated herein is precise, high frequency editing of a
variety of genes in numerous working examples as exemplified in
pig, goat, and cattle genomes. In some embodiments, the gene edits
are indistinguishable from alleles that exist within a species or
clade and represent the first demonstration of marker-free,
non-meiotic allele introgression. High-efficiency and precise gene
editing was achieved in certain commercially important loci in the
genomes of livestock that are useful for agriculture, for research
tools, or for biomedical purposes.
[0160] These processes have expanded the livestock gene-editing
toolbox to include TALEN- and CRISPR/Cas9-stimulated
homology-directed repair (HDR) using plasmid, rAAV, and
oligonucleotide templates. Examples show that the bovine POLLED
allele was introgressed into horned Holstein fibroblasts. This
example demonstrates that various breeds of dairy cattle can be
created that do not have horns. And this change can be made without
disturbing other genes, or other parts of the genome, of the
animals or cells. Single nucleotide alterations or small indels
were introduced into other genes in pig, goat and cattle
fibroblasts using TALEN mRNA and oligonucleotide transfection with
efficiencies of 10-50% in populations. Several of the chosen edits
mimicked naturally occurring performance enhancing or disease
resistance alleles including, for the first time, alteration of
single base pairs (bp). Up to 70% of fibroblasts colonies
propagated without selection harbored the intended edits, of which
over one half were homozygous. These efficiencies are sufficiently
high that these changes can be made without reporters and/or
without selection markers. These methods demonstrate meiosis-free
intra- and inter-specific introgression of select alleles in
livestock cells, large mammals, and livestock for research,
agricultural and biomedical applications.
[0161] Sequences that are similar to, but differ somewhat from, the
particular sequences described herein may be used, such as for
generation of TALENs, guide RNAs, or homology-dependent repair
templates. For instance, in some cases, sequences may be used that
have at least 80% homology to the sequences described with
particularly herein. The term "homology," as used herein, generally
refers to calculations of "homology" or "percent homology" between
two or more nucleotide or amino acid sequences that can be
determined by aligning the sequences for optimal comparison
purposes (e.g., gaps can be introduced in the sequence of a first
sequence). The nucleotides at corresponding positions may then be
compared, and the percent identity between the two sequences is a
function of the number of identical positions shared by the
sequences (i.e., % homology=# of identical positions/total # of
positions.times.100). For example, if a position in the first
sequence is occupied by the same nucleotide as the corresponding
position in the second sequence, then the molecules are identical
at that position. The percent homology between the two sequences is
a function of the number of identical positions shared by the
sequences, taking into account the number of gaps, and the length
of each gap, which need to be introduced for optimal alignment of
the two sequences. In some embodiments, the length of a sequence
aligned for comparison purposes is at least about 80%, at least
about 85%, at least about 90%, at least about 91%, at least about
92%, at least about 93%, at least about 94%, at least about 95%, at
least about 96%, at least about 97%, at least about 98%, or at
least about 99%, of the length of the reference sequence. In some
cases, a sequence homology may be from about 70% to 100%. In some
cases, a sequence homology may be from about 80% to 100%. In some
cases, a sequence homology may be from about 90% to 100%. In some
cases, a sequence homology may be from about 95% to 100%. In some
cases, a sequence homology may be from about 80% to 99%. In some
cases, a sequence homology may be from about 90% to 99%. In some
cases, a sequence homology may be from about 95% to 99%. A
BLAST.RTM. search may determine homology between two sequences. The
two sequences can be genes, nucleotides sequences, protein
sequences, peptide sequences, amino acid sequences, or fragments
thereof.
Genetically Modified Animals
[0162] Animals may be modified using TALENs, zinc finger nucleases,
or other genetic engineering tools, including various vectors that
are known. A genetic modification made by such tools may comprise
inactivation of a gene. The term inactivation of a gene refers to
preventing the formation of a functional gene product. A gene
product is functional only if it fulfills its normal (wild-type)
functions. Materials and methods of genetically modifying animals
are further detailed in U.S. Ser. No. 13/404,662 filed Feb. 24,
2012, Ser. No. 13/467,588 filed May 9, 2012, and Ser. No.
12/622,886 filed Nov. 10, 2009 which are hereby incorporated herein
by reference for all purposes; in case of conflict, the instant
specification is controlling. The term trans-acting refers to
processes acting on a target gene from a different molecule (i.e.,
intermolecular). A trans-acting element is usually a DNA sequence
that contains a gene. This gene codes for a protein (or microRNA or
other diffusible molecule) that is used in the regulation of the
target gene. The trans-acting gene may be on the same chromosome as
the target gene, but the activity is via the intermediary protein
or RNA that it encodes. Inactivation of a gene using a dominant
negative generally involves a trans-acting element. The term
cis-regulatory or cis-acting means an action without coding for
protein or RNA; in the context of gene inactivation, this generally
means inactivation of the coding portion of a gene, or a promoter
and/or operator that is necessary for expression of the functional
gene.
[0163] Various techniques known in the art can be used to introduce
nucleic acid constructs into non-human animals to produce founder
lines, in which the nucleic acid construct is integrated into the
genome. Such techniques include, without limitation, pronuclear
microinjection (U.S. Pat. No. 4,873,191), retrovirus mediated gene
transfer into germ lines (Van der Putten et al. (1985) Proc. Natl.
Acad. Sci. USA 82, 6148-1652), gene targeting into embryonic stem
cells (Thompson et al. (1989) Cell 56, 313-321), electroporation of
embryos (Lo (1983) Mol. Cell. Biol. 3, 1803-1814), sperm-mediated
gene transfer (Lavitrano et al. (2002) Proc. Natl. Acad. Sci. USA
99, 14230-14235; Lavitrano et al. (2006) Reprod. Fert. Develop. 18,
19-23), and in vitro transformation of somatic cells, such as
cumulus or mammary cells, or adult, fetal, or embryonic stem cells,
followed by nuclear transplantation (Wilmut et al. (1997) Nature
385, 810-813; and Wakayama et al. (1998) Nature 394, 369-374).
Pronuclear microinjection, sperm mediated gene transfer, and
somatic cell nuclear transfer are particularly useful techniques,
as well as cytoplasmic injection, primordial germ cell
transplantation (Brinster), and blastocyst chimera production
whereby a germ cell is propagated in an embryo.
[0164] Typically, in embryo/zygote pronuclear microinjection, a
nucleic acid construct or mRNA is introduced into a fertilized egg;
1 or 2 cell fertilized eggs are used as the pronuclei containing
the genetic material from the sperm head and the egg are visible
within the protoplasm. Pronuclear staged fertilized eggs can be
obtained in vitro or in vivo (i.e., surgically recovered from the
oviduct of donor animals). In vitro fertilized eggs can be produced
as follows. For example, swine ovaries can be collected at an
abattoir, and maintained at 22-28.degree. C. during transport.
Ovaries can be washed and isolated for follicular aspiration, and
follicles ranging from 4-8 mm can be aspirated into 50 mL conical
centrifuge tubes using 18 gauge needles and under vacuum.
Follicular fluid and aspirated oocytes can be rinsed through
pre-filters with commercial TL-HEPES (Minitube, Verona, Wis.).
Oocytes surrounded by a compact cumulus mass can be selected and
placed into TCM-199 OOCYTE MATURATION MEDIUM (Minitube, Verona,
Wis.) supplemented with 0.1 mg/mL cysteine, 10 ng/mL epidermal
growth factor, 10% porcine follicular fluid, 50 .mu.M
2-mercaptoethanol, 0.5 mg/ml cAMP, 10 IU/mL each of pregnant mare
serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG)
for approximately 22 hours in humidified air at 38.7.degree. C. and
5% CO2. Subsequently, the oocytes can be moved to fresh TCM-199
maturation medium, which will not contain cAMP, PMSG or hCG and
incubated for an additional 22 hours. Matured oocytes can be
stripped of their cumulus cells by vortexing in 0.1% hyaluronidase
for 1 minute.
[0165] For swine, mature oocytes can be fertilized in 500 .mu.l
Minitube PORCPRO IVF MEDIUM SYSTEM (Minitube, Verona, Wis.) in
Minitube 5-well fertilization dishes. In preparation for in vitro
fertilization (IVF), freshly-collected or frozen boar semen can be
washed and resuspended in PORCPRO IVF Medium to 4.times.105 sperm.
Sperm concentrations can be analyzed by computer assisted semen
analysis (SPERMVISION, Minitube, Verona, Wis.). Final in vitro
insemination can be performed in a 10 .mu.l volume at a final
concentration of approximately 40 motile sperm/oocyte, depending on
boar. Incubate all fertilizing oocytes at 38.7.degree. C. in 5.0%
CO.sub.2 atmosphere for 6 hours. Six hours post-insemination,
presumptive zygotes can be washed twice in NCSU-23 and moved to 0.5
mL of the same medium. This system can produce 20-30% blastocysts
routinely across most boars with a 10-30% polyspermic insemination
rate. Linearized nucleic acid constructs can be injected into one
of the pronuclei, or e.g., transposons or cytoplasmic injection may
be used. Then the injected eggs can be transferred to a recipient
female (e.g., into the oviducts of a recipient female) and allowed
to develop in the recipient female to produce the transgenic
animals. In particular, in vitro fertilized embryos can be
centrifuged at 15,000.times.g for 5 minutes to sediment lipids
allowing visualization of the pronucleus. The embryos can be
injected with using an Eppendorf FEMTOJET injector and can be
cultured until blastocyst formation. Rates of embryo cleavage and
blastocyst formation and quality can be recorded.
[0166] Embryos can be surgically transferred into uteri of
asynchronous recipients. Typically, 100-200 (e.g., 150-200) embryos
can be deposited into the ampulla-isthmus junction of the oviduct
using a 5.5-inch TOMCAT.RTM. catheter. After surgery, real-time
ultrasound examination of pregnancy can be performed.
[0167] In somatic cell nuclear transfer, a transgenic artiodactyl
cell (e.g., a transgenic pig cell or bovine cell) such as an
embryonic blastomere, fetal fibroblast, adult ear fibroblast, or
granulosa cell that includes a nucleic acid construct described
above, can be introduced into an enucleated oocyte to establish a
combined cell. Oocytes can be enucleated by partial zona dissection
near the polar body and then pressing out cytoplasm at the
dissection area. Typically, an injection pipette with a sharp
beveled tip is used to inject the transgenic cell into an
enucleated oocyte arrested at meiosis 2. In some conventions,
oocytes arrested at meiosis-2 are termed "eggs." After producing a
porcine or bovine embryo (e.g., by fusing and activating the
oocyte), the embryo is transferred to the oviducts of a recipient
female, about 20 to 24 hours after activation. See, for example,
Cibelli et al. (1998) Science 280, 1256-1258 and U.S. Pat. No.
6,548,741. For pigs, recipient females can be checked for pregnancy
approximately 20-21 days after transfer of the embryos.
[0168] Standard breeding techniques can be used to create animals
that are homozygous for the target nucleic acid from the initial
heterozygous founder animals. Homozygosity may not be required in
some instances, however. Transgenic pigs described herein can be
bred with other pigs of interest.
[0169] In some embodiments, a nucleic acid of interest and a
selectable marker can be provided on separate transposons and
provided to either embryos or cells in unequal amount, where the
amount of transposon containing the selectable marker far exceeds
(5-10 fold excess) the transposon containing the nucleic acid of
interest. Transgenic cells or animals expressing the nucleic acid
of interest can be isolated based on presence and expression of the
selectable marker. Because the transposons will integrate into the
genome in a precise and unlinked way (independent transposition
events), the nucleic acid of interest and the selectable marker are
not genetically linked and can easily be separated by genetic
segregation through standard breeding. Thus, transgenic animals can
be produced that are not constrained to retain selectable markers
in subsequent generations, an issue of some concern from a public
safety perspective.
[0170] Once transgenic animal have been generated, expression of a
target nucleic acid can be assessed using standard techniques.
Initial screening can be accomplished by Southern blot analysis to
determine whether or not integration of the construct has taken
place. For a description of Southern analysis, see sections
9.37-9.52 of Sambrook et al., 1989, Molecular Cloning, A Laboratory
Manual, second edition, Cold Spring Harbor Press, Plainview; NY.
Polymerase chain reaction (PCR) techniques also can be used in the
initial screening. PCR refers to a procedure or technique in which
target nucleic acids are amplified. Generally, sequence information
from the ends of the region of interest or beyond is employed to
design oligonucleotide primers that are identical or similar in
sequence to opposite strands of the template to be amplified. PCR
can be used to amplify specific sequences from DNA as well as RNA,
including sequences from total genomic DNA or total cellular RNA.
Primers typically are 14 to 40 nucleotides in length, but can range
from 10 nucleotides to hundreds of nucleotides in length. PCR is
described in, for example PCR Primer: A Laboratory Manual, ed.
Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press,
1995. Nucleic acids also can be amplified by ligase chain reaction,
strand displacement amplification, self-sustained sequence
replication, or nucleic acid sequence-based amplified. See, for
example, Lewis (1992) Genetic Engineering News 12:1; Guatelli et
al. (1990) Proc. Natl. Acad. Sci. USA 87:1874; and Weiss (1991)
Science 254:1292. At the blastocyst stage, embryos can be
individually processed for analysis by, e.g., PCR, Southern
hybridization and splinkerette PCR (see, e.g., Dupuy et al. Proc
Natl Acad Sci USA (2002) 99:4495).
[0171] Expression of a nucleic acid sequence encoding a polypeptide
in the tissues of transgenic pigs can be assessed using techniques
that include, for example, Northern blot analysis of tissue samples
obtained from the animal, in situ hybridization analysis, Western
analysis, immunoassays such as enzyme-linked immunosorbent assays,
and reverse-transcriptase PCR (RT-PCR).
Founder Animals, Animals Lines, Traits and Reproduction
[0172] Founder animals may be produced by cloning and other methods
described herein. The founders can be homozygous for a genetic
modification, as in the case where a zygote or a primary cell
undergoes a homozygous modification. Similarly, founders can also
be made that are heterozygous. The founders may be genomically
modified, meaning that all of the cells in their genome have
undergone modification. Founders can be mosaic for a modification,
as may happen when vectors are introduced into one of a plurality
of cells in an embryo, typically at a blastocyst stage. Progeny of
mosaic animals may be tested to identify progeny that are
genomically modified. An animal line is established when a pool of
animals has been created that can be reproduced sexually or by
assisted reproductive techniques, with heterogeneous or homozygous
progeny consistently expressing the modification.
[0173] In livestock, many alleles are known to be linked to various
traits such as production traits, type traits, workability traits,
and other functional traits. Artisans are accustomed to monitoring
and quantifying these traits, e.g., Visscher et al., Livestock
Production Science, 40 (1994) 123-137, U.S. Pat. No. 7,709,206, US
2001/0016315, US 2011/0023140, and US 2005/0153317. An animal line
may include a trait chosen from a trait in the group consisting of
a production trait, a type trait, a workability trait, a fertility
trait, a mothering trait, and a disease resistance trait. Further
traits include expression of a recombinant gene product.
[0174] Animals with a desired trait or traits may be modified to
prevent their sexual maturation. Since the animals are sterile
until matured, it is possible to regulate sexual maturity as a
means of controlling dissemination of the animals. Animals that
have been bred or modified to have one or more traits can thus be
provided to recipients with a reduced risk that the recipients will
breed the animals and appropriate the value of the traits to
themselves. Embodiments of the invention include genetically
modifying a genome of an animal with the modification comprising an
inactivated sexual maturation gene, wherein the sexual maturation
gene in a wild type animal expresses a factor selective for sexual
maturation. Embodiments include treating the animal by
administering a compound to remedy a deficiency caused by the loss
of expression of the gene to induce sexual maturation in the
animal.
[0175] Breeding of animals that require administration of a
compound to induce sexual maturity may advantageously be
accomplished at a treatment facility. The treatment facility can
implement standardized protocols on well-controlled stock to
efficiently produce consistent animals. The animal progeny may be
distributed to a plurality of locations to be raised. Farms and
farmers (a term including a ranch and ranchers) may thus order a
desired number of progeny with a specified range of ages and/or
weights and/or traits and have them delivered at a desired time
and/or location. The recipients, e.g., farmers, may then raise the
animals and deliver them to market as they desire.
[0176] Embodiments include delivering (e.g., to one or more
locations, to a plurality of farms) a genetically modified
livestock animal having an inactivated neuroendocrine gene
selective for sexual maturation. Embodiments include delivery of
animals having an age of between about 1 day and about 180 days.
The animal may have one or more traits (for example one that
expresses a desired trait or a high-value trait or a novel trait or
a recombinant trait). Embodiments further include providing said
animal and/or breeding said animal.
Polypeptides
[0177] There are a variety of conservative changes that can
generally be made to an amino acid sequence without altering
activity. These changes are termed conservative substitutions or
mutations; that is, an amino acid belonging to a grouping of amino
acids having a particular size or characteristic can be substituted
for another amino acid. Substitutes for an amino acid sequence may
be selected from other members of the class to which the amino acid
belongs. For example, the nonpolar (hydrophobic) amino acids
include alanine, leucine, isoleucine, valine, proline,
phenylalanine, tryptophan, and tyrosine. The polar neutral amino
acids include glycine, serine, threonine, cysteine, tyrosine,
asparagine and glutamine. The positively charged (basic) amino
acids include arginine, lysine and histidine. The negatively
charged (acidic) amino acids include aspartic acid and glutamic
acid. Such alterations are not expected to substantially affect
apparent molecular weight as determined by polyacrylamide gel
electrophoresis or isoelectric point. Exemplary conservative
substitutions include, but are not limited to, Lys for Arg and vice
versa to maintain a positive charge; Glu for Asp and vice versa to
maintain a negative charge; Ser for Thr so that a free --OH is
maintained; and Gln for Asn to maintain a free NH.sub.2. Moreover,
point mutations, deletions, and insertions of the polypeptide
sequences or corresponding nucleic acid sequences may in some cases
be made without a loss of function of the polypeptide or nucleic
acid fragment. Substitutions may include, e.g., 1, 2, 3, or more
residues. The amino acid residues described herein employ either
the single letter amino acid designator or the three-letter
abbreviation. Abbreviations used herein are in keeping with the
standard polypeptide nomenclature, J. Biol. Chem., (1969), 243,
3552-3559. All amino acid residue sequences are represented herein
by formulae with left and right orientation in the conventional
direction of amino-terminus to carboxy-terminus.
[0178] In some cases a determination of the percent identity of a
peptide to a sequence set forth herein may be required. In such
cases, the percent identity is measured in terms of the number of
residues of the peptide, or a portion of the peptide. A polypeptide
of, e.g., 90% identity, may also be a portion of a larger peptide.
Embodiments include such polypeptides that have the indicated
identity and/or conservative substitution of sequence set forth
herein.
[0179] The term purified as used herein with reference to a
polypeptide refers to a polypeptide that either has no naturally
occurring counterpart (e.g., a peptidomimetic), or has been
chemically synthesized and is thus substantially uncontaminated by
other polypeptides, or has been separated or purified from other
most cellular components by which it is naturally accompanied
(e.g., other cellular proteins, polynucleotides, or cellular
components). An example of a purified polypeptide is one that is at
least 70%, by dry weight, free from the proteins and naturally
occurring organic molecules with which it naturally associates. A
preparation of a purified polypeptide therefore can be, for
example, at least 80%, at least 90%, or at least 99%, by dry
weight, the polypeptide. Polypeptides also can be engineered to
contain a tag sequence (e.g., a polyhistidine tag, a myc tag, or a
FLAG.RTM. tag) that facilitates the polypeptide to be purified or
marked (e.g., captured onto an affinity matrix, visualized under a
microscope). Thus a purified composition that comprises a
polypeptide refers to a purified polypeptide unless otherwise
indicated.
[0180] Polypeptides may include a chemical modification; a term
that, in this context, refers to a change in the
naturally-occurring chemical structure of amino acids. Such
modifications may be made to a side chain or a terminus, e.g.,
changing the amino-terminus or carboxyl terminus. In some
embodiments, the modifications are useful for creating chemical
groups that may conveniently be used to link the polypeptides to
other materials, or to attach a therapeutic agent.
Interfering RNAs
[0181] A variety of interfering RNA (RNAi) are known.
Double-stranded RNA (dsRNA) induces sequence-specific degradation
of homologous gene transcripts. RNA-induced silencing complex
(RISC) metabolizes dsRNA to small 21-23-nucleotide small
interfering RNAs (siRNAs). RISC contains a double stranded RNAse
(dsRNase, e.g., Dicer) and ssRNase (e.g., Argonaut 2 or Ago2). RISC
utilizes antisense strand as a guide to find a cleavable target.
Both siRNAs and microRNAs (miRNAs) are known. A method of
inactivating a gene in a genetically modified animal comprises
inducing RNA interference against a target gene and/or nucleic acid
such that expression of the target gene and/or nucleic acid is
reduced.
[0182] For example the exogenous nucleic acid sequence can induce
RNA interference against a nucleic acid encoding a polypeptide. For
example, double-stranded small interfering RNA (siRNA) or small
hairpin RNA (shRNA) homologous to a target DNA can be used to
reduce expression of that DNA. Constructs for siRNA can be produced
as described, for example, in Fire et al. (1998) Nature 391:806;
Romano and Masino (1992) Mol. Microbiol. 6:3343; Cogoni et al.
(1996) EMBO J. 15:3153; Cogoni and Masino (1999) Nature 399:166;
Misquitta and Paterson (1999) Proc. Natl. Acad. Sci. USA 96:1451;
and Kennerdell and Carthew (1998) Cell 95:1017. Constructs for
shRNA can be produced as described by McIntyre and Fanning (2006)
BMC Biotechnology 6:1. In general, shRNAs are transcribed as a
single-stranded RNA molecule containing complementary regions,
which can anneal and form short hairpins.
[0183] The probability of finding a single, individual functional
siRNA or miRNA directed to a specific gene is high. The
predictability of a specific sequence of siRNA, for instance, is
about 50% but a number of interfering RNAs may be made with good
confidence that at least one of them will be effective.
[0184] Embodiments include an in vitro cell, an in vivo cell, and a
genetically modified animal such as a livestock animal that express
an RNAi directed against a neuroendocrine gene selective for sexual
maturation. An embodiment is an RNAi directed against a gene in the
group consisting of Gpr54, Kiss1, and GnRH1. The RNAi may be, for
instance, selected from the group consisting of siRNA, shRNA,
dsRNA, RISC and miRNA.
Vectors and Nucleic Acids
[0185] A variety of nucleic acids may be introduced into the
artiodactyl or other cells, for knockout purposes, or to obtain
expression of a gene for other purposes. Nucleic acid constructs
that can be used to produce transgenic animals include a target
nucleic acid sequence. As used herein, the term nucleic acid
includes DNA, RNA, and nucleic acid analogs, and nucleic acids that
are double-stranded or single-stranded (i.e., a sense or an
antisense single strand). Nucleic acid analogs can be modified at
the base moiety, sugar moiety, or phosphate backbone to improve,
for example, stability, hybridization, or solubility of the nucleic
acid. Modifications at the base moiety include deoxyuridine for
deoxythymidine, and 5-methyl-2'-deoxycytidine and
5-bromo-2'-doxycytidine for deoxycytidine. Modifications of the
sugar moiety include modification of the 2' hydroxyl of the ribose
sugar to form 2'-O-methyl or 2'-O-allyl sugars. The deoxyribose
phosphate backbone can be modified to produce morpholino nucleic
acids, in which each base moiety is linked to a six membered,
morpholino ring, or peptide nucleic acids, in which the
deoxyphosphate backbone is replaced by a pseudopeptide backbone and
the four bases are retained. See, Summerton and Weller (1997)
Antisense Nucleic Acid Drug Dev. 7(3):187; and Hyrup et al. (1996)
Bioorgan. Med. Chem. 4:5. In addition, the deoxyphosphate backbone
can be replaced with, for example, a phosphorothioate or
phosphorodithioate backbone, a phosphoroamidite, or an alkyl
phosphotriester backbone.
[0186] The target nucleic acid sequence can be operably linked to a
regulatory region such as a promoter. Regulatory regions can be
porcine regulatory regions or can be from other species. As used
herein, operably linked refers to positioning of a regulatory
region relative to a nucleic acid sequence in such a way as to
permit or facilitate transcription of the target nucleic acid.
[0187] Any type of promoter can be operably linked to a target
nucleic acid sequence. Examples of promoters include, without
limitation, tissue-specific promoters, constitutive promoters, and
promoters responsive or unresponsive to a particular stimulus.
Suitable tissue specific promoters can result in preferential
expression of a nucleic acid transcript in beta cells and include,
for example, the human insulin promoter. Other tissue specific
promoters can result in preferential expression in, for example,
hepatocytes or heart tissue and can include the albumin or
alpha-myosin heavy chain promoters, respectively. In other
embodiments, a promoter that facilitates the expression of a
nucleic acid molecule without significant tissue- or
temporal-specificity can be used (i.e., a constitutive promoter).
For example, a beta-actin promoter such as the chicken beta-actin
gene promoter, ubiquitin promoter, miniCAGs promoter,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, or
3-phosphoglycerate kinase (PGK) promoter can be used, as well as
viral promoters such as the herpes simplex virus thymidine kinase
(HSV-TK) promoter, the SV40 promoter, or a cytomegalovirus (CMV)
promoter. In some embodiments, a fusion of the chicken beta actin
gene promoter and the CMV enhancer is used as a promoter. See, for
example, Xu et al. (2001) Hum. Gene Ther. 12:563; and Kiwaki et al.
(1996) Hum. Gene Ther. 7:821.
[0188] An example of an inducible promoter is the tetracycline
(tet)-on promoter system, which can be used to regulate
transcription of the nucleic acid. In this system, a mutated Tet
repressor (TetR) is fused to the activation domain of herpes
simplex virus VP16 trans-activator protein to create a
tetracycline-controlled transcriptional activator (tTA), which is
regulated by tet or doxycycline (dox). In the absence of
antibiotic, transcription is minimal, while in the presence of tet
or dox, transcription is induced. Alternative inducible systems
include the ecdysone or rapamycin systems. Ecdysone is an insect
molting hormone whose production is controlled by a heterodimer of
the ecdysone receptor and the product of the ultraspiracle gene
(USP). Expression is induced by treatment with ecdysone or an
analog of ecdysone such as muristerone A. The agent that is
administered to the animal to trigger the inducible system is
referred to as an induction agent.
[0189] Additional regulatory regions that may be useful in nucleic
acid constructs, include, but are not limited to, polyadenylation
sequences, translation control sequences (e.g., an internal
ribosome entry segment, IRES), enhancers, inducible elements, or
introns. Such regulatory regions may not be necessary, although
they may increase expression by affecting transcription, stability
of the mRNA, translational efficiency, or the like. Such regulatory
regions can be included in a nucleic acid construct as desired to
obtain optimal expression of the nucleic acids in the cell(s).
Sufficient expression, however, can sometimes be obtained without
such additional elements.
[0190] A nucleic acid construct may be used that encodes signal
peptides or selectable markers. Signal peptides can be used such
that an encoded polypeptide is directed to a particular cellular
location (e.g., the cell surface). Non-limiting examples of
selectable markers include puromycin, ganciclovir, adenosine
deaminase (ADA), aminoglycoside phosphotransferase (neo, G418,
APH), dihydrofolate reductase (DHFR),
hygromycin-B-phosphtransferase, thymidine kinase (TK), and
xanthin-guanine phosphoribosyltransferase (XGPRT). Such markers are
useful for selecting stable transformants in culture. Other
selectable markers include fluorescent polypeptides, such as green
fluorescent protein or yellow fluorescent protein.
[0191] In some embodiments, a sequence encoding a selectable marker
can be flanked by recognition sequences for a recombinase such as,
e.g., Cre or Flp. For example, the selectable marker can be flanked
by loxP recognition sites (34-bp recognition sites recognized by
the Cre recombinase) or FRT recognition sites such that the
selectable marker can be excised from the construct. See, Orban, et
al., Proc. Natl. Acad. Sci. (1992) 89:6861, for a review of Cre/lox
technology, and Brand and Dymecki, Dev. Cell (2004) 6:7. A
transposon containing a Cre- or Flp-activatable transgene
interrupted by a selectable marker gene also can be used to obtain
transgenic animals with conditional expression of a transgene. For
example, a promoter driving expression of the marker/transgene can
be either ubiquitous or tissue-specific, which would result in the
ubiquitous or tissue-specific expression of the marker in F0
animals (e.g., pigs). Tissue specific activation of the transgene
can be accomplished, for example, by crossing a pig that
ubiquitously expresses a marker-interrupted transgene to a pig
expressing Cre or Flp in a tissue-specific manner, or by crossing a
pig that expresses a marker-interrupted transgene in a
tissue-specific manner to a pig that ubiquitously expresses Cre or
Flp recombinase. Controlled expression of the transgene or
controlled excision of the marker allows expression of the
transgene.
[0192] In some embodiments, the target nucleic acid encodes a
polypeptide. A nucleic acid sequence encoding a polypeptide can
include a tag sequence that encodes a "tag" designed to facilitate
subsequent manipulation of the encoded polypeptide (e.g., to
facilitate localization or detection). Tag sequences can be
inserted in the nucleic acid sequence encoding the polypeptide such
that the encoded tag is located at either the carboxyl or amino
terminus of the polypeptide. Non-limiting examples of encoded tags
include glutathione S transferase (GST) and FLAG.TM. tag (Kodak,
New Haven, Conn.).
[0193] In other embodiments, the target nucleic acid sequence
induces RNA interference against a target nucleic acid such that
expression of the target nucleic acid is reduced. For example the
target nucleic acid sequence can induce RNA interference against a
nucleic acid encoding a cystic fibrosis transmembrane conductance
regulatory (CFTR) polypeptide. For example, double-stranded small
interfering RNA (siRNA) or short hairpin RNA (shRNA) homologous to
a CFTR DNA can be used to reduce expression of that DNA. Constructs
for siRNA can be produced as described, for example, in Fire et al.
(1998) Nature 391:806; Romano and Masino (1992) Mol. Microbiol.
6:3343; Cogoni et al. (1996) EMBO J. 15:3153; Cogoni and Masino
(1999) Nature 399:166; Misquitta and Paterson (1999) Proc. Natl.
Acad. Sci. USA 96:1451; and Kennerdell and Carthew (1998) Cell
95:1017. Constructs for shRNA can be produced as described by
McIntyre and Fanning (2006) BMC Biotechnology 6:1. In general,
shRNAs are transcribed as a single-stranded RNA molecule containing
complementary regions, which can anneal and form short
hairpins.
[0194] Nucleic acid constructs can be methylated using an SssI CpG
methylase (New England Biolabs, Ipswich, Mass.). In general, the
nucleic acid construct can be incubated with S-adenosylmethionine
and SssI CpG-methylase in buffer at 37.degree. C. Hypermethylation
can be confirmed by incubating the construct with one unit of
HinPII endonuclease for 1 hour at 37.degree. C. and assaying by
agarose gel electrophoresis.
[0195] Nucleic acid constructs can be introduced into embryonic,
fetal, or adult artiodactyl cells of any type, including, for
example, germ cells such as an oocyte or an egg, a progenitor cell,
an adult or embryonic stem cell, a primordial germ cell, a kidney
cell such as a PK-15 cell, an islet cell, a beta cell, a liver
cell, or a fibroblast such as a dermal fibroblast, using a variety
of techniques. Non-limiting examples of techniques include the use
of transposon systems, recombinant viruses that can infect cells,
or liposomes or other non-viral methods such as electroporation,
microinjection, or calcium phosphate precipitation, that are
capable of delivering nucleic acids to cells.
[0196] In transposon systems, the transcriptional unit of a nucleic
acid construct, i.e., the regulatory region operably linked to a
target nucleic acid sequence, is flanked by an inverted repeat of a
transposon. Several transposon systems, including, for example,
Sleeping Beauty (see, U.S. Pat. No. 6,613,752 and U.S. Publication
No. 2005/0003542); Frog Prince (Miskey et al. (2003) Nucleic Acids
Res. 31:6873); To12 (Kawakami (2007) Genome Biology 8(Supp1.1):S7;
Minos (Pavlopoulos et al. (2007) Genome Biology 8(Supp1.1):S2);
Hsmar1 (Miskey et al. (2007)) Mol Cell Biol. 27:4589); and Passport
have been developed to introduce nucleic acids into cells,
including mice, human, and pig cells. The Sleeping Beauty and
Passport transposon is particularly useful. A transposase can be
delivered as a protein, encoded on the same nucleic acid construct
as the target nucleic acid, can be introduced on a separate nucleic
acid construct, or provided as an mRNA (e.g., an in
vitro-transcribed and capped mRNA).
[0197] Insulator elements also can be included in a nucleic acid
construct to maintain expression of the target nucleic acid and to
inhibit the unwanted transcription of host genes. See, for example,
U.S. Publication No. 2004/0203158. Typically, an insulator element
flanks each side of the transcriptional unit and is internal to the
inverted repeat of the transposon. Non-limiting examples of
insulator elements include the matrix attachment region-(MAR) type
insulator elements and border-type insulator elements. See, for
example, U.S. Pat. Nos. 6,395,549, 5,731,178, 6,100,448 and
5,610,053, and U.S. Publication No. 2004/0203158.
[0198] Nucleic acids can be incorporated into vectors. A vector is
a broad term that includes any specific DNA segment that is
designed to move from a carrier into a target DNA. A vector may be
referred to as an expression vector, or a vector system, which is a
set of components needed to bring about DNA insertion into a genome
or other targeted DNA sequence such as an episome, plasmid, or even
virus/phage DNA segment. Vector systems such as viral vectors
(e.g., retroviruses, adeno-associated virus and integrating phage
viruses), and non-viral vectors (e.g., transposons) used for gene
delivery in animals have two basic components: 1) a vector
comprised of DNA (or RNA that is reverse transcribed into a cDNA)
and 2) a transposase, recombinase, or other integrase enzyme that
recognizes both the vector and a DNA target sequence and inserts
the vector into the target DNA sequence. Vectors most often contain
one or more expression cassettes that comprise one or more
expression control sequences, wherein an expression control
sequence is a DNA sequence that controls and regulates the
transcription and/or translation of another DNA sequence or mRNA,
respectively.
[0199] Many different types of vectors are known. For example,
plasmids and viral vectors, e.g., retroviral vectors, are known.
Mammalian expression plasmids typically have an origin of
replication, a suitable promoter and optional enhancer, and also
any necessary ribosome binding sites, a polyadenylation site,
splice donor and acceptor sites, transcriptional termination
sequences, and 5' flanking non-transcribed sequences. Examples of
vectors include: plasmids (which may also be a carrier of another
type of vector), adenovirus, adeno-associated virus (AAV),
lentivirus (e.g., HIV-1, SIV or FIV), retrovirus (e.g., ASV, ALV or
MoMLV), and transposons (e.g., Sleeping Beauty, P-elements, Tol-2,
Frog Prince, piggyBac).
[0200] As used herein, the term nucleic acid refers to both RNA and
DNA, including, for example, cDNA, genomic DNA, synthetic (e.g.,
chemically synthesized) DNA, as well as naturally occurring and
chemically modified nucleic acids, e.g., synthetic bases or
alternative backbones. A nucleic acid molecule can be
double-stranded or single-stranded (i.e., a sense or an antisense
single strand). The term transgenic is used broadly herein and
refers to a genetically modified organism or genetically engineered
organism whose genetic material has been altered using genetic
engineering techniques. A knockout artiodactyl is thus transgenic
regardless of whether or not exogenous genes or nucleic acids are
expressed in the animal or its progeny.
[0201] The nucleic acid sequences set forth herein are intended to
represent both DNA and RNA sequences, according to the conventional
practice of allowing the abbreviation "T" stand for "T" or for "U",
as the case may be, for DNA or RNA. Polynucleotides are nucleic
acid molecules of at least three nucleotide subunits.
Polynucleotide analogues or polynucleic acids are chemically
modified polynucleotides or polynucleic acids. In some embodiments,
polynucleotide analogues can be generated by replacing portions of
the sugar-phosphate backbone of a polynucleotide with alternative
functional groups. Morpholino-modified polynucleotides, referred to
herein as "morpholinos," are polynucleotide analogues in which the
bases are linked by a morpholino-phosphorodiamidate backbone (see,
e.g., U.S. Pat. Nos. 5,142,047 and 5,185,444). In addition to
morpholinos, other examples of polynucleotide analogues include
analogues in which the bases are linked by a polyvinyl backbone,
peptide nucleic acids (PNAs) in which the bases are linked by amide
bonds formed by pseudopeptide 2-aminoethyl-glycine groups,
analogues in which the nucleoside subunits are linked by
methylphosphonate groups, analogues in which the phosphate residues
linking nucleoside subunits are replaced by phosphoroamidate
groups, and phosphorothioated DNAs, analogues containing sugar
moieties that have 2' O-methyl group). Polynucleotides of the
invention can be produced through the well-known and routinely used
technique of solid phase synthesis. Alternatively, other suitable
methods for such synthesis can be used (e.g., common molecular
cloning and chemical nucleic acid synthesis techniques). Similar
techniques also can be used to prepare polynucleotide analogues
such as morpholinos or phosphorothioate derivatives. In addition,
polynucleotides and polynucleotide analogues can be obtained
commercially. For oligonucleotides, examples of pharmaceutically
acceptable compositions are salts that include, e.g., (a) salts
formed with cations such as sodium, potassium, ammonium, etc.; (b)
acid addition salts formed with inorganic acids, for example,
hydrochloric acid, hydrobromic acid (c) salts formed with organic
acids e.g., for example, acetic acid, oxalic acid, tartaric acid;
and (d) salts formed from elemental anions e.g., chlorine, bromine,
and iodine.
[0202] A sequence alignment is a way of arranging the sequences of
DNA, RNA, or protein to identify regions of similarity. Aligned
sequences of nucleotide or amino acid residues are typically
represented as rows within a matrix, with gaps are inserted between
the residues so that identical or similar characters are aligned in
successive columns.
Dominant Negatives
[0203] Genes may thus be inactivated not only by removal or RNAi
suppression but also by creation of a dominant negative phenotype.
A dominant negative version of a gene product lacks one or more
functions of the wild-type phenotype and dominantly interferes with
the function of a normal gene product expressed in the same cell,
with a result that the dominant negative phenotype effectively
decreases or inactivates the physiological outcome normally
expected to be elicited by a gene's normal function. For example,
the function of most proteins requires their interaction with other
proteins. Such interactions are often required for proper protein
localization, ligand binding, protein activation, or the downstream
transduction of upstream signals. The mutation of one or more of
the components of a multi-protein complex can interfere with one
these processes. Thus, the expression of a mutant form of a protein
can interfere with a proteins function, even in the presence of a
normal gene product, acting as a poison "pill" or a "monkey wrench"
into the gearbox. GPCRs are seven-transmembrane (7TM) domain
receptors which are trafficked through the biosynthetic pathway to
the cell surface in a tightly regulated mechanism with multiple
steps and a stringent quality control system to ensure correct GPCR
folding and targeting. Association of GPCRs with accessory proteins
or chaperones are a key step for the forward trafficking through
the endoplasmic reticulum (ER) and Golgi. The life of GPCRs begins
in the ER where they are synthesized, folded and assembled. During
their migration to the cell surface, GPCRs undergo
post-translational modifications to attain mature status. Because
the ER forms part of the cellular quality control machinery where
functionally inactive mutant GPCRs can be prevented from expression
at the cell surface.
[0204] Conditions such as X-linked nephrogenic-diabetes insipidus,
familial hypocalciuric hypercalcemia, familial glucocorticoid
deficiency or hypogonadodotropic hypogonadism are associated with
mutations in GPCRs which result in intracellular retention in the
ER or Golgi compartments. In numerous cases the defect in cell
surface membrane expression is due to intracellular association of
receptors, with a dominant-negative (DN) effect of the misfolded
receptor on its wild-type counterpart; this DN effect may limit, or
even abrogate, plasma membrane expression of the normal receptor
and thus provoke a loss-of-function disease (Ulloa-Aguirre et al.,
2004a).
[0205] Loss-of-function mutations in the GnRHR can lead to partial
or complete hypogonadotropic hypogonadism (HH), a failure of
pituitary gonadotropes to respond to GnRH, which results in
decreased or apulsatile gonadotropin release and reproductive
failure. A large number of mutations leading to receptor misfolding
and resultant misrouting of the gonadotropin hormone-releasing
hormone receptor (GnRHR) in patients with HH have been described
(Janovick et al., 2002; Leanos-Miranda et al., 2002; Ulloa-Aguirre
et al., 2004b). Many of these mutations act as Dominant negatives
for GnRHR function (Pask A J et al, 2005 Mol Endocrinol; Brothers S
P et al, 2004 Mol Endocrinol; Leanos-Miranda A et al, 2003 J Clin
Endocrinol Metab). Thus, purposeful expression of a DN GnRHR gene
is expected to cause sterility in transgenic animals.
[0206] As discussed, GPR54 is a gatekeeper of the reproductive
cascade that initiates puberty. Animal studies demonstrate that
engagement of GPR54 by endogenous peptide ligands, termed
kisspeptins, potently stimulates gonadotropin-releasing hormone
release from hypothalamic neurons to activate the
hypothalamic-pituitary-gonadal axis. Furthermore, the
characterization of GPR54 KO mice, which phenocopy the human
condition of idiopathic hypogonadotropic hypogonadism, confirmed
the essential role of GPR54 for reproductive function. GPCRs are
now recognized to exist as multiprotein complexes composed of
GPCR-interacting proteins (GIPs) that impart precise spatial and
temporal regulation of expression, trafficking, ligand binding, and
signaling. GPR54 has been determined to specifically interact with
these GIPs. Because the majority of truncated GPCR splice variants
act as dominant-negative mutations (Wise 2012, J Mol Signal), the
expression of GPR54 lacking one or more transmembrane domains is
expected to disrupt the processing/trafficking of endogenous GPR54,
thus interfering with its function. Thus, purposeful expression of
a DN GPR54 gene is expected to cause sterility in transgenic
animals.
Templated and Non-Templated Repairs
[0207] TALENs, zinc finger nucleases, CRISPR nuclease (e.g.,
CRISPR/Cas9) and recombinase fusion proteins may be used with or
without a template. A template is an exogenous DNA added to the
cell for cellular repair machinery to use as a guide (template) to
repair double stranded breaks (DSB) in DNA. This process is
generally referred to as homology directed repair (HDR). Processes
without a template involve making DSBs and providing for cellular
machinery to make repairs that are often less than perfect, so that
an insertion or deletion (an indel) is made. The cellular pathway
referred to as non-homologous end joining (NHEJ) typically mediates
non-templated repairs of DSBs. The term NHEJ is commonly used to
refer to all such non-templated repairs regardless of whether the
NHEJ was involved, or an alternative cellular pathway.
[0208] Extended Hypothermia for Template-Directed Repair
[0209] Experiments surprisingly showed that an extended period of
hypothermic culture could enhance the efficiency of templating
processes. Hypothermic cell cultures are known to be useful for up
to about three days to introduce double-stranded DNA breaks.
Conventional theories for this effect revolve around the idea that
the active enzymes are being diluted or the DNA is stabilized by
inhibiting division.
[0210] The data herein, however, are not consistent with these
other theories. Instead, it is believed that hypothermia minimizes
re-repair of altered chromosomes as guided by the sister chromatid.
In other words, even if there is successful integration, the cell
may use the sister chromatid at the altered site to undo the
changed allele. Moreover, these data are the first to show that
hypothermia could be used to impact templating processes. A
surprising aspect of the experiments was that the extended
hypothermic culture did not improve the efficiency of copying the
template into the cellular DNA. What it improved was the stability
of the exogenous allele after it had been copied. In fact, this
process almost tripled the level of SNP HDR-edited alleles.
[0211] An embodiment is a hypothermic method of template-directed
repair to change a chromosomal DNA of a cell, comprising
introducing into a living cell a targeted nuclease system and a
nucleic acid template, wherein the targeted nuclease system and the
template operate to alter the chromosomal DNA to have identity to
the template sequence wherein the living cell is maintained at a
hypothermic culturing temperature below a physiological temperature
for a time period. The length of the culture can be varied as
appropriate, e.g., more than 3 days to 31 days or 72 to 800 hours;
artisans will immediately appreciate that all ranges and values
within the explicitly stated range are contemplated; e.g., 72 to 80
hours, 80 to 600 hours, 3 days to 5 days, 4 days to 15 days, 3.1
days to two weeks, and so forth. Extended culture times at about
20.degree. C. have been successful (data not shown). The
hypothermic culture temperature ranges from 20 to 34.degree. C.;
artisans will immediately appreciate that all ranges and values
within the explicitly stated range are contemplated; e.g., 20 to
25.degree. C., 21 to 26.degree. C., 22 to 27.degree. C., 23 to
28.degree. C., 24 to 29.degree. C., 21 to 30.degree. C. Moreover
embodiments include maintaining the culture at a specific
temperature within the range as well as allowing the culture
temperature to change while remaining within the range. The term
"kept within a range" in this context includes both these
embodiments. Embodiments include culturing to provide a stability
of an allele introduced into a cell; for example, a modified allele
may remain stable (i.e., continue to be present in the population)
for more than 5 cell divisions, or at least 3 cell divisions, or a
value between 3 and 10 cell divisions; artisans will immediately
appreciate that all ranges and values within the explicitly stated
range are contemplated.
SNPs
[0212] These experimental results provide a process for placing
single nucleotide polymorphisms (SNPs) into chromosomal DNA. The
SNPs can be placed at a predetermined position. This control over
placement is without precedent. For instance an SNP can be placed
into an endogenous allele without other SNPs or modifications at
other locations. Moreover, and crucially, an endogenous allele can
be replaced with an exogenous allele that differs by only one SNP.
An endogenous allele can be edited to another allele by the
creation of an SNP within the allele. And the replacements are made
with minimal alterations to chromosomal DNA at any location in
genome of the cell. One or more SNPs may be introgressed.
[0213] An embodiment is a method of creating a single nucleotide
polymorphism (SNP) in a chromosomal DNA of a cell, comprising
introducing a targeted nuclease system and a HDR template into the
cell, with the targeted nuclease system comprising a DNA-binding
member for specifically binding an endogenous cognate sequence in
the chromosomal DNA, wherein the targeted nuclease system and the
HDR template operate to alter the chromosomal DNA to have identity
to the HDR template sequence, wherein the HDR template sequence
comprises a SNP. The HDR template may have a plurality of SNPs or
only one. Other changes may be present, e.g., insertions,
deletions, or substitutions. Or the changes may be limited to a
single SNP, or one or a plurality of SNPs introgressed into the
endogenous allele. The HDR template sequence may comprise an
exogenous allele that replaces an endogenous allele, with the
exogenous allele comprising an SNP in a sequence alignment with the
endogenous allele.
[0214] Further embodiments include placing an SNP into a cognate
site for a DNA-binding member of a targeted nuclease system. The
SNP may be chosen to reduce binding to the DNA-binding member. One
SNP may be thusly placed, or a plurality. Further changes, SNPs, or
others, may be present in the allele, or not. The chromosomal DNA
may be free of all other changes.
[0215] Embodiments include a genetically modified animal, the
animal belonging to a breed of animals having an endogenous allele,
the animal comprising a genetic change at an SNP to change the
chromosomal DNA of the animal from the endogenous allele to an
exogenous allele found in another species or another breed of
animal. The animal may comprise one or more of: a plurality of SNPs
to change the chromosomal DNA of the animal from the endogenous
allele to an exogenous allele found in another species or another
breed of animal; further being free or reporters; being homozygous
for the polymorphism, SNP or SNPs; being a livestock, primate,
swine, cow, horse, sheep, goat, avian, chicken, rabbit, fish, dog,
mouse, cat, rat, and laboratory animal.
[0216] These various embodiments can be performed in a
reporter-free system and to make an SNP or an embodiment relating
to an SNP. The cells or animals may be, e.g., livestock, primate,
swine, cow, horse, sheep, goat, avian, chicken, rabbit, fish, dog,
mouse, cat, rat, and laboratory animal.
Targeted Nuclease Systems
[0217] Genome editing tools such as transcription activator-like
effector nucleases (TALENs) and zinc finger nucleases (ZFNs) have
impacted the fields of biotechnology, gene therapy and functional
genomic studies in many organisms. More recently, RNA-guided
endonucleases (RGENs) are directed to their target sites by a
complementary RNA molecule. The Cas9/CRISPR system is a RGEN.
tracrRNA is another such tool. These are examples of targeted
nuclease systems: these system have a DNA-binding member that
localizes the nuclease to a target site. The site is then cut by
the nuclease. TALENs and ZFNs have the nuclease fused to the
DNA-binding member. Cas9/CRISPR are cognates that find each other
on the target DNA. The DNA-binding member has a cognate sequence in
the chromosomal DNA. The DNA-binding member is typically designed
in light of the intended cognate sequence so as to obtain a
nucleolytic action at nor near an intended site. Certain
embodiments are applicable to all such systems without limitation;
including, embodiments that minimize nuclease re-cleavage,
embodiments for making SNPs with precision at an intended residue,
embodiments for making indels with precision at an intended residue
and placement of the allele that is being introgressed at the
DNA-binding site.
Gene Editing to Avoid Re-Binding by Nuclease Systems
[0218] Experimental results suggested that targeted (endo)nuclease
systems were effectively cutting dsDNA at the intended cognate
sites. Analysis of the data suggested that the nucleases would bind
to sites that had already been templated and re-cleave the site,
causing a reversion of the dsDNA to its original sequence. Targeted
nuclease systems include a motif that binds to the cognate DNA,
either by protein-to-DNA binding, or by nucleic acid-to-DNA
binding. Experiments demonstrated that templates that contain
polymorphisms can be selected to confound the re-binding or
re-cutting by the targeted nuclease, thereby increasing
significantly the number of precisely introgressed cellular
clones.
[0219] Embodiments for reducing re-binding include a method of
homology-directed repair (HDR) to introgress an exogenous allele
into chromosomal DNA of a cell, comprising introducing a targeted
nuclease system and a HDR template that comprises the exogenous
allele into the cell, with the targeted nuclease system comprising
a DNA-binding member for specifically binding an endogenous cognate
sequence in the chromosomal DNA, wherein the targeted nuclease
system and the HDR template operate to alter the chromosomal DNA to
have identity to the HDR template sequence and to introgress the
exogenous allele into the chromosomal DNA in place of an endogenous
allele. In one embodiment the HDR template sequence is designed to
reduce specific binding of the DNA-binding member to the HDR
template sequence. In one embodiment the HDR template sequence is
designed to introduce a polymorphism intended to reduce the
specific binding of the DNA-binding member to genomic sequence once
introgressed. Alternatively, the DNA-binding member of the targeted
nuclease can be designed to recognize nucleotide sequences that
aren't present in endogenous or exogenous sequence. Whereas the
level of this hobbled DNA-binding member is sufficient to enable
cleavage of the endogenous allele, the intended polymorphisms from
the HDR template further alter the target site and decreases
re-cleavage of precisely introgressed alleles. This results in a
higher frequency of cellular clones within a population that
contain those precise introgression events.
[0220] The term allele means one of two or more forms of a gene. A
population or species of organisms typically includes multiple
alleles at each locus among various individuals. Allelic variation
at a locus is measurable as the number of alleles (polymorphisms)
present, or the proportion of heterozygotes in the population. The
term natural allele as used herein means an allele found in nature
in the same species of organism that is being modified. The term
novel allele means a non-natural allele. A human allele placed into
a goat is a novel allele. The term synthetic allele means an allele
that has not yet been found in nature. An exogenous allele is one
that is introduced into an organism, and the endogenous allele is
the one that is already in the cell, usually the one that is in the
organism in its wild-type unmodified state. Animals that are
heterozygous have two alleles. In some cases, it is desirable to
introduce an exogenous allele to make an animal homozygous for an
allele that is already present in the heterozygous animal. Movement
of an allele interspecies means from one species of animal to
another and intraspecies means movement between animals of the same
species. The term exogenous allele is broad and includes DNA with,
e.g., native, novel or synthetic SNPs or indels, reporters,
endonuclease digestion sites, promoters, and vectors.
[0221] Homology directed repair (HDR) is a mechanism in cells to
repair ssDNA and double stranded DNA (dsDNA) lesions. This repair
mechanism can be used by the cell when there is an HDR template
present that has a sequence with significant homology to the lesion
site. Specific binding, as that term is commonly used in the
biological arts, refers to a molecule that binds to a target with a
relatively high affinity compared to non-target sequences, and
generally involves a plurality of non-covalent interactions, such
as electrostatic interactions, van der Waals interactions, hydrogen
bonding, and the like. Specific binding involves processes of
binding to a substrate and releasing from a substrate; as such it
can be affected by changes in the efficiency of binding and release
from a substrate as well as by a strength of the binding to the
substrate. Accordingly, a reduction in specific binding may result
from a lesser affinity to a substrate that reduces the number of
binding events, or it may result from a reduced strength of binding
to the substrate that reduces how long the binding is maintained.
In the context of targeted endonucleases, without being bound to a
particular theory, a change in specific binding of the endonuclease
or guide sequence to the DNA can affect not only that actual
binding but also be involved in an incompletely understood process
of forming complexes with targeted and/or template DNA or RNA.
Therefore specific binding can be measured relative to the actual
DNA-binding events and is a useful feature for manipulating those
processes, even if the actual events at the chromosomal level
involve more or less than actual DNA-binding. Specific
hybridization is a form of specific binding between nucleic acids
that have complementary sequences. Proteins can also specifically
bind to DNA, for instance, in TALENs or CRISPR/Cas9 systems or by
Gal4 motifs. Introgression of an allele refers to a process of
copying an exogenous allele over an endogenous allele with a
template-guided process. The endogenous allele might actually be
excised and replaced by an exogenous nucleic acid allele in some
situations but present theory is that the process is a copying
mechanism. Since alleles are gene pairs, there is significant
homology between them. The allele might be a gene that encodes a
protein, or it could have other functions such as encoding a
bioactive RNA chain or providing a site for receiving a regulatory
protein or RNA.
[0222] The HDR template is a nucleic acid that comprises a sequence
that, when inserted into the target genome, results in an altered
allele. The template may be a dsDNA or a single-stranded DNA
(ssDNA). ssDNA templates are preferably from about 20 to about 5000
residues although other lengths can be used. Artisans will
immediately appreciate that all ranges and values within the
explicitly stated range are contemplated; e.g., from 500 to 1500
residues, from 20 to 100 residues, and so forth. The template may
further comprise flanking sequences that provide homology to DNA
adjacent to the endogenous allele. The template may also comprise a
sequence that is bound to a targeted nuclease system, and is thus
the cognate binding site for the system's DNA-binding member. The
term cognate refers to two biomolecules that typically interact,
for example, a receptor and its ligand. In the context of HDR
processes, one of the biomolecules may be designed with a sequence
to bind with an intended, i.e., cognate, DNA site or protein
site.
[0223] One embodiment for reducing specific binding to a targeted
nuclease system comprises making changes in the HDR template
relative to its alignment with the endogenous DNA. One type of
change is designed to create mismatches between the cognate
members. One change is an insertion or a deletion of one or more
residues. Another change is a substitution of one residue for
another residue that does not promote binding. The term residue
refers to a unit in a molecular chain, e.g., an amino acid in a
protein or a base in a nucleic acid. One place to make the change
is at the cognate binding site for the system's DNA-binding
member.
[0224] Another type of change is designed to interfere with
operation of the nucleases by making the change is in the spacer in
systems that operate with a spacer, e.g., TALENs pairs, the change
may be made in the spacer area. These changes may include a
deletion, e.g., so that the nucleases are hindered from making
cuts. These various changes are generally referred to as mismatches
herein since they create mismatches when the sequences are aligned;
in this context, a deletion, insertion, or substitution is a
mismatch. Artisans routinely make alignments of sequences so that
mismatches are readily identified with specificity. Pairs of
nucleases require a spacing that provides a cooperativity; their
activity can be disrupted by additions or subtractions to the
spacer.
[0225] Further embodiments place a mismatch in the exogenous
allele. The system's DNA-binding member is designed to bind at a
site that at least partially overlaps with the endogenous allele.
Once it is introgressed to have identity with the exogenous allele,
the DNA-binding member has reduced binding. The DNA-binding
member's cognate site thus changes from a preferred endogenous
allele to a not-preferred exogenous allele. The cognate site may
encompass all of the allele, or just a part of it. It is surprising
that the introduction of a mismatch into the exogenous allele is
required to stabilize the introgression of the exogenous allele.
Apparently the problem of re-cleavage has a very large impact on
stability of introgressed alleles. The data that shows this impact
was not previously obtained by others because processes with a
comparable efficiency were not conventionally available.
[0226] Embodiments include creating, with an HDR templating
process, mismatches at these various places by insertion, deletion,
or substitution of a residue. For instance, from 1-60 residues may
be inserted, deleted, or substituted; artisans will immediately
appreciate that all ranges and values within the explicitly stated
range are contemplated; e.g., 1-3 residues, at least 10 residues, 4
residues, 4-20 residues, and so forth. One or more of these may be
combined, e.g., an insertion at one place, a deletion at another,
and a substitution at other places.
[0227] Embodiments include designing the DNA-binding member of the
targeting endonuclease to place a mismatch in the DNA-binding
member sequence as aligned with the endogenous chromosomal DNA. The
mismatch would typically also be a mismatch for the exogenous DNA.
These mismatches reduce targeted nuclease rebinding. Further
mismatches may be used in combination with this method as already
described, e.g., with the DNA-binding sites of the endonucleases
chosen at positions wherein introgression of the exogenous allele;
the HDR template having mismatches at the DNA-binding cognates; or
in the spacer region to change the spacing.
[0228] These various embodiments can be performed in a
reporter-free system and to make an SNP or an embodiment relating
to an SNP. The cells or animals may be, e.g., vertebrate,
livestock, primate, swine, cow, horse, sheep, goat, chicken,
rabbit, fish, dog, mouse, cat, rat, and laboratory animal.
Zinc Finger Nucleases
[0229] Zinc-finger nucleases (ZFNs) are artificial restriction
enzymes generated by fusing a zinc finger DNA-binding domain to a
DNA-cleavage domain. Zinc finger domains can be engineered to
target desired DNA sequences and this enables zinc-finger nucleases
to target unique sequences within complex genomes. By taking
advantage of endogenous DNA repair machinery, these reagents can be
used to alter the genomes of higher organisms. ZFNs may be used in
methods for inactivating genes.
[0230] A zinc finger DNA-binding domain has about 30 amino acids
and folds into a stable structure. Each finger primarily binds to a
triplet within the DNA substrate. Amino acid residues at key
positions contribute to most of the sequence-specific interactions
with the DNA site. These amino acids can be changed while
maintaining the remaining amino acids to preserve the necessary
structure. Binding to longer DNA sequences is achieved by linking
several domains in tandem. Other functionalities like non-specific
FokI cleavage domain (N), transcription activator domains (A),
transcription repressor domains (R) and methylases (M) can be fused
to a ZFPs to form ZFNs respectively, zinc finger transcription
activators (ZFA), zinc finger transcription repressors (ZFR, and
zinc finger methylases (ZFM). Materials and methods for using zinc
fingers and zinc finger nucleases for making genetically modified
animals are disclosed in, e.g., U.S. Pat. No. 8,106,255
US20120192298, US20110023159, and US20110281306.
[0231] TALENs
[0232] The term TALEN, as used herein, is broad and includes a
monomeric TALEN that can cleave double stranded DNA without
assistance from another TALEN, e.g., as in Beurdeley, M. et al.
Compact designer TALENs for efficient genome engineering. Nat.
Commun. 4:1762 doi: 10.1038/ncomms2782 (2013). The term TALEN is
also used to refer to one or both members of a pair of TALENs that
are engineered to work together to cleave DNA at the same site.
TALENs that work together may be referred to as a left-TALEN and a
right-TALEN, which references the handedness of DNA or a
TALEN-pair.
[0233] One of the challenges to making TALEN-modified livestock or
other animals is that the efficiency of making a modification to an
animal cell is only a few percent with conventional best practices.
Achievement of a deletion or an insertion at an intended site does
not necessarily mean success because it may not actually create the
intended effect, such as expressing an exogenous protein or
stopping expression of an endogenous protein. Even a low efficiency
can be useful for the creation of genetically modified lower
animals such as fruit flies or mice because they have short and
prolific reproductive cycles that provide for the creating,
testing, and screening of hundreds of animals to determine if there
are a few that have been successfully modified. These levels of
efficiency that are conventionally achieved, however, are not
suited to livestock artiodactyls that have much longer gestational
times and comparatively few progeny per pregnancy. U.S. Ser. No.
13/404,662 filed Feb. 24, 2012 "Genetically modified animals and
methods for making the same", which is hereby incorporated herein
by reference for all purposes (in case of conflict, the
specification is controlling) provides certain methods that address
these conventional limitations.
[0234] Another barrier to using TALENs to modify livestock is that
TALEN-mediated modification of DNA in primary cells is difficult
because the cells are unstable. U.S. Pub. No. 2011/0197290 filed
Feb. 11, 2011 provides useful methods for modifying these cells,
and is hereby incorporated herein by reference for all purposes; in
case of conflict, the specification is controlling. Indeed, it is
shown herein that frequency of TALEN-modified cells decreases
significantly over time in the absence of enrichment or selection
methods. Without being bound to a particular theory, it is
theorized that DNA cleavage at non-intended sites can compromise
the stability of the cell by inducing apoptosis or disabling
non-target genes.
[0235] The term primary cell means a cell isolated from a living
animal, wherein the cell has undergone between 0 and 2, 0 and 3, 0
and 4, 0 and 5, 0 and 6, 0 and 7, 0 and 8, 0 and 9, or 0 and 10
replications since its isolation from the tissue. TALENs may be
used to make genetically modified artiodactyl primary cells. These
modifications are suited to making founders of genetically modified
animal lines by cloning. Also described herein are direct-embryonic
injections that that may be used to modify zygotes or embryos, with
the modified zygotes or embryos being suited to implant into
surrogate females for gestation and delivery of founder animal
lines.
[0236] As a result, techniques customarily used to create and test
transformed cells for successful genetic modification can not be
used in primary cells due to their propensity to senesce.
TALEN-modified cells are customarily destroyed to assay their
genetic modification, or isolated to grow clonal lines with many
identical cells from one parent. However, primary cells are
inherently unstable and typically undergo genetic changes,
senescence, and/or cell death when attempts are made to genetically
modify and clonally expand them. TALEN-modified cells are even less
stable, as documented herein for the first time. As a result, it is
unreasonable to expect high rates of success when using
conventional approaches that involve modifying a primary cell for
somatic cell nuclear transfer or other animal cloning technique. As
reported herein, however, TALENs have been used to make genetically
modified artiodactyl primary cells. These modifications are suited
to making founders of genetically modified animal lines by cloning
or direct-embryonic injections. Also described herein are
direct-embryonic injections that were used to modify zygotes, with
the modified zygotes being suited to implant into surrogate females
for gestation and delivery of founder animal lines.
[0237] A typical approach to testing for an actual TALEN-mediated
insertion/deletion event is to sequence the modified cell or
zygote, which is a destructive process. Thus when a zygote or
embryo is modified before implantation to a surrogate, its
modification cannot be verified with any degree of convenience
until the animal is born. It is not conventionally appreciated that
an actual production process for making genetically modified
animals by cloning will benefit from a process for testing for the
presence of a genetic modification. There are inventions presented
herein that provide for an indication of genetic modification at
the single cell, zygote, or oocyte stage. As shown herein,
expression of a reporter gene that is not coupled to TALEN
modification is, despite not being part of the reporter gene
expression cassette, nonetheless generally predictive of a desired
genetic modification. More specifically, the expression of the
reporter gene indicates that the nucleic acids were effectively
delivered and being expressed in a cell or embryo; a
reporter-expressing cell or embryo is more likely to have undergone
TALEN-based modification.
[0238] Another technique for making modified organisms was the use
of a co-transfection, co-selection technique. The cells that
express the reporter are selected for, and may be used for making
genetically modified animals. The reporter may be chosen to require
transposase activity. Without being bound to a specific theory, it
is theorized that cells that have undergone transposition have 1)
been transfected and 2) been competent for double stranded DNA
repair, thus increasing the likelihood of TALEN-based modification
in selected clones. This also facilitates enrichment/selection for
transposed cells (and by extension TALEN-modified cells). The fact
that the transposon is operably but not physically linked to the
TALEN modification permits their segregation away from each other
by breeding. A benefit of a co-transfection strategy is that the
reporter, or reporters, may be placed on a chromosome that is not
the same chromosome that is modified by TALENs. This process
provides for the creation of founder animals that have no reporter
genes. For example, some animals were made by using plasmids
carrying reporter genes that were independent of the genetic
modification, which was orchestrated separately in the cells. This
scheme was based on a theory of operation that cells that
incorporate new reporter genes will also incorporate genetic
modifications. For instance, data provided herein shows that cells
can be transfected with four independent plasmids and the
successful incorporation of the gene product of one plasmid is
predictive of successful incorporation of the other plasmid gene
products and also for the success of TALEN-mediated changes.
Conventional wisdom is that transfection with so many plasmids
would not be successful and would yield unhealthy cells.
Unexpectedly, however, these techniques were effective.
[0239] Miller et al. (Miller et al. (2011) Nature Biotechnol
29:143) reported making TALENs for site-specific nuclease
architecture by linking TAL truncation variants to the catalytic
domain of FokI nuclease. The resulting TALENs were shown to induce
gene modification in immortalized human cells by means of the two
major eukaryotic DNA repair pathways, non-homologous end joining
(NHEJ) and homology directed repair. The TALENs can be engineered
for specific binding. Specific binding, as that term is commonly
used in the biological arts, refers to a molecule that binds to a
target with a relatively high affinity compared to non-target
tissues, and generally involves a plurality of non-covalent
interactions, such as electrostatic interactions, van der Waals
interactions, hydrogen bonding, and the like. Specific binding
interactions characterize antibody-antigen binding,
enzyme-substrate binding, and specifically binding protein-receptor
interactions.
[0240] The cipher for TALs has been reported (PCT Application WO
2011/072246) wherein each DNA binding repeat is responsible for
recognizing one base pair in the target DNA sequence. The residues
may be assembled to target a DNA sequence, with: (a) HD for
recognition of C/G; (b) NI for recognition of A/T; (c) NG for
recognition of T/A; (d) NS for recognition of C/G or A/T or T/A or
G/C; (e) NN for 30 recognition of G/C or A/T; (f) IG for
recognition of T/A; (g) N for recognition of C/G; (h) HG for
recognition of C/G or T/A; (i) H for recognition of T/A; and (j) NK
for recognition of G/C. In brief, a target site for binding of a
TALEN is determined and a fusion molecule comprising a nuclease and
a series of RVDs that recognize the target site is created. Upon
binding, the nuclease cleaves the DNA so that cellular repair
machinery can operate to make a genetic modification at the cut
ends. The term TALEN means a protein comprising a Transcription
Activator-like (TAL) effector binding domain and a nuclease domain
and includes monomeric TALENs that are functional per se as well as
others that require dimerization with another monomeric TALEN. The
dimerization can result in a homodimeric TALEN when both monomeric
TALENs are identical or can result in a heterodimeric TALEN when
monomeric TALENs are different. TALENs can be used to induce gene
modification in immortalized human cells by means of the two major
eukaryotic DNA repair pathways, non-homologous end joining (NHEJ)
and homology directed repair.
[0241] Various working examples for the introduction of TALENs into
cells or embryos, and the formation of animals therefrom are
provided herein. Cells for treatment by TALENs include a cultured
cell, an immortalized cell, a primary cell, a primary somatic cell,
a zygote, a germ cell, a primordial germ cell, a blastocyst, or a
stem cell. Example 18 (FIG. 26) details experimental results for
modifying spermatogonial stem cells. These cells offer another
method for genetic modification of animals, e.g., livestock.
Genetic modification or gene edits can be executed in vitro in
spermatogonial stem cells (male germ-line stem cells, herein
abbreviated GSC's) isolated from donor testes. Modified cells are
transplanted into germ-cell depleted testes of a recipient.
Implanted spermatogonial stem cells produce sperm that carry the
genetic modification(s) that can be used for breeding via
artificial insemination (AI) or in vitro fertilization (IVF) to
derive founder animals. This method has advantages beyond
generation of genetically modified founders. One such advantage is
apparent when founders for a particular disease model are unhealthy
and not suitable for growth to reproductive age. The same
modifications introduced into GSC's could thus be implanted into
the testes of a healthy individuals allowing propagation of the
line from a healthy animal to generate disease models in newborn
piglets.
[0242] In some embodiments, a monomeric TALEN can be used. TALENs
typically function as dimers across a bipartite recognition site
with a spacer, such that two TAL effector domains are each fused to
a catalytic domain of the FokI restriction enzyme, the
DNA-recognition sites for each resulting TALEN are separated by a
spacer sequence, and binding of each TALEN monomer to the
recognition site allows FokI to dimerize and create a double-strand
break within the spacer. Monomeric TALENs also can be constructed,
however, such that single TAL effectors are fused to a nuclease
that does not require dimerization to function. One such nuclease,
for example, is a single-chain variant of FokI in which the two
monomers are expressed as a single polypeptide. Other naturally
occurring or engineered monomeric nucleases also can serve this
role. The DNA recognition domain used for a monomeric TALEN can be
derived from a naturally occurring TAL effector. Alternatively, the
DNA recognition domain can be engineered to recognize a specific
DNA target. Engineered single-chain TALENs may be easier to
construct and deploy, as they require only one engineered DNA
recognition domain. A dimeric DNA sequence-specific nuclease can be
generated using two different DNA binding domains (e.g., one TAL
effector binding domain and one binding domain from another type of
molecule). TALENs may function as dimers across a bipartite
recognition site with a spacer. This nuclease architecture also can
be used for target-specific nucleases generated from, for example,
one TALEN monomer and one zinc finger nuclease monomer. In such
cases, the DNA recognition sites for the TALEN and zinc finger
nuclease monomers can be separated by a spacer of appropriate
length. Binding of the two monomers can allow FokI to dimerize and
create a double-strand break within the spacer sequence. DNA
binding domains other than zinc fingers, such as homeodomains, myb
repeats or leucine zippers, also can be fused to FokI and serve as
a partner with a TALEN monomer to create a functional nuclease.
[0243] In some embodiments, a TAL effector can be used to target
other protein domains (e.g., non-nuclease protein domains) to
specific nucleotide sequences. For example, a TAL effector can be
linked to a protein domain from, without limitation, a DNA 20
interacting enzyme (e.g., a methylase, a topoisomerase, an
integrase, a transposase, or a ligase), a transcription activators
or repressor, or a protein that interacts with or modifies other
proteins such as histones. Applications of such TAL effector
fusions include, for example, creating or modifying epigenetic
regulatory elements, making site-specific insertions, deletions, or
repairs in DNA, controlling gene expression, and modifying
chromatin structure.
[0244] The spacer of the target sequence can be selected or varied
to modulate TALEN specificity and activity. The flexibility in
spacer length indicates that spacer length can be chosen to target
particular sequences with high specificity. Further, the variation
in activity has been observed for different spacer lengths
indicating that spacer length can be chosen to achieve a desired
level of TALEN activity.
[0245] The TALENs described herein as Carlson +63 were surprisingly
found to be very efficient in use. A comparison to the most similar
TALENs is shown in FIGS. 16 and 18. Referring to FIG. 16 and using
the position numbers therein, there is a leading N-terminal portion
from about 1 to about 42, a 5' portion from about 43 to about 178,
and RVD portion from about 179 to about 197, a +63 domain from
about 198 to about 261, and a FokI portion from about 262 to the
end at about 400. A number of residues are different between the
sequences, for instance at about 10 positions that are circled in
FIG. 16A. The N-terminal leader portion is also different, with the
Carlson +63 TALEN being about 20 residues shorter and having about
16 other differences. Embodiments of the N-terminal leader portion
are sequences of between about 10 to about 30 residues; artisans
will immediately appreciate that all the ranges and values within
the explicitly stated ranges are contemplated.
[0246] FIG. 17 provides a sequence listing for the vector used with
the Carlson +63 sequence. Some parts of the vector are indicated in
the Figure: the T3 primer binding site, a 5' UTR, the TALEN 5' for
Carlson +63, a LacZ-stuffer fragment (see Cermak et. al. 2011 for
blue white screening of clones), a Fok I homodimer, a 3'
TALEN+18-+63 (note that 3' TALEN+1-17 provided by last TALEN repeat
in final cloning step), a 3' UTR-polyA, and a Poly-C that
potentially protects the mRNA from degradation. In use, as is known
to artisans, the amino acids that provide specific binding are
inserted in between the portions labeled as the 5' portion and the
half RVD sequence. FIG. 17 shows the Carlson +63 TALEN scaffold
with various features for production of mRNA. The vector has some
features in common with a pT3TS plasmid previously described
(Hyatt, T. M. & Ekker, S. C. Vectors and techniques for ectopic
gene expression in zebrafish. Methods Cell Biol 59, 117-126
(1999)). A significant improvement to the Hyatt et al. vector was
made by removal of a LacZ promoter that was previously located 5'
of the T3 promoter sequence indicated in FIG. 17. Removal of the
LacZ promoter was found to be required for reliable cloning of gene
specific TALENs and propagation of the plasmid. The Carlson +63
vector has a T3 site for mRNA transcription with T3 mRNA
polymerase. The features include a T3 promoter binding site from
which transcription can be initiated, 5' and 3' UTR sequence from
the Xenopus .beta.-globin gene, and a poly-C stretch. The 5' and 3'
portions of the TALEN scaffold flank a LacZ stuffer fragment that
is removed when the gene specific RVD sequences are cloned in as
described in Cermak, T. et al. Efficient design and assembly of
custom TALEN and other TAL effector-based constructs for DNA
targeting. Nucleic Acids Research 39, e82 (2011).
[0247] Alternative embodiments use alternative mRNA polymerases and
cognate binding sites such as T7 or SP6. Other embodiments relate
to the use of any of several alterations of the UTR sequences;
these could benefit translation of the mRNA. Some examples are:
addition of a cytoplasmic polyadenylation element binding site in
the 3' UTR, or exchanging the Xenopus .beta.-globin UTRs with UTR
sequences from human, pig, cow, sheep, goat, zebrafish, from genes
including B-globin. UTRs from genes may be selected for regulation
of expression in embryonic development or in cells. Some examples
of UTRs that may be useful include .beta.-actin, DEAH (SEQ ID NO:
527), TPT1, ZF42, SKP1, TKT, TP3, DDX5, EIF3A, DDX39, GAPDH, CDK1,
Hsp90ab1, Ybx1 f Eif4b Rps27a Stra13, Myc, Paf1 and Foxo1, or CHUK.
Such vector or mRNA improvements could be used to direct special or
temporal expression of ectopic TALENs for study of gene depletion
at desired stages of development. TALEN mRNA produced by these
vectors are generally useful as described herein, including, for
example, for creation of knockout or knockin cells lines or animals
to generate models of disease, animal improvement or screening of
for genes that interact with environmental stimuli (example; drugs,
heat, cold, UV light, growth factors, stress).
[0248] Embodiments include a vector comprising a sequence having
85% to 100% identity with the Carlson +63 vector or TALEN; artisans
will immediately appreciate that all the ranges and values within
the explicitly stated ranges are contemplated, e.g., 85%, 90%, and
95%. Embodiments include a Carlson +63 TALEN with a number of
conservative substitutions ranging from 1 to 50; artisans will
immediately appreciate that all the ranges and values within the
explicitly stated ranges are contemplated, e.g., 5 to 10, 1 to 20,
or about 12. Artisans will immediately appreciate that the RVD
portions of these sequences are to be excluded from these
comparisons since the RVD sequences are to be changed according to
the target intended by a user. Embodiments include a TALEN that
comprises at least one portion of a Carlson +63 TALEN chosen from
the group consisting of N-terminal leader portion, 5' portion, and
+63 domain (and % variations/substitutions thereof).
[0249] The Carlson +63 TALEN has a 22-residue N-terminal leader
sequence of MASSPPKKKRKVSWKDASGWSR (SEQ ID NO: 132). Embodiments
include a TALEN vector or mRNA that comprises at least one portion
of a Carlson +63 TALEN vector chosen from the group consisting of
3' primer biding site, 5'UTR, lacz stuffer fragment, 3' TALEN,
3'UTR, PolyC, and nucleic acids encoding the Carlson +63 N-terminal
leader portion, 5' portion, or +63 domain (and
variations/substitutions thereof). Alternatively, a sequence may be
assembled using one or more of the alternatives indicated above,
e.g., for T7 or SP6 or any of the various alternative UTRs.
Embodiments include sequences with between 85% and 100% identity to
the same, as well as a number of conservative substitutions ranging
from 0 to 50.
[0250] In some embodiments, a monomeric TALEN can be used. TALEN
typically function as dimers across a bipartite recognition site
with a spacer, such that two TAL effector domains are each fused to
a catalytic domain of the FokI restriction enzyme, the
DNA-recognition sites for each resulting TALEN are separated by a
spacer sequence, and binding of each TALEN monomer to the
recognition site allows FokI to dimerize and create a double-strand
break within the spacer. Monomeric TALENs also can be constructed,
however, such that single TAL effectors are fused to a nuclease
that does not require dimerization to function. One such nuclease,
for example, is a single-chain variant of FokI in which the two
monomers are expressed as a single polypeptide. Other naturally
occurring or engineered monomeric nucleases also can serve this
role. The DNA recognition domain used for a monomeric TALEN can be
derived from a naturally occurring TAL effector. Alternatively, the
DNA recognition domain can be engineered to recognize a specific
DNA target. Engineered single-chain TALENs may be easier to
construct and deploy, as they require only one engineered DNA
recognition domain. A dimeric DNA sequence-specific nuclease can be
generated using two different DNA binding domains (e.g., one TAL
effector binding domain and one binding domain from another type of
molecule). TALENs may function as dimers across a bipartite
recognition site with a spacer. This nuclease architecture also can
be used for target-specific nucleases generated from, for example,
one TALEN monomer and one zinc finger nuclease monomer. In such
cases, the DNA recognition sites for the TALEN and zinc finger
nuclease monomers can be separated by a spacer of appropriate
length. Binding of the two monomers can allow FokI to dimerize and
create a double-strand break within the spacer sequence. DNA
binding domains other than zinc fingers, such as homeodomains, myb
repeats or leucine zippers, also can be fused to FokI and serve as
a partner with a TALEN monomer to create a functional nuclease.
[0251] The term nuclease includes exonucleases and endonucleases.
The term endonuclease refers to any wild-type or variant enzyme
capable of catalyzing the hydrolysis (cleavage) of bonds between
nucleic acids within a DNA or RNA molecule, preferably a DNA
molecule. Non-limiting examples of endonucleases include type II
restriction endonucleases such as FokI, HhaI, HindIII, NotI, BbyCI,
EcoRI, BgIII, and AlwI. Endonucleases comprise also rare-cutting
endonucleases when having typically a polynucleotide recognition
site of about 12-45 basepairs (bp) in length, more preferably of
14-45 bp. Rare-cutting endonucleases induce DNA double-strand
breaks (DSBs) at a defined locus. Rare-cutting endonucleases can
for example be a homing endonuclease, a chimeric Zinc-Finger
nuclease (ZFN) resulting from the fusion of engineered zinc-finger
domains with the catalytic domain of a restriction enzyme such as
FokI or a chemical endonuclease. In chemical endonucleases, a
chemical or peptidic cleaver is conjugated either to a polymer of
nucleic acids or to another DNA recognizing a specific target
sequence, thereby targeting the cleavage activity to a specific
sequence. Chemical endonucleases also encompass synthetic nucleases
like conjugates of orthophenanthroline, a DNA cleaving molecule,
and triplex-forming oligonucleotides (TFOs), known to bind specific
DNA sequences. Such chemical endonucleases are comprised in the
term "endonuclease" according to the present invention. Examples of
such endonuclease include I-See I, I-Chu L I-Cre I, I-Csm PI-See L
PI-Tti L PI-Mtu I, I-Ceu I, I-See IL 1-See III, HO, PI-Civ I,
PI-Ctr L PI-Aae I, PI-Bsu PI-Dha I, PI-Dra L PI-May L PI-Meh I,
PI-Mfu L PI-Mfl I, PI-Mga L PI-Mgo I, PI-Min L PI-Mka L PI-Mle I,
PI-Mma I, PI-30 Msh L PI-Msm I, PI-Mth I, PI-Mtu I, PI-Mxe I,
PI-Npu I, PI-Pfu L PI-Rma I, PI-Spb I, PI-Ssp L PI-Fae L PI-Mja I,
PI-Pho L PI-Tag L PI-Thy I, PI-Tko I, PI-Tsp I, I-MsoI.
[0252] A genetic modification made by TALENs or other tools may be,
for example, chosen from the list consisting of an insertion, a
deletion, insertion of an exogenous nucleic acid fragment, and a
substitution. The term "insertion" is used broadly to mean either
literal insertion into the chromosome or use of the exogenous
sequence as a template for repair. In general, a target DNA site is
identified and a TALEN-pair is created that will specifically bind
to the site. The TALEN is delivered to the cell or embryo, e.g., as
a protein, mRNA or by a vector that encodes the TALEN. The TALEN
cleaves the DNA to make a double-strand break that is then
repaired, often resulting in the creation of an indel, or
incorporating sequences or polymorphisms contained in an
accompanying exogenous nucleic acid that is either inserted into
the chromosome or serves as a template for repair of the break with
a modified sequence. This template-driven repair is a useful
process for changing a chromosome, and provides for effective
changes to cellular chromosomes.
[0253] The term exogenous nucleic acid means a nucleic acid that is
added to the cell or embryo, regardless of whether the nucleic acid
is the same or distinct from nucleic acid sequences naturally in
the cell. In some cases, the exogenous nucleic acid differs in
sequence from any nucleic acid sequence that occurs naturally
within the cell. The term nucleic acid fragment is broad and
includes a chromosome, expression cassette, gene, DNA, RNA, mRNA,
or portion thereof. The cell or embryo may be, for instance, chosen
from the group consisting of livestock, an artiodactyl, cattle, a
swine, a sheep, a goat, a chicken, a rabbit, and a fish. The term
"livestock" means domesticated animals that are raised as
commodities for food or biological material. The term artiodactyl
means a hoofed mammal of the order Artiodactyla, which includes
cattle, deer, camels, hippopotamuses, sheep, and goats, that have
an even number of toes, usually two or sometimes four, on each
foot.
[0254] Some embodiments involve a composition or a method of making
a genetically modified livestock and/or artiodactyl comprising
introducing a TALEN-pair into livestock and/or an artiodactyl cell
or embryo that makes a genetic modification to DNA of the cell or
embryo at a site that is specifically bound by the TALEN-pair, and
producing the livestock animal/artiodactyl from the cell. Direct
injection may be used for the cell or embryo, e.g., into a zygote,
blastocyst, or embryo. Alternatively, the TALEN and/or other
factors may be introduced into a cell using any of many known
techniques for introduction of proteins, RNA, mRNA, DNA, or
vectors. Genetically modified animals may be made from the embryos
or cells according to known processes, e.g., implantation of the
embryo into a gestational host, or various cloning methods. The
phrase "a genetic modification to DNA of the cell at a site that is
specifically bound by the TALEN", or the like, means that the
genetic modification is made at the site cut by the nuclease on the
TALEN when the TALEN is specifically bound to its target site. The
nuclease does not cut exactly where the TALEN-pair binds, but
rather at a defined site between the two binding sites.
[0255] Some embodiments involve a composition or a treatment of a
cell that is used for cloning the animal. The cell may be a
livestock and/or artiodactyl cell, a cultured cell, a primary cell,
a primary somatic cell, a zygote, a germ cell, a primordial germ
cell, or a stem cell. For example, an embodiment is a composition
or a method of creating a genetic modification comprising exposing
a plurality of primary cells in a culture to TALEN proteins or a
nucleic acid encoding a TALEN or TALENs. The TALENs may be
introduced as proteins or as nucleic acid fragments, e.g., encoded
by mRNA or a DNA sequence in a vector.
[0256] Genetic modification of cells may also include insertion of
a reporter. The reporter may be, e.g., a florescent marker, e.g.,
green fluorescent protein and yellow fluorescent protein. The
reporter may be a selection marker, e.g., puromycin, ganciclovir,
adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo,
G418, APH), dihydrofolate reductase (DHFR),
hygromycin-B-phosphtransferase, thymidine kinase (TK), or
xanthin-guanine phosphoribosyltransferase (XGPRT). Vectors for the
reporter, selection marker, and/or one or more TALEN may be a
plasmid, transposon, transposase, viral, or other vectors, e.g., as
detailed herein.
[0257] TALENs may be directed to a plurality of DNA sites. The
sites may be separated by several thousand or many thousands of
base pairs. The DNA can be rejoined by cellular machinery to
thereby cause the deletion of the entire region between the sites.
Embodiments include, for example, sites separated by a distance
between 1-5 megabases or between 50% and 80% of a chromosome, or
between about 100 and about 1,000,000 basepairs; artisans will
immediately appreciate that all the ranges and values within the
explicitly stated ranges are contemplated, e.g., from about 1,000
to about 10,000 basepairs or from about 500 to about 500,000
basepairs. Alternatively, exogenous DNA may be added to the cell or
embryo for insertion of the exogenous DNA, or template-driven
repair of the DNA between the sites. Modification at a plurality of
sites may be used to make genetically modified cells, embryos,
artiodactyls, and livestock. One or more genes may be chosen for
complete or at least partial deletion, including a sexual
maturation gene or a cis-acting factor thereof.
[0258] The possibility and efficiency of generating TALEN-mediated
indels in spermatogonial stem cells was explored by transfection of
plasmids encoding TALENs targeted to exon 7 of the porcine Duchene
Muscular Dystrophy locus (DMD). Testing of several nuclefection
conditions, plasmid quantities and incubation temperature yielded a
maximum efficiency of 19% NHEJ despite a germ cell transfection
rate of 25%, as shown in FIG. 26. TALEN activity was highest in
replicates cultured at 30.degree. C. GSCs remained viable after
over 5 days of culture at 30.degree. C., though overall, germ cell
survival was higher at 37.degree. C. Transfection of TALEN encoding
mRNA, versus plasmid DNA, resulted in both greater activity and
viability of livestock somatic cells and GSCs. Notably, while peak
activity of mRNA transfection did not exceed plasmid DNA
transfection in this experiment, a significantly lower quantity of
mRNA was required to achieve the same level of modification.
Example 19 details successful TALEN-stimulated HDR in primordial
germ cells (avian).
[0259] In some embodiments, a monomeric TALEN can be used. TALEN
typically function as dimers across a bipartite recognition site
with a spacer, such that two TAL effector domains are each fused to
a catalytic domain of the FokI restriction enzyme, the
DNA-recognition sites for each resulting TALEN are separated by a
spacer sequence, and binding of each TALEN monomer to the
recognition site allows FokI to dimerize and create a double-strand
break within the spacer. Monomeric TALENs also can be constructed,
however, such that single TAL effectors are fused to a nuclease
that does not require dimerization to function. One such nuclease,
for example, is a single-chain variant of FokI in which the two
monomers are expressed as a single polypeptide. Other naturally
occurring or engineered monomeric nucleases also can serve this
role. The DNA recognition domain used for a monomeric TALEN can be
derived from a naturally occurring TAL effector. Alternatively, the
DNA recognition domain can be engineered to recognize a specific
DNA target. Engineered single-chain TALENs may be easier to
construct and deploy, as they require only one engineered DNA
recognition domain. A dimeric DNA sequence-specific nuclease can be
generated using two different DNA binding domains (e.g., one TAL
effector binding domain and one binding domain from another type of
molecule). TALENs may function as dimers across a bipartite
recognition site with a spacer. This nuclease architecture also can
be used for target-specific nucleases generated from, for example,
one TALEN monomer and one zinc finger nuclease monomer. In such
cases, the DNA recognition sites for the TALEN and zinc finger
nuclease monomers can be separated by a spacer of appropriate
length. Binding of the two monomers can allow FokI to dimerize and
create a double-strand break within the spacer sequence. DNA
binding domains other than zinc fingers, such as homeodomains, myb
repeats or leucine zippers, also can be fused to FokI and serve as
a partner with a TALEN monomer to create a functional nuclease.
Recombinases
[0260] Embodiments of the invention include administration of a
TALEN or TALENs with a recombinase or other DNA-binding protein
associated with DNA recombination. A recombinase forms a filament
with a nucleic acid fragment and, in effect, searches cellular DNA
to find a DNA sequence substantially homologous to the sequence. An
embodiment of a TALEN-recombinase embodiment comprises combining a
recombinase with a nucleic acid sequence that serves as a template
for HDR. The HDR template sequence has substantial homology to a
site that is targeted for cutting by the TALEN/TALEN pair. As
described herein, the HDR template provides for a change to the
native DNA, by placement of an allele, creation of an indel,
insertion of exogenous DNA, or with other changes. The TALEN is
placed in the cell or embryo by methods described herein as a
protein, mRNA, or by use of a vector. The recombinase is combined
with the HDR template to form a filament and placed into the cell.
The recombinase and/or HDR template that combines with the
recombinase may be placed in the cell or embryo as a protein, an
mRNA, or with a vector that encodes the recombinase. The disclosure
of US Pub 2011/0059160 (U.S. Ser. No. 12/869,232) is hereby
incorporated herein by reference for all purposes; in case of
conflict, the specification is controlling. The term recombinase
refers to a genetic recombination enzyme that enzymatically
catalyzes, in a cell, the joining of relatively short pieces of DNA
between two relatively longer DNA strands. Recombinases include Cre
recombinase, Hin recombinase, RecA, RAD51, Cre, and FLP. Cre
recombinase is a Type I topoisomerase from P1 bacteriophage that
catalyzes site-specific recombination of DNA between loxP sites.
Hin recombinase is a 21 kD protein composed of 198 amino acids that
is found in the bacteria Salmonella. Hin belongs to the serine
recombinase family of DNA invertases in which it relies on the
active site serine to initiate DNA cleavage and recombination.
RAD51 is a human gene. The protein encoded by this gene is a member
of the RAD51 protein family which assist in repair of DNA double
strand breaks. RAD51 family members are homologous to the bacterial
RecA and yeast Rad51 genes. Cre recombinase is an enzyme that is
used in experiments to delete specific sequences that are flanked
by loxP sites. FLP refers to Flippase recombination enzyme (FLP or
Flp) derived from the 2.mu. plasmid of the baker's yeast
Saccharomyces cerevisiae.
[0261] Herein, "RecA" or "RecA protein" refers to a family of
RecA-like recombination proteins having essentially all or most of
the same functions, particularly: (i) the ability to position
properly oligonucleotides or polynucleotides on their homologous
targets for subsequent extension by DNA polymerases; (ii) the
ability topologically to prepare duplex nucleic acid for DNA
synthesis; and, (iii) the ability of RecA/oligonucleotide or
RecA/polynucleotide complexes efficiently to find and bind to
complementary sequences. The best characterized RecA protein is
from E. coli; in addition to the original allelic form of the
protein a number of mutant RecA-like proteins have been identified,
for example, RecA803. Further, many organisms have RecA-like
strand-transfer proteins including, for example, yeast, Drosophila,
mammals including humans, and plants. These proteins include, for
example, Rec1, Rec2, Rad51, Rad51B, Rad51C, Rad51D, Rad51E, XRCC2
and DMC1. An embodiment of the recombination protein is the RecA
protein of E. coli. Alternatively, the RecA protein can be the
mutant RecA-803 protein of E. coli, a RecA protein from another
bacterial source or a homologous recombination protein from another
organism.
[0262] RecA is known for its recombinase activity to catalyze
strand exchange during the repair of double-strand breaks by
homologous recombination (McGrew and Knight, 2003) Radding, et al.,
1981; Seitz et al., 1998). RecA has also been shown to catalyze
proteolysis, e.g., of the LexA and .lamda., repressor proteins, and
to possess DNA-dependent ATPase activity. After a double-strand
break occurs from ionizing radiation or some other insult,
exonucleases chew back the DNA ends 5' to 3', thereby exposing one
strand of the DNA (Cox, 1999; McGrew and Knight, 2003). The
single-stranded DNA becomes stabilized by single-strand binding
protein (SSB). After binding of SSB, RecA binds the single-stranded
(ss) DNA and forms a helical nucleoprotein filament (referred to as
a filament or a presynaptic filament). During DNA repair, the
homology-searching functions of RecA direct the filament to
homologous DNA and catalyze homologous base pairing and strand
exchange. This results in the formation of DNA heteroduplex. After
strand invasion, DNA polymerase elongates the ssDNA based on the
homologous DNA template to repair the DNA break, and crossover
structures or Holliday junctions are formed. RecA also shows a
motor function that participates in the migration of the crossover
structures (Campbell and Davis, 1999).
[0263] Recombinase activity comprises a number of different
functions. For example, polypeptide sequences having recombinase
activity are able to bind in a non-sequence-specific fashion to
single-stranded DNA to form a nucleoprotein filament. Such
recombinase-bound nucleoprotein filaments are able to interact in a
non-sequence-specific manner with a double-stranded DNA molecule,
search for sequences in the double-stranded molecule that are
homologous to sequences in the filament, and, when such sequences
are found, displace one of the strands of the double-stranded
molecule to allow base-pairing between sequences in the filament
and complementary sequences in one of the strands of the double
stranded molecule. Such steps are collectively denoted
"synapsis."
[0264] RecA and RecA-like proteins (called Rad51 in many eukaryotic
species) have been examined for stimulating gene targeting and
homologous recombination in a variety of eukaryotic systems. In
tobacco cells, expression of bacterial RecA containing a nuclear
localization signal (NLS) increases the repair of mitomycin
C-induced DNA damage by homologous recombination and somatic
intrachromosomal recombination (recombination between homologous
chromosomes) from three to ten fold (Reiss et al., 1996).
Expression of NLSRecA in tobacco can also stimulate sister
chromatid exchange 2.4-fold over wild-type levels (Reiss et al.,
2000). In somatic mammalian cells, overexpression of NLSRecA
stimulates gene-targeting by homologous recombination 10-fold
(Shcherbakova et al., 2000). However, in human cells,
overexpression of a human homologue of RecA, hRAD51, only
stimulates recombination 2 to 3-fold over wild type levels under
the antibiotic selection (Yanez and Porter, 1999). In zebrafish, a
mutant form of the enhanced green fluorescent protein (EGFP) was
corrected at low frequency by injecting ssDNA-RecA filaments
directly (Cui et al., 2003). Rad52, a member of the Rad51 epistasis
group, also promotes single-strand annealing and low level gene
disruption in zebrafish using mutated oligonucleotides (Takahashi
and Dawid, 2005). Taken together, these studies indicate that
ectopic expression of RecA or Rad51 results in a modest stimulation
of homologous recombination but does not increase levels
sufficiently to be useful for gene-targeting.
[0265] Thus recombinase activities include, but are not limited to,
single-stranded DNA-binding, synapsis, homology searching, duplex
invasion by single-stranded DNA, heteroduplex formation, ATP
hydrolysis and proteolysis. The prototypical recombinase is the
RecA protein from E. coli. See, for example, U.S. Pat. No.
4,888,274. Prokaryotic RecA-like proteins have also been described
in Salmonella, Bacillus and Proteus species. A thermostable RecA
protein, from Thermus aquaticus, has been described in U.S. Pat.
No. 5,510,473. A bacteriophage T4 homologue of RecA, the UvsX
protein, has been described. RecA mutants, having altered
recombinase activities, have been described, for example, in U.S.
Pat. Nos. 6,774,213; 7,176,007 and 7,294,494. Plant RecA homologues
are described in, for example, U.S. Pat. Nos. 5,674,992; 6,388,169
and 6,809,183. RecA fragments containing recombinase activity have
been described, for example, in U.S. Pat. No. 5,731,411. Mutant
RecA proteins having enhanced recombinase activity such as, for
example, RecA803 have been described. See, for example, Madiraju et
al. (1988) Proc. Natl. Acad. Sci. USA 85:6592-6596.
[0266] A eukaryotic homologue of RecA, also possessing recombinase
activity, is the Rad51 protein, first identified in the yeast
Saccharomyces cerevisiae. See Bishop et al., (1992) Cell 69:439-56;
Shinohara et al, (1992) Cell: 457-70; Aboussekhra, et al., (1992)
Mol. Cell. Biol. 72, 3224-3234 and Basile et al., (1992) Mol. Cell.
Biol. 12, 3235-3246. Plant Rad51 sequences are described in U.S.
Pat. Nos. 6,541,684; 6,720,478; 6,905,857 and 7,034,117. Another
yeast protein that is homologous to RecA is the Dmc1 protein.
RecA/Rad51 homologues in organisms other than E. coli and S.
cerevisiae have been described. Morita et al. (1993) Proc. Natl.
Acad. Sci. USA 90:6577-6580; Shinohara et al. (1993) Nature Genet.
4:239-243; Heyer (1994) Experientia 50:223-233; Maeshima et al.
(1995) Gene 160:195-200; U.S. Pat. Nos. 6,541,684 and
6,905,857.
[0267] Herein, "RecA" or "RecA protein" refers to a family of
RecA-like recombination proteins having essentially all or most of
the same functions, particularly: (i) the ability to position
properly oligonucleotides or polynucleotides on their homologous
targets for subsequent extension by DNA polymerases; (ii) the
ability topologically to prepare duplex nucleic acid for DNA
synthesis; and, (iii) the ability of RecA/oligonucleotide or
RecA/polynucleotide complexes efficiently to find and bind to
complementary sequences. The best characterized RecA protein is
from E. coli; in addition to the original allelic form of the
protein a number of mutant RecA-like proteins have been identified,
for example, RecA803. Further, many organisms have RecA-like
strand-transfer proteins including, for example, yeast, Drosophila,
mammals including humans, and plants. These proteins include, for
example, Rec1, Rec2, Rad51, Rad51B, Rad51C, Rad51D, Rad51E, XRCC2
and DMC1. An embodiment of the recombination protein is the RecA
protein of E. coli. Alternatively, the RecA protein can be the
mutant RecA-803 protein of E. coli, a RecA protein from another
bacterial source or a homologous recombination protein from another
organism.
[0268] Additional descriptions of proteins having recombinase
activity are found, for example, in Fugisawa et al. (1985) Nucl.
Acids Res. 13:7473; Hsieh et al. (1986) Cell 44:885; Hsieh et al.
(1989) J. Biol. Chem. 264:5089; Fishel et al. (1988) Proc. Natl.
Acad. Sci. USA 85:3683; Cassuto et al. (1987) Mol. Gen. Genet.
208:10; Ganea et al. (1987) Mol. Cell Biol. 7:3124; Moore et al.
(1990) J. Biol. Chem.:11108; Keene et al. (1984) Nucl. Acids Res.
12:3057; Kimiec (1984) Cold Spring Harbor Symp. 48:675; Kimeic
(1986) Cell 44:545; Kolodner et al. (1987) Proc. Natl. Acad. Sci.
USA 84:5560; Sugino et al. (1985) Proc. Natl. Acad, Sci. USA 85:
3683; Halbrook et al. (1989) J. Biol. Chem. 264:21403; Eisen et al.
(1988) Proc. Natl. Acad. Sci. USA 85:7481; McCarthy et al. (1988)
Proc. Natl. Acad. Sci. USA 85:5854; and Lowenhaupt et al. (1989) J.
Biol. Chem. 264:20568, which are incorporated herein by reference.
See also Brendel et al. (1997) J. Mol. Evol. 44:528.
[0269] Examples of proteins having recombinase activity include
recA, recA803, uvsX, and other recA mutants and recA-like
recombinases (Roca (1990) Crit. Rev. Biochem. Molec. Biol. 25:415),
(Kolodner et al. (1987) Proc. Natl. Acad. Sci. U.S.A. 84:5560;
Tishkoff et al. (1991) Molec. Cell. Biol. 11:2593), RuvC
(Dunderdale et al. (1991) Nature 354:506), DST2, KEM1 and XRN1
(Dykstra et al. (1991) Molec. Cell. Biol. 11:2583), STPa/DST1
(Clark et al. (1991) Molec. Cell. Biol. 11:2576), HPP-1 (Moore et
al. (1991) Proc. Natl. Acad. Sci. U.S.A. 88:9067), other eukaryotic
recombinases (Bishop et al. (1992) Cell 69:439; and Shinohara et
al. (1992) Cell 69:457); incorporated herein by reference.
[0270] In vitro-evolved proteins having recombinase activity have
been described in U.S. Pat. No. 6,686,515. Further publications
relating to recombinases include, for example, U.S. Pat. Nos.
7,732,585, 7,361,641, 7,144,734. For a review of recombinases, see
Cox (2001) Proc. Natl. Acad. Sci. USA 98:8173-8180.
[0271] A nucleoprotein filament, or "filament" may be formed. The
term filament, in the context of forming a structure with a
recombinase, is a term known to artisans in these fields. The
nucleoprotein filament so formed can then be, e.g., contacted with
another nucleic acid or introduced into a cell. Methods for forming
nucleoprotein filaments, wherein the filaments comprise polypeptide
sequences having recombinase activity and a nucleic acid, are
well-known in the art. See, e.g., Cui et al. (2003) Marine
Biotechnol. 5:174-184 and U.S. Pat. Nos. 4,888,274; 5,763,240;
5,948,653 and 7,199,281, the disclosures of which are incorporated
by reference for the purposes of disclosing exemplary techniques
for binding recombinases to nucleic acids to form nucleoprotein
filaments.
[0272] In general, a molecule having recombinase activity is
contacted with a linear, single-stranded nucleic acid. The linear,
single-stranded nucleic acid may be a probe. The methods of
preparation of such single stranded nucleic acids are known. The
reaction mixture typically contains a magnesium ion. Optionally,
the reaction mixture is buffered and optionally also contains ATP,
dATP or a nonhydrolyzable ATP analogue, such as, for example,
.gamma.-thio-ATP (ATP-.gamma.-S) or .gamma.-thio-GTP
(GTP-.gamma.-S). Reaction mixtures can also optionally contain an
ATP-generating system. Double-stranded DNA molecules can be
denatured (e.g., by heat or alkali) either prior to, or during,
filament formation. Optimization of the molar ratio of recombinase
to nucleic acid is within the skill of the art. For example, a
series of different concentrations of recombinase can be added to a
constant amount of nucleic acid, and filament formation assayed by
mobility in an agarose or acrylamide gel. Because bound protein
retards the electrophoretic mobility of a polynucleotide, filament
formation is evidenced by retarded mobility of the nucleic acid.
Either maximum degree of retardation, or maximum amount of nucleic
acid migrating with a retarded mobility, can be used to indicate
optimal recombinase:nucleic acid ratios. Protein-DNA association
can also be quantitated by measuring the ability of a
polynucleotide to bind to nitrocellulose.
Creation of Genetically Modified Livestock Via TALEN Technologies;
Verification of TALEN Modification; Co-Selection of Modified Cells;
Elimination of Reporter Genes from Genetically Modified Animals
[0273] TALEN function in livestock embryos was investigated using
in vitro prepared (IVP) bovine and porcine embryos. Example 1
describes direct injection of TALENs (a left TALEN and a right
TALEN) into bovine embryos to produce genetically modified animals
with a modification at the site where the TALENs specifically
bound. The modifications included homozygous-biallelic and
heterozygous-biallelic modifications. TALEN mRNAs were directly
injected into the embryos and successful genetic modifications were
observed. Expression of the reporter was predictive of a successful
genetic modification, with about 35% of the embryos expressing the
reporter, and about 30% of these animals having a TALEN-based
indel. Of the animals with indels, about 35% of them were either
homozygous or heterozygous bi-allelic mutants (FIG. 4). Direct
embryo modification using TALENs was thus shown to be a viable
approach to livestock genome modification. Embryos may thus be
prepared and implanted into surrogate females for gestation and
delivery of animal founder lines using well known processes.
Moreover, it is possible to use a reporter to select cells (e.g.,
primary cells, zygotes, oocytes, blastocysts) for further use in
cloning or other processes.
[0274] Methods for TALEN-mediated genetic modification of livestock
(or zebrafish, dogs, mice, rats, avian, chicken, or a laboratory
animal) by cloning were also developed. Example 2 describes
development of suitable TALENs and TALEN modification of somatic
primary cells of swine and cows. The efficiency of successful
modification was somewhat low and no reporters for measuring
success of the modification were used. Nucleofection is a means for
introducing foreign nucleic acids into a cell with high efficiency,
but it is expensive, results in high levels of cytotoxicity, and is
not available to many researchers. Therefore, a common cationic
lipid transfection reagent was used as a vehicle for genetic
modification. As shown in Example 3, despite a less than 5%
transfection efficiency with cationic lipids, modification levels
were significantly enriched by transposon co-selection. Whereas
gene modification was below detection in day 3 populations (data
not shown) and day 14 populations without transposon-mediated
selection, modification levels in selected populations reached 31,
13 and 20 percent for DMD7.1, DMD6 and LDLR2.1 respectively (FIG.
7). Transposon co-selection was then applied to cells transfected
by nucleofection where >90% transfection efficiency is routine.
Transposon co-selection was effective for maintenance modified
cells transfected by Nucleofection, however, with the exception of
ACAN12, nucleofection did not significantly enrich for modified
cells over day 3 levels (FIG. 7). Thus, transposon co-selection is
an effective enrichment method when transfection efficiency is low
and an effective maintenance method when transfection efficiency is
high. Co-selection processes were also effective when feeder cells
were used, as demonstrated in Example 4. An unexpectedly high
proportion of bi-allelic modifications (about 17% to about 35%
depending on the TALEN-pair) were observed.
[0275] An embodiment of the invention is a composition and a method
for using TALENs to genetically modify livestock such as
artiodactyls or zebrafish, dogs, mice, rats, fish, avian, chicken,
or a laboratory animal. Many of the problems making these animals
using conventional processes have been discussed above. The genetic
modification may be, for example, chosen from the list consisting
of an insertion, a deletion, insertion of or change to an exogenous
nucleic acid fragment, an inversion, a translocation, interspecies
allele migration, intraspecies allele migration, and gene
conversion to a natural, synthetic, or a novel allele. For
instance, an undesired mutation in a chromosome or chromosome pair
may be replaced with a normal sequence. In general, a target DNA
site is identified and a TALEN-pair is created that will
specifically bind to the site. The TALEN is delivered to the cell
or embryo, e.g., as a protein, mRNA or by a vector that encodes the
TALEN. The TALEN cleaves the DNA to make a double-strand break that
is then repaired, often resulting in the creation of an indel, or
incorporating sequences or polymorphisms contained in an
accompanying exogenous nucleic acid that is either inserted or
serves as a template for repair of the break with a modified
sequence. An exogenous sequence refers to a sequence used to change
the target cell, regardless of whether the sequence is actually a
nucleic acid inserted into chromosomal DNA or if the sequence is
used as a template to change the cellular DNA. The term nucleic
acid fragment is broad and includes a chromosome, expression
cassette, gene, DNA, RNA, mRNA, or portion thereof. The term ssDNA
includes ss-oligonucleotides. The cell or embryo may be, for
instance, chosen from the group consisting of livestock, an
artiodactyl, a cow, a swine, a sheep, a goat, a bird, a chicken, a
rabbit, and a fish. One embodiment is directed to a composition or
a method of making a genetically modified livestock and/or
artiodactyl or a zebrafish, dogs, mice, bird, fish, avian, chicken,
rats or a laboratory animal comprising introducing a TALEN-pair
into livestock and/or an artiodactyl cell or an embryo that makes a
genetic modification to DNA of the cell or embryo at a site that is
specifically bound by the TALEN-pair, and producing the livestock
animal/artiodactyl/other animal from the cell. Direct injection may
be used for the cell or embryo, e.g., into a zygote, blastocyst, or
embryo. Alternatively, the TALEN and/or other factors may be
introduced into a cell using any of many known techniques for
introduction of proteins, RNA, mRNA, DNA, or vectors. Genetically
modified animals may be made from the embryos or cells according to
known processes, e.g., implantation of the embryo into a
gestational host, or various cloning methods. The phrase "a genetic
modification to DNA of the cell at a site that is specifically
bound by the TALEN", or "at a targeted chromosomal site", or the
like, means that the genetic modification is made at the site cut
by the nuclease on the TALEN when the TALEN is specifically bound
to its target site. The nuclease does not cut exactly where the
TALEN-pair binds, but rather at a defined site between the two
binding sites.
[0276] Another such embodiment involves a composition or a
treatment of a cell that is used for cloning the animal. The cell
may be of a livestock and/or artiodactyl cell, fish, zebrafish,
dog, mice, rat, laboratory animal, bird, fish, chicken, a cultured
cell, an immortalized cell, a primary cell, a primary somatic cell,
a zygote, a germ cell, a primordial germ cell, a blastocyst, or a
stem cell. For example, an embodiment is a composition or a method
of creating a genetic modification comprising exposing a plurality
of primary cells in a culture to TALEN proteins or a nucleic acid
encoding a TALEN or TALENs. The TALENs may be introduced as
proteins or as nucleic acid fragments, e.g., encoded by mRNA or a
DNA sequence in a vector.
[0277] Genetic modification of animals may also include
transfection with a reporter. As discussed above, primary cells
were observed to be unstable as a result of cellular modifications
mediated by the TALENs and/or TALENs introduction. As a result,
success in the modification of primary cells (among other cell
types), and/or the creation of new lines of livestock from such
cells is not reasonably expected using conventional means. It is
theorized, without being bound to a specific theory that cells that
express a gene cassette from a first vector are also likely to be
successfully modified by a TALEN delivered independently by mRNA or
another vector. Expression of a reporter at the embryo/cell-level
modification stage allows for elimination of cells that do not
express the reporter. Alternatively, it allows for moving cells
that express the reporter from the culture for use in animals by
cloning or other transgenic animal techniques, or into a second
culture for further cultivation and/or expansion in number and/or
addition of further vectors and/or nucleic acids and/or TALENs
and/or other genetic modifications. Selecting cells based on their
expression of a reporter that is independent of the gene of
interest is a type of co-selection process.
[0278] The term reporter, as used herein, refers to genes or
transgenes that encode reporters and selection markers. The term
selection marker, as used herein, refers to a genetically expressed
biomolecule that confers a trait that permits isolation by either
positive or negative survival selection criteria. The reporter may
be, e.g., a fluorescent marker, e.g., green fluorescent protein and
yellow fluorescent protein. The reporter may be a selection marker,
e.g., puromycin, ganciclovir, adenosine deaminase (ADA),
aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate
reductase (DHFR), hygromycin-B-phosphtransferase, thymidine kinase
(TK), or xanthin-guanine phosphoribosyltransferase (XGPRT).
Phenotypic markers are markers based on discernible physical traits
(e.g., epitopes or color), growth rate, and/or viability.
[0279] The term selection marker, as used herein, refers to a
genetically expressed biomolecule that confers a trait that permits
isolation by either positive or negative survival selection
criteria. The reporter may be, e.g., a florescent marker, e.g.,
green fluorescent protein and yellow fluorescent protein. The
reporter may be a selection marker, e.g., puromycin, ganciclovir,
adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo,
G418, APH), dihydrofolate reductase (DHFR),
hygromycin-B-phosphtransferase, thymidine kinase (TK), or
xanthin-guanine phosphoribosyltransferase (XGPRT). For instance, a
selection marker may allow a cell to survive in the presence of a
small molecule, thereby enabling selection. Other phenotypic
markers may be used to select animals, such markers are based on
discernible physical traits (e.g., epitopes or color), growth rate,
and/or viability.
[0280] Embodiments of the invention include introducing a reporter
(for instance by use of a vector) and a TALEN (e.g., by an
independent vector or mRNA) into a cell or embryo. The cell may be
from a livestock and/or artiodactyl, bovine, avian, chicken,
zebrafish, dog, mice, rats or a laboratory animal. The TALEN and/or
reporter may be directly introduced, e.g., by injection, or other
means, e.g., involving cell culture. A cell culture may be made
comprising cultured cells (primary cells, zygotes, oocytes,
immortalized cells, germ cells, primordial germ cells, stem cells),
a first nucleic acid encoding a TALEN, e.g., mRNA or a vector with
DNA encoding the TALEN, and an independent vector having a DNA
sequence encoding a reporter. The mRNA or first vector do not
encode any reporters and the second vector does not encode any TALs
and does not encode any TALENs.
[0281] Vectors for the reporter, selection marker, and/or one or
more TALEN may be a plasmid, transposon, transposase, viral, or
other vectors, e.g., as detailed herein. Transposases may be used.
One embodiment involving a transposases provides a vector that
encodes a transposase. Other vectors encode a transposon that is
recognized by the transposase and has a nucleic acid fragment of
interest, e.g., a reporter, selection marker, exogenous nucleic
acid for insertion or as a template for modification, or one or
more TALENs. Accordingly, a cell or embryo may be transfected with
a number of vectors between, for example, 1 and about 6; artisans
will immediately appreciate that all the ranges and values within
the explicitly stated ranges are contemplated, e.g., 2, 3, 4, 5,
and 6. More vectors may be used. The reporter may be used to
identify cells that are likely to have undergone modification by
TALENs. Or a selection marker may be used to enrich the proportion
of TALEN-modified cells by destroying cells or embryos that do not
express the selection marker.
[0282] An embodiment of the invention is a cell or embryo culture
exposed to, or injected with, a plurality of vectors. A first
vector comprises a TALEN or TALEN-pair; alternatively there are two
TALEN vectors that independently provide a left TALEN and a right
TALEN. A second vector comprises a reporter. The reporter may
provide for non-destructive identification or may be a selection
marker. A vector encoding a selection marker may be used as an
alternative to the reporter vector, or in addition to the reporter
vector. A further vector may encode an exogenous nucleic acid.
[0283] A process for making TALEN-modified cells, embryos, or
animals can comprise assaying a cell or embryo exposed to a TALEN
for expression of a reporter and using that cell or embryo in a
method or composition for making a genetically modified livestock
and/or artiodactyl or other animal (fish, zebrafish, dogs, mice,
avian, chicken, rats or a laboratory animal). For instance, a
primary cell may be removed from a cell culture and used for
cloning. Or, a primary cell may be removed from culture and placed
in a second culture to make a clonal line or for further processes.
Or, an embryo or zygote expressing the reporter may be used for
either implantation into a surrogate dam or can be used for
cloning, while other embryos or zygotes that do not express the
reporter not used for cloning. In some embodiments, the reporter is
a selection marker that is used to select for cells or embryos that
express the marker.
Allele Introgression in Pig, Goat and Cattle Genomes
[0284] While plasmid templates were effective for introgression of
POLLED and GDF8, the inventors believe that many desirable alleles
correspond to SNPs. A set of experiments used oligonucleotide
templates that had an overlap in their cognate TALEN-binding sites
and that also introduced a 4 bp indel into the spacer region for
restriction fragment length polymorphism (RFLP) analysis. Primary
fibroblasts were transfected with plasmid- or mRNA-encoded TALENs
plus oligo templates and incubated 3 days at either 30 or
37.degree. C. TALENs delivered as mRNA consistently outperformed
plasmid in cells incubated at 30.degree. C. (FIG. 37A). Despite
appreciable levels of TALEN activity measured by the SURVEYOR
assay, HDR was consistently higher (>2-fold) when TALENs were
delivered as mRNA compared to plasmids. This observation was
surprising, and it was speculated that could have been a result of
favorable kinetics; e.g., TALENs from mRNA were more rapidly
translated allowing utilization of the template prior to oligo
degradation. However, a time-course experiment showed little
difference in the onset of HDR between TALENs encoded by plasmid
versus mRNA (FIG. 37B). Among replicates using TALEN mRNA at
30.degree. C., the levels of cumulative mutation and total HDR were
similar, suggesting the majority of mutant alleles corresponded to
the intended introgression.
[0285] In some studies, TALEN-induced indels declined 50-90% after
extended culture where selection processes or markers were not used
(Carlson, D. F. et al. Efficient TALEN-mediated gene knockout in
livestock, Proceedings of the National Academy of Sciences,
109:17382-17387 (2012), herein "Carlson 2012"). In other words, in
some instances, when indels were made, they were often not stable
and a selection marker process was used to identify stable changes.
In contrast, it was observed herein that HDR levels at four loci
were roughly equivalent when measured at days 3 and 10 without
selective enrichment, indicating that these HDR indel alleles were
stable in culture (FIG. 37A). The consistently high rate (25-50%)
and stability of gene edits at all four loci suggested that edited
cells should be recoverable by dilution cloning without selective
enrichment, reporters or selection markers. Further experimental
work involving analysis of about 1,000 colonies for defined indel
alleles in eight separate loci revealed a recovery rate of 10-65%
(average 42%) where up to 32% of the colonies are homozygous for
the intended edit (Table 7). The data shows that introducing TALENs
as mRNA into the cell is helpful for efficiency and stability;
extended culture times at 30.degree. C. were also helpful.
Production of Biomedical Model Animals with Gene-Edited Alleles
[0286] Two gene-edited loci in the porcine genome were selected to
carry through to live animals--APC and DAZL. Mutations in the
adenomatous polyposis coli (APC) gene are not only responsible for
familial adenomatous polyposis (FAP), but also play a rate-limiting
role in a majority of sporadic colorectal cancers. Dazl (deleted in
azoospermia-like) is an RNA binding protein that is important for
germ cell differentiation in vertebrates. The DAZL gene is
connected to fertility, and is useful for infertility models as
well as spermatogenesis arrest. Colonies with HDR-edited alleles of
DAZL or APC for were pooled for cloning by chromatin transfer. Each
pool yielded two pregnancies from three transfers, of which one
pregnancy each was carried to term. A total of eight piglets were
born from DAZL modified cells, each of which reflected genotypes of
the chosen colonies consistent with either the HDR allele or
deletions resulting from NHEJ. Three of the DAZL piglets were
stillborn. Of the six piglets from APC modified cells, one was
stillborn, three died within one week, and another died after 3
weeks, all for unknown reasons likely related to cloning. All six
APC piglets were heterozygous for the intended HDR-edited allele
and all but one either had an in-frame insertion or deletion of 3
bp on the second allele. Remaining animals are being raised for
phenotypic analyses of spermatogenesis arrest (DAZL-/- founders) or
development of colon cancer (APC+/-founders).
[0287] Template-driven introgression methods are detailed herein.
Embodiments of the invention include template-driven introgression,
e.g., by HDR templates, to place an APC or a DAZL allele into a
non-human animal, or a cell of any species.
[0288] This method, and methods generally herein, refer to cells
and animals. These may be chosen from the group consisting of
vertebrate, livestock, an artiodactyl, a primate, cattle, a swine,
a sheep, a goat, a bird, a chicken, a rabbit, fish, dog, mice, rat,
cat or laboratory animal. The term livestock means domesticated
animals that are raised as commodities for food or biological
material. The term artiodactyl means a hoofed mammal of the order
Artiodactyla, which includes cattle, deer, camels, hippopotamuses,
sheep, pigs and goats that have an even number of toes, usually two
or sometimes four, on each foot.
Alleles for Introgression
[0289] Allele introgression has many important applications. The
Allelic Introgression Table, below, and Table 7 (Frequencies for
recovery of colonies with HDR alelles) describe certain genes and
their applications. Artisans reading this application will be able
to make and use the introgressions and resultant cells and animals.
Artisans can readily apply the processes set forth herein for the
use of these alleles as templates or targets for disruption.
Embodiments include making a genetically modified cell or animal
(for instance, a lab animal, an F0 founder, or animal line) whose
genome has received a gene from Table 7 or the Allelic
introgression Table, e.g., by insertion or template-driven allele
introgression that replaces the endogenous allele with an allele
from Table 7 or the Allelic introgression Table. Alleles for some
genes are reported to provide livestock production advantages, but
are at very low frequencies or are absent in some breeds or species
(see items 1-9). Introgression of these alleles can be of
significant value for production traits. For example, the Polled
allele (item 1) from beef breeds results in animals that do not
have horns, whereas dairy breeds do not have this allele so have
horns and need to be dehorned as a production practice. Allele
introgression from beef breeds into horned (dairy) breeds will lead
to hornless dairy cattle which is has value for both production and
animal welfare. Other examples relate to alleles that can increase
or enhance characteristics of agricultural products such as meat
(items 4-6) and milk (items 7-8). Item 9 is useful for disease
resistance.
[0290] Many commercial and commonly used animal breeds have been
carefully bred to establish desirable traits but, in the process of
that breeding, have accumulated genetic errors that reduce their
reproductive success because of losses in fertility or by
increasing miscarriages. Deleterious alleles for some genes are
present in animal populations. As explained elsewhere herein, the
inventive techniques provide for changing alleles only at an
intended location in a target animal, without other modifications
resulting from genetic tools or from meiotic recombinations.
Therefore, for the first time, it is possible to clean-up the
genetic errors that have accumulated in livestock and animal breeds
without disrupting the genome of the animals and, consequently,
disrupting traits or causing unintended consequences. Alleles for
some genes can be used to control animal fertility for genetic
control of breeding stock (items 2-3). The term breed is a term of
art that refers to domestic animals that, through selection and
breeding, have come to resemble one another and pass those traits
uniformly to their offspring. The animals that belong to a
particular breed are known to artisans that practice in these arts.
Breed specific characteristics, also known as breed traits, are
inherited, and purebred animals pass such traits from generation to
generation. Thus, all specimens of the same breed carry several
genetic characteristics of the original foundation animal(s). In
order to maintain the breed, a breeder would select those animals
with the most desirable traits to achieve further maintenance and
developing of such traits. At the same time, the breed would avoid
animals carrying characteristics undesirable or not typical for the
breed, including faults or genetic defects. In our examples, we
recruit genetic benefits (specific traits) from one breed into
another without the traits that are considered negative in a
certain breed.
[0291] Many useful animal models can be made. Certain alleles are
useful, see Allelic introgression Table items 10-39. Some of these
are established in animals. Others of the genes are known to cause
human disease, so introgressing these alleles into livestock, lab
animals, or other animals is useful to create biomedical models of
human disease.
[0292] Embodiments of the invention include a method of making a
genetically modified animal, said method comprising exposing
embryos or cells to an mRNA encoding a TALEN, with the TALEN
specifically binding to a target chromosomal site in the embryos or
cells, cloning the cells in a surrogate mother or implanting the
embryos in a surrogate mother, with the surrogate mother thereby
gestating an animal that is genetically modified without a reporter
gene and only at the TALEN targeted chromosomal site wherein the
allele is a member of the group consisting of (a) horn polled locus
(b) a gene recessive for fertility defects, e.g., CWC15 and/or
ApaF1 (c) genes for enhancing a livestock trait, e.g., meat
production (GDF8, IGF2, SOCS2, or a combination thereof) and/or
milk production (DGAT1 and/or ABCG2) (d) a gene for changing animal
size (PLAG1, GHRHR) (e) genes that potential tumor growth (e.g.,
TP53, APC, PTEN, RB1, Smad4, BUB1B, BRCA1, BRCA2, ST14 or a
combination thereof) (f) human oncogenes for animal models of
cancer (e.g., AKT1, EGF, EGFR, KRAS, PDGFRA/B or a combination
thereof) (g) genes in animal models for hypercholesterolemia (to
induce atherosclerosis, stroke, and Alzheimer's disease models),
e.g., LDLR, ApoE, ApoB or a combination thereof (h) Inflammatory
Bowel disease, e.g., NOD2 (i) spina bifida, e.g., VANGL1 and/or
VANGL2 (j) pulmonary hypertension, e.g., miR-145 (k) genes for
cardiac defects, e.g., BMP10, SOS1, PTPN11, Nrg1, Kir6.2, GATA4,
Hand2, or a combination thereof and (1) celiac disease genes, e.g.,
HLA-DQA1.
TABLE-US-00001 Allelic Introgression Table Genes; Species Item
[Gene Reference Identification] Application 1 Horn-Polled Locus;
Bovine Transfer allele into cows of [UMD3.1:1:1705490:1706389:1]
various breeds to make bovine lines of those species without horns;
see Medugorac, I., D. Seichter, et al., (2012). "Bovine polledness
- an autosomal dominant trait with allelic heterogeneity." PloS
one, 7(6):e39477. 2 CWC15 (JH1) Use natural allele as template to
[hs Gene ID: 51503] restore wildtype sequence to animal lines and
breeds with 3 ApaF1 (HH1) defective alleles; see VanRaden, [hs Gene
ID: 317] P. M., K. M. Olson, et al., (2011). "Harmful recessive
effects on fertility detected by absence of homozygous haplotypes."
J Dairy Sci., 94(12):6153-6161. 4 GDF8 Enhancement of growth for
meat [hs Gene ID: 2660] production. 5 IGF2 [hs Gene ID: 3481] 6
SOCS2 [hs Gene ID: 8835] 7 DGAT1 Alleles of these genes are known
[hs Gene ID: 8694] to influence the amount and 8 ABCG2 composition
of milk. Hs Gene ID: 9429] 9 GHRHR Size reduction of animals for
[hs Gene ID: 2692] Biomedical modeling. 10 TP53 Tumor suppressor
genes; [hs Gene ID: 7157] heterozygous knockout to 11 APC
potentiate tumor growth. [hs Gene ID: 324] 12 PTEN [hs Gene ID:
5728] 13 RB1 [hs Gene ID: 5925] 14 Smad4 [hs Gene Id: 4089] 15
BUB1B [hs Gene ID: 701] 16 BRCA1 [hs Gene ID: 672] 17 BRCA2 [hs
Gene ID: 675] 18 ST14 [hs Gene ID: 6768] 19 AKT1 Oncogenes.
Activated human [hs Gene ID: 207] alleles will be introgressed into
20 EGF pigs to model cancers. [hs Gene ID: 1950] 21 EGFR [hs Gene
ID: 1956] 22 KRAS [hs Gene ID: 3845] 23 PDGFRA/B [hs Gene IDs:
5156/ 5159] 24 LDLR Hypercholesterolemia to induce [hs Gene ID:
3949] atherosclerosis, stroke and 25 ApoE Alzheimer's disease
models. [hs Gene ID: 348] 26 ApoB [hs Gene ID: 338] 27 NOD2
Inflammatory Bowel disease for [hs Gene ID: 64127] animal models.
28 VANGL1 Spina Bifida is associated with [hs Gene ID: 81839]
alleles of these genes. Transfer of 29 VANGL2 these alleles in
livestock will [hs Gene ID: 57216] generate models for biomedical
research. 30 miR-145 Pulmonary hypertension is [hs Gene ID: 611795]
associated with alleles of these genes. Transfer of these alleles
in swine will generate models for biomedical research. 31 BMP10
Cardiac defects associated with [hs Gene ID: 27302] alleles of
these genes. Transfer of 32 SOS1 these alleles will generate models
[hs Gene ID: 6654] for biomedical research. 33 PTPN11 [hs Gene ID:
5781] 34 Nrg1 [hs Gene ID: 3084] 35 Kir6.2 [hs Gene ID: 3767] 36
GATA4 [hs Gene ID: 2626] 37 Hand2 [hs Gene ID: 9464] 38 HLA-DQA1
Alleles associated with celiac [hs Gene ID: 3117] disease will be
transferred to livestock to create an animal model.
Differential Stability of Gene-Edits
[0293] It was not known if it was possible to have introgression of
stable SNPs by NHEJ or HDR. As indicated in Table 7, both day-3
levels of HDR (7-18%) and the isolation of cellular clones with the
intended SNP alleles (3-15%) within cattle and swine GDF8 or pig
p65 was significantly lower than for indel alleles, where HDR
ranged from 10 to about 50%. This data suggested a hypothesis that
indels were more stable than SNP because the introduction or
elimination of at least 4 bp in the TALEN spacer region would be
expected to reduce re-cleavage of the locus, consistent with
constraints on TALEN spacer length. And even a 4 bp insertion
allele was more efficient than SNP alleles, based comparison of HDR
frequencies with oligo within the same locus suggested (FIG. 38).
This hypothesis also explained why sequence analysis revealed that
nearly half of the isolated SNP-positive colonies for GDF8 or pig
p65 harbored concomitant indels expected to change TALEN spacing.
Regardless, it was possible to recover colonies with homozygous
conversion of G938A in GDF8 (both pigs and cattle) and T1591C in
pig p65 at up to nearly a 5 percent level without any additional
changes to the locus (Table 7). It was also possible to introgress
small polymorphisms for the sheep FecB and Callipyge loci into the
goat genome. This ability to precisely alter a single nucleotide or
1-3 nucleotides is surprising as well as significant. As a
comparison, it was also possible to design CRISPR gRNAs that
overlapped the T1591C site of p65 and to compare introgression
using the two platforms. Despite efficient production of DSB at the
intended site, CRISPR/Cas9-mediated HDR was lower than 6 percent at
day-3 and below detection at day-10 (FIG. 39). Recovery of modified
clones with CRISPR-mediated HDR was also lower than with TALENs
even though the TALENcleavage site was 35 bp away from the SNP site
(Table 7). Analysis of CRISPR/Cas9 induced targeting at a second
locus, ssAPC14.2, was much more efficient, but still did not reach
the level of HDR induced by TALENs at this site, circa 30 versus
60% (FIG. 40).
Strategies for Introgression of Alleles and for Stabilizing
Introgressed SNP Alleles
[0294] Given the conservation of the 5'-thymidine nucleotide
immediately preceding TAL-binding sites, it was reasoned that
altering these bases in the oligo HDR template (referred to as
blocking mutations (BM)) would inhibit re-cleavage of edited
alleles. Surprisingly, the BMs had no significant impact on the
maintenance of SNP alleles at the pig LDLR or GDF8 loci (FIG. 41
panel a). This suggested that either the conversion tract for
oligo-templated HDR is quite short and does not incorporate the BM,
or that altering the 5'-thymidine does not completely abolish TALEN
activity.
[0295] ILLUMINA deep sequencing was conducted for 200-250 bp
amplicons flanking the target sites from populations of cells
transfected with oligos and TALEN mRNA. The results from five loci
in pigs and cattle showed that insertion alleles were in general
more prevalent and stable in the population (FIG. 42). Whereas BMs
had little influence on the preservation of intended alleles in
culture, there was a slight bias towards incorporation of BMs in
SNP edited alleles versus insertional edits (FIG. 43). with our
colony analysis, reads sorted on the basis of incorporating the
intended SNP (iSNP), G938A or T1591C conversion in btGDF8 and p65,
revealed that nearly half of reads with the iSNP had an additional
mutation (iSNP+Mut) (FIG. 42 panel b), the majority of which were
indels (FIG. 43). The majority of iSNP btGDF8 reads with indels in
the spacer also contained one or both BM (data not shown)
demonstrating that modification of the conserved 5'-thymidine was
not able to suppress re-cleavage and subsequent indel generation.
Thus, this base must be less critical to TALEN-binding than
suggested by conservation, and provides a molecular basis for the
inability of BMs to preserve alleles as described above.
[0296] Another strategy to reduce re-cutting of the SNP edits is to
design TALENs such that their binding sites overlap the target
SNPs. The influence of RVD/nucleotide mismatches within the
TALEN-binding site for introgression of G938A SNP into cattle GDF8
was evaluated. Two pairs of TALENs were generated, one that bound
the wildtype "G" allele (btGDF83.6-G) and another that bound the
intended "A" allele (btGDF83.6-A) (FIG. 41 panel b). HDR with each
TALEN pair was similar at day-3 whereas levels measured at day-12
were significantly higher using the TALENs that bound the wildtype
"G" allele, indicating that recleavage was more prevalent with
btGDF83.6-A which targets the repaired allele perfectly. Different
RVD/nucleotide mismatches may have greater influence on maintenance
of HDR alleles since the NN-RVD used for the wildtype "G" TALENs is
able to bind both G and A nucleotides. For modification of porcine
EIF4GI, it was found that three RVD/nucleotide mismatches were
sufficient for protection of the HDR-edit as nearly 70% of isolated
colonies contained an edited allele, greater than half of those
being homozygotes (Table 7 and FIG. 44). Thus, the intentional
alteration of the target locus to resist recleavage is an effective
strategy for preserving edits.
[0297] It was hypothesized that gene-editing is a dynamic process.
TALEN cleavage and re-cleavage are theorized to be in flux with
repair by NHEJ, HDR with oligo template, and HDR with the sister
chromatid as template. It was hypothesized that the observed loss
of SNP alleles might be reduced by extending the hypothermic
treatment, slowing cell proliferation long enough to outlast the
burst of TALEN activity from TALEN mRNA transfection. Indeed, and
surprisingly, this extension almost tripled the level of SNP
HDR-edited alleles recovered after extended culture (FIG. 45).
[0298] For biomedical applications, alterations of bases besides
the key bases that create the desired functionality is acceptable
so long as the desired phenotype is achieved and the other changes
are apparently without functional relevance. The inventors believe,
however, that it is desirable for animals used in agriculture, to
duplicate natural (native) alleles without further changes or to
make only the intended edits without further changes. In contrast
to the approaches where the mismatches are derived from successful
introgression of the HDR construct, mismatches can be derived from
changes in the RVD sequence. For TALENs, this process requires the
TALEN monomers to be constructed with RVDs that do not bind to
their corresponding nucleotides in the native alleles (FIG. 46
panel c). This concept of an intentional mismatch in the design of
the nuclease (in this case TALENs) to prevent re-cutting of a
desired is novel and operates under the following theory. TALENs
can only tolerate some mismatches in their binding regions before
their binding activity is essentially eliminated. Thus, it is
possible to develop TALENs that have intentional mismatches with
the native allele that will still cut, but as more mismatches are
created, binding will be abolished. The theory of intentional
mismatch is that after introgression of the desired allele, the new
mismatch will have an additive effect to the engineered mismatches
in the TALEN code to pass a critical tipping point to render the
TALEN inactive. Counterintuitively, decreasing nuclease affinity
for a target by intentional mismatching of RVDs provides a strategy
to introgress a specific mutation down to a single nucleotide
polymorphism (SNP), and reduce to undesired indels as a result of
re-cutting.
[0299] As an example, a TALEN pair (caCLPG 1.1) was designed with
zero mismatches to target the CLPG locus in the goat (Capra
aegagrus hircus) genome (FIG. 46 panel a). The desired mutation was
an adenine to guanine SNP, which has been linked to an increase in
hindquarter muscle hypertrophy. The SNP allowed easy genotyping of
colonies due to a loss of an AvaII restriction site. Initial
restriction digest assays showed several colonies with promising
results, however when the alleles of each colony were sequenced,
zero of fourteen were our intended product as each contained an
undesired indel in addition to the desired SNP (FIG. 46 panel b and
Table 6 labeled Success rate using intentional mismatches). To test
the intentional mismatch approach, an additional three TALEN pairs
were developed with different numbers and locations of intentional
mismatches (FIG. 46 panel c). These TALENs were able to cut the
wild-type allele at similar frequencies to the original caCLPG1.1
TALEN pair (FIG. 46 panel d). To observe the effect on HDR and
reducing of undesired indels, individual colonies were derived from
cells transfected with caCLPG 1.1c (two mismatches) and the HDR
template. In contrast to the results with the original caCLPG1.1
TALENs, three of fifteen (20%) of AvaII resistant colonies were
positive for the desired SNP and contained no additional mutations
(3/15=20%) (FIG. 46 panel e and Table 6). Thus, derivation of the
intended allele was dependent on intentional mismatch. TALEN pair
btPRLR 9.1 (see Tables 6, 10, and 14) was used to cause a
frameshift in the bovine prolactin receptor gene (see FIGS. 66 and
67).
TABLE-US-00002 TABLE 6 Success Rate Using Intentional Mismatch
TABLE 6: Success of intentional Mismatch and HDR at Agriculturally
relevant loci. Number of Species/Cell Allele RVD Gene type desired
mismatches TALEN ID RFLP pos. Confirmed CLPG Goat/ A to G 0
caCLPG1.1 NA 0/14 Fibroblasts CLPG Goat/ A to G 2 caCLPG1.1c NA
3/15 Fibroblasts DGAT Cow/ K232A 0 btDGAT 14.2 19/96 0/12
Fibroblasts DGAT Cow/ K232A 1 btDGAT 14.4 15/96 0/12 Fibroblasts
DGAT Cow/ K232A 1 btDGAT 14.5 16/96 2/12 Fibroblasts DGAT Cow/
K232A 1 btDGAT 14.6 15/96 3/12 Fibroblasts PRLR Cow/ Trunc461 0
btPRLR 9.1 NA 2/11 Fibroblasts SOCS2 Pig/ Trunc10 0 ssSocs 2.1
75%.sup.b Fibroblasts SLC35A3 Cow/ V180F.sup.a 0 SLC35A3 8.3
18%.sup.b Fibroblasts .sup.aRepair of the missense allele that
results in complex vertebral malformation (Thomsen, B; Genome Res.
2006 January; 16(1): 97-105.) .sup.bPercentage of HDR on the
population level CLPG (callipyge gene); DGAT (Diacylglycerol
O-Acyltransferase); PRLR (Prolactin Receptor); SOCS2 (Suppressor of
cytokine signaling 2); SLC35A3 (Solute Carrier Family 35 Member
A3)
[0300] In a further example, the intention was to alter
specifically two bases in the bovine DGAT gene. As with the CLPG
locus, attempts to introgress the desired mutation without
intentional mismatch failed as 0/12 RFLP colonies that were
positive for the HindIII site were free of indels (FIG. 47 panel d
and Table 6). The intentional mismatch method was used, and found
overall rates of HDR on the population level (FIG. 47 panel c).
Sequencing from individual colonies however revealed that two of
three of the intentional mismatch designs were successful, giving
rise to 2/12 and 3/12 correct alleles for 14.5 and 14.6
respectively (FIG. 47 panel e and Table 6). As with the CLPG locus,
derivation of the intended allele was dependent on RVD-encoded
intentional mismatch. The data in Table 7 demonstrated that
combining mRNAs encoding TALENS plus oligonucleotides as templates
for directing HDR achieved several benchmarks for a genome-editing
strategy: 1) only target nucleotides were changed and mRNA
transfection avoided unintended integration of plasmid DNA, 2) gene
edits were efficient; from about 10% for SNPs to above 50% for some
larger alterations, and 3) the method was reliable; targeted
alteration of 16/16 sites (15 genes) was achieved. The efficiency
and precision reported here is very surprising.
TABLE-US-00003 TABLE 7 Frequencies for recovery of colonies with
HDR alleles Mutation aa Day 3% Bi-allelic Reagent ID Species type
nt change change HDR HDR+ (%) HDR+ (%) TALEN ssLDLR2.1.sup.a Pig
Ins/FS 141(Ins4) 47.DELTA.PTC 38 55/184 (30) 4/184 (2) TALEN
ssDAZL3.1.sup.b Pig Ins/FS 173(Ins4) 57.DELTA.PTC 25 34/92 (37)
8/92 (9) TALEN ssDAZL3.1.sup.Rep Pig Ins/FS 173(Ins4) 57.DELTA.PTC
30 42/124 (34) 7/124 (6) TALEN ssAPC14.2.sup.b Pig Ins/FS
2703(Ins4) 902.DELTA.PTC 48 22/40 (55) 4/40 (10) TALEN
ssAPC14.2.sup.Rep Pig Ins/FS 2703(Ins4) 902.DELTA.PTC 50 57/96 (60)
19/96 (20) TALEN ssAPC14.2.sup.Ld Pig Ins/FS 2703(Ins4)
902.DELTA.PTC 34 21/81 (26) 1/81 (1) TALEN ssTp53 Pig Ins/FS
463(Ins4) 154.DELTA.PTC 22 42/71 (59) 12/71 (17) TALEN ssRAG2.1 Pig
Ins/FS 228(Ins4) 76.DELTA.PTC 47 32/77 (42) 13/77 (17) TALEN
btRosa1.2.sup.c Cow Ins/mloxP Ins34 NA 45 14/22 (64) 7/22 (32)
TALEN ssSRY3.2 Pig Ins/mloxP Ins34 NA 30 ND ND TALEN ssKissR3.2 Pig
Ins/FS 322(Ins6) 107.DELTA.PTC 53 57/96 (59) 17/96 (18) 323(del2)
TALEN btGDFB3.1 Cow del/FS 821 (del11) FS ~10 7/72 (10) 2/72 (3)
TALEN ssEIF4GI14.1 Pig SNPs G2014A N572D 52 68/102 (67) 40/102 (39)
T2017C C2019T L673F TALEN btGDFB3.6N Cow SNPs G938A C313Y 18 8/94
(9) 3/94 (3) T945C TALEN btGDFB3.6N.sup.d Cow SNP G938A C313Y NA
7/105 (7) 2/105 (2) TALEN ssP65.8 Pig SNP T1591C S531P 18 6/40 (15)
3/40 (8) TALEN ssP65.8.sup.Rep Pig SNP T1991C S531P 7 9/63 (14)
3/63 (8) TALEN ssGDF83.6.sup.d Pig SNP G938A C313Y NA 3/90 (3) 1/90
(1) TALEN caFecB6.1 Goat SNP A747G Q249R 17 17/72 (24) 3/72 (4)
TALEN caCLPG1.1 Goat SNP A.fwdarw.G Non- 4 ND ND coding CRISPR
ssP68 G1s Pig SNP T1591C S531P 6 6/96 (6) 2/96 (2) CRISPR ssP65 G2a
Pig SNP T1591C S531P 3 2/45 (4) 0/45 CRISPR APC14.2 G1a Pig Ins/FS
2703 (Ins4) 902.DELTA.PTC 32 ND ND
[0301] Two concerns in gene editing are stabilizing the changes at
the targeted site and avoiding modification of unintended sites.
With regard to the first, evidence was found that HDR-edits
directing single basepair changes, i.e., SNPs, could be lost (FIG.
41 and FIG. 42 panel b). Based on the prediction that a thymidine
preceding the targeted DNA sequence influences TAL binding, it was
attempted to block re-cleavage of introgressed alleles by
introducing BMs. However, it was found that BMs did not prevent
TALEN activity and re-cleavage of edited alleles (FIG. 41 and FIGS.
43 and 44). In contrast, introduction of multiple SNPs or
additional sequence (FIG. 37A and FIG. 44) resulted in more stable
HDR226 edits. Surprisingly, it was found that extension of
hypothermic culture resulted in the stabilization of introgressed
SNP alleles. It is theorized that hypothermia slows cell
proliferation primarily by prolonging G1-phase of the cell cycle so
that this treatment differentially favors oligo-HDR versus sister
chromatid templated repair in a cell-cycle dependent manner.
Regardless of the mechanism, this approach offers a
straight-forward strategy for recovering cells with precise
introgression of SNP alleles.
[0302] A variety of objectives were achieved by precise gene
editing (Table 7). Knockout of genes of biomedical relevance was
accomplished by interrupting coding sequences with 4 bp indels.
This strategy was reliable and generally resulted in HDR-edits in
about 40% of the clones (range 26-60%), and of those, up to
one-third were homozygotes. At similar frequencies, a modified loxP
(mloxP) site was integrated into ROSA26 and SRY loci in cattle and
pigs that can be used as a landing pad (also referred to as a safe
harbour) for insertion of novel sequences in livestock via
recombinase-mediated cassette exchange. Previously, only NHEJ edits
had been demonstrated for the Y chromosome of livestock, however,
TALENs are suitable for direct stimulation of knockout/knock-in, at
least as demonstrated in mice. Also, there was an introgression of
native alleles between species/breeds, including the
double-muscling mutations of GDF8 (SNP G938A23, 25 or 821del1123-25
from Piedmontese and Belgian Blue cattle respectively) into the
genome of Wagyu cattle and Landrace pigs.
[0303] In some cases gene targeting with a standard plasmid vector
and homologous recombination cassette will not be suitable for
transgene delivery. Some cases could include when attempting to
place a transgene in a site surrounded by repetitive elements or
low complexity DNA. In these cases, the short homology required by
oligo HDR may be preferred to integrate a transgene into a small
region of unique sequence. However, the cargo capacity for oligo
HDR is not sufficient to deliver a transgene. To circumvent this
problem, we sought to combine the efficiency of oligo HDR for
delivery of small insertions (e.g., LoxP sites) and the large cargo
capacity of recombinase mediated cassette exchange (RMCE) for site
specific integration of transgenes. Recombinase-mediated cassette
exchange (RMCE) is a method based on the features of site-specific
recombination processes (SSRs). This process allows for systematic,
repeated modification of higher eukaryotic genomes by targeted
integration. This result is achieved with RMCE by the clean
exchange of a preexisting gene cassette for an analogous cassette
carrying the gene of interest (GOI).
[0304] There are problems with using RMCE to make genetically
modified animals in the higher vertebrates, such as livestock. A
significant problem is that due to the short lifespan of primary
livestock cells prior to senescence, this process must occur in a
single treatment. It would be possible in some other types of cells
to perform the RMCE process serially wherein a cellular clone with
the inserted LoxP site is isolated prior to transfection with the
RCME machinery and isolation of clones to identify those with the
correct targeting event. Applicants attempted to perform this
process by simultaneously transfecting primary fibroblasts with
four components: 1) SRY TALENs 2) an oligo with homology to SRY
that includes two RMCE compatible loxP sites 3) a RMCE compatible
transgene and 4) a source of Cre recombinase. In FIG. 48, the RMCE
transgene was the puromycin resistance gene enabling selection for
integration events. The number of puromycin resistant colonies was
significantly increased when YFC-Cre was provided in contrast to
the control group that included a mCherry expression cassette in
place of YFC-Cre. Among puromycin resistant colonies (selected from
cells treated for 3 days at either 30.degree. C. or 37.degree. C.)
eight (n=95) and four percent (n=95) were positive for correct
targeting of the RMCE vector. These results showed that it was
possible to simultaneously provide the TALENS, HDR template
containing loxP site, a transgene of interest flanked by loxP, and
a Cre-recombinase mRNA resulting in RMCE mediated recombination
into a TALEN targeted locus.
[0305] Embodiments of the invention include a process of homology
dependent repair using an HDR template with a sequence that is
introduced into the host cell or embryo that is a landing pad,
e.g., for exogenous genes. The term landing pad is used according
to its customary meaning to refer to a site-specific recognition
sequence or a site-specific recombination site that is stably
integrated into the genome of a host cell. Presence in the host
genome of the heterologous site-specific recombination sequence
allows a recombinase to mediate site-specific insertion of a
heterologous polynucleotide or an exogenous into the host
genome.
[0306] Embodiments include, kits, uses, compositions, and a method
of creating a landing pad in a chromosomal DNA of a cell,
comprising introducing a targeted nuclease system and a HDR
template into the cell, with the targeted nuclease system
comprising a DNA-binding member for specifically binding an
endogenous cognate sequence in the chromosomal DNA, wherein the
targeted nuclease system and the HDR template operate to alter the
chromosomal DNA to have identity to the HDR template sequence,
wherein the HDR template sequence comprises a landing pad. The
method may be applied in a primary cell or embryo. Embodiments
include introducing the targeting nuclease, the HDR template
encoding the landing pad, the exogenous gene that is compatible
with the landing pad, and a source of recombinase compatible with
the same; all of these may be introduced simultaneously. The term
simultaneous is in contrast to a hypothetical process of treating
cells multiple times in seriatim; the term must be kept in context,
with an appreciation that it refers to a literally simultaneous
introduction or an introduction calculated to having all of the
factors bioactive at the same time. The landing site may be, e.g.,
RMCE compatible loxP sites, FRT, rox, VloxP, SloxP. The recombinase
may be, e.g., Cre, FLP, Dre.
[0307] In other experiments, for improvement of animal welfare, the
POLLED allele was transferred from a beef producing breed into
cells from horned dairy cattle. A candidate SNP allele for African
swine fever virus resilience (T1591C of p6539) was transferred from
warthog to the genome of conventional swine cells and introgressed
sheep SNPs responsible for elevated fecundity (FecB; BMPR-IB) and
parent-of-origin dependent muscle hypertrophy (Callipyge) were
transferred into the goat genome. Such introgression was previously
impossible by breeding and will enable the assessment of defined
genetic effects in related species. Non-meiotic allele
introgression has not conventionally been possible without
selective enrichment, and efficiencies reported herein are
10.sup.3-10.sup.4-fold higher than results previously obtained with
selection. Such high levels of unselected single-allele
introgression suggests it will be feasible to alter multiple
alleles in a single generation of farm animals, decreasing the
impact of long generation intervals on genetic improvement.
Furthermore, efficient editing to homozygosity will greatly
increase the rate of introgression per breeding interval.
[0308] As further elaboration of inventions described here
customized endonucleases were used to generate live animals with
precise edits at two independent loci. Pigs edited to disrupt the
DAZL gene are useful as a model for studying the restoration of
human fertility by germ cell transplantation, or for the production
of genetically modified offspring by transfer of genetically
modified germline stem cells as demonstrated in pigs, goats, and
rodents. Gene edited alleles of APC provide a size-relevant model
of colon cancer for pre-clinical evaluation of therapeutics,
surgical intervention or detection modalities. These results
demonstrate an introduction of genetic modifications, including
polymorphisms, and including modifications that mimic natural
polymorphisms into livestock. Gene-editing technology is useful to
accelerate genetic improvement of agricultural products by intra-
and interspecific allele introgression to help meet the growing
global demand for animal protein. It also is useful for the
development of large animals with defined genetics for drug and
device testing, or for the development of therapeutic cells and
organs. Other uses include making cells that can be used in vitro
for research to understand the mechanisms of congenital and
infectious disease, and to improve the methods for gene editing and
control.
Gross Chromosomal Deletions and Inversions; Genetically Modified
Animals
[0309] Experiments were performed with TALENs directed to a
plurality of DNA sites. The sites were separated by several
thousand base pairs. It was observed that the DNA could be rejoined
with the deletion of the entire region between the sites.
Embodiments include, for example, sites separated by a distance
between 1-5 megabases or between 50% and 80% of a chromosome, or
between about 100 and about 1,000,000 basepairs; artisans will
immediately appreciate that all the ranges and values within the
explicitly stated ranges are contemplated, e.g., from about 1,000
to about 10,000 basepairs or from about 500 to about 500,000
basepairs. Alternatively, exogenous DNA may be added to the cell or
embryo for insertion of the exogenous DNA, or template-driven
repair of the DNA between the sites. Modification at a plurality of
sites may be used to make genetically modified cells, embryos,
artiodactyls, and livestock. Example 5 describes the deletion of
several thousand basepairs of DNA, with rejoining of the ends
verified biochemically.
[0310] Unexpectedly, TALEN-cleavage at separated sites also
resulted in frequent inversion of the entire region between TALEN
targets. As an additional surprise, as detailed in Example 5, these
inversions were accomplished with great fidelity. Forty one out of
43 of the tested inversions were positive at both the 5' and 3'
junctions. And sequencing of PCR products confirmed both deletion
and inversion events with addition or deletion of very few
nucleotides at their junctions (FIG. 11, 12). This result was
highly surprising and unprecedented. Cells or embryos with these
deletions or inversions have many uses as assay tools for
genetics.
[0311] These cells are also useful for making animals, livestock,
and animal models. The term animal model includes, for example,
zebrafish, dogs, mice, rats or other laboratory animals. Large
deletions provide for gene inactivation. Also, for instance, a
deletion strain may be made of cells, livestock, or animal models.
Crossing the deletion strains with an organism bearing a mutation
for comparison to a wild-type helps to rapidly and conveniently
localize and identify the mutation locus. Deletion strains are well
known in these arts and involve sets of organisms made with a
series of deletions in a gene. Deletion mapping involves crossing a
strain which has a point mutation in a gene with the deletion
strains. Wherever recombination occurs between the two strains to
produce a wild-type (+) gene, the mutation cannot lie within the
region of the deletion. If recombination cannot produce any
wild-type genes, then it is reasonable to conclude that the point
mutation and deletion are found within the same stretch of DNA.
This can be used for example to identify causative mutations, or to
identify polymorphisms underlying quantitative trait loci.
[0312] Cells, embryos, livestock, artiodactyls, and animal models
with inversions are also useful for fixing a genetic trait in
progeny of an organism or an animal line or animal breed.
Recombinations typically occur between homologous regions of
matching chromosomes during meiosis. Inversion of a chromosomal
region destroys homology and suppresses meiotic recombination.
Methods and compositions described herein may be used to make such
organisms or animals. For example, DNA in a somatic bovine or
porcine cell may be cut at a plurality of loci by TALENs, and cells
with an inversion may be isolated, or cells expressing reporters
may be used as likely candidates for successful inversions. The
cells may be used to clone animals that harbor chromosomal regions
that are incapable of meiotic recombination. Alternatively, it is
expected that inversions will also occur at reasonable frequencies
in embryos treated with multiple TALEN-pairs at plurality of
sites.
[0313] An embodiment of this method is identifying a DNA region
encoding a genetic trait and cutting a DNA in a cell or embryo on
each side of the encoded trait at sites using a plurality of
TALENs. The modified cell or embryo may be used for creating a
genetically modified animal. The method may comprise isolating a
genetically modified animal that has the inversion.
Animals Genetically Modified without any Reporters; TALENs
Techniques; Allelic Migration
[0314] Certain embodiments of the invention are directed to
processes of modifying cells or embryos without the use of
reporters and/or selection markers. In general, it was initially
observed that the frequency of TALEN-modified cells decreases
significantly over time in the absence of enrichment or selection
methods such as the use of reporter genes. This observation lead to
approaches such as the co-transfection, co-selection technique
reported herein that involves reporter genes.
[0315] It has been discovered, however, that TALENs modification
can be performed with an efficiency that is so great that reporters
are not needed and their use merely delays the creation of
transgenic animal lines. Without being bound to a particular
theory, a number of factors independently contributed to the
invention of the reporter-free embodiments. One is the realization
that TALENs tend to act quickly and at a high efficiency. However,
TALENs modifications tended to be unstable over a time frame of
several days such that efficiencies can seem to be low depending on
the time of sampling. Further, it was conventional wisdom that only
stably modified organisms should be used to make transgenic animals
so that there is little incentive to understand short-term
modifications. There is an incentive to use cell survival genes to
select for stable incorporation, as is conventionally done in other
systems. Another factor is that TALENs mRNA is unexpectedly
effective as compared to vectors that express the TALENs. Direct
introduction of mRNA encoding TALENs is, in general, useful, and
was used in Examples 12 to 17.
[0316] Another factor is that, when an HDR template is desired,
direct introduction of ssDNA, e.g., single stranded (ss)
oligonucleotides, is useful, as demonstrated in Example 11. A
confounding effect is that the timing of the delivery of ssDNA was
important. In Example 11, delivery of the ss oligonucleotides at
the same time as the TALENs encoded from plasmid DNA was not
effective, but delaying introduction of the ss oligonucleotides for
24 hours resulted in high efficiencies. On the other hand, Example
15 showed that simultaneous introduction of ss oligonucleotide
templates and TALENs mRNA was effective. Since TALENs were
introduced in Example 11 as plasmid DNA expression cassettes, there
may have been 12 or more hours of delay between transfection and
accumulation of enough TALEN protein to begin cleaving the target.
Perhaps the oligonucleotides introduced with the TALENs in Example
11 were degraded by the cells or otherwise un-available
(compartmentalized or in complex with proteins) to act as template
for HR at the same time that TALENs were actively cleaving the
target. Another confounding factor, surprisingly, was that the ss
nucleotides have a biphasic effect (Example 15). That is to say,
too little or too much ss oligonucleotide results in a low
frequency of HDR. Embodiments of the invention include those
wherein the ssDNA is introduced into the cell after a vector
encoding a TALEN is introduced into the cell, for instance, between
about 8 hours and about 7 days afterwards; artisans will
immediately appreciate that all the ranges and values within the
explicitly stated ranges are contemplated, e.g., from about 1 to
about 3 days hours. Embodiments of the invention include those
wherein the ssDNA is introduced into the cell at about the same
time as mRNA encoding a TALENs is directly introduced, with the
term "about the same time" meaning within less than about 7 hours
of each other.
[0317] Another factor contributing to discovery of reporter-free
embodiments was that there is an unexpected synergy between ssDNA
(ss oligonucleotide) templates and TALENs activity. For example,
delivery of 0.5-10 micrograms TALEN-encoding mRNAs to
500,000-750,000 cells by nucleofection followed by 3 days of
culture at 30 degrees Celsius results in consistent levels of
modification. But supplementation of these same conditions with
0.2-1.6 nMol of ssODN led to an increase in TALENs activity, as
observed by increased NHEJ as assayed by SURVEYOR assay (Example
15). Typically, a transfection consists of 1-4 micrograms of TALEN
mRNA and 0.2-0.4 nMol of ssDNA. Embodiments include introducing to
a cell or an embryo, an amount of TALEN mRNA that is more than
about 0.05 .mu.g per 500,000 cells, or in a range of from about
0.05 .mu.g to about 100 .mu.g per 500,000 cells; artisans will
immediately appreciate that all the ranges and values within the
explicitly stated ranges are contemplated. Embodiments include
further introducing ssDNA at a concentration of more than about
0.02 nMol or in a range of from about 0.01 to about 10 nMol of
ssDNA.
[0318] The term direct introduction, e.g., direct mRNA
introduction, refers to introduction of mRNA material. In contrast,
introduction by means of a vector encoding the mRNA is termed
indirect introduction. Many processes of direct introduction are
known, e.g., electroporation, transfection, lipofection, liposome,
nucleofection, biolistic particles, nanoparticles, lipid
transfection, electrofusion, and direct injection.
[0319] Certain embodiments of the invention are directed to
processes of modifying cells or embryos without the use of
reporters and/or selection markers. In general, it was observed
that TALENs and CRISPR/Cas9 modifications were unstable over a time
frame of several days. Accordingly, processes described herein for
stabilizing changes may be used, as well as other processes
described in US 2013/0117870: for instance, direct mRNA
introduction and/or use of ssDNA templates. The term direct
introduction, e.g., direct mRNA introduction, refers to
introduction of mRNA material. In contrast, introduction by means
of a vector encoding the mRNA is termed indirect introduction. Many
processes of direct introduction are known, e.g., electroporation,
transfection, lipofection, liposome, nucleofection, biolistic
particles, nanoparticles, lipid transfection, electrofusion, and
direct injection.
[0320] Founder animals can be immediately created from modified
cells or embryos without the need to create initially modified
animals that are subsequently bred to create the basis for a new
transgenic line. The term founder or founder animal is used to
refer to a first-generation ("F0") transgenic animal that develops
directly from the cloned cell or treated/injected embryo that is
modified. Methods reported herein provide for creation of founders
genetically modified only at the chromosomal target site, and
without intermediate steps of breeding and/or inbreeding. Moreover,
embodiments include founders that are homozygous for the
modification. The founders may be prepared without ever exposing
cells and/or embryos to reporter genes (and/or selection marker
genes).
[0321] Embodiments include a method of making a genetically
modified animal, said method comprising exposing embryos or cells
to an mRNA encoding a TALEN, with the TALEN specifically binding to
a chromosomal target site in the embryos or cells, cloning the
cells in a surrogate mother or implanting the embryos in a
surrogate mother, with the surrogate mother gestating an animal
that is genetically modified without a reporter gene and only at
the chromosomal target site bound by the TALEN. The animal may be
free of all reporter genes or may be free of selection markers,
e.g., is free of selection markers but has a reporter such as a
fluorescent protein. Options include directly introducing the
TALENs as mRNA and/or a ss oligonucleotide that provides a template
for a genetic modification, e.g., an allele.
[0322] A method of making a genetically modified animal comprises
introducing TALENs and/or vectors into cultured cells, e.g.,
primary livestock cells. The TALENs are directed to specific
chromosomal sites and cause a genetic alteration at the site. An
HDR template may also be introduced into the cell, e.g., as a
double stranded vector, single stranded DNA, or directly as a ss
nucleotide. The cultured cells are subsequently cultured to form
colonies of clonal cells. The colonies are tested by PCR and/or
sequenced, or otherwise assayed for a genetic modification,
preferably without a reporter gene and/or without a selection
marker. Cells are taken from colonies that are genetically modified
at the intended site and used in cloning. For example, from 10 to
50,000 cells are used to make from 10 to 50,000 embryos that are
implanted into surrogates, e.g., in sets of 1-500 embryos per
surrogate; artisans will immediately appreciate that all the ranges
and values within the explicitly stated ranges are contemplated.
Embodiments comprise exposing the cells to the TALEN without a
reporter gene, creating colonies of clonal cells, and testing a
subset of members of the colonies to identify colonies
incorporating the modification at the chromosomal target site.
[0323] Processes of making colonies of clonal cells from cultured
cells are known. One such method involves dispersing cells from a
first culture into a second culture wherein the various cells are
not in contact with each other, e.g., by diluting the cells into
multiwall plates or into a plate with a relatively large surface
area for the number of cells placed therein. The cells are cultured
for a period of time that allows the cells to multiply. The
multiplying cells are cultured in conditions where they are not
likely to move far away from their original location. As a result,
a user may observe the cells after the period of time and see
various colonies that are all made of a single cell and its
progeny. A subset of the cells in the colony may be sampled without
destroying the other cells in the colony.
[0324] Assays for a genetic modification may include destructive
assays, meaning an assay that destroys the cell that is tested to
determine if it has a certain property. Destructive assays provide
an opportunity to rapidly, thoroughly, and directly test for a
medication. Destructive assays are made practical by a taking a
sample of a clonal colony. Many such assays are highly efficient,
particularly when the intended modification is known. For example,
PCR may be performed to identify indels or mismatches in
pre-existing sequences, or to detect a sequence of a HDR template.
Or, for example, cellular DNA may be nucleolytically assayed, e.g.,
to determine if a novel nuclease target sequence has been
successfully introduced or knocked-out. Example 17 uses a
nucleolytic destructive assay. Other processes may be used that
involve, e.g., sequencing or SDS-PAGE to find a band that is
indicative of a modification. Other processes may be used that
involve, e.g., sequencing or SDS-PAGE to find a band that is
indicative of a modification. Testing processes may be, e.g.,
chosen from the group consisting of a nucleolytic assay,
sequencing, PAGE, PCR, primer extension, or hybridization.
[0325] Allele migration has many important applications. The
Allelic Migration Table, below, describes certain genes and their
applications. Artisans reading this application will be able to
make and use the migrations and resultant cells and animals.
Artisans can readily apply the processes set forth herein for the
use of these alleles as templates or targets for disruption.
Embodiments include making a genetically modified cell or animal
(for instance, a lab animal, an F0 founder, or animal line) that
has a genome with a has received a gene from the Table, e.g., by
insertion or template-driven allele migration. Alleles for some
genes are reported to provide livestock production advantages, but
are at very low frequencies or are absent in some breeds or species
(see items 1-9). Introgression of these alleles can be of
significant value for production traits. For example, the Polled
allele (item 1) from beef breeds results in animals that do not
have horns, whereas dairy breeds do not have this allele so have
horns and need to be dehorned as a production practice. Allele
migration from beef breeds into horned (dairy) breeds will lead to
hornless dairy cattle which is has value for both production and
animal welfare. Other examples relate to alleles that can increase
or enhance characteristics of agricultural products such as meat
(items 4-6) and milk (items 7-8). Item 9 is useful for disease
resistance.
[0326] Many commercial and commonly used animal breeds have been
carefully bred to establish desirable traits but, in the process of
that breeding, have accumulated genetic errors that reduce their
reproductive success because of losses in fertility or by
increasing miscarriages. Deleterious alleles for some genes are
present in animal populations. As explained elsewhere herein, the
inventive techniques provide for changing alleles only at an
intended location in a target animal, without other modifications
resulting from genetic tools or from meiotic recombinations.
Therefore, for the first time, it is possible to clean-up the
genetic errors that have accumulated in livestock and animal breeds
without disrupting the genome of the animals and, consequently,
disrupting traits or causing unintended consequences. Alleles for
some genes can be used to control animal fertility for genetic
control of breeding stock (items 2-3).
[0327] Many useful animal models can be made. Certain alleles are
useful, see items 10-39. Some of these are established in animals.
Others of the genes are known to cause human disease, so
introgressing these alleles into livestock, lab animals, or other
animals is useful to create biomedical models of human disease.
[0328] Embodiments of the invention include a method of making a
genetically modified animal, said method comprising exposing
embryos or cells to an mRNA encoding a TALEN, with the TALEN
specifically binding to a target chromosomal site in the embryos or
cells, cloning the cells in a surrogate mother or implanting the
embryos in a surrogate mother, with the surrogate mother thereby
gestating an animal that is genetically modified without a reporter
gene and only at the TALEN targeted chromosomal site wherein the
allele is a member of the group consisting of (a) horn polled locus
(b) a gene recessive for fertility defects, e.g., CWC15 and/or
ApaF1 (c) genes for enhancing a livestock trait, e.g., meat
production (GDF8, IGF2, SOCS2, or a combination thereof) and/or
milk production (DGAT1 and/or ABCG2) (d) a gene for resistance to
African swine fever (P65/RELA) (e) a gene for reduction of animal
size (GHRHR) (f) genes that potential tumor growth (e.g., TP53,
APC, PTEN, RB1, Smad4, BUB1B, BRCA1, BRCA2, ST14 or a combination
thereof) (g) human oncogenes for animal models of cancer (e.g.,
AKT1, EGF, EGFR, KRAS, PDGFRA/B or a combination thereof) (h) genes
in animal models for hypercholesterolemia (to induce
atherosclerosis, stroke, and Alzheimer's disease models), e.g.,
LDLR, ApoE, ApoB or a combination thereof (i) Inflammatory Bowel
disease, e.g., NOD2 (j) spina bifida, e.g., VANGL1 and/or VANGL2
(k) pulmonary hypertension, e.g., miR-145 (1) genes for cardiac
defects, e.g., BMP10, SOS1, PTPN11, Nrg1, Kir6.2, GATA4, Hand2, or
a combination thereof and (1) celiac disease genes, e.g.,
HLA-DQA1.
Movement of Alleles
[0329] Some livestock traits are related to alleles such as
polymorphisms (large or small), single nucleotide polymorphisms,
deletions, insertions, or other variations. For instance, a
myostatin allele (an 11-bp deletion) from Belgian Blue cattle
causes a double-muscling phenotype. Example 6 shows, using the
Belgian Blue allele, how to precisely transfer specific alleles
from one livestock breed to another by homology-dependent repair
(HDR). Bovine fibroblasts received the allele and may readily be
used to make transgenic cattle. This allele does not interfere with
normal development and the methods taught herein place the allele
with precision and without disruption of other genes or the
incorporation of exogenous genes. As already discussed, results
presented herein show that the frequency of allele conversion in
livestock fibroblasts is high when sister chromatids are used for
an HDR template, therefore allele introgression into one sister
chromatid can be anticipated frequently to result in
homozygosity.
[0330] An embodiment of this invention is a method of transfer of
an allele from a first livestock line or breed to a second
livestock line or breed, comprising cutting DNA with a pair of
TALENs in a cell or embryo of the second livestock line/breed in a
presence of a nucleic acid that encodes the allele of the first
livestock line/breed. The embryo or cell may be used to create an
animal of the second line/breed that has the allele of the first
line/breed. The DNA that encodes the allele provides a template for
homology-dependent repair. As a template, it has homology to
portions of the DNA on each side of the cut and also contains the
desired allele.
[0331] Embodiments of the invention comprise moving a plurality of
alleles from one breed to another breed. For instance, alleles may
be moved from Wagyu or Nelore cattle to Belgian Blue cattle, or
vice versa. As set forth elsewhere herein, the TALENs may be
delivered a protein or encoded by a nucleic acid, e.g., an mRNA or
a vector. A reporter may also be transfected into the cell or
embryo and used as a basis for selecting TALEN-modified cells. The
reporter may be assayed non-destructively and/or may comprise a
selection marker. Similarly, allele migration may be practiced in
an animal model.
[0332] A population or species of organisms typically includes
multiple alleles at each locus among various individuals. Allelic
variation at a locus is measurable as the number of alleles
(polymorphisms) present, or the proportion of heterozygotes in the
population. For example, at the gene locus for the ABO blood type
carbohydrate antigens in humans, classical genetics recognizes
three alleles, IA, IB, and IO, that determine compatibility of
blood transfusions. An allele is a term that means one of two or
more forms of a gene.
[0333] In livestock, many alleles are known to be linked to various
traits such as production traits, type traits, workability traits,
and other functional traits. Artisans are accustomed to monitoring
and quantifying these traits, e.g., Visscher et al., Livestock
Production Science, 40 (1994) 123-137, U.S. Pat. No. 7,709,206, US
2001/0016315, US 2011/0023140, and US 2005/0153317. Accordingly,
the allele that is transferred may be linked to a trait or chosen
from a trait in the group consisting of a production trait, a type
trait, a workability trait, a fertility trait, a mothering trait,
and a disease resistance trait.
[0334] The term natural allele in the context of genetic
modification means an allele found in nature in the same species of
organism that is being modified. The term novel allele means a
non-natural allele. A human allele placed into a goat is a novel
allele. The term synthetic allele means an allele that is not found
in nature. Thus a natural allele is a variation already existing
within a species that can be interbred. And a novel allele is one
that does not exist within a species that can be interbred.
Movement of an allele interspecies means from one species of animal
to another and movement intraspecies means movement between animals
of the same species. Moving an allele from one breed to another by
conventional breeding processes involves swapping many alleles
between the breeds. Recombination during meiosis inevitably
exchanges genetic loci between the breeds. In contrast,
TALENs-modified livestock and other animals are free of genetic
changes that result from meiotic recombination events since the
cells or embryos are modified at a time when cells are exclusively
mitotic. As a result, a TALEN-modified animal can easily be
distinguished from an animal created by sexual reproduction.
[0335] The processes herein provide for editing the genomes of
existing animals. The animal has a fixed phenotype and cloning the
animal, e.g., by somatic cell cloning, effectively preserves that
phenotype. Making a specific change or changes in a cellular genome
during cloning allows for a known phenotype to be altered.
Processes herein alternatively provide for altering a genome of an
embryo that has yet to develop into an animal with fixed traits.
Embryos with sound genetics may nonetheless not express all of the
traits that are within the genetic potential of their genetics,
i.e., animals do not always express the traits that their line is
bred for. Embodiments include providing embryos having genetics
known to be capable of expressing a set of traits and exposing the
embryos to the TALEN (optionally without a reporter gene and/or
selection marker) and screening the gestated animal for the
modification and for expression of the set of traits. Accordingly,
the introgression of desirable alleles into livestock can be
achieved by editing the genomes of animals previously determined to
be of significant genetic value by somatic cell modification and
cloning, or by editing the genomes of animals prior to determining
their implicit genetic value by treatment/injection of embryos. In
the case of cloning, genetically superior animals could be
identified and subjected to gene editing for the correction of a
loss of function allele or the introgression of desirable alleles
that are not already present. This approach provides for a
controlled and characterized outcome at every step of the process
as only cells harboring the desired changes would be cloned.
[0336] Editing could also be applied by the direct treatment of
embryos. Embryos of unknown genetic merit would be treated and
screening of offspring may consist of analysis for the desired
change and analysis of genetic merit of the animal, e.g., analysis
for the change plus analysis of various traits that the animal
expresses. A beneficial aspect of this approach is it can be
applied simultaneous with genetic improvement by marker assisted
selection whereas cloning results in the loss of 1+ generation
intervals. The efficiency of such modifications would need to be
sufficiently high to offset any losses in reproductive rate
engendered by embryo treatment. In the case of simple
gene-inactivation, the frequency of success is very high (75%),
with even homozygous modification in 10-20% of embryos (Examples 1
and 8). Embodiments include exposing embryos (or cells) to a TALEN
(optionally without a reporter gene and/or without a marker gene
with more than about 1% of the embryos incorporating the
modification at the TALEN-targeted chromosomal site (heterozygous
or homozygous); artisans will immediately appreciate that all the
ranges and values within the explicitly stated ranges are
contemplated, e.g., from about 1% to about 85%, or at least about
5% or at least about 10%. Cells may similarly have TALENs
introduced successfully at vey high efficiencies, with the same
ranges being contemplated, i.e., more than about 1%. Conventional
processes achieve a lower percentage. Moreover, precision genome
editing can also be used to introduce alleles that do not currently
exist within a species by homology-driven allelic substitution.
Introgression of POLLED Allele
[0337] To protect the welfare of dairy farm operators and cattle,
horns are routinely manually removed from the majority of dairy
cattle in the U.S., Europe, and in other regions. De-horning is
painful, elicits a temporary elevation in animal stress, adds
expense to animal production and, despite the intent of protecting
animals from subsequent injury, the practice is viewed by some as
inhumane. Some beef breeds are naturally horn-free (e.g., Angus), a
trait referred to as POLLED that is dominant. The techniques set
forth herein improve animal well-being by providing animals that do
not have to undergo dehorning. Two allelic variants conferring
polledness have recently been identified on chromosome 1. Dairy
cows with either of these mutations are rare and generally rank
much lower on the dairy genetic selection indices than their horned
counterparts. Meiotic introgression of the POLLED allele into
horned breeds can be accomplished by traditional crossbreeding, but
the genetic merit of crossbred animals would suffer and require
many lengthy generations of selective breeding to restore to
productivity.
[0338] It is possible, however, to create polledness in animals,
and to do so without disturbing the animals' genome. The
non-meiotic introgression of the Celtic POLLED allele (duplication
of 212 bp that replaces 10 bp) was achieved in fibroblasts derived
from horned dairy bulls. A plasmid HDR template containing a 1594
bp fragment including the Celtic POLLED allele was taken from the
Angus breed (FIG. 35 panel a and FIG. 72). TALENs were designed
such that they could cleave the HORNED allele but leave the POLLED
allele unaffected. Surprisingly, this experiment showed that one
pair of TALENs delivered as mRNA had similar activity compared to
plasmid expression cassettes (FIG. 36), Accordingly, experiments
were performed that delivered TALENs as mRNA to eliminate the
possible genomic integration of TALEN expression plasmids. Five of
226 colonies (2%) passed each PCR test shown in FIG. 6 panel b to
confirm introgression of POLLED. Three of the five clones were
homozygous for POLLED introgression and confirmed by sequencing to
be 100% identical to the intended allele. U.S. Ser. No. 14/154,906
filed Jan. 14, 2014, which is hereby incorporated by reference
herein, provides additional information regarding polledness.
[0339] Embodiments of the invention comprise moving a polled allele
from one breed to another breed. For instance, alleles may be moved
from Angus cattle to other cattle. Horned breeds include: Hereford,
Shorthorn, Charolais, Limousin, Simmental, Brahman, Brangus, Wagyu,
and Santa Gertrudis, Ayrshire, Brown Swiss, Canadienne, Dutch
Belted, Guernsey, Holstein (Holstein-Friesian), Jersey, Kerry,
Milking Devon, Milking Shorthorn, Norwegian Red, Busa, Canadienne,
Estonian Red, Fleckveih, Frieian, Girolando, Illawarra, Irish
Moiled, Lineback, Meuse Rhine Issel, Montbeliarede, Normande,
Randall, Sahhiwal, Australian Milking Zebu, Simmental, Chianina
Marchigiana, Romagnola. Some of the above listed breeds also have
polled variants, but the lines in which there genetics are often
inferior to the horned version. Examples of polled breeds include:
Angus, Red Angus, Red Poll, Galloway, Belted Galloway, American
White Park, British White, Amerifax, Jamaica Black, Jamaica Red,
Murray Grey, Brangus, Red Brangus, Senopol. As set forth elsewhere
herein, the site-specific endonuclease tools, e.g., TALENs, may be
delivered as a protein or encoded by a nucleic acid, e.g., an mRNA
or a vector.
[0340] Geneticists have hunted for the genetic locus of polledness
for decades. In brief, polledness has been an object of intense
modern research for twenty years. See Allais-Bonnet et al. (2013)
Novel Insights into the Bovine Polled Phenotype and Horn
Ontogenesis in Bovidae. PLoS ONE 8(5): e63512. The polled mutation
was quickly mapped to bovine chromosome 1 in many breeds, but the
actual site of the genetic cause of polledness was elusive for
various reasons. Quite recently, however, it was shown that there
are at least two polled alleles (one "Celtic" and one "Friesian")
and candidate mutations were proposed for each of them. Medugorac
et al. (2012) Bovine polledness--an autosomal dominant trait with
allelic heterogeneity. PLoS One 7:e39477. None of these mutations
were located in known coding or regulatory regions. Herein, the
inventors show that making genetic changes at comparable sites in
non-polled (horned) animals can result in polled phenotypes.
[0341] Two cattle alleles for polled have been identified on
chromosome 1 in cattle (Medugorac, 2012). PC, Celtic origin (212
bp, 1,705,834-1,706,045 bp) is duplicated (and replaces a sequence
of 10 bp (1,706,051-1,706,060 bp). Some breeds with this allele
include Angus, Galloway, Fleckvieh, Gelbvieh and
Murnau-Werdenfelser. A second polled allele of, PF, is of Friesian
origin is characterized by the following, P5ID (replace 7 bp
(CGCATCA with TTCTCAGAATAG (SEQ ID NO: 177); 1,649,163-1,649,169)
and 80,128 bp duplication (1,909,352-1,989,480 bp P80 kbID, plus
five point mutations at the positions (G1654405A, C1655463T,
T1671849G, T1680646C, C1768587A). These changes are generally
inherited as a fixed block. All chromosomal coordinates are from
the UMD 3.1 cattle genome build.
[0342] The inventors show herein that the bovine POLLED allele was
introgressed into horned Holstein fibroblasts. This example
demonstrates that various breeds of dairy cattle can be created
that do not have horns. And this change can be made without
disturbing other genes, or other parts of the genome, of the
animals. These processes have been developed by the inventors to
achieve efficiencies that are so high that genetic changes can be
made without reporters and/or without selection markers. Moreover,
the processes can be used in the founder generation to make
genetically modified animals that have only the intended change at
the intended site. These methods demonstrate meiosis-free intra-
and inter-specific introgression of polled and hornless alleles in
livestock cells, large mammals, and livestock for research,
agricultural and biomedical applications. Since the polled allele
relates to the non-development of horns, embryos modified (direct
injection or by cloning) to be polled are expected to successfully
gestate and result in live births of healthy animals. Cells have
been modified from a horned allele to a polled allele and, as of
the time of filing, steps have been taken to clone animals from
these cells and to generate live birthed animals.
[0343] FIG. 61 describes experiments for determining if
site-specific nucleases could be made that bind to, and cleave,
appropriate sites in bovine DNA. One of the problems was to
determine if tandem repeats could be bound, bearing in mind that
repeated sequences at the desired binding site can confound
targeting due to the high likelihood of intermolecular
recombination. Moreover, these bindings have to be efficient and
mutually cooperate in a live cell in culture. The horned allele, in
particular, is a challenge due to the high similarity of polled
allele to the horned allele. The chosen location for TALEN binding
sites was not obvious; the TALENs designs that were successful can
cleave and bind the horned locus but do not allow TALENs to cleave
the polled allele. Discovering these designs was an important
achievement in the research of the invention. The success of this
approach could not be predicted. As shown in FIG. 61, SEQ ID NOS:
146-153, the horned allele chosen as the target had 212 residues
and the polled allele had a repeat of those 212 residues. The
polled allele further had a 10 base pair (bp) deletion in between
the repeats. Panel a) depicts the 212 bp sequence, with the 10 bp
that are to be deleted at the end, in between the left TALEN
(marked by a solid inverted triangle) and the right TALEN (marked
by a solid triangle). The TALENs pairs were thus placed on either
edge of the 10 bp deletion site. The TALENs pairs cleaved the
horned allele in the area of the 10 bp deletion. A homologous
dependent recombination (HDR) template was used to guide insertion
of the 212 residue repeat (actually 202 residues since it is a
repeat with a 10 bp deletion) between the locations where the
TALENs were binding. As depicted in panel a) at Polled, the Left
TALEN and Right TALEN are then separated by 202 residues. And
recleavage of the polled allele is reduced. Various TALENs were
made to determine if binding and cleavage could be reasonably
accomplished. The table in panel b) lists some of the TALENs that
were tested. Panel c) shows the test results with their
effectiveness measured by the % NHEJ. The TALEN in the third lane,
HP1.3, was subsequently used for introgression of polled
alleles.
[0344] FIG. 62 shows the research strategy and results for
introgression of a polled allele into a cell with a horned allele.
The Horned allele has 1546 bp between PCR primers F1 and R1. In
this sequence, there are 365 bp between PCR primers F2 and R2. The
horned allele with a 212 bp sequence represented by an arrow is in
this area. The POLLED allele, bottom, has a tandem repeat of the
212 bp (shown as two arrows) with a 10 bp deletion (not shown). The
length between PCR primers F2 and R2 is 567 bp; the 567 bp equals
the 365 bp in the horned allele plus the 212 bp repeat minus to 10
bp deletion. The length of the HDR template was 1594 bp. Once the
template sequence is introgressed into the cell's chromosome, there
are 1746 bp between primers F1 and R1; the 1746 equals the 1546 bp
of the horned allele plus 212 bp of the repeat minus to 10 bp
deletion. Further, a PCR product unique to the polled allele is
indicated as P, in the tandem repeat area. TALENs were developed to
specifically target the HORNED allele (FIG. 61) which could be
repaired by homologous recombination using the HDR template (SEQ ID
NO: 381). Cells that received the TALENs and HDR template were
diluted and plated as single-cells that were cultured and allowed
to replicate in clonal colonies. Members of the colonies were
tested for the polled allele. Panel b shows representative images
of colonies with homozygous or heterozygous introgression of
POLLED. Three primer sets were used for positive classification of
candidate colonies: F1+R1, F2+R2 and F1+P (POLLED specific).
Identity of the PCR products was confirmed by sequencing F1+R1
amplicons.
[0345] FIG. 63 is an example of polled conversion. The polled
allele was introgressed into cells in a manner similar to that
described for FIGS. 1 and 2, except that a different HDR template
was used. The template was 591 bp in length:
TABLE-US-00004 (SEQ ID NO: 522)
GAAGGCGGCACTATCTTGATGGAACTCAGTCTCATCACCTGTGAAATGAA
GAGTACGTGGTACCAACTACTTTCTGAGCTCACGCACAGCTGGACGTCTG
CGCCTTTCTTGTTATACTGCAGATGAAAACATTTTATCAGATGTTTGCCT
AAGTATGGATTACATTTAAGATACATATTTTTCTTTCTTGTCTGAAAGTC
TTTGTAGTGAGAGCAGGCTGGAATTATGTCTGGGGTGAGATAGTTTTCTT
GGTAGGCTGTGAAATGAAGAGTACGTGGTACCAACTACTTTCTGAGCTCA
CGCACAGCTGGACGTCTGCGCCTTTCTTGTTATACTGCAGATGAAAACAT
TTTATCAGATGTTTGCCTAAGTATGGATTACATTTAAGATACATATTTTT
CTTTCTTGTCTGAAAGTCTTTGTAGTGAGAGCAGGCTGGAATTATGTCTG
GGGTGAGATAGTTTTCTTTGCTCTTTAGATCAAAACTCTCTTTTCATTTT
TAAGTCTATCCCAAAAGTGTGGGAGGTGTCCTTGATGTTGAATTATAGGC
AGAGGGTCAGTTTATCAACACCCAAGACCAACATCTCTGCC.
[0346] As indicated by the arrowhead, one of the 12 colonies had a
PCR product that demonstrated introgression of the polled
allele.
[0347] FIG. 64 depicts another scheme for introgression of a polled
allele into a cell. A 325 bp HDR template was used:
5'gtctggggtgagatagttttcttggtaggctgtgaaatgaagagtacgtggtaccaactactttctgagct-
cacgcacagctggacgtctgcgcc
tttcttgttatactgcagatgaaaacattttatcagatgtttgcctaagtatggattacatttaagatacata-
tttttctttcttgtctgaaagtctttgtagtga
gagcaggctggaattatgtctggggtgagatagttttctttgctctttagatcaaaactctcttttcattttt-
aagtctatcccaaaagtgtgggaggtgtc cttgatgttgaattataggcag (SEQ ID
NO:14).
[0348] The introgressed allele was Red Angus polled and the
recipient was horned Holstein fibroblasts. The template had 29 bp
of upstream overlap and 84 bp of downstream overlap. The 212 bp
repeat was in between the overlaps. The repeat was used as a
replacement for the 10 bp deletion of the native 212 bp sequence.
This process was similar to those described in FIGS. 1-3 except
that a heat denatured (single stranded) oligomer of TALENs was
used. As shown in FIG. 64, panel's b and c, there were two
conditions tested. In panel b), the cells were transfected with 2
.mu.g of TALEN mRNA+500 ng of ssDNA coated with Gal4:RecA. Each
lane/PCR reaction consists of -3 cell equivalents diluted from a
transfected population. PCR using primers btHP-F1 and btHP-R1 from
horn cells results in a product of 389 bp. Conversion to polled
results in a net insertion of 202 base pairs; thus the PCR product
of the same primers results in a 591 bp product (arrow in left
margin). The number of reactions with products indicative of polled
conversion is shown in the upper right corner. Panel c) PCR
assessment of polled conversion in horned Holstein fibroblasts
transfected with 2 ug of TALEN mRNA+1,500 ng of ssDNA. The number
of reactions with products indicative of polled conversion is shown
in the upper right corner.
[0349] FIG. 65 shows allele introgression with CRISPR/Cas9. This
method is compared to a TALENs method. The introgressed allele is
Adenomatous polyposis coli (APC). At panel a) the APC14.2 TALENs
and the gRNA sequence APC14.2 G1a are shown relative to the wild
type APC sequence. Below, the HDR oligo is shown which delivers a 4
bp insertion (see boxed section) resulting in a novel HindIII site.
Pig fibroblasts transfected with 2 .mu.M of oligo HDR template, and
either 1 .mu.g TALEN mRNA, 1 .mu.g each plasmid DNA encoding hCas9
and the guidance RNA (gRNA) expression plasmid; or 1 .mu.g mRNA
encoding hCas9 and 0.5 .mu.g of gRNA expression plasmid, were then
split and cultured at either 30 or 37.degree. C. for 3 days before
expansion at 37.degree. C. until day 10. At panel b) the charts
display RFLP and Surveyor assay results. TALEN stimulated HDR was
most efficient at 30.degree. C., while CRISPR/Cas9 mediated HDR was
most effective at 37.degree. C. For this locus, TALENs were more
effective than the CRISPR/Cas9 system for stimulation of HDR
despite similar DNA cutting frequency measured by Surveyor assay.
In contrast to TALENs, there was little difference in HDR when
hCas9 was delivered as mRNA versus plasmid.
[0350] Control of Maturation in Animals
[0351] It is desirable to produce livestock in a way that conserves
environmental and energy resources. Sexually immature animals
generally consume less food per pound of weight than mature or
maturing animals. Livestock, in general, do not reach a desirable
size before maturation. Set forth herein, however, are animals that
can be grown to a desirable size before maturation.
[0352] In fact, methods are described herein whereby an animal does
not sexually mature at all. It can be grown past the normal age of
maturity without passing through pubescence. Sexually immature
animals are sterile. The efficient production of sterile animals is
therefore a significant challenge since sexual reproduction is cost
effective, and even assisted reproductive techniques (ARTs) require
a mature animal to provide ova and sperm. In some embodiments, the
livestock animal does not pass into puberty and remains permanently
sexually immature unless specifically treated to allow it to pass
into sexual maturity. Such animals, after treatment to induce
maturity, can then be bred.
[0353] An advantage of making livestock incapable of maturing is
that they are unable to reproduce. In the case of sexually-bred or
genetically modified fish, for instance, concerns about their
accidental release into the wild are eliminated. Other animals that
are similarly modified will also be unable to reproduce, so that
animals with valuable genetic traits can be sold without concerns
of uncontrolled breeding of the animals by the buyers. Further, in
many farm animals (e.g., cows, poultry, and fish) sterilization
will increase productivity as well as meat quality, improvements in
lipid content, pigmentation and texture. The term cow is a
colloquial term for cattle; cattle are large ungulates, are the
most widespread species of the genus Bos. And, in the case of fish,
sterile fish should demonstrate greater performance in culture by
conserving energy for growth rather than gonad development and
sexual differentiation. Currently, sterilization through ploidy
manipulation (specifically triploidy, which adds of one extra set
of chromosomes) is the only commercially scalable technique
available to aquaculture producers. However, inconsistent results
have raised concerns with respect to the efficacy of the technique.
In addition, triploid induction, in general, often negatively
impacts survival and/or performance of treated populations. And the
application of the technology is labor intensive, logistically
complicated and costly.
[0354] An embodiment of the invention is a genetically modified
livestock animal comprising a genome that comprises an inactivation
of a neuroendocrine gene selective for sexual maturation, with the
inactivation of the gene preventing the animal from becoming
sexually mature. The gene is selectively directed to sexual
maturation processes and, if knocked-out of an animal, the animal
will be comparable to wild-type animals in terms of its development
as measured by size and weight until such time as the wild type
animals undergo sexual maturation. The term gene means a locatable
region of genomic sequence, corresponding to a unit of inheritance,
which is associated with regulatory regions, transcribed regions,
and or other functional sequence regions. The term gene, as used
herein, includes the functional sequence regions as well as those
portions that encode a protein or other factor. The term
knocked-out, as used herein, refers to the direct or indirect
disruption of a gene that either inactivates function in the
resulting protein or eliminates production of the protein
product.
[0355] Since the genetic modifications are directed to a specific
gene or gene product to prevent sexual maturation, the factor that
is needed for maturation is known and can generally be
supplied.
Inducible Systems
[0356] An inducible system may be used to control expression of a
sexual maturation gene. Various inducible systems are known that
allow spatiotemporal control of expression of a gene. Several have
been proven to be functional in vivo in transgenic animals.
[0357] An example of an inducible system is the tetracycline
(tet)-on promoter system, which can be used to regulate
transcription of the nucleic acid. In this system, a mutated Tet
repressor (TetR) is fused to the activation domain of herpes
simplex virus VP16 trans-activator protein to create a
tetracycline-controlled transcriptional activator (tTA), which is
regulated by tet or doxycycline (dox). In the absence of
antibiotic, transcription is minimal, while in the presence of tet
or dox, transcription is induced. Alternative inducible systems
include the ecdysone or rapamycin systems. Ecdysone is an insect
molting hormone whose production is controlled by a heterodimer of
the ecdysone receptor and the product of the ultraspiracle gene
(USP). Expression is induced by treatment with ecdysone or an
analog of ecdysone such as muristerone A. The agent that is
administered to the animal to trigger the inducible system is
referred to as an induction agent.
[0358] The tetracycline-inducible system and the Cre/loxP
recombinase system (either constitutive or inducible) are among the
more commonly used inducible systems. The tetracycline-inducible
system involves a tetracycline-controlled transactivator
(tTA)/reverse tTA (rtTA). A method to use these systems in vivo
involves generating two lines of genetically modified animals. One
animal line expresses the activator (tTA, rtTA, or Cre recombinase)
under the control of a selected promoter. Another set of transgenic
animals express the acceptor, in which the expression of the gene
of interest (or the gene to be modified) is under the control of
the target sequence for the tTA/rtTA transactivators (or is flanked
by loxP sequences). Mating the two strains of mice provides control
of gene expression.
[0359] The tetracycline-dependent regulatory systems (tet systems)
rely on two components, i.e., a tetracycline-controlled
transactivator (tTA or rtTA) and a tTA/rtTA-dependent promoter that
controls expression of a downstream cDNA, in a
tetracycline-dependent manner. In the absence of tetracycline or
its derivatives (such as doxycycline), tTA binds to tetO sequences,
allowing transcriptional activation of the tTA-dependent promoter.
However, in the presence of doxycycline, tTA cannot interact with
its target and transcription does not occur. The tet system that
uses tTA is termed tet-OFF, because tetracycline or doxycycline
allows transcriptional down-regulation. Administration of
tetracycline or its derivatives allows temporal control of
transgene expression in vivo. rtTA is a variant of tTA that is not
functional in the absence of doxycycline but requires the presence
of the ligand for transactivation. This tet system is therefore
termed tet-ON. The tet systems have been used in vivo for the
inducible expression of several transgenes, encoding, e.g.,
reporter genes, oncogenes, or proteins involved in a signaling
cascade.
[0360] The Cre/lox system uses the Cre recombinase, which catalyzes
site-specific recombination by crossover between two distant Cre
recognition sequences, i.e., loxP sites. A DNA sequence introduced
between the two loxP sequences (termed foxed DNA) is excised by
Cre-mediated recombination. Control of Cre expression in a
transgenic animal, using either spatial control (with a tissue- or
cell-specific promoter) or temporal control (with an inducible
system), results in control of DNA excision between the two loxP
sites. One application is for conditional gene inactivation
(conditional knockout). Another approach is for protein
over-expression, wherein a floxed stop codon is inserted between
the promoter sequence and the DNA of interest. Genetically modified
animals do not express the transgene until Cre is expressed,
leading to excision of the floxed stop codon. This system has been
applied to tissue-specific oncogenesis and controlled antigene
receptor expression in B lymphocytes. Inducible Cre recombinases
have also been developed. The inducible Cre recombinase is
activated only by administration of an exogenous ligand. The
inducible Cre recombinases are fusion proteins containing the
original Cre recombinase and a specific ligand-binding domain. The
functional activity of the Cre recombinase is dependent on an
external ligand that is able to bind to this specific domain in the
fusion protein.
[0361] Embodiments include an in vitro cell, an in vivo cell, and a
genetically modified animal such as a livestock animal that
comprise a neuroendocrine gene selective for sexual maturation that
is under control of an inducible system. The genetic modification
of an animal may be genomic or mosaic. An embodiment is a gene in
the group consisting of Gpr54, Kiss1, and GnRH1 that is under
control of an inducible system. The inducible system may be, for
instance, selected from the group consisting of Tet-On, Tet-Off,
Cre-lox, and Hiflalpha.
Neuroendocrine Genes Selective for Sexual Maturation
[0362] Sexual development of animals may be prevented by blocking
neuroendocrine genes selective for sexual maturation. Sexual
development, accelerated growth, and adrenal maturation is
initiated when gonadotropin-releasing hormone (GnRH1) begins to be
secreted by the hypothalamus. The gene GnRH1 encodes the GnRH11
precursor. In mammals, the linear decapeptide end-product is
generally synthesized from a 92-amino acid preprohormone.
Gonadotropin-releasing hormone (GnRH1), also known as
Luteinizing-hormone-releasing hormone (LHRH) and luliberin, is
responsible for the release of follicle-stimulating hormone (FSH)
and luteinizing hormone (LH). GnRH1 belongs to
gonadotropin-releasing hormone family. Embodiments of the invention
include inactivating GnRH1 in a livestock animal.
Gonadotropin-releasing hormone or analogues may be administered to
the animal to bring it to sexual maturity. Sequences for GnRH1
across multiple species are well known, e.g., Gene IDs 768325 for
Bos Taurus, 770134 for Gallus gallus, or 397516 for Sus scrofa.
GPR54, also known as the Kisspeptin receptor (also referred to as
GpR54, KissR, Kiss1R, kissR and the like), binds to the hormone
Kisspeptin (formerly known as metastin). Kisspeptin is a product
derived from the KiSS1 gene (also referred to as Kiss, Kiss1, KiSS,
kiss1 and the like). Kisspeptin-GPR54 signaling has a role in
initiating secretion of GnRH1. Kisspeptin is an RFamide
neuropeptide with multiple functions, involving varied whole body
physiological systems and acting at all levels of the reproductive
axis--brain, pituitary, gonad (BPG), and accessory organs.
Kisspeptin can directly stimulate GnRH release (Messager et al.,
2005), relaying steroid hormone negative and positive feedback
signals to GnRH neurons, serving as a gatekeeper to the onset of
puberty, and relaying photoperiodic information.
[0363] Embodiments of the invention include inactivating the gene
GPR54 and/or KiSS1 in a livestock animal. Kisspeptin may be
administered to make-up for a loss of KiSS1 and thereby achieve
sexual maturity. Or, KiSS1 and/or GPR54 is suppressed, and
gonadotropin-releasing hormone may be administered to the animal to
bring it to sexual maturity. Another embodiment is inactivation of
the Kisspeptin-GPR54 interaction by inserting a dominant negative
GPR54 into the genome of a livestock animal. Expression of the
dominant negative GPR54 prevents initiation of sexual maturation.
Expression of the dominant negative GPR54 interferes with signal
transduction downstream of the receptor, preventing signal
propagation and release of GnRH1. Sequences for GPR54 are well
known across multiple species, e.g., 84634 for Homo sapiens, 561898
for Danio rerio, or 733704 for Sus scrofa. Sequences for Kiss1 are
well known across multiple species, e.g., 615613 for Bos taurus,
733704 for Sus scrofa, or 100294562 for Ovis aries.
[0364] The Gpr54/Kiss pathway is highly conserved among most
vertebrate species and is known to be the gatekeeper to puberty in
humans and mice. (Seminara et al., 2003). Infertility due to
inactivation of the Gpr54 and/or Kiss gene in humans and mice has
been reverted by ectopic GnRH administration. Studies in mice and
humans demonstrate that inactivation Gpr54 effectively leads to
infertility of both sexes due to hypogonadotropic hypogonadism
(d'Anglemont de Tassigny et al., 2007; de Roux et al., 2003). The
Kiss-Gpr54 system is highly conserved in vertebrates (Tena-Sempere
et al., 2012) particularly in mammals where only one Kiss and Gpr54
gene is present. Whereas multiple distinct Kiss genes have been
identified in fish, the receptor Gpr54 is encoded by one gene in
all but one species examined. Humans and mice with Gpr54 mutations
displayed normal levels of hypothalamic GnRH suggesting Kiss/Gpr54
signaling was responsible for the release of GnRH into the blood
stream (Seminara et al., 2003). This presented an opportunity to
bypass Kiss/Gpr54 signaling by injection of GnRH or gonadotropins
directly into Gpr54-deficient subjects. Indeed, both
Gpr54-deficient humans and were responsive to GnRH injection
(Seminara et al., 2003) indicating that downstream signaling
components of puberty remain intact.
[0365] Direct evidence of a piscine kisspeptin role in reproductive
biology publications is lacking or limited. However, administration
of kiss peptide has been shown to stimulate gonadotropin gene
expression in the pituitary of sexually mature female zebrafish
(Kitahashi et al. 2008) and orange grouper, or secretion of LH and
FSH in European sea bass (Felip et al., 2008) and goldfish. Thus,
in theory, the fertility of sexually immature and sterile fish with
knockouts of GPR54 and/or KiSS1 can be rescued by exogenous
delivery of kisspeptin analogues (e.g., Kisspeptin 10) or
gonadotropin analogues (LH or FSH). With this concept, homozygous
kiss or kiss receptor knockout-broodstock can be bred in captivity
if administered the corrective hormone, ensuring reversible control
over fertility. The progeny from this KO-broodstock inherits the
alteration. This would provide economic and environmental
benefit.
[0366] Neuroendocrine genes selective for sexual maturation can be
inactivated by a number of processes. Inactivation of the gene
prevents expression of a functional factor encoded by the gene,
such as a protein or an RNA. One kind of inactivation comprises an
insertion, deletion, or substitution of one or more bases in a
sequence encoding the sexual maturation factor and/or a promoter
and/or an operator that is necessary for expression of the factor
in the animal. The inactivation may be a knock-out of a gene. The
gene may be inactivated by removal of at least a portion of the
gene from a genome of the animal, alteration of the gene to prevent
expression of a functional factor encoded by the gene, an
interfering RNA (expressed by a gene in a genome of the animal or
in a plurality of cells of the animal), or expression of a dominant
negative factor by an exogenous gene.
[0367] Another system for revertible-infertility is Tac3/TacR3
(Young, J., Bouligand, J., Francou, B., Raffin-Sanson, M. L.,
Gaillez, S., Jeanpierre, M., Grynberg, M., Kamenicky, P., Chanson,
P., Brailly-Tabard, S., et al. (2010). TAC3 and TACR3 defects cause
hypothalamic congenital hypogonadotropic hypogonadism in humans. J
Clin Endocrinol Metab 95, 2287-2295. As with Kiss/Gpr54, humans
deficient for these genes display hypogonadotropic hypogonadism
which was revertible by pulsatile GnRH treatment (Young et al.,
2010). Tac and/or Tac3 may be inactivated using methods described
or referenced herein.
[0368] Embodiments of the invention include methods of inactivating
one or more genes selected from the group consisting of GnRH1,
GPR54, KiSS1, Tac and Tac3 in animals selected from the group
consisting of cattle, sheep, pigs, chickens, turkeys, goats, sheep,
fish, buffalo, emu, rabbits, ungulates, avians, rodents, and
livestock. The genes may be inactivated in cells and/or embryos and
in animals resulting therefrom. Various methods are described
herein, e.g., knocking out a gene in a cell or embryo using TALENs
or Zinc Finger Nucleases, and cloning and/or implanting the
cell/embryo in a surrogate to make a founder animal.
[0369] FIG. 49 illustrates an embodiment of the invention, with
bovine cells being modified in vitro and used to clone calves. The
calves may be raised to a suitable weight for slaughter or treated
with factors that allow them to pass into maturity, e.g.,
gonadotropin analogues or a factor that directly supplied a
knocked-out genetic factor.
[0370] Example 20 describes techniques for making changes to cells
with a TALEN system. Example 21 describes the dilution cloning
technique used for the results of Table 7 (SEQ ID NOS: 328-335 and
464, 465). Example 22 describes the techniques of mutation
detection and RFLP analysis. Example 41 (FIG. 50) describes
introgression of an 11-basepair deletion into exon-3 of bovine GDF8
(Belgium Blue mutation)(SEQ ID NOS:428 and 431). FIG. 51 depicts
results for a similar process that introgressed an allele from one
species into another species. Example 42 describes testing for the
same as well as introgression of alleles into cow cells using oligo
HDR. In Example 42, TALEN-induced homologous recombination
eliminated the need for linked selection markers. When transfected
alone, the btGDF8.1 TALEN pair (SEQ ID NOS: 428 and 431) cleaved up
to 16% of chromosomes at the target locus. Co-transfection with a
supercoiled homologous DNA repair template harboring the 11 bp
deletion resulted in a gene conversion frequency (HDR) of 0.5 to 5%
at day 3 without selection for the desired event. Gene conversion
was identified in 1.4% of isolated colonies that were screened by
PCR, which was a rapid method to identify successful alterations.
Example 43 (FIG. 52) describes the modification of four intended
loci in pig and cattle fibroblasts The TALEN pairs used were
ssILRG2.1 (SEQ ID NOS: 484 and 485); ssRAG2.1 (SEQ ID NOS:488 and
489); btGGTA9.1(SEQ ID NOS:490 and 491); and ssLDLR2.1 (SEQ ID
NOS:438 and 439). Example 44 (FIG. 53) shows analysis of
modifications made to genes APC (SEQ ID NOS:482 and 483), LDLR (SEQ
ID NOS:438 and 439), p53 (SEQ ID NOS:452 and 453), p65 (SEQ ID
NOS:440 and 441), and btGDF8 (SEQ ID NOS:428 and 431). Example 45
(Table 7) shows a recovery rate for intended indels of 10-64%
(average, 45%), with up to 32% of the colonies homozygous for the
modification. Example 46 (FIG. 54) describes cloned pigs that were
made with modified deleted in azoospermia-like (DAZL, SEQ ID NOS:
182-183) and adenomatous polyposis coli (APC, SEQ ID NOS:188-189)
genes. Example 47 (FIG. 55) describes GPR54 (SEQ ID NO: 196)
knockouts, made according to the indicated gene targeting strategy;
Example 48 details methods for making modified animals with the
GPR54 knockout. Example 49 describes modifications made with
custom-made CRISPR/Cas9 endonucleases.
[0371] These results demonstrated techniques that effectively make
modifications at an intended gene, without the aid of a linked
selection marker. Cells with the modifications can be used for
cloning animals. The intended genetic modifications can be
controlled with specificity, for instance, for introgressing an
allele or to modify a gene. Modifications may be, for instance, a
deletion or an insertion to disrupt a gene or knock it out, or to
replace part of the gene to make a nonfunctional gene product or an
alternative product.
[0372] Fish (tilapia) with a knockout of KiSS1 and GpR54 (also
referred to as GPR54, Kiss-receptor, KissR, Kiss1R) have been made.
FIGS. 56 and 57 depict the targeted regions for KISS and GpR54. The
structural organization of the Kiss gene is conserved and contains
two coding exons, one encoding both the signal peptide and part of
the kisspeptin precursor, the other encoding the remainder of the
precursor including the kisspeptin-10 sequence. Example 51 details
the steps that were used to make founder fish with Kiss or KissR
knockouts. Techniques based on TALENs were used to knock out the
genes and melt analysis was used to detect indels (FIG. 58).
Various modifications at the targeted genes were confirmed (FIG.
59), including nine different nucleotide deletions, two insertions,
and three combinations of nucleotide insertions and deletions.
Sequencing indicated that a knockout would result from at least
some of these modifications. Germ line mutations were confirmed
(see FIG. 60). F1 heterozygous mutants with a Kiss or KissR
knockout were created and bred. F2 generations, which are expected
to show the inactivation phenotype, are presently being grown.
[0373] Disclosed herein are processes to make transgenic animals
that have changes only at an intended site. Additionally, the
processes can make specifically intended changes at the intended
site. It is not necessary to remove other changes resulting from
problems like the use of linked-reporter genes, or linked positive
and negative selection genes, or random transgene integration are
bypassed. Moreover, the processes can be used in the founder
generation to make genetically modified animals that have only the
intended change at the intended site. Other processes are also
disclosed that involve unlinked marker genes and the like.
[0374] Compositions and Kits
[0375] The present invention also provides compositions and kits
containing, for example, nucleic acid molecules encoding TALENs,
TALEN polypeptides, compositions containing such nucleic acid
molecules or polypeptides, or TALEN engineered cell lines. Such
items can be used, for example, as research tools, or
therapeutically.
[0376] The present invention also provides compositions and kits
containing, for example, nucleic acid molecules encoding
site-specific endonucleases, CRISPR, Cas9, ZNFs, TALENs,
polypeptides of the same, compositions containing such nucleic acid
molecules or polypeptides, or engineered cell lines. An HDR may
also be provided that is effective for introgression of a polled
allele. Such items can be used, for example, as research tools, or
therapeutically
Example 1: Genetically Modified Artiodactyl Livestock (Bovine)
Produced by Direct Injection of TALENs
[0377] Three TALEN pairs were designed and assembled as described
in Cermak et. al. (2011) Nuc. Acids Res. 39:e82 (FIG. 3) and mRNA
was injected into the cytoplasm of bovine embryos at about 19 hours
post fertilization. The ACAN gene was targeted. Aggrecan
Proteoglycan (ACAN) is an extracellular matrix protein that can be
found in cartilagenous tissues. Mutations of the ACAN gene are
known to cause dwarfism in both dogs and cattle. More particularly,
bulldog dwarfism in Dexter cattle is caused by mutations in ACAN.
Bulldog dwarfism in Dexter cattle is one of the earliest
single-locus disorders described in animals. Affected fetuses
display extreme disproportionate dwarfism, reflecting abnormal
cartilage development (chondrodysplasia). Typically, they die
around the seventh month of gestation, precipitating a natural
abortion. Heterozygotes show a milder form of dwarfism, most
noticeably having shorter legs. Homozygosity mapping in candidate
regions in a small Dexter pedigree suggested aggrecan (ACAN) as the
most likely candidate gene. Mutation screening revealed a 4-bp
insertion in exon 11 (2266_2267insGGCA) (called BD1 for diagnostic
testing) and a second, rarer transition in exon 1 (-198C>T)
(called BD2) that cosegregate with the disorder. In chondrocytes
from cattle heterozygous for the insertion, mutant mRNA is subject
to nonsense-mediated decay, showing only 8% of normal expression.
Genotyping in Dexter families throughout the world shows a
one-to-one correspondence between genotype and phenotype at this
locus. The heterozygous and homozygous-affected Dexter cattle could
prove invaluable as a model for human disorders caused by mutations
in ACAN.
[0378] Injected embryos were cultured in vitro and collected at the
blastocysts stage (FIG. 3). Individual blastocyst genomic DNA was
amplified by whole genome amplification (WGA) (Carlson et al.
(2011) Trangenic Res. 20:29) and screened for indels using the
SURVEYOR nuclease assay (FIGS. 3, 4A, and 4B). Cleavage products
indicative of TALEN activity were observed in 10% of injected
embryos (e.g., FIGS. 3, 4A, and 4B). Mutations in the predicted
region were confirmed in 2 blastocysts injected with either ACAN11
(SEQ ID NO: 377) or ACAN12 (SEQ ID NO: 378) TALEN pairs (FIG. 3).
ACAN exon 11 from Bos taurus breed Hereford chromosome 21 genomic
scaffold targeted by btau_4.2 TALEN pairs and ACAN exon 12 from Bos
taurus breed Hereford chromosome 21 genomic scaffold targeted by
btau_4.2 were chosen. These mutations are loss of function alleles,
and thus our hypothesis was that TALEN mediated KO of ACAN by
targeting exons 11 (ACAN11) or 12 (ACAN12) would cause a profound
and easily observed phenotype in mutant offspring. A significant
decrease in the developmental competence of TALEN-injected embryos
was not observed. A second round of injections was then performed
using the ACAN12 TALEN pair at mRNA dosages ranging from 10-100
ng/.mu.l. Comparison of the blastocyst formation rate between
rounds 1 (33%) and 2 (5%) (10 ng/.mu.l conditions) revealed poor
embryo quality. Despite the poor quality of the embryos, 12
putative mutants (27% of injected) were identified using the
SURVEYOR assay. The genotypes of each SURVEYOR positive embryo were
analyzed with 14 sequencing reads from cloned PCR products.
Sequencing revealed mosaicism in gene modification. Indels were
identified in 4 SURVEYOR positive embryos (SEQ IDS: 2-5) and of
these, indel positive sequence reads accounted for 7-29% of the
total reads for each embryo, FIG. 6 and SEQ ID NOS: 28-36.
Processes for the creation of animal founder lines based on embryo
transfer are well known. TALEN treated embryos were successfully
transferred to surrogate cows to establish pregnancies. These
results demonstrated that TALENs functioned in artiodactyl embryos.
Gene modification of embryos with Zinc Finger Nucleases (ZFNs) and
TALENs has been reported for model organisms by direct injection of
ZFN or TALEN mRNAs encoding a nuclease pair Geurts et al. (2009)
Science 325:433; Carbery et al., (2010) Genetics 186:451; Mashimo
et al. (2010) PLoS One 5:e8870; Tesson et al. (2011) Nature
Biotechnol. 29:695. The sequence of the ACAN12 gene is found in
FIG. 6 (SEQ ID NO: 26).
Example 2: Genetically Modified Artiodactyl Livestock Produced by
Genetic Modification of Bovine and Swine Somatic Cells
[0379] Several additional TALEN pairs were assembled as described
in Cermark et al. (2011) Nuc. Acids Res. 39:e82 for targets in pigs
and cattle chosen based on either biomedical or agricultural
relevance, such as DMD. Mammalian animal models have proven
invaluable in defining the complexity of muscle disease and have
enabled the development of several promising therapeutic strategies
for Duchenne Muscular Dystrophy (DMD). However, the development of
regenerative therapies would greatly benefit from more faithful and
reproducible models. Muscle degeneration in the mdx mouse model is
mild in comparison to DMD patients, perhaps due to smaller muscle
forces in rodents, or because of partial functional redundancy.
Several dystrophin-deficient dogs have been identified and the
causative genetic lesion defined in at least three. The
best-characterized and closest in phenotype to DMD is the golden
retriever muscular dystrophy (GRMD) dog caused by a splice-site
mutation in Exon 6. However, the phenotype of the GRMD varies
significantly with age and genetic background, confounding the
utility of the dog model.
[0380] Pigs represent a socially and scientifically preferred large
animal for modeling DMD. The musculoskeletal and cardiovascular
physiology, myogenic program, and size of pigs is striking in its
similarity to humans. Like mice, the pig genome can be efficiently
manipulated to create hypomorphic and null alleles by genome
engineering. We hypothesized that TALEN mediated mutation in
porcine exons 7 or 8 (DMDE6; DMDE7) would produce a reliable swine
mode of DMD.
[0381] TALEN pairs DMDE6 to target DMD exon 6 (SEQ ID NO: 379) and
DMDE7.1 to target DMD exon 7 (SEQ ID NO: 380) were chosen because a
high percentage of Duchene's Muscular Dystrophy (DMD) is caused by
gross deletions, providing the opportunity to mimic the human
condition in a porcine model. Binding domains of six TALEN pairs
were placed in the context of two TALEN scaffolds (+231, Christian
et. al. 2010 (op cit) and Carlson +63, see Miller et. al. 2011 (op
cit)) (FIG. 5). Each TALEN pair was transfected via plamid into
primary livestock fibroblasts, and genome modification was measured
at day 3 by the SURVEYOR assay (Guschin, et al. (2010) Methods Mol.
Biol. 649:247. TALEN pair sequences are listed in Table 13 and
Table 14. The most active TALEN pairs, DMDE7.1 and ACAN12,
displayed cleavage of 38% and 25% of chromosomes, respectively, and
Sanger sequencing revealed an assortment of indels characteristic
of NHEJ mediated DNA repair (FIG. 5, FIG. 6, FIG. 9, and SEQ ID
NOS: 56-58). The TALENs scaffold had a significant effect on
activity in fibroblasts. In total, 4 of 6 loci targeted with the
+63 isoform cleaved at 3.5% or greater while only the DMDE7.1 TALEN
pair cleaved above 1% in the +231 scaffold (FIG. 5). As noted in
Doyon et al. (2010) Nature Methods 8:74 and Miller, (2011) op.
cit.), a 72 hour incubation at 30.degree. C. after transfection
also had a positive effect on activity, and was required for
activity of 3 TALEN pairs. The success rate for generating active
Carlson +63 TALEN pairs has been high. Data collected shows that 23
of 36 (64%) TALEN pairs were detectably active (>1.0% NHEJ) at
15 genes scattered across the pig and cow genome, on autosomes and
both the X and Y chromosomes. Three quarters of the active pairs
cleaved with high efficiency (19-40%) with an average modification
level of 25%. Clonal processes for the creation of animal founder
lines based on modified fibroblasts are well known. The sequence of
the DMDE gene is found in FIG. 9A (SEQ ID NO: 55).
Example 3: Extended Culture and Indel Enrichment by Transposon
Co-Transfection
[0382] TALEN pairs were transfected into fibroblasts and cultured
cells for 14+ days with or without transposon co-selection prior to
measurement of modification levels. The targeted genes include
bovine GDF8 (btGDF8), Bovine ACAN (ACAN12), Porcine DMD (DMDE7.1
(A); DMDE6 (TALENs targeted to exon 6 of the DMD gene.)), Porcine
LDLR (C) (LDLR2.1) (see Tables 13 and 14). The results are
summarized in FIG. 7, panel C. At day zero (D0), cells are
transfected with a mixture of plasmids including an expression
cassette for each TALEN (two plasmids), a transposon encoding a
selection marker (a third plasmid, encoding puromycin, and a
transposase-expression cassette (fourth plasmid). The TALEN
plasmids are the main component (4-fold excess by mass) of each
transfection. Transfected cells are cultured for 3 days at either
30 or 37.degree. C. prior to splitting, collection of a sample for
SURVEYOR assay and re-plating for extended culture+/- selection for
transposon integration. All cells are cultured at 37.degree. C.
after day 3. Cells cultured for 14+ days are collected for SURVEYOR
assay and cryopreserved for downstream applications, i.e., SCNT.
For comparison, other fibroblasts were transfected by nucleofection
and percent NHEJ was measured at day 3, and in day 14+ non-selected
(NS) and selected (S) populations. For comparison, fibroblasts were
also transfected using cationic-lipids.
TABLE-US-00005 TABLE 2 TALEN activity in bovine zygotes SURVEYOR
mRNA total Number Blast Candidates/ NHEJ Target Trial Scaffold
ng/ul Inj. rate assayed Confirmed Non inj. 1 -- -- 60 41% -- --
Buffer 1 -- -- 68 36% -- -- ACAN11 1 231 10 67 22% 2/24 1/2 ACAN11
1 231 2 87 28% 1/32 0/1 ACAN12 1 231 10 57 33% 0/22 -- ACAN12 1 231
2 54 37% 1/23 1/1 PRNP3.2 1 231 10 65 14% 0/19 -- PRNP3.2 1 231 2
50 30% 0/17 -- Subtotal- 380 4 (3%) 2/4 (1.5% assayed) ACAN12 2 231
10 59 5% 1/10 0/1 ACAN12 2 231 25 58 16% 3/16 2/3 ACAN12 2 231 50
59 2% 2/9 1/2 ACAN12 2 231 100 51 0% 1/10 .sup. 1/1.sup.a Subtotal-
227 7 (16%) 4/7 (9% assayed) Non inj. 3 -- -- 51 43% -- -- Buffer 3
-- -- 35 23% -- -- GDF83.1 3 GT .sup. 2.sup.b 62 24% -- 6/14
GDF83.1 3 GT .sup. 10.sup.b 53 8% -- .sup. 3/4.sup.c Subtotal- 328
9/18 (50% assayed) .sup.a3 indels in one embryo .sup.beGFP mRNA was
added to a final concentration of 2 ng/ul. .sup.ctwo bi-allelic
modification ACAN--Aggrecan, candidate for model of congenital
achondroplasia. PRNP--Major prion protein, implicated in spongiform
encephalopathy. GDF8--Growth differentiation factor 8 (myostatin),
regulator of muscle growth.
Example 4: Isolation of Mono- and Bi-Allelic KO Clones
[0383] Transgenic primary fibroblasts can be effectively expanded
and isolated as colonies when plated with non-transgenic
fibroblasts (feeder-cells) at standard densities (>150
cells/cm2) and subjected to drug selection using the transposon
co-selection technique applied above (Carlson et al. (2011)
Transgenic Res. 20:1125). To evaluate this approach,
puromycin-resistant colonies for cells treated with six TALEN pairs
were isolated and their genotypes evaluated by SURVEYOR assay or
direct sequencing of PCR products spanning the target site (FIGS.
8A and 8B). In general, the proportion of indel positive clones was
similar to predictions made based on day 3 modification levels.
Bi-alleic knockout clones were identified for 5 of 7 different
TALEN pairs, occurring in up to 35 percent of indel positive cells
(Table 1). In the majority of examples, (15 of 23), indels were
homozygous (same indel on each allele) rather than unique indels on
each allele suggesting that sister chromatid-templated repair is
common (FIG. 9). Notably, among modified clones, the frequency of
bi-alleic modification (17-60 OR35%) for the majority of TALEN
pairs exceed predictions based on day 3 modification (10-17
OR15.6%) if chromosome cleavages are treated as independent events.
The sequence of the LDLR gene is found in FIG. 9B (SEQ ID NO: 68).
Examples of bi-alleleic sequences are further shown in FIGS. 8 and
9 using LDLR2.1 and DMDE7.1 TALENs. The sequences corresponding to
the TALENs listed in table 1 can be found in Tables 13 and 14.
TABLE-US-00006 TABLE 1 Genotype distribution in fibroblast clones.
Predicted Predicted % Day 3 % Mod Bi-allelic Observed Mod Observed
Bi- TALEN pair Mod Clones Mod Clones (%) allelic Mod (%) LDLRE2.1
Pig 19 34.5 10.5 30/81 (37) 5/26 (19) LDLRE2.1 Pig 21.5 38.3 12
23/76 (30) 8/23 (35).dagger. LDLRE2.1 Pig 14.4 26.7 7.7 12/94 (13)
2/12 (.gtoreq.17).sup.A LDLRE2.1-2x.sup.B Pig 19.7 35.5 10.9 8/24
(33) 2/8/(.gtoreq.25).sup.A LDLRE4.2 Pig 20 36 11.1 4/48 (8.3)
1/4/(25).sup.A LDLRE4.2 Pig 19 34.4 10 8/47 (17) 0/8.sup.A DMDE6
Pig 25 43.8 15.6 17/35 (49) NA DMDE7.1 Pig 27 47 15.6 12/29 (41)
3/10 (30) DMDE7.1-2x.sup.B Pig 22 39.2 12.4 22/41 (54) 7/22
(.gtoreq.32).sup.A.dagger. GHRHR2.3 Pig 29 50 17 26/43 (60) 15/26
(.gtoreq.58).sup.C.dagger. ACAN12 Cow 29 50 17 27/35 (77) 2/6
(NA).sup.D btGDF83.1 Cow 17 31 9.3 7/24/(29) 0/7 .sup.ABi-allelic
KO were identified by sequencing of PCR products. Only overlapping
or homozygous deletions can be identified using this technique.
.sup.BFibroblasts were transfected and recovered twice within two
weeks with the same TALEN pair. .sup.C5/15 Bi-allelic colonies were
confirmed as double frame-shift alleles. .sup.DOnly colonies with
distinguishable gross deletions in the PCR amplicon were analyzed.
.dagger.95% Confidence interval exceeds expected bi-allelic null
hypothesis
Example 5: Chromosomal Deletions and Inversions with TALENs
[0384] It was hypothesized that simultaneous delivery of two TALEN
pairs targeting the same chromosome could induce large chromosomal
deletions. These were achieved and, further, large inversions were
incidentally discovered. The TALEN pairs, DMDE6 (SEQ ID NOS:434 and
437) and DMDE7.1 (SEQ ID NOS:408-411) were tested because of their
high activity and the fact that a high percentage of Duchene's
Muscular Dystrophy is caused by gross deletions (Blake, 2002) such
that a porcine model would match to the human condition. The
results are summarized in FIG. 10. Day 3 gene modification levels
were high for each TALEN pair (24% for DMDE6 and 23% DMDE7.1),
albeit slightly lower that when either TALEN pair was transfected
individually (FIG. 10). To determine if the sequence between the
two TALEN pairs had been deleted, PCR was attempted with primers
spanning the TALEN target sites. If the 6.5 kb sequence had been
removed, a band of -500 bp was expected, whereas the wild type band
of 7 kb would not be amplified with the PCR conditions chosen. A
band near 500 bp was observed in replicates where both TALEN pairs
were introduced, but was absent when either TALEN pair was
introduced alone (FIG. 10). The sequence of the DMD gene is found
in FIG. 9A (SEQ ID NO: 61).
[0385] Next, the cell population was assayed for inversion events
by PCR across presumptive new 5' and 3' junctions. Products were
observed at the expected size for both the 5' and 3' junctions of
the presumptive inversion only when both TALEN pairs were
introduced (FIG. 10). To validate further that the inversions,
colonies were generated using the transposon co-selection strategy
and screened for deletion and inversion events. Both deletion and
inversion events were recovered with high frequency (10.3% and 4.1%
respectively; n >1000) (Table S4). Deletion and inversion events
occurred with remarkable fidelity. Forty one out of 43 of the
inversion positive colonies were positive at both the 5' and 3'
junctions. Finally, sequencing of PCR products confirmed both
deletion and inversion events with addition or deletion of very few
nucleotides at their junctions (FIG. 11, 12).
Example 6: TALEN-Induced Homologous Recombination Eliminates Need
for Linked Selection Markers
[0386] A mutant myostatin allele (an 11 bp deletion) from Belgian
Blue cattle was placed into the genome of wild-type Wagyu cattle
(Grobet et al. (1997) Nature Genet. 17:71) (FIG. 13). When
transfected alone, the btGDF8.1 TALEN pair (SEQ ID NOS: 428 and
431) cleaved up to 16% of chromosomes at the target locus (FIG.
13). TALENs (btGDF83.1, SEQ ID NOS:428 and 431) and a dsDNA
template (BB-HDR) (SEQ ID NO: 504) were designed to introduce an
11-bp deletion in exon-3 of bovine GDF8 (Belgium Blue mutation) by
DSB induced homologous recombination. Half of the binding site for
the left TALEN was missing in the BB-HDR template, to make it
resistant to TALEN cleavage. A SURVEYOR assay demonstrated activity
of btGDF83.1 TALENs at both 37 and 30.degree. C. The PCR product
used for this assay was generated using primers b and b' (shown
panel A of FIG. 13). The BB-HDR template was not included in these
replicates since it would confound estimates of btGDF83.1 activity.
Allele specific PCR demonstrated that HDR induction was dependent
on co-transfection of TALENs and the BB-HDR template. The PCR assay
was developed to specifically detect HDR modified GDF8 alleles
using primers c and c' (shown panel a of FIG. 13). The 3' end of
primer c' spanned the 11-bp deletion, and cannot amplify the wild
type allele "wt". Five hundred cell equivalents were included in
each PCR reaction including the positive control "C". Percent HDR
was determined by comparative densitometry between experimental and
control reactions. Co-transfection with a supercoiled DNA template
harboring a 1623 bp DNA fragment from Belgian Blue cattle resulted
in a gene conversion frequency (HDR) of 0.5% to 5% as suggested by
semi-quantitative PCR at day 3, without selection for the desired
event (FIG. 13). These results demonstrated that TALENs can be used
to effectively place exogenous nucleic acid sequences in livestock,
including alleles--and without markers. To assess the frequency of
placement in individual colonies, the transposon co-selection
strategy was implemented to isolate and expand individual colonies
for DNA sequencing. Gene conversion using template from Belgian
Blue cattle was detected in 5 colonies out of 366 examined by PCR.
Amplification with primers outside the Belgian Blue HDR template
and sequencing confirmed the presence of the expected 11 bp
deletion in 4 of the colonies (FIG. 14). A second repeat experiment
was performed with consistent results, with about 1% of all tested
colonies being positive for bi-allelic conversion and about 0.5% to
about 1% of all tested colonies being heterozygous for allele
conversion.
Example 7: TALEN Mediated DNA Cleavage as a Target for HDR in
Livestock Cells
[0387] TALEN pair LDLR2.1 (SEQ ID NO: 438 and 439) targeted to the
fourth exon of the swine low density lipoprotein receptor (LDLR)
gene (SEQ ID NO: 349) was co-transfected with the supercoiled
plasmid Ldlr-E4N-stop (Table 12, SEQ ID NO: 350) (designed to
insert a stop codon into exon 4), which contains homology arms
corresponding to the swine LDLR gene and a gene-trap enabling
expression of Neomycin phosphotransferase upon HDR (FIG. 15). After
3 days of culture PCR analysis revealed that, even without
antibiotic selection, a band corresponding to an HDR event can be
detected at the targeted locus (lane 4) at 30.degree. C. Selection
of populations of cultured cells for 14 days with geneticin (G418)
resulted in significant enrichment of HDR cells (lanes 11 &
13). Cloning of such modified cells by somatic cell nuclear
transfer was performed, with surrogate sows presently gestating the
embryos.
TABLE-US-00007 TABLE 12 Description of sequence of the LDLR-E4N
stop plasmid Name Type Mini Maximum Len 5' Homology Arm misc_feat
5,523 257 899 left ITR LTR 5,374 5,514 141 pUC origin misc_feat
4,701 5,368 668 Amp resistance CDS 3,693 4,550 858 f1 ori misc_feat
2,868 3,174 307 Right ITR LTR 2,636 2,776 141 3' Homology Arm
misc_feat 2,330 2,627 298 Lox P misc_bindi 2,283 2,316 34 Neo CDS
1,186 1,977 792 ECMV IRES misc_feat 576 1,185 610 Exon C_region 504
566 63 BPSA splicing si 401 506 106 Lox P misc_bindi 330 363 34
Example 8: TALEN Activity in Bovine Zygotes
[0388] This Example compares results obtained with the Carlson +63
TALENS to a +231 scaffold. The methods described in Example 1 were
followed. Table 2 summarizes the results using the GDF83.1 TALEN
pair (SEQ ID NOS: 428 and 431) targeted to exon 3 of the bovine
GDF8 locus, with the GDF83.1 being based on the Carlson +63
scaffold. Mutation frequency using the CARLSON+63 TALENs
significantly exceeded previous injections. Six of 14 blastocysts
(43%) injected with a low mRNA dosage (2 ng/.mu.1) displayed indels
without a significant reduction in development rate. Three of four
blastocysts in the high dosage group (10 ng/.mu.1) displayed
indels, with bi-allelic modification occurring in 2 of 3 mutant
blastocysts (Table 3).
TABLE-US-00008 TABLE 3 Indels for GDF83.1 Bi-allelic Modification
SEQ ID NOS SEQUENCES 147 Wt. ACTCCACAGAATCTCGATGCTGT
CGTTACCCTCTAACTGTGGATT 148 1a. ACTCCACAGAATCTCGATGCT:: X9
:GTTACCCTCTAACTGTGGATT 135 1b. ACTCCACAGAATCTCGATG:::: X2
:::::::CTCTAACTGTGGATT 136 1c. ACTCCACAGAATCTCGATGC::: X1
:::TACCCTCTAACTGTGGATT 137 2a. ACTCCACAGAAT::::::::::: X3
::::::CCTCTAACTGTGGATT 138 2b. ACTCCACAGAATCTCGATGCT:: X1
::GTTACCTCTAACTGTGGATT 139 2c. ACTCCACAGAATCTCGATGCT:T X2
CGTTACCCTCTAACTGTGGATT 2/9 Bi-allelic
Example 9: Cloning of TALEN-Modified Cells
[0389] Cells from Example 4 that were modified with LDLR2 TALEN
pairs (SEQ ID NOS:438 and 439) were grown as clones. Transposon
co-selected Ossabaw swine colonies with mono- and bi-allelic
modification of the Class A domain 1 of the LDLR gene were pooled
disproportionately (pools A--4 genotypes, B--3 genotypes and C--5
genotypes) and cloned by chromatin transfer. Pregnancy was
established in 7/9 transfers (1/2 for pool A, 2/3 for pool B, and
4/4 for pool C). Seven of the 9 sows became pregnant, and 6 of the
7 pregnant sows had live births. 17 piglets were born that appear
to be in good health for purposes of raising to maturity. The
piglets had various genotypes, referred to as B1, B2, C1 and C2 in
Table 4, below. Two of the genotypes were deletions, one was a
single base insertion and one genotype had modifications of both
alleles, an insertion in one allele and deletion in the other.
TABLE-US-00009 TABLE 4 SEQ ID NOS. 141-145 SEQ ID NO SEQUENCE 140
Wt: CTCCTACAAGTGGATTGTGATGGGAACACC GAGTGCAAGGACGGGTCCG B1:
(289_290INS34; 285_287delATG) 10 born; 9 live 141 1.
CTCCTACAAGTGGATTTGTGATGGGA i34 ACACCGAGTGCAAGGACGGGTCCG 142 2.
CTCCTACAAGTGGATTTGTG:::GGAACAC CGAGTGCAAGGACGGGTCCG B2:
(211_292de1128) One stillborn 143 1.
AGGGAGTATGGTCAC:::::::.DELTA.128::AC CGAGTGCAAGGACGGGTCCG C1:
(289_290de110) 3 born (one stillborn, one euthanized due to clone
defects) 144 1. CTCCTACAAGTGGATTTGTGATGGG::::: :::::GCAAGGACGGGTCCG
C2: (289_290insA) 8 born; 8 live 145 1.
CTCCTACAAGTGGATTTGTGATGGGAAACA CCGAGTGCAAGGACGGGTCCG
Example 10: An Adeno-Associated Virus (AAV) is an Effective
Template for TALEN Stimulated Homologous Recombination (HR)
[0390] In another study, similar to Example 6, a mutant myostatin
allele (11 bp deletion) from Belgian Blue cattle was introgressed
into the genome of wild-type Wagyu cattle (Grobet, 1997, Kambadur,
1997) (FIG. 18). Four micrograms of TALEN encoding plasmids (SEQ ID
NOS: 428 and 431) were transfected into Wagyu cells and 24 hours
later an adeno-associated virus (AAV-BB-HDR) harboring a 1,623 bp
DNA fragment from Belgian Blue cattle was added. (SEQ ID NO: 505)
Semi-quantitative PCR at day three suggests an allele conversion
frequency of up to 5% only when both GDF8 TALENs and the AAV vector
were added. To assess the frequency of introgression in individual
colonies, the transposon co-selection strategy was implemented to
isolate and expand individual colonies for DNA sequencing. Thirteen
percent of isolated colonies were PCR positive for introgression of
the BB allele. These results demonstrate that TALENs and an AAV
homologous recombination template is an effective method for
targeted allele introgression in livestock and represents a
significant improvement over supercoiled plasmid homologous
recombination template for the same locus (Example 6).
Example 11: Single Stranded DNA for Templating
[0391] FIG. 19 summarizes the results of the transfection of TALEN
encoding plasmids, containing an 11 base pair Belgian Blue cattle
mutation, into Wagyu cells. Single stranded oligodeoxynucleotides
(ssODNs) were found to be an effective template for TALEN
stimulated HR. The same loci as above (Examples 6 and 10) were
targeted to introgress the 11 base pair Belgian Blue cattle
mutation into Wagyu cells. Two 76 base pair ssODNs (SEQ ID NOS: 501
and 502) were designed to mimic either the sense or antisense
strand of the BB GDF8 gene including the 11 base pair deletion.
Four micrograms of TALEN encoding plasmids were transfected into
Wagyu cells, and 0.3 nMol of ssODNs were either co-transfected with
TALENS (N) or delivered 24 hours after TALEN nucleofection by
either MirusLT1 (M) reagent or Lipofectamine LTX reagent (L).
Semi-quantitative PCR at day three suggests an allele conversion
frequency of up to 5% in conditions where ssODNs were delivered
with LIPOFECTAMINE LTX reagent 24 hours after TALEN transfection.
No difference in PCR signal was observed between sense and
antisense ssODNs designed against the target.
Example 12: Transfection of Livestock Cells with mRNAs Encoding
TALENs Results in Efficient Target Cleavage
[0392] FIG. 20 summarizes the efficient target cleavage produced by
the transfection of TALEN encoding mRNAs into livestock cells. The
TALEN sequences can be found in Table 10. TALEN cDNAs (TALEN pairs
p6511.1 (SEQ ID NOS: 440, 441) and DMD7.1 (SEQ ID NOS: 410, 411))
were cloned downstream of the T3 promoter in the pT3TS cloning
vector transcribed as described in Carlson, 2010 and purified using
the MINELUTE PCR purification kit (Qiagen) prior to mRNA synthesis
using the MMESSAGE MACHINE T3 kit (Applied Biosciences) according
to the manufacturers protocol. Modified mRNA was synthesized from
the same vectors with the MMESSAGE MACHINE T3 kit (Applied
Biosciences) substituting a ribonucleotide cocktail consisting of
3'-O-Me-m7G(5')ppp(5')G RNA cap analog (New England Biolabs),
5-methylcytidine triphosphate pseudouridine triphosphate (TriLink
Biotechnologies, San Diego, Calif.) and two standard
ribonucleotides, adenosine triphosphate and guanosine triphosphate.
mRNA synthesis reactions were DNAse treated prior to purification
using the MEGACLEAR REACTION CLEANUP kit (Applied Biosciences). a)
The indicated quantities of p6511.1 TALENs were transfected into
pig fibroblasts (500,000-750,000 cells per replicate) using the
NEON nucleofection system (Life Technologies) with the following
settings: 1 pulse, 1800 v; 20 ms width and a 100 .mu.l tip.
Transfected cells were culture 3 days at either 30 or 37 degrees
Celsius prior to indel analysis by the SURVEYOR assay
(Transgenomic). Percent NHEJ was calculated as described in
Guischin et. al., 2010, and plotted on the graph. Four micrograms
of plasmid DNA (pDNA) encoding the p6511.1 TALENs was also
transfected under the same conditions for comparison of % NHEJ. b)
mRNA structure, composition or in vitro synthesis reaction scheme
have little effect on TALEN activity. mRNA encoding the DMD7.1
TALENs was synthesized either by individually ("I" left and right
TALENs in a separate reaction) or in the same reaction (Dual "D")
using standard or modified ribonucleotides. The reactions were then
split into two replicates, one of which an additional polyA tail
was added using the Poly(A) Tailing Kit (Ambion) according to the
manufacturers protocol.
[0393] Expression of TALENs from plasmid DNA has been an effective
method for induction of TALEN mediated indels in livestock cells;
however, integration of the TALEN encoding plasmids into the
genomes of cells is possible. In contrast, mRNA cannot integrate
into the genomes of host cells. To avoid the integration of TALEN
encoding plasmids, an experiment was performed to determine if
similar levels of TALEN activity could be achieved by transfection
of mRNAs encoding TALENs. mRNA for TALENs encoding the p6511.1
TALEN pair was generated using either standard or modified
ribonucleotides. Two quantities of each TALEN mRNA preparation were
transfected into pig fibroblasts by nucleofection, cultured 3 days
at 30 or 37 degrees Celsius prior to analysis of indels. Percent
NHEJ was similar for all mRNA transfections incubated at 30 degrees
Celsius while a dosage response could be observed for transfected
cells incubated at 37 degrees Celsius. A significant difference in
percent NHEJ between modified and standard ribonucleotides could
not be detected in this replicate, however, equivalent quantities
were not used. Notably, mRNA transfection in all groups incubated
at 30 degrees C. significantly outperformed the p6511.1 TALENs
transfected as plasmid DNA under the same conditions.
[0394] Another experiment was performed to examine the influence of
modified versus standard nucleotide synthesized mRNA at a second
locus, porcine DMD. This experiment also evaluated whether addition
of a polyA tail influenced TALEN activity, and whether each TALEN
monomer (left and right monomers) could be synthesized in the same
transcription reaction (Dual) or if they must be synthesized
individually and mixed prior to transfection. One or four
micrograms of DMD7.1 TALEN mRNA were transfected into pig
fibroblasts and cultured 3 days at 30 or 37 degrees Celsius. As
with the p6511.1 TALENs, little difference was observed in TALEN
activity in cells cultured at 30 degrees Celsius suggesting that
neither modified nucleotides, in vitro poly adenylation of mRNAs or
dual transcription of mRNAs had an influence on activity. A dosage
response could again be observed in the 37 degree cultured
replicates as 4 .mu.g of mRNA outperformed 1 .mu.g transfections.
Also, polyadenylated mRNAs appeared to outperform non adenlyated
mRNAs in 37 degree replicates.
[0395] Notably when plasmid DNA encoding the DMD7.1 TALENs was
transfected into pig fibroblasts, a significant reduction (40-60%)
in % NHEJ levels measured at day 3 versus cells cultured to day 14
was noticed (Example 3). No such reduction in % NHEJ was observed
for any of the mRNA transfected replicates shown here, data not
shown for day 14 modification levels. Thus mRNA transfection
appears to be superior to DNA transfection not only for TALEN
activity, but also for maintaining a high proportion of modified
cells after an extended period in culture. Without being bound to a
particular theory, it is believed that this result is due to
improved cell viability when transfected with mRNA versus plasmid
DNA.
Example 13: Analysis of Colonies Created by mRNA Transfection with
No Selection
[0396] One to four micrograms of mRNA encoding TALENs were added,
as in Example 12, to bovine or swine primary fibroblasts. The cells
were grown at 30.degree. C. for three days after exposure to TALENs
and cells were enumerated and plated at a range of densities 1-20
cells/cm2 on 10 cm dishes. Cells were cultured for 10-15 days until
individual colonies of 3-4 mm in diameter could be observed.
Colonies were aspirated with a p-200 pipettor under gentle
aspiration and expelled into a well of 24-well plate with 500 .mu.l
of growth medium (Carlson, 2011). Plates with clearly defined
colonies (.about.10-30/plate) were chosen for colony aspiration to
limit the chance of aspirating cells from multiple colonies. Once a
colony reached 70-90 percent confluent in the 24-well dish, a
portion was harvested for indel analysis and the remainder was
cryopreserved. The results of the indel analysis are located in the
last five lines of Table 5. These results demonstrate that colonies
can be readily isolated from TALEN mRNA transfected fibroblasts
without the use of selection markers. Mutation frequency in
analyzed clones were accurately predicted by the modification
levels of the source population at day 3. Clones with bi-allelic
modifications could also be readily identified. The results of this
Example are summarized in Table 5. The target sequences are LDLR
(SEQ ID NO: 242) (TALEN SEQ ID NOS: 438 and 439, 414-417), DMD exon
6 (SEQ ID NO:379) (TALEN SEQ NOS:434 and 437), DMD exon 7 (SEQ ID
NO: 380) (TALEN SEQ ID NOS: 408-411), GHRHR (Gene ID 2692) (TALEN
SEQ ID NOS:478 and 479), ACAN12 (SEQ ID NO: 378) (TALEN SEQ ID NOS:
401-404), and GDF8 (SEQ ID NOS: 351-353) (TALEN SEQ ID NOS:428 and
431).
TABLE-US-00010 TABLE 5 Genotype Distribution in Fibroblast Clones
Table of Genotype distribution in fibroblast clones. Predicted %
Predicted % Observed Mod Observed Bi- TALEN pair Selection Day 3
Mod Mod Clones Bi-allelic Mod Clones (%) allelic Mod (%) LDLRE2.1
Puro Pig 19 34.5 10.5 30/81 (37) 5/26 (19) LDLRE2.1 Puro Pig 21.5
38.3 12 23/76 (30) 8/23 (35).dagger. LDLRE2.1 Puro Pig 14.4 26.7
7.7 12/94 (13) 2/12 (.gtoreq.17).sup.A LDLRE2.1-2x.sup.B Puro Pig
19.7 35.5 10.9 8/24 (33) 2/8 (.gtoreq.25).sup.A LDLRE4.2 Puro Pig
20 36 11.1 4/48 (8.3) 1/4 (25).sup.A LDLRE4.2 Puro Pig 19 34.4 10
8/47 (17) 0/8.sup.A- DMDE6 Puro Pig 25 43.8 15.6 17/35 (49) NA
DMDE7.1 Puro Pig 27 47 15.6 12/29 (41) 3/10 (30) DMDE7.1-2x.sup.B
Puro Pig 22 39.2 12.4 22/41 (54) 7/22 (.gtoreq.32).sup.A.dagger.
GHRHR2.3 G-418 Pig 29 50 17 26/43 (60) 15/26
(.gtoreq.58).sup.C.dagger. ACAN12 Puro Cow 29 50 17 27/35 (77) 2/6
(NA).sup.D btGDF83.1 Puro Cow 17 31 9.3 7/24 (29) 0/7 GHRHR2.3 None
Pig 32.5 55 19.4 21/25 (84) 6/21 (.gtoreq.29).sup.A GHRHR2.3 None
Pig 35 58 21 13/13 (100) 3/13 (.gtoreq.23).sup.A LDLR2.1 None Pig
34 57 20 88/166 (53) 5/16 (31%) btGDF83.1 None Cow 29 50 17 23/45
(51) 2/23 (.gtoreq.9).sup.E btGDF83.1 None Cow 35 58 21 23/41 (56)
7/23 (.gtoreq.30).sup.E .sup.ABi-allelic KO were identified by
sequencing of PCR products. Only overlapping or homozygous
deletions can be identified using this technique. .sup.BFibroblasts
were transfected and recovered twice within two weeks with the same
TALEN pair. .sup.C5/15 Bi-allelic colonies were confirmed as double
frame-shift alleles. .sup.DOnly colonies with distinguishable gross
deletions in the PCR amplicon were analyzed. .sup.EBi-allelic KO
colonies were identified by high definition melt analysis. Only
homozygous modifications can be identified. .dagger.95% Confidence
interval exceeds expected bi-allelic null hypothesis
Example 14: Co-Transfection of mRNA Encoded TALENs and ssODNs
Enhances HDR
[0397] FIG. 21 sets forth a summary of experimental results for
modifying Wagyu cells with a combination of mRNA encoding TALENs
and single-stranded oligonucleotides. The cells were Waygu cells
and the allele was the Belgian Blue. Experimentation, cell type and
locus assayed was the same as in Example 11 with the exception that
TALEN encoding mRNA (2 ug) was delivered in place of DNA encoded
TALENs (where indicated) and only the sense ssODN was used. No
selection markers were introduced in these cells at any stage.
Population analysis at day three revealed HDR in both DNA and mRNA
transfected cells when the ssODN was introduced 24 hours after
TALENs. Peak activity (.about.10%) was observed in cells
co-transfected with the ssODN and TALEN mRNA by nuclofection. This
result contrasts the previous result with DNA encoding TALENs which
were unable to stimulate HDR at a measurable frequency. Among
individual colonies, prepared as in Example 12, both heterozygous
and homozygous introgression of the Belgian Blue allele could be
observed at 5 and 2 percent, respectively.
Example 15: Introduction of Single Base Alterations Using ssODNs
and mRNA Encoding TALENs
[0398] FIGS. 22 and 23 depict results of another study wherein a
single nucleotide polymorphism was replicated. This polymorphism
was known to cause a coding change to the bovine GDF8 locus, C313Y,
known to cause hypermuscularity in Piedmontese cattle (Kambadur,
1997; Genome Res. 1997 7: 910-915 An additional SNP was introduced
into the ssODN to create a silent EcoRI site to aid in screening
and/or quantification of HDR. mRNA and ssODNs were introduced
simultaneously by nucleofection as indicated in Examples 11 and 13
with relative quantities indicated. (SEQ ID NOS: 503 and 431) FIGS.
22 and 23 show results when transfected cells are incubated at 30
and 37 degrees Celsius for three days. Peak levels of homologous
recombination were significantly higher at 30 degrees Celsius
(11.3%) than at 37 (1.7%), despite similar activity of the TALENs.
(SEQ ID NOS: 442 and 443) The data shows that from about 0.2 to
about 0.4 nmol ssDNA is effective for homologous recombination both
at 30 and 37 degrees Celsius. Surprisingly, a bi-phasic effect was
observed, with too great of an oligonucleotide concentration/amount
abolishing the recombination. No selection markers were used in
these cells at any stage.
Example 16: Alleles Introduced into Pig (Ossabaw) Cells Using Oligo
HDR
[0399] FIG. 24 sets forth a summary of experimental results for
modifying cells with a combination of mRNA encoded TALENs and
single-stranded oligonucleotides to place an allele that occurs
naturally in one species to another species (interspecific
migration). Piedmontese GFD8 SNP C313Y (SEQ ID NOS: 444 and 445),
as in Example 15, was chosen as an example and was introduced into
Ossabow swine cells. Experiments were performed as in Example 15
with Ossabaw swine cells substituted for Wagyu cells. No markers
were used in these cells at any stage. A similar peak in HDR was
observed between pig and cattle cells at 0.4 nmol ssODN, (FIG. 22,
23) however, HDR was not extinguished by higher concentrations of
ssODN in Ossabaw fibroblasts.
Example 17: Cloning for Alleles Introduced into Cells Using Oligo
HDR
[0400] FIG. 25 sets forth a summary of experimental results for
modifying cells with a combination of mRNA encoded TALENs and
single-stranded oligonucleotides to place an allele into cells for
cloning animals. A new allele (BamH1) was introduced into Ossabaw
swine cells designed to introduce a 4 base pair insertion that
would both create frame-shift allele and introduce a novel BamH1
site. Two or 1 micrograms of ssLDLR2.1 TALEN mRNA (SEQ ID NOS: 438
and 439) and 0.3 nmol of ssODN was introduced into Ossabaw cells as
in Examples 11 and 13. (SEQ ID NO: 506) Surprisingly, there was
synergy between the ssODNs and the TALEN activity as the previous
maximum for this TALEN pair without ssODN was 25% NHEJ. This
synergy was unexpected and not predictable based on current
understanding of the relevant molecular mechanisms. HDR was
detected by restriction digest of PCR amplicons with BamH1. HDR
levels were similar to NHEJ levels suggesting that the majority of
TALEN induced breaks were repaired with the ssODN. Analysis of
individual colonies, generated, as in example 13, revealed
heterozygous and homozygous modification of up to 30 and 2.5
percent respectively. No selection markers were used in these
animals at any stage. TALEN treated cells were cloned by chromatin
transfer, implanted into surrogate sows and resulted in the
establishment of pregnancies.
Example 18: DNA and mRNA Encoded TALENs are Active in
Spermatigonial Stem Cells
[0401] Results are summarized in FIG. 26. Porcine germ cells were
isolated from 10 wk old boars, and enriched by differential.
Plasmids encoding eGFP and DMD-specific TALENs were transfected
into germ cells using the AMAXA NUCLEOFECTOR system Amaxa solutions
"V"- and "L" and "B" using programs X-001 and X-005. (SEQ ID NOS:
504, 505, 506) Each transfection reaction was performed with
10.sup.6 of enriched germ cells, and indicated micrograms of TALEN
encoding plasmid DNA. The same methods were used to deliver mRNAs
encoding DMD7.1 TALENs. After nucleofection, the cells were
cultured for 5 days in 5% CO.sub.2 atmosphere at 37.degree. C. or
30.degree. C. Transfection efficiency was evaluated by
immunofluorescence analysis for co-localization of expression of
GFP and UCH-L1. Cell viability was evaluated by trypan blue
exclusion.
Example 19: TALEN Stimulated HDR in Primordial Germ Cells
[0402] TALEN stimulated HDR was also tested in chicken primordial
germ cells (PGCs) at the chicken Ddx4 locus. Two TALEN pairs were
constructed, on to intron 1 (Tal1.1) (SEQ ID NOS: 446 and 447) and
exon 7 (Ta17.1) (SEQ ID NOS: 448 and 449) and their function was
verified in DF1 chicken cells, see FIG. 27. Tal1.1 lies within the
homologous sequence of the donor targeting vector. Tal7.1 lies
outside the homologous sequence of the donor targeting vector. See
also Example 7. Subsequently, each TALEN pair was co-transfected
with the donor targeting vector designed to fuse GFP with Exon 2 of
the Ddx4 gene (Panel b). As expected cleavage with Tal 1.1
stimulated homologous recombination (panel c) whereas Tal 7., which
lies outside of the homologous sequence in the donor targeting
vector, did not stimulate HDR.
Example 20: TALEN Designing and Production
[0403] Candidate TALEN target DNA sequences and RVD sequences for
examples 20-40 were identified using the online tool "TAL EFFECTOR
NUCLEOTIDE TARGETER". Plasmids for TALEN DNA transfection or in
vitro TALEN mRNA transcription were then constructed by following
the Golden Gate Assembly protocol using pCGOLDYTALEN (Addgene ID
38143) and RClscript-GOLDYTALEN (Addgene ID 38143) as final
destination vectors (Carlson 2012). The final pC-GoldyTALEN vectors
were prepared by using PureLink.RTM. HIPURE PLASMID MIDIPREP Kit
(Life Technologies) and sequenced before usage. Assembled RClscript
vectors prepared using the QIAPREP SPIN MINIPREP kit (Qiagen) were
linearized by SacI to be used as templates for in vitro TALEN mRNA
transcription using the mMESSAGE mMACHINE.RTM. T3 Kit (Ambion) as
indicated elsewhere. Modified mRNA was synthesized from
RCIScript-GOLDYTALEN vectors as described in Carlson 2012
substituting a ribonucleotide cocktail consisting of
3'-O-Mem7G(5')ppp(5')G RNA cap analog (New England Biolabs),
5-methylcytidine triphosphate pseudouridine triphosphate (TriLink
Biotechnologies, San Diego, Calif.) and adenosine triphosphate
guanosine triphosphate. Final nucleotide reaction concentrations
are 6 mM for the cap analog, 1.5 mM for guanosine triphosphate, and
7.5 mM for the other nucleotides. Resulting mRNA was DNAse treated
prior to purification using the MEGACLEAR REACTION CLEANUP kit
(Applied Biosciences).
Example 21: CRISPR/Cas9 Design and Production
[0404] Gene specific gRNA sequences were cloned into the Church lab
gRNA vector (Addgene ID: 41824) according their methods. The Cas9
nuclease was provided either by co-transfection of the hCas9
plasmid (Addgene ID: 41815) or mRNA synthesized from
RCIScript-hCas9. This RCIScript-hCas9 was constructed by
sub-cloning the XbaI-AgeI fragment from the hCas9 plasmid
(encompassing the hCas9 cDNA) into the RCIScript plasmid. Synthesis
of mRNA was conducted as above except that linearization was
performed using KpnI.
Example 22: Donor Repair Template Preparation
[0405] A) Bb-Hdr (1,623 Bp) Plasmid.
[0406] A 1,695 bp fragment encompassing the Belgian Blue allele was
PCR amplified (btGDF8 BB 5-1: 5'-CAAAGTTGGTGACGTGACAGAGGTC (SEQ ID
NO:328); btGDF8 BB 3-1: 5'-GTGTGCCATCCCTACTTTGTGGAA (SEQ ID
NO:329)) from Belgian Blue genomic DNA and TOPO cloned into the PCR
2.1 vector (Life Technologies). This plasmid was used as positive
control template for analytical primer sets and for derivation of
the 1,623 bp BB-HDR template by PCR with following primers (BB del
HR 1623 5-1: 5'-GATGTATTCCTCAGACTTTTCC (SEQ ID NO:330); BB del HR
1623 3-1: 5'-GTGGAATCTCATCTTACCAA, SEQ ID NO:331) and TOPO cloned
as before. Each plasmid was sequence verified prior to use.
Transfection grade plasmid was prepared using the Fast-Ion MIDI
PLASMID ENDO-FREE kit (IBI Scientific). rAAV packaging. BB-HDR was
cloned into pAAV-MCS and packaged into using the ADENO-ASSOCIATED
VIRUS HELPER-FREE system (Agilent). Briefly, a 10 cm dish AAV-293
cells was transfected with 5 .mu.g each: pAAV-Helper, pAAV-RC and
the AAV-BB-HDR plasmid. Two days post transfection, the cells were
removed from the plate by scraping into 1 ml of growth media. Viral
particles were released by 3 freeze-thaw cycles prior to
centrifugation at maximum speed in a microcentrifuge for 5 minutes.
The supernatant was aspirated and used directly for infection of
target cells.
[0407] B) Polled 1592 Template.
[0408] A 1,784 bp fragment encompassing 383 the POLLED allele was
PCR amplified (F1: 5'-GGGCAAGTTGCTCAGCTGTTTTTG (SEQ ID NO:332);
R1-5'-TCCGCATGGTTTAGCAGGATTCA, SEQ ID NO:333) from angus genomic
DNA and TOPO cloned into the PCR 2.1 vector (Life Technologies).
This plasmid was used as positive the control template for
analytical primer sets and for derivation of the 1,592 bp HDR
template by PCR with following primers (1594 F:
5'-ATCGAACCTGGGTCTTCTGCATTG SEQ ID NO:334; R1:
5'-TCCGCATGGTTTAGCAGGATTCA, SEQ ID NO:335) and TOPO cloned as
before. Each plasmid was sequence verified prior to use.
Transfection grade plasmid was prepared using the Fast-Ion MIDI
Plasmid Endo-Free kit (IBI Scientific) and 5 .mu.g or 10 .mu.g was
transfected along with 2 .mu.g HP1.3 TALEN mRNA (SEQ ID NOS: 464
and 465) Oligonucleotide templates. All oligonucleotide templates
were synthesized by Integrated DNA Technologies, 100 nmole
synthesis purified by standard desalting, and resuspended to 400
.mu.M in TE.
Example 23: Tissue Culture and Transfection
[0409] Pig or cattle fibroblasts were maintained at 37 or
30.degree. C. (as indicated) at 5% CO2 in DMEM supplemented with
10% fetal bovine serum, 100 I.U./ml penicillin and streptomycin,
and 2 mM L-Glutamine. For transfection, all TALENs and HDR
templates were delivered through transfection using the Neon
Transfection system (Life Technologies) unless otherwise stated.
Briefly, low passage Ossabaw, Landrace, Wagyu, or Holstein
fibroblasts reaching 100% confluence were split 1:2 and harvested
the next day at 70-80% confluence. Each transfection was comprised
of 500,000-600,000 cells resuspended in buffer "R" mixed with
plasmid DNA or mRNA and oligos and electroporated using the 100
.mu.l tips by the following parameters: input Voltage; 1800V; Pulse
Width; 20 ms; and Pulse Number; 1. Typically, 2-4 .mu.g of TALEN
expression plasmid or 1-2 .mu.g of TALEN mRNA and 2-3 .mu.M of
oligos specific for the gene of interest were included in each
transfection. Deviation from those amounts is indicated in the
figure legends. After transfection, cells were divided 60:40 into
two separate wells of a 6-well dish for three days' culture at
either 30 or 37.degree. C. respectively. After three days, cell
populations were expanded and at 37.degree. C. until at least day
10 to assess stability of edits.
Example 24: Dilution Isolation of Cellular Clones
[0410] Three days post transfection, 50 to 250 cells were seeded
onto 10 cm dishes and cultured until individual colonies reached
about 5 mm in diameter. At this point, 6 ml of TrypLE (Life
Technologies) 1:5 (vol/vol) diluted in PBS was added and colonies
were aspirated, transferred into wells of a 24-well dish well and
cultured under the same 420 conditions. Colonies reaching
confluence were collected and divided for cryopreservation and
genotyping. Sample preparation: Transfected cells populations at
day 3 and 10 were collected from a well of a 6-well dish and 10-30%
were resuspended in 50p1 of 1.times.PCR compatible lysis buffer: 10
mM Tris-Cl pH 8.0, 2 mM EDTA, 0.45% Tryton X-100 (vol/vol), 0.45%
Tween-20 (vol/vol) freshly supplemented with 200 .mu.g/ml
Proteinase K. The lysates were processed in a thermal cycler using
the following program: 55.degree. C. for 60 minutes, 95.degree. C.
for 15 minutes. Colony samples from dilution cloning were treated
as above using 20-30 .mu.l of lysis buffer.
Example 25: Plasmid and rAAV HDR in Wagyu Fibroblasts
[0411] Low passage Wagyu fibroblasts were cultured to 70-90%
confluence and transfected by NUCLEOFECTION (Lonza) with 2 .mu.g
each TALEN expression plasmid (btGDF83.1L+NR, SEQ ID NO: 428) along
with 750 ng of SLEEPING BEAUTY transposon components as described
in Carlson 2012. For conditions where plasmid HDR template was
used, 2 .mu.g of BB-HDR plasmid was also included in the
transfection. Transfected cells were split between two wells of a
6-well plate for culture at 30 or 37.degree. C. For conditions
using rAAV HDR template, 150 .mu.l of viral lysate was added to
each well 2 hours post transfection. After incubation for three
days, cells were harvested by trypsinization, a portion of which
were lysed for analysis of HDR at day 3, and the remainder were
plated for colony isolation as described in Carlson 2012.
Example 26: Mutation Detection and RFLP Analysis
[0412] PCR flanking the intended sites was conducted using PLATINUM
TAQ DNA POLYMERASE HIFI (Life Technologies) with 1 .mu.l of the
cell lysate according to the manufacturer's recommendations. The
frequency of mutation in a population was analysed with the
SURVEYOR MUTATION DETECTION Kit (Transgenomic) according to the
manufacturer's recommendations using 10 ul of the PCR product as
described above. RFLP analysis was performed on 10 .mu.l of the
above PCR reaction using the indicated restriction enzyme. SURVEYOR
and RFLP reactions were resolved on a 10% TBE polyacrylamide gels
and visualized by ethidium bromide staining. Densitometry
measurements of the bands were performed using ImageJ; and mutation
rate of SURVEYOR reactions was calculated as described in Guschin
et al., 2010. Percent HDR was calculated via dividing the sum
intensity of RFLP fragments by the sum intensity of the parental
band+RFLP fragments. For analysis of mloxP insertion, small PCR
products spanning the insertion site were resolved on 10%
polyacrylamide gels and the insert versus wild type alleles could
be distinguished by size and quantified. RFLP analysis of colonies
was treated similarly except that the PCR products were amplified
by 1.times.MYTAQ RED Mix (Bioline) and resolved on 2.5% agarose
gels. For analysis of clones for introgression of the GDF8
G938A-only (oligos lacked a novel RFLP), colonies were initially
screened by a three primer assay that could distinguish between
heterozygous ad homozygous introgression. Briefly, lysates from pig
or cattle colonies were analysed by PCR using 1.times.MYTAQ RED MIX
(Bioline) using the following primers and programs. Cattle GDF8
(Outside F1: 5'-CCTTGAGGTAGGAGAGTGTTTTGGG, SEQ ID NO:336, Outside
R1: 5'-TTCACCAGAAGACAAGGAGAATTGC, SEQ ID NO:337, Inside F1:
5'-TAAGGCCAATTACTGCTCTGGAGACTA, SEQ ID NO:338; and 35 cycles of
(95.degree. C., 20 s; 62.degree. C., 20 s; 72.degree. C., 60 s).
Pig GDF8: Outside F1: 5'-CCTTTTTAGAAGTCAAGGTAACAGACAC, SEQ ID
NO:339, Outside R1: 5'-TTGATTGGAGACATCTTTGTGGGAG, SEQ ID NO:340
Inside F1: 5'-TAAGGCCAATTACTGCTCTGGAGATTA, SEQ ID NO:341; and 35
cycles of (95.degree. C., 20 s; 58.degree. C., 20 s; 72.degree. C.,
60 s). Amplicons from candidates were sequenced directly and/or
TOPO cloned (Life Technologies) and sequenced by Sanger sequencing.
To detect TALEN-mediated HDR at with the BB-HDR template, either 1
.mu.l or 1 .mu.l of a 1:10 dilution of PCR-lysate (1,000 cells/ul)
was added to a PCR reaction with PCR primers bt GDF8 BB 5-1 (primer
"c") and primer "c" (BB-Detect 3-1-5'-GCATCGAGATTCTGTCACAATCAA, SEQ
ID NO:342) and subjected to PCR with using 1.times. MYTAQ RED MIX
(Bioline) for 40 cycles (9 459 5.degree. C., 20 s; 66.degree. C.,
20 s; 72.degree. C., 60 s). To confirm HDR in colonies identified
by the above PCR, amplification of the entire locus was performed
with primers bt GDF8 BB 5-1 and bt GDF8 BB 3-1 followed by TOPO
cloning (Life Technologies) and sequencing.
Example 27: Detection of POLLED Introgression
[0413] Detection of POLLED introgression was performed by PCR using
the F1 primer (see above) and the "P" primer
(5'-ACGTACTCTTCATTTCACAGCCTAC, SEQ ID NO:343) using 1.times.MyTaq
Red mix (Bioline) for 38 cycles (95.degree. C., 25 s; 62.degree.
C., 25 s; 72.degree. C., 60 s). A second PCR assay was performed
using (F2: 5'-GTCTGGGGTGAGATAGTTTTCTTGG, SEQ ID NO:344;
R2-5'-GGCAGAGATGTTGGTCTTGGGTGT, SEQ ID NO:345). Candidates passing
both tests were analysed by PCR using the flanking F1 and R1
primers followed by TOPO cloning and sequencing. Detection of FecB
introgression was performed as previously described for sheep.
Callipyge introgression was detected by an AVAII RFLP assay. See
results in FIG. 35.
Example 28: Amplicon Sequencing and Analysis
[0414] DNA was isolated from transfected populations and 100-250 ng
was added to a 50 .mu.l PLATINUM TAQ DNA POLYMERASE HIGH FIDELITY
(Life Technologies) assembled per the manufacturer's
recommendations. Each sample was assigned a primer set with a
unique barcode to enable multiplex sequencing. A portion of the PCR
product was resolved on a 2.5% agarose gel to confirm size prior to
PCR cleanup using the MINELUTE PCR PURIFICATION Kit (Qiagen).
Samples were quantified and pooled into a single sample for
sequencing. The single combined sample was spiked with 25% PhiX
(for sequence diversity) and sequenced on an Illumina MISEQ
sequencer generating 150 base-pair paired-end reads. Read quality
was assessed using FASTQC Read-pairs with overlapping ends were
joined using FASTQ-JOIN from the EA-UTILS package. A custom PERL
script was used to demultiplex the joined reads and count insert
types. Exact matches to the forward and reverse primers were
required in the demultiplexing step. Cloned animals were genotyped
by RFLP assay and sequencing.
Example 29 Evaluation of Transfected mRNA as a Source of TALENs
[0415] Referring to FIG. 36, TALENs were introduced into pig
fibroblasts encoded by either unmodified mRNA, modified mRNA (mod
mRNA) or plasmid DNA (pDNA). Two quantities of each TALEN
preparation were transfected into cells by nucleofection (Lonza),
cultured 3 days at 30.degree. C. or 37.degree. C. prior to analysis
of indels. Percent NHEJ was similar for all mRNA transfections
incubated at 30.degree. C., while a dosage response could be
observed for transfected cells incubated at 37.degree. C. Notably,
mRNA transfection in all groups incubated at 30.degree. C.
significantly outperformed the TALENs transfected as plasmid DNA
under the same conditions. There was little difference between
modified and unmodified mRNA in this test. TALENs:
CTCCTCCATTGCGGACATGGACTTCTCAGCCCTTCTGAGTCAGATC (SEQ ID NO:346),
underlines indicate TALENs binding sites.
Example 30: Kinetics of TALEN Induced HDR with Oligonucleotide
Templates
[0416] Referring to FIG. 37A, an mRNA source of TALENs stimulated
efficient and consistent HDR using an oligo donor. Each chart
displays results of targeting a specific locus in fibroblasts
(e.g., ssIL2RG; "ss" for Sus scrofa and "bt" for Bos taurus) using
oligo donor templates and TALENs delivered as plasmid DNA or mRNA.
(Insets) ssIL2RG2.1 (SEQ. ID NOS: 484 and 485); ssRAG2.1 (SEQ ID
NOS: 488 and 489); btGGTA9.1 (SEQ ID NOS: 490 and 491); ssLDLR2.1
(SEQ ID NOS: 438 and 439) Diagrams of the oligo templates, in which
the shaded boxes represent the TALEN-binding site and the spacers
are shown in white. Each oligo contains either a 4-bp insertion
(ins4) or deletion (del4) that introduces a novel restriction site
for RFLP analysis. Presumptive BMs replace the conserved -1
thymidine (relative to the TALEN-binding site) with the indicated
nucleotide. Fibroblasts were transfected with either TALEN-encoding
plasmids (3 .mu.g) or mRNA (1 .mu.g) along with 3 .mu.M of their
cognate oligo-homologous template. Cells were then incubated at
37.degree. C. or 30.degree. C. for 3 d before expansion at
37.degree. C. until day 10. TALEN activity was measured by the
Surveyor assay at day 3 (Day3 Surveyor), and HDR was measured at
days 3 and 10 by RFLP analysis (Day3% HDR and Day10% HDR). Each bar
displays the average and SEM from three replicates.
[0417] Referring to FIG. 37B, porcine fibroblasts were transfected
with either TALEN-encoding mRNA or plasmid DNA and oligos with 4
base pair insertions targeting LDLR or APC genes. Cells from each
transfection were then evenly split into seven 24-well plate wells,
cultured at 30.degree. C. and assayed by RFLP at the indicated time
points. Panel a) RFLP analysis on cell populations at indicated
time points. Panel b) Results from panel a were quantified by
densitometry and the averages were plotted as a function of time
with SEM (n=3). HDR signal first appears 12 hours post-transfection
and accumulates over time. The onset of HDR at LDLR was independent
of TALEN source, but the rate of HDR between 24 and 72 hours was
much higher when mRNA was used compared to plasmid DNA.
Example 31: Influence of Mutation Type on the Frequency of HDR
[0418] Referring to FIG. 38, panel a) The sequence of five oligos
used to target ssLDLR. Oligos vary in length and type of mutation.
TALEN binding sites are indicated in boxed text and the novel BamHI
site is underlined. SNPs including BMs and insertions are circled.
Panel b) Cells were transfected with LDLR2.1 TALEN mRNA (1 .mu.g)
and oligos (2 .mu.M final). HDR at day 3 was determined by RFLP
analysis and the average with SEM (n=3) was plotted. The results
suggest that insertion alleles are more efficiently incorporated
than SNPs or deletions, but that homology length from 46-90 bp has
negligible influence on HDR efficiency. c) Cattle cells were
transfected with btRosa1.2 TALEN mRNA and either 41 mloxP or 60
loxP oligos (2 .mu.M final). The numbers 41 and 60 refer to the
number of homologous bases. Each oligo contains a 34 bp loxP site,
either a modified (mloxP) or wild type (loxP) version, in the
center of the spacer. Densitometry at day 3 and 15 show that
insertion of loxP sites is both efficient and stable.
Example 32: CRISPR/Cas9 Mediated HDR to Introgress the p65 S531P
Mutation from Warthogs into Conventional Swine
[0419] Referring to FIG. 39, panel a) The S531P missense mutation
is caused by a T-C transition at nucleotide 1591 of porcine p65.
The S-P HDR template includes the causative TC transition mutation
(oversized text) which introduces a novel XmaI site and enables
RFLP screening. Two gRNA sequences (P65_GIS and P65_G2A) are shown
along with the p65.8 TALENs used in previous experiments. Panel b)
Landrace fibroblasts were transfected with S-P-HDR oligos (2
.mu.M), two quantities of plasmid encoding hCas9 (0.5 .mu.g or 2.0
.mu.g); and five quantities of the G2A transcription plasmid (0.05
to 1.0 .mu.g). Cells from each transfection were split 60:40 for
culture at 30 and 37.degree. C. respectively for 3 days before
prolonged culture at 37.degree. C. until day 10. Surveyor assay
revealed activity ranging from 16-30%. Panels c and d) RFLP
analysis of cells sampled at days 3 and 10. Expected cleavage
products of 191 and 118 bp are indicated by black arrows. Despite
close proximity of the double stranded break (DSB) to the target
SNP, CRISPR/Cas9 mediated HDR was less efficient than TALENs for
introgression of S531P. Individual colonies were also analyzed
using each gRNA sequence (data not shown).
[0420] Referring to FIG. 40, experiments were made for comparison
of TALENs and CRISPR/Cas9 mediated HDR at porcine APC. Panel a)
APC14.2 TALENs and the gRNA sequence APC14.2 G1a are shown relative
to the wild type APC sequence. Below, the HDR oligo is shown which
delivers a 4 bp insertion (orange text) resulting in a novel
HindIII site. Pig fibroblasts transfected with 2 .mu.M of oligo HDR
template, and either 1 .mu.g TALEN mRNA, 1 .mu.g each plasmid DNA
encoding hCas9 and the gRNA expression plasmid; or 1 .mu.g mRNA
encoding hCas9 and 0.5 .mu.g of gRNA expression plasmid, were then
split and cultured at either 30 or 37.degree. C. for 3 days before
expansion at 37.degree. C. until day 10. Panel b) Charts displaying
RFLP and Surveyor assay results. TALEN stimulated HDR was most
efficient at 30.degree. C., while CRISPR/Cas9 mediated HDR was most
effective at 37.degree. C. For this locus, TALENs were more
effective than the CRISPR/Cas9 system for stimulation of HDR
despite similar DNA cutting frequency measured by Surveyor assay.
In contrast to TALENs, there was little difference in HDR when
hCas9 was delivered as mRNA versus plasmid.
Example 33: SNP Introgression Using Oligo Donors
[0421] Referring to FIG. 41, panel a) The influence of blocking
mutations (BM) on maintenance of HDR alleles was evaluated in pig
LDLR and GDF8. Each oligo was designed to introduce the same
SNPs/restriction 313 site plus or minus blocking mutations. HR was
quantified in transfected populations initially cultured at
30.degree. C. for three days and further maintained at 37.degree.
C. until day 12 by RFLP assay. The average and SEM (n=3) is shown.
Panel b) Introgression of myostatin C313Y into Wagyu fibroblasts.
The C313Y missense mutation is caused by a G-A transition
(indicated by oversized text) at nucleotide 938 of bovine myostatin
The HDR template also includes a T to C transition (circled) to
introduce a novel EcoRI site for RFLP screening. Two left TALENs
were designed against the locus, btGDF83.6-G, targeting the wild
type alelle (Wt), and btGDF83.6-A targeting the mutant allele
(C313Y); both share a common right TALEN. Transfection, culture and
measurement were conducted as above. The average and SEM for
btGDF83.6-G (n=30) and btGDF83.6-A (n=5) represent twelve and three
biological replicates, respectively. A two-sided student's t-test
was used to compare averages between groups; the p values are
indicated.
Example 34: SNPs
[0422] FIG. 42 is a plot that shows results for sequence analysis
of TALEN stimulated HDR alleles. PCR amplicons flanking the target
site (200-250 bp total) derived from TALEN mRNA and oligo
transfected cell populations were sequenced by ILLUMINA sequencing.
Total read count ranged from 10,000 328 to 400,000 per sample. The
count of perfect, intended HR reads versus the wild type reads is
plotted for insertion (panel a) and SNP alleles (panel b). The
target locus, time point and whether or not BMs were included in
the oligo are indicated below. Panel c). Reads from btGDF8 and p65
were sorted for incorporation of the target SNP and then classified
intended (iSNP) versus those with an additional mutation (iSNP+Mut)
and plotted against the total number of reads.
Example 35: Sequence Analysis of HDR Alleles
[0423] Referring to FIG. 43, sequencing reads containing the
correct insertion (Panel a) or SNP allele (Panel b) were analyzed
for incorporation of BM. The target locus, time point and whether
or not BMs were included in the oligo are indicated below each
graph. In general, the 5' BM was incorporated most frequently into
the HDR conversion tract, followed by inclusion of both BMs, or the
3' BM only. The distribution of BM is somewhat skewed towards
incorporation of both BM when the intended mutation to LDLR is a
SNP versus a 4 bp insertion allele. It is also interesting to note
that the majority of intended reads for btGDF8 have incorporated at
least one BM, but seldom have the 3' BM alone. Thus, while BM did
not have a significant impact on the frequency of maintaining the
intended SNP (iSNP) allele in culture, their enrichment relative to
other loci suggests that they might have offered some protection
from TALEN re-cleavage. c). The data of FIG. 42 panel c was further
classified by mutation type and compared. Some reads contained only
the iSNP, others had a concomitant indel (iSNP+indel), or a
concomitant unintended SNP (iSNP+uSNP). There appears to be some
elevation in the frequency of iSNP+indel when BMs were not included
in the template, and the majority of indels were located in the
spacer region so are likely to be the result of re-cutting of
already converted alleles.
Example 36: Multiple SNPs in the TALEN DNA-Binding Site Stabilize
HDR Alleles
[0424] Referring to FIG. 44, the EIF4GI gene was stabilized with
multiple SNPs in the TALEN DNA binding site. Panel a) A portion of
wild type EIF4GI Wt-NL is shown. One pair of TALENs was designed to
cut the wild type EIF4GI to stimulate homologous recombination.
Also aligned to the Wt sequence is the core sequence of the donor
oligo, DF-HDR, used to introduce three SNPs (red oversized letters)
into the genome. The third SNP creates a novel EagI restriction
site that was used for RFLP analysis. Pig fibroblasts were
transfected with EIF4GI14.1 TALEN mRNA (2 .mu.g) and DF-HDR (2
.mu.M) and then cultured at 30.degree. C. for 3 days prior to
analysis and colony propagation. Panel b) RFLP analysis on
population three days post transfection. Expected product sizes of
344, 177 and 167 bp are indicated by filled triangles. Panel c)
RFLP assay on isolated cellular clones. Day 3 cells were used to
derive monoclonal colonies through dilution cloning. An example of
colonies with heterozygous (open triangles) or homozygous (filled
triangles) HDR alleles are indicated.
Example 37: Hypothermic Treatment for Maintenance of SNP HDR
Alleles
[0425] Referring to FIG. 45, pig fibroblasts were transfected with
TALEN mRNA (1 .mu.g) and oligos (3 .mu.M). Cells from two
independent transfections were pooled for each replicate and evenly
distributed into six wells of a 6-well plate and cultured at
30.degree. C. Samples were collected from these populations for
RFLP analysis on days 1-7 (minus day 6, 1D to 7D along X-axis)
post-transfection and the remaining cells were transferred to
37.degree. C. Samples for each condition were collected again at
day 12 for RFLP analysis. The average HDR and SEM (n=3) is shown at
the initial collection and once again at day 12.
Example 38: Intentional RVD Mismatches for Introgression of
SNPs
[0426] Referring to FIG. 46, panel a) A TALEN pair (caCLPG 1.1) was
designed to target the caCLPG region. Oligo driven HDR was utilized
to introduce the desired Adenine to Guanine SNP (the targeted
Adenine is boxed). The desired SNP allowed genotyping by a loss of
an AvaII restriction site. Each TALEN monomer is indicated in
shading above their respective binding locations. The N- and
C-termini are indicated with N and C, respectively. b) Each allele
of single-cell derived colonies that were resistant to AvaII were
sequenced (only AvaII resistant alleles are shown). All of the
alleles that contained our SNP or interest (boxed) also contained
deletions (marked with dashes in the AvaII Resistant Allele
sequences) or insertions (marked with dashes in the WT sequence).
c) To reduce the possibility of re-binding, and subsequently
re-cutting, intentional mismatches (italicized circled text) were
introduced into the RVD sequence. The mismatches were placed in the
RVDs directly before and/or after the RVD that would bind to the
desired SNP (boxed) in right monomer of the TALEN. d) TALEN
activity was measured via a Cell assay. The percent of
non-homologous end joining (% NHEJ) was equivalent for 1.1 and 1.1b
(28%), but was greater than 1.1 for 1.1a and 1.1c (30% and 31%
respectively). The no-RNA negative control showed no TALEN activity
(0%). e) Both alleles of AvaII-resistant single-cell derived
colonies produced with caCLPG 1.1c were sequenced. The desired SNP
is boxed. Colony 37 and 78 were heterozygous for the desired SNP
and showed no additional indels. Colony 142 was homozygous for the
desired SNP, but contained a 4 bp insertion on one allele.
Example 39: Mismatch Required for SNP Introgression
[0427] Referring to FIG. 47, a mismatch was required for SNP
introgression. A schematic of the bovine DGAT sequence around
K323A. The grey arrows represent the TALEN monomers where they bind
to the DGAT sequence. The left arm consists of 16 RVDs, the right
arm consists of 15 RVDs, and the spacer is 16 base pairs long. The
GC and ggagct, boxed, are the targeted base pairs. The DGAT oligo
converts the GC to an AA to create the desired DGAT mutant. As a
marker for HDR, the boxed GGGAGC is converted to AAGCTT that
creates a novel HindIII restriction site. Since this change is in
the spacer, it should not affect TALEN binding as to not interfere
with the intentional mismatch results. b) DGAT TALEN RVD sequences.
btDGAT 14.2 contains no intentional mismatches in the RVDs. btDGAT
14.4, 14.5, and 14.6 each contain one intentional RVD mismatch at
either position 1, 3, or 5 of the left TALEN monomer (circled). c)
Bovine fibroblasts were transfected with 1 ug of talen and 0.4
nmoles of oligo. Three days after transfection cells were lysed,
the DGAT sequence was amplified by PCR, digested with HindIII and
ran on an acrylamide gel. The percent efficiency of HDR was
determined by densitometry (HR). d) Sequence analysis of colonies
produce with the original 14.2 TALENs. Of twelve colonies, none
that were positive for the HindIII RFLP contained the desired
mutation due to indels overlapping the site. e) Colonies derived
from TALENs 14.5 and 14.6 produced the correct DGAT mutation and
HindIII restriction site. These two TALEN pairs produced a total of
two homozygous (HH) and three heterozygous (Hh) colonies. TALEN
14.4 did not produce any colonies with the correct DGAT mutation
(data not shown).
Example 40: All-in-One TALEN-HDR/Cre-RMCE
[0428] FIG. 48 depicts a process of TALEN-HDR/RMCE. The floxed
cassette is transfected along with TALENs compatible with the
oligo, the loxP oligo and a source of Cre recombinase. For this
process to work, TALENs must cut the target loci followed by repair
with the loxP oligo prior to Cre-mediated RMCE into the repaired
site. The bar graph shows the number of puromycin resistant
colonies produced by this method when YFC-Cre versus mCherry was
included in the transfection. To confirm targeting to the SRY
locus, PCR was conducted across the predicted junction (as
indicated) will result in a 370 bp product. This product is
apparent only when Cre is included. For this set of experiments,
the following conditions were used: 600,000 cells transfected with
1 ug SRY TALENs+0.3 nMol of SSCY_LoxP oligo+CLP-YFP-Cre (0.5
ug)+Floxed PTK (2 ug). The negative control had 0.5 ug of mCherry
plasmid in place of CLP-YFP-Cre. SSCY_LoxP oligo:
TABLE-US-00011 (SEQ ID NO: 320)
TTTTATATACATTTTACACACATATATATGAAACATAACTTCGTATAGGA
GACTTTATACGAAGTTATGGATCCAAGCTTATAACTTCGTATAATGTATG
CTATACGAAGTTATTGACAGTATTAATGGCCTGAACCTAGCCAGAACT
Example 41: Confirmation of Belgian Blue Introgression by
Sequencing
[0429] The schematics of Wagyu wild-type GDF8 and the Belgian Blue
template (BB-HDR) are shown in FIG. 50. PCR was conducted using
primers located outside of the homology arms (c and d) on five PCR
positive colonies followed by cloning and sequencing with primer
b'. Comparison to the wild-type sequence reveals the expected
11-basepair deletion characteristic the Belgian Blue allele
(heterozygous) in 4 of 5 colonies. TALENs (btGDF83.1, SEQ ID
NOS:428 and 431) and a dsDNA template (BB-HDR) were designed to
introduce an 11-basepair deletion into exon-3 of bovine GDF8
(Belgium Blue mutation) by double-strand break-induced homologous
recombination. (SEQ ID NO: 504) Half of the binding site for the
left TALEN is missing in the BB-HDR template and thus should be
resistant to TALEN cleavage. SURVEYOR assay demonstrated activity
of btGDF83.1 TALENs at both 37 and 30.degree. Celsius.
Allele-specific PCR demonstrated that HDR induction was dependent
on co-transfection of TALENs and the BB-HDR template. The PCR assay
was developed to specifically detect HDR modified GDF8 alleles
using primers c and c'. The 3' end of primer c' spans the
11-basepair deletion, and cannot amplify the wild type allele (wt).
Five hundred cell equivalents were included in each PCR reaction
including the positive control. Percent HDR was determined by
comparative densitometry between experimental and control
reactions.
Example 42: Precision Alteration of Intended Gene in Wild-Type
Wagyu Cattle
[0430] A gene of wild-type Wagyu cattle was altered by making a
deletion in a targeted area of the gene (an 11 bp deletion) in
Wagyu fibroblasts as can be seen in FIG. 50. This alteration made
the Wagyu cattle have the allele of Beligan Blue cattle. When
transfected alone, the btGDF8.1 TALEN pair (SEQ ID NO: 428 and 431)
cleaved up to 16% of chromosomes at the target locus. TALENs
(btGDF83.1) and a dsDNA template (BB-HDR) were designed to
introduce an 11-bp deletion in exon-3 of bovine GDF8 (Belgium Blue
mutation) by DSB induced homologous recombination. (SEQ ID NO: 504)
Half of the binding site for the left TALEN was missing in the
BB-HDR template, to make it resistant to TALEN cleavage. A SURVEYOR
assay demonstrated activity of btGDF83.1 TALENs at both 37 and
30.degree. Celsius. The PCR product used for this assay was
generated using primers b and b' (not shown). The BB-HDR template
was not included in these replicates since it would confound
estimates of btGDF83.1 activity. Allele specific PCR demonstrated
that HDR induction was dependent on co-transfection of TALENs and
the BB-HDR template. The PCR assay was developed to specifically
detect HDR modified GDF8 alleles using primers c and c' (not
shown). The 3' end of primer c' spanned the 11-bp deletion so that
it could not amplify the wild type allele "wt". Five hundred cell
equivalents were included in each PCR reaction including the
positive control "C". Percent HDR was determined by comparative
densitometry between experimental and control reactions.
Co-transfection with a supercoiled DNA template harboring a 1623 bp
DNA fragment from Belgian Blue cattle resulted in a gene conversion
frequency (HDR) of 0.5% to 5% as suggested by semi-quantitative PCR
at day 3, without selection for the desired event. These results
demonstrated that TALENs can be used to effectively place exogenous
nucleic acid sequences in livestock, including alleles--and without
markers. To assess the frequency of placement in individual
colonies, the transposon co-selection strategy was implemented to
isolate and expand individual colonies for DNA sequencing. Gene
conversion using template from Belgian Blue cattle was detected in
5 colonies out of 366 examined by PCR. Amplification with primers
outside the Belgian Blue HDR template and sequencing confirmed the
presence of the expected 11 bp deletion in 4 of the colonies.
[0431] A second repeat experiment was performed with consistent
results, with about 1% of all tested colonies being positive for
bi-allelic conversion and about 0.5% to about 1% of all tested
colonies being heterozygous for allele conversion.
[0432] Similarly, alleles were also introduced into pig (Ossabaw)
cells using oligo HDR. The cells were modified with a combination
of mRNA encoded TALENs and single-stranded oligonucleotides to
place an allele that occurs naturally in one species to another
species (interspecific migration) as can be seen in FIG. 51.
Piedmontese GDF8 SNP C313Y, were chosen as an example and was
introduced into Ossabow swine cells. No markers were used in these
cells at any stage. A similar peak in HDR was observed between pig
and cattle cells at 0.4 nmol ssODN, (not shown) however, HDR was
not extinguished by higher concentrations of ssODN in Ossabaw
fibroblasts. (SEQ ID NOS: 444, 445 and 507)
Example 43: Modification at Intended Targets
[0433] Consistent modification of targeted genes was made.
Referring to FIG. 52, each chart displays results of targeting a
specific locus in fibroblasts (e.g., ssIL2RG; "ss" for Sus scrofa
and "bt" for Bos taurus) using oligo donor templates and TALENs
delivered as plasmid DNA or mRNA. (Insets) Diagrams of the oligo
templates, in which the shaded boxes represent the TALEN-binding
site and the spacers are shown in white. Each oligo contains either
a 4-bp insertion (ins4) or deletion (del4) that introduces a novel
restriction site for RFLP analysis, see Table 15 below. (SEQ ID
NOS: 508-513) Presumptive blocking mutations (BM) replace the
conserved -1 thymidine (relative to the TALEN-binding site) with
the indicated nucleotide. Fibroblasts were transfected with either
TALEN-encoding plasmids (3 .mu.g) or mRNA (1 .mu.g) along with 3
.mu.M of their cognate oligo-homologous template. Cells were then
incubated at 37.degree. C. or 30.degree. C. for 3 d before
expansion at 37.degree. C. until day 10. TALEN activity was
measured by the Surveyor assay at day 3 (Day3 Surveyor), and HDR
was measured at days 3 and 10 by RFLP analysis (Day3% HDR and Day
10% HDR). Each bar displays the average and SEM from three
replicates. Each of the targeted loci was successfully modified.
The TALEN pairs used were ssILRG2.1 (SEQ ID NOS: 484 and 485);
ssRAG2.1 (SEQ ID NOS:488 and 489); btGGTA9.1 (SEQ ID NOS:490 and
491); and ssLDLR2.1 (SEQ ID NOS:438 and 439).
TABLE-US-00012 TABLE 15 Oligonucleotide HDR templates TALEN FIG./
ssODN pair panel design Sequence ssLDLR2.1 46_SNPs
CCTACAAGTGGATTTGTGGGATCCACACCGAG BamHI TGCAAGGACGGGTC (SEQ ID NO:
508) ssLDLR2.1 53B 90_SNPs TGCCGAGACGGGAAATGCATCTCCTACAAGTG BamHI
GATTTGTGGGATCCACACCGAGTGCAAGGACG GGTCCGATGAGTCCCTGGAGACGTGC (SEQ ID
NO: 509) ssLDLR2.1 53A 90_ins4_BM CCGAGACGGGAAATGCACCTCCTACAAGTGGA
BamHI TTTGTGATGGATCCGAACACCGAGTGCAAGGA CGGGTCCGCTGAGTCCCTGGAGACGT
(SEQ ID NO: 510) ssLDLR2.1 53B 90_SNPs_BM
TGCCGAGACGGGAAATGCACCTCCTACAAGTG BamH1
GATTTGTGGGATCCACACCGAGTGCAAGGACG GGTCCGCTGAGTCCCTGGAGACGTGC (SEQ ID
NO: 511) ssLDLR2.1 60_SNPs_BM TGCACCTCCTACAAGTGGATTTGTGGGATCCA
BamH1 CACCGAGTGCAAGGACGGGTCCGCTGAG (SEQ ID NO: 512) ssLDLR2.1
86_de14_BM TGCCGAGACGGGAAATGCACCTCCTACAAGTG BamH1
GATTTGGGATCCACCGAGTGCAAGGACGGGTC CGCTGAGTCCCTGGAGACGTGC (SEQ ID NO:
513) ssAPC14.2 53A 90_ins4_BM CCAGATCGCCAAAGTCACGGAAGAAGTATCAG
HindIII CCATTCATCCCTCCCAGTGAAGCTTACAGAAA TTCTGGGTCGACCACGGAGTTGCACT
(SEQ ID NO: 514) ssTp53 53A 90_ins5_BM
AGCTCGCCACCCCCGCCGGGCACCCGTGTCCG HindIII
CGCCATGGCCATCTAAGCTTAAAGAAGTCAGA GTACATGCCCGAGGTGGTGAGGCGCT (SEQ ID
NO: 515) btGDF83.6-G 53B 90_SNPs_BM
CTAAAAGATATAAGGCCAATTACCGCTCTGGA EcoRI
GAATATGAATTCGTATTTTTGCAAAAGTATCC TCATCCCCATCTTGTGCACCAAGCAA (SEQ ID
NO: 516) btGDF83.6-G 53B 90_SNP CTAAAAGATATAAGGCCAATTACTGCTCTGGA
GAATATGAATTTGTATTTTTGCAAAAGTATCC TCATACCCATCTTGTGCACCAAGCAA (SEQ ID
NO: 517) ssP65.8 53B 90_SNP GGGCCTCTGGGCTCACCAACGGTCTCCTCCCG XmaI
GGGGACGAAGACTTCTCCTCCATTGCGGACAT GGACTTCTCAGCCCTTCTGAGTCAGA (SEQ ID
NO: 518)
Example 44: High Efficiency for Making Intended Changes in
Genes
[0434] FIG. 53 shows analysis of changes made to genes APC (SEQ ID
NOS:482 and 483), LDLR (SEQ ID NOS:438 and 439), p53 (SEQ ID
NOS:452 and 453), p65 (SEQ ID NOS:440 and 441), and btGDF8 (SEQ ID
NOS:428 and 431) (TALEN pairs shown in parentheses). FIG. 53 shows
three graphs: (a) shows data from pig fibroblasts, (b) shows data
from pig fibroblasts (LDLR, p65) and cattle fibroblasts (DGF8), and
(c) shows data from pig fibroblasts (p65) and cattle fibroblasts
9GDF8). In some cases insertions were intended, while SNPs were
intended in other cases. Changes were made with TALENs and HDR
templates, as described above. Table 15, above, lists the HDR
templates. (SEQ ID NOS: 509-511 and 514-518) The count of perfect,
intended HR reads versus the wild type reads is plotted for:
insertion (panel a) and SNP alleles (panel b). Sequence analysis of
TALEN stimulated HDR alleles was made. PCR amplicons flanking the
target site (200-250 bp total) derived from TALEN mRNA and oligo
transfected cell populations were sequenced by ILLUMINA sequencing.
Total read count ranged from 10,000 to 400,000 per sample. The
target locus, time point and whether or not BMs were included in
the oligo are indicated below. Panel c shows reads from btGDF8 and
p65, as sorted for incorporation of the target SNP and then
classified intended (iSNP) versus those with an additional mutation
(iSNP+Mut) and plotted against the total number of reads.
Accordingly, in the case where only a single SNP was intended,
there were also additional changes, as indicated.
Example 45: Frequencies for Recovery of Colonies with HDR
Alleles
[0435] Table 7, entitled Frequencies for recovery of colonies with
HDR alleles, lists the results of an analysis of about 650 colonies
of cells for intended indel alleles in eight separate loci. The
analysis revealed a recovery rate of 10-64% (average, 45%), with up
to 32% of the colonies homozygous for the edit. Changes were made
with TALENs and HDR templates, as described above. The colonies
were obtained by dilution cloning without drug selection.
Example 46: Cloned Pigs with HDR Alleles of DAZL and APC
[0436] FIG. 54 shows a genetic analysis of cloned animals. Two
gene-edited loci in the porcine genome, deleted in azoospermia-like
(DAZL, SEQ ID NOS: 182-183) and adenomatous polyposis coli (APC,
SEQ ID NOS:188-189) were chosen. Colonies of cultured cells treated
with HDR- or NHEJ edited alleles of DAZL or APC were pooled for
cloning by chromatin transfer (CT). Each pool yielded two
pregnancies from three transfers, of which one pregnancy each was
carried to term. A total of eight piglets were born from
DAZL-modified cells, white composite pig fibroblasts, each of which
reflected genotypes of the chosen colonies consistent with either
the HDR allele (founders 1650, 1651, and 1657) or deletions
resulting from NHEJ (FIG. 53A, FIG. 54). Three of the DAZL piglets
(founders 1655-1657) were stillborn. Of the six piglets from
APC-modified cells, one was stillborn, three died within 1 wk, and
another died after 3 wk, leaving only founder 1661 alive. The lack
of correlation between genotype and survival suggests that the
early deaths were related to cloning rather than to gene edits. All
six APC piglets were heterozygous for the intended HDR-edited
allele, and all but one piglet had either an in-frame insertion or
deletion of 3 bp on the second allele (FIGS. 54 A and B) in Ossabaw
pig fibroblasts. The remaining animals are being raised for
phenotypic analyses of spermatogenesis arrest (DAZL-/- founders) or
development of colon cancer (APC+/-founders). Referring to FIG. 6,
(a) RFLP analysis of cloned piglets derived from DAZL- and
APC-modified landrace and Ossabaw fibroblasts, respectively.
Expected RFLP products for DAZL founders are 312, 242, and 70 bp
(open triangles), and those for APC are 310, 221, and 89 bp (filled
triangles). The difference in size of the 312-bp band between WT
and DAZL founders reflects the expected deletion alleles. (b)
Sequence analysis confirming the presence of the HDR allele in
three of eight DAZL founders, and in six of six APC founders. BMs
in the donor templates (HDR) are indicated with arrows, and
inserted bases are enclosed in blocks. The bold text in the top WT
sequence indicates the TALEN-binding sites.
Example 47: GPR54 Knockout
[0437] FIG. 55 depicts GPR54 (SEQ ID NO: 196) knockouts, made
according to the indicated gene targeting strategy. TALENs designed
to bind porcine exon 3 (underlined text in SEQ ID NO: 197, 492 and
493) were co-transfected with an oligonucleotide homology template
(HDR) designed to introduce a premature stop codon (boxed) and a
HindIII restriction site. For the experimental results shown in
panel b, 2 micrograms of TALENs encoding mRNA (SEQ ID NO: 519) plus
0.2 nMol (2 uM) of the HDR template were transfected into pig
fibroblasts 500,000 pig fibroblasts using the NEON nucleofection
system (Life Technologies) with the following settings: 1 pulse,
1800 v; 20 ms width and a 100 ul tip. The cells were grown at
30.degree. C. for three days after exposure to TALENs and cells
were enumerated and plated at a range of densities 1-20 cells/cm2
on 10 cm dishes. Cells were cultured for 10-15 days until
individual colonies of 3-4 mm in diameter could be observed.
Colonies were aspirated with a p-200 pipettor under gentle
aspiration and expelled into a well of 24-well plate with 500 ul of
growth medium (Carlson, 2011). Plates with clearly defined colonies
(.about.10-30/plate) were chosen for colony aspiration to limit the
chance of aspirating cells from multiple colonies. Once a colony
reached 70-90 percent confluent in the 24-well dish, a portion was
harvested for RFLP analysis and the remainder was cryopreserved.
panel b) A total of 96 colonies were analyzed for homology
dependent repair by HindIII RFLP assay. DNA from each colony was
added to a PCR reaction that included PCR primers flanking the
target site; forward (5'-aaggatgtcagcacctctctggg (SEQ ID NO: 159))
and reverse (5'-ACCCACCCGGACTCTACTCCTACCA (SEQ ID NO: 160)). PCR
products (389 bp) were added to a HindIII restriction digest and
resolved on a 2.5% agarose gel. Each lane represents one colony
(see FIG. 81). Cleavage products of 231 and 158 bp are indicative
of homology dependent repair. Colonies with the parent band of 389
bp are classified as heterozygous (open triangle) and those without
are classified as homozygous (filled triangle) for the HDR,
knockout allele. Cells prepared by this technique were used to
clone pigs using customary techniques (see Example 48). Indeed,
GPR54 knockout pigs were born through somatic cell nuclear
transfer. Underdeveloped testes were apparent in 6-12 month old
male pigs, and such pigs did not exhibit boar taint. Rather, such
pigs acted like barrows, with little to no agression observed.
Example 48: Creation of Livestock that do not Mature without
Treatment
[0438] Livestock with GPR54 knockout(s) can be prepared, including
cattle, pig, and chicken. The preceding example details one such
process. The following specific methods are described for pigs;
artisans will be able to adapt the experiments to other livestock
after reading this application. TALENs for Gpr54 (SEQ ID NO: 196)
were developed and used to generate heterozygous and homozygous
knockout cell lines (SEQ ID NO: 197, 492 and 493). Analysis of the
colony isolation and screening can be seen in FIG. 81. Pregnancy
was established using male and female Gpr54-/- and/or cell lines
heterozygous for Gpr54+/- with Gpr54-/- animals generated by
intercross. The development and fertility of Gpr54-/- animals was
evaluated. The already-demonstrated ability to generate efficient
TALENs, isolate mutant colonies and produce transgenic animals from
cells or zygotes has been well documented herein, see also Tan et
al., PNAS, 110(41): 16526-16531, 2013.
[0439] Generation of Gpr54-/- male and female pigs. Ten bi-allelic
KO male and female clones, as generated in Example 10 through
somatic cell nuclear transfer (SCNT), harboring frame shift
mutations of both alleles were pooled for cloning by SCNT. Two
rounds of cloning (3 transfers each) were conducted. Three
transfers were performed and two sows were impregnated. A total of
19 piglets were born alive and two were stillborn. Genotypes of the
resulting animals were characterized by sequencing of the targeted
region of Gpr54 as can be seen in FIG. 82. Because Gpr54+/- cells
were used for cloning, Gpr54-/- animals were generated by
intercross.
[0440] Phenotypic evaluation of Gpr54-/- pigs. Serum levels of
testosterone and FSH (>3 per sex) were quantified every two
weeks for Gpr54-/- animals and age-matched controls beginning at 5
months and continuing to 9 months of age. For males, testicular
size was measured and plotted against body weight and age.
Underdeveloped testes were apparent in 6-12 month old male pigs. No
boar-taint odor was present and they acted like barrows in that
little to no aggression was observed in the animals.
Example 49: CRISPR/Cas Mediated HDR
[0441] CRISPR gRNAs that overlapped the T1591C site of p65 were
made and evaluated for introgression in pig fibroblasts (target
sequence identified in SEQ ID NO: 372). Efficient production of
double stranded breaks (DSBs) at the intended site was observed.
CRISPR/Cas9-mediated HDR was <6% at day 3 and below the limit of
detection at day 10. Recovery of modified clones was lower with
CRISPR-mediated HDR than with TALENs, even though the TALENs cut 35
bp away from the SNP site (Table 7). Analysis of
CRISPR/Cas9-induced targeting at a second locus, sAPC14.2, was more
efficient, although it did not reach the level of HDR induced by
TALENs at this site (.about.30% vs. 60%). See also, Tan et al.,
PNAS, 110(41): 16526-16531, 2013). The CRISPR/Cas9 endonucleases
were generated based on the Church laboratory system and methods,
Mali P, et al. (2013) RNA-guided human genome engineering via Cas9.
Science 339(6121):823-826.
TABLE-US-00013 TABLE 11 TALEN Sequences (left) and DNA Target
Sequences for CRISPR (right). Table 11. TALEN sequences and DNA
target sequence of the TALENs DNA Target sequence, spacer
underlined TALEN pair TALEN RVD sequence (Sense strand) ssLDLR2.1
HD NG HD HD NG NI HD NI NI CTCCTACAAGTGGATTTGTGATGGG NN NG NN NN NI
NG NG NG HD AACACCGAGTGCAAGGACGGGTCCG NN NN NI HD HD HD NN NG HD
SEQ ID NO: 354 HD NG NG NN HD NI HD NG btGDF83.1L + NN NG NN NI NG
NN NI NI HD GTGATGAACACTCCACAGAATCTCG NR NI HD NG HD HD NI HD NI NN
ATGCTGTCGTTACCCTCTAACTGTG NI NI NG HD NG NG HD NI NI GATTTTGA SEQ
ID NO: 355 NI NI NG HD HD NI HD NI NN NG NG NI NN NI NN ssDAZL3.l
NN NN NI NG NN NI NI NI HD GGATGAAACCGAAATTAGAAGTTTC HD NN NI NI NI
NG NG HD NG TTTGCTAGATATGGTTCAGTAAAAG NG NG NG NI HD NG NN NI NI
SEQ ID NO: 356 HD HD NI NG NI NG ssAPC14.2 NN NN NI NI NN NI NI NN
NG GGAAGAAGTATCAGCCATTCATCCC NI NG HD NI NN HD HD NI NG
TCCCAGGAAGACAGAAATTCTGGGT NN NI HD HD HD NI NN NI NI C SEQ ID NO:
357 NG NG NG HD NG NN NG ssTp53 NN NN HD NI HD HD HD NN NG
GGCACCCGTGTCCGCGCCATGGCCA NN NG HD HD NN HD NN HD HD
TCTACAAGAAGTCAGAGTACATG NI NG NN NG NI HD NG HD NG SEQ ID NO: 358
NN NI HD NG NG ssKissR3.2 NN HD NG HD NG NI HD NG HD
GCTCTACTCTACCCCCTACCAGCCT NG NI HD HD HD HD NN HD NI
GGGTGCTGGGCGACTTCATGTGC HD NI NG NN NI NI NN NG HD SEQ ID NO: 359
NN HD HD HD NI ssEIF4GI14.1 HD HD NN NG HD HD NG NG NG
CCGTCCTTTGCCAACCTTGGCCGAC NN HD HD NI NI HD HD NG NG
CAGCCCTTAGCAACCGTGGGCCCCC NG NN NN NN NN NN HD HD HD A SEQ ID NO:
360 NI HD NN NN NG NG NN HD NG btGGTA9.1 HD NG NN HD NN HD NG HD HD
CTGCGCTCCTTCAAAGTGTTTAAGA NG NG HD NI NI NI NN NG NN
TCAAGCCTGAGAAGAGGTGGCAGGA NG HD HD NG NN HD HD NI HD C SEQ ID NO:
361 HD NG HD NG NG HD NG ssRAG2.1 NI HD HD NG NG HD HD NG HD
ACCTTCCTCCTCTCCGCTACCCAGC HD NG HD NG HD HD NN HD NG
CACTTGCACATTCAAAAGCAGCTTA HD NG NI NI NN HD NG NN HD G SEQ ID NO:
362 NG NG NG NG NN NI NI NG ssIL2Rg2.1 HD HD HD NI NI NI NN NN NG
CCCAAAGGTTCAGTGTTTTGTGTTC NG HD NI NN NG NN NG NG NG
AATGTTGAGTACATGAATTGCACTT HD HD NI NI NN NG NN HD NI GG SEQ ID NO:
363 NI NG NG HD NI NG NN NG NI HD NG btGDF83.6A NN HD NG HD NG NN
NN NI NN GCTCTGGAGAATATGAATTTGTATT NI NI NG NI NG NI NG NN NI
TTTGCAAAAGTATCCTCAT NN NN NI NG NI HD NG NG NG SEQ ID NO: 364 NG
btGDF83.6-G NN HD NG HD NG NN NN NI NN GCTCTGGAGAATGTGAATTTGTATT NI
NI NG NN NG NI NG NN NI TTTGCAAAAGTATCCTCAT NN NN NI NG NI HD NG NG
NG SEQ ID NO: 365 NG ssGDF83.6 NI HD NG NN HD NG HD NG NN
ACTGCTCTGGAGAGTGTGAATTTGT NN NI NN NI NN NG NN NG NN
ATTTTTACAAAAATACCCTCAC NI NN NN NN NG NI NG NG NG SEQ ID NO: 366 NG
NG NN NG btRosa1.2 HD NG HD NN HD NI NG NG NN
CTCGCATTGCCCACTGGGTGGGTGC HD HD HD NI HD NG HD NG HD
TTAGGTAGGTAGGGTGGAGAGAG NG HD NG HD HD NI HD HD HD SEQ ID NO: 367
NG NI HD HD NG ssSRY3.2 NI NG NI HD NI NG NG NG NG
ATACATTTTACACACATATATATGA NI HD NI HD NI HD NI NG NI
AACTGACAGTATTAATGGCCTGAAC NG NI NN NN NG NG HD NI NN CT SEQ ID NO:
368 NN HD HD NI NG NG NI NI NG caFEcB6.l NI HD NI NN NI NN NN NI NN
ACAGAGGAGGCCAGCTGGTTCCGAG NN HD HD NI NN HD NG NN NN
AGACAGAAATATATCAGACGGTGTT NG NG HD NI NG HD NI NI HD GATG SEQ ID
NO: 369 NI HD HD NN NG HD NG NN NI NG NI NG caCLPG1.1 NN NI NN NI
NN HD NN HD NI GAGAGCGCAGGAATCCAGGCGCAGG NN NN NI NI NG HD HD NI NN
GGCCCGAGGGCTGGGACCACCTGTC NN HD NG NN NI HD NI NN NN AG SEQ ID NO:
370 NG NN NN NG HD HD HD NI NN HD btHP1.3 NG NG NG HD NG NG NN NN
NG TTTCTTGGTAGGCTGGTATTCTTGC NI NN NN HD NG NN NN NI NI
TCTTTAGATCAAAACTCTCTTTTC NI NI NN NI NN NI NN NG NG SEQ ID NO: 371
NG NG NN NI NG ssP65_11.1 NN HD HD HD HD HD HD HD NI
GCCCCCCCACACAGCTGAGCCCATG HD NI HD NI NN HD NG NI NG
CTGATGGAGTACCCTGAGGCTAT NI NN HD HD NG HD NI NN NN SEQ ID NO: 372
NN NG NI HD NG ssP65.8 HD NG HD HD NG HD HD NI NG
CTCCTCCATTGCGGACATGGACTTC NG NN HD NN NN NI NN NI NG
TCAGCCCTTCTGAGTCAGATC HD NG NN NI HD NG HD NI NN SEQ ID NO: 346 NI
NI NN
Example 50: Kiss Gene Conservation
[0442] Referring to FIG. 56, the structural organization of the
kiss gene is conserved and contains two coding exons, one encoding
both the signal peptide and part of the kiss peptin precursor, the
other encoding the remainder of the precursor including the
kisspeptin-10 sequence. The position of the intron on tilapia Kiss
mRNA (corresponding cDNA, SEQ ID NO: 376) is indicated by a
triangle glyph. The location of the forward and reverse primers for
PCR amplification of the target region (442 bp) and the binding
sites for the two engineered pairs of TALENs, Kiss1.1a (SEQ ID NOS:
456, 457) and Kiss1.1b (SEQ ID NOS:458, 459) are indicated in black
and gray boxes. Panel b shows a schematic representation of the
targeted kiss genomic region showing the location of the
kisspeptin-10 biologically active peptide and each kiss1.1a and 1b
TALENs recognition sites. PCR (442 bp) and qPCR primer pairs (138
bp amplicon) for analysis of indels are shown as well.
Example 51: Kiss and KissR Knockout in Fish
[0443] A. Construction of TALEN Expression Vectors
Table Showing Construction:
TABLE-US-00014 [0444] Sense Left TALEN - Sense Spacer - Antisense
Right TALEN Kiss1.1a ACAACCCTCTCAGCCTTCGCTTTGGGAAACGCT
ACAATGGCTACATTTAC(SEQ ID NO: 161) Kiss1.1b
CGCTTTGGGAAACGCTACAATGGCTACATTTAC AGAAGAGCTGTTAAAAGAGCC(SEQ ID NO:
162) KissRE2 CCCCTTCACCGCCACCCTTTACCCCCTCCCTGG
ATGGATCTTTGGCAACTTCATGTGC(SEQ ID NO: 163) KissRE3
CTACCCCCTGAAATCTCTTCGGCACCGAACCCC CAAAGTAGCCATGATTGTCAGC(SEQ ID NO:
164)
TABLE-US-00015 Table of primers used Target Primer Primer sequence
site Name (5'-3') Experiment KissRE2 QPCRE2 GCCACTGACATCATC qPCR
SEQ ID F TTCTTG (112 bp) NO: 165 QPCRE2 GAAACAGAAAGTTGA SEQ ID R2
AGTGG NO: 166 KissRE3 QPCRE3 TCACCCTGACTGCTA qPCR SEQ ID F TGAGTGGA
(143 bp) NO: 167 sequencing QPCRE3 ATGAGTCAGTCGATA SEQ ID R2
ATGACACG NO: 168 KissRE2 GKRE2 F TTATGCAAAAGAAGA PCR SEQ ID AAGGTG
(622 bp) NO: 169 GKRE2 R GCAGAGTTCGACCTA SEQ ID CTTTCATTG NO: 170
KissRE3 GKRE3 F TATACATAGCCCCCA PCR SEQ ID TTTTCAGTG (702 bp) NO:
171 GKRE3 R GGCAGCAGGTAGGCA SEQ ID GCAA NO: 172 Kiss1.1a Kiss F
GTCCTCTGCATTCAG PCR SEQ ID and b GAGAACAG (442 bp) NO: 173 Kiss R
CTAAAAGTATTTTAT SEQ ID TTACATAGT NO: 174 Kiss1.1a QPCR
AGGCAGCTCCTTTGC qPCR SEQ ID kiss F AATGAT (138 bp) NO: 175
sequencing QPCR AGAGAAGGGTGAAAA SEQ ID kiss R CTTTTT NO: 176
[0445] B. Talen mRNA Synthesis.
[0446] MINIPREP DNA of pT3 Ts-TALEN were digested with 5-10.times.
Units of SacI-high fidelity for 2 hours in a 200-.mu.L reaction.
Restriction digest was treated with 8-4, RNAsecure (Ambion) and
incubate at 60.degree. C. for ten minutes. RNAsecure treated DNA
was purified using the MINIELUTE PCR cleanup kit from Qiagen and
eluted in 10-4, of RNAase free injection buffer (5 mM Tris Cl, pH
7.5; 0.1 mM EDTA). Synthetic mRNA were produced using the mMESSAGE
MACHINE T3 kit (Ambion) using 1 ug of linearized template and 1.5
hours incubate at 37.degree. C. After 15 minutes treatment with
Turbo DNAase the mRNA was purified using the Ambion MEGACLEAR kit
and eluted 2.times. with 50-.mu.L of heated H.sub.2O.
[0447] C. Microinjection of TALENs Pairs
[0448] RNA encoding each TALEN arm were combined and resuspended in
nuclease free water at a concentration of 10-200 ng/.mu.L.
5-20-.mu.L were injected into one cell stage tilapia embryos.
Injected embryos survival was measured at 6 days post fertilization
against a non injected control group. RNA concentration giving a
50% rate of survival was used for repeat/standard injections to
generate Knock outs. To confirm that injected embryos died from
TALENs induced mutagenesis, deformed embryos were collected and
mutation at the target site was investigated using a QPCR melt
profile analysis.
[0449] D. Tissue Collection and DNA Extraction of Control and RNA
Treated Tilapia.
[0450] Six day old RNA treated embryos (deformed) were
dechorionated anesthetized and the yolk sac was removed using a
razor blade. Embryonic tissue was digestion overnight in lysis
buffer; 10 mM Tris, 10 mM EDTA, 200 mM NaCl, 0.5% SDS, 100 mg/ml
proteinase K and extracted with automated Research X-tractor,
Corbett robotic system using whatmanTM unifilter 800, 96 well
plates (GE Healthcare, UK). Embryos that survived microinjection
and developed normally (from groups with .about.50% survival rate)
were raised to 1 month of age, anaesthetized; fin clipped and place
in individual jars while their fin DNA was analyzed (overnight
digestion in lysis buffer followed by DNA extraction as described
above). Sperm was stripped from G0 males carrying somatic mutations
at the kiss or kissR loci and gDNA extracted using DNAzol Reagent
(Life Technolgies) following standard procedure. Extracted DNA was
resuspended in 30 .mu.l of MQ H2O.
[0451] E. Identification of Mutation by QPCR
[0452] Real-time qPCR was performed ROTOR-GENE RG-3000 REAL TIME
PCR SYSTEM (Corbett Research). 6-.mu.L genomic DNA (gDNA) template
(diluted at 1 ng/.mu.l) was used in a total volume of 15 .mu.L
containing 0.4 .mu.M concentrations each of the forward and reverse
primers and 7.5 .mu.L of 2.times. Brilliant II SYBR GREEN QPCR
MASTER MIX (Agilent Technologies). qPCR primers were designed using
DNAstar software (See above: Table of Primers Used). The qPCR was
performed using 40 cycles of 15 seconds at 95.degree. C., 60
seconds at 60.degree. C., followed by melting curve analysis to
confirm the specificity of the assay (67.degree. C. to 97.degree.
C.). In this approach, to detect the occurrence of a DNA
polymorphism at the targeted kiss and kissR loci, short PCR
amplicons (approx 100-140 bp) that include the region of interest
are generated from a gDNA sample, subjected to
temperature-dependent dissociation (melting curve). When
TALEN-induced polymorphisms are present in the template gDNA,
heteroduplex as well as different homoduplex molecules will be
formed. The presence of multiple forms of duplex molecules is
detected by Melt profile, showing whether duplex melting acts as a
single species or more than one species. Generally, the symmetry of
the melting curve and melting temperature infers on the homogeneity
of the dsDNA sequence and its length. For example, if small
insertion or deletions resulting from repair of TALENs-induced DSBs
by NHEJ are generated then that melting temperature will positively
correlate to the length of the deletion or insertion,
proportionally to the energy required to break the base-base
hydrogen bonding. If multiple forms of duplex molecules are
present, the temperature dependant denaturation will detect
together the most instable heteroduplex and the most stable
homoduplex giving a modified (dissymmetric) melt profile. The Melt
analysis is performed by comparison with reference DNA sample (from
non-injected tilapia control or plasmid containing the genomic
region of interest) amplified in parallel with the same master mix
reaction. In short, variation in melt profile distinguishes
sequences carrying TALEN induced mutation from wild type sequence,
thus facilitating the screen.
[0453] F. Calculating Mutation Rates in Somatic Cells or Germ Cells
of Microinjected Tilapia and Characterization of TALEN Induced
Mutations.
[0454] Fish whose somatic or germ cells gDNA produced asymmetric
qPCR melt profiles (candidate mutant) were further analyzed to
measure the mutagenic frequency. Genomic PCR products containing
the target site (442 bp for Kiss and 720 bp for KissR) were
obtained from fin-DNA or sperm-DNA. The PCRs were carried out in a
25-.mu.L reaction mixture, which contained 120-180 ng template
gDNA, 0.1 .mu.l of Platinum Taq DNA polymerase, 0.2 mM dNTPs,
1.times.Taq DNA polymerase buffer, 2 mM Mg2+, and 0.2 .mu.M of each
primer. DNA amplification was done under the following conditions:
95.degree. C. for 5 min, followed by 35 cycles of 94.degree. C. for
30 s, 55.degree. C. for 30 s, and 72.degree. C. for 45 s, with a
final extension at 72.degree. C. for 2 min. The PCR products were
cloned into TOPO 2.1 TA vector (Invitrogen), and transformed into
competent E. coli cells (ONE SHOT, Top 10F', Invitrogen).
Transformant colonies were randomly picked with a sterile pipette
tips and transferred directly onto individual qPCR reaction tubes
before replating on selective agar media. qPCR were performed using
primers that span the TALENs target sites of interest (100-140 bp
amplicons). QPCR reactions showing specific product amplification
were compared against a reference DNA sample control (wild type
sequence) to identify melt profile variants (FIG. 10 panels c and
d). DNA mutation rate was calculated as the number of mutant
sequences (colonies with variant melt) divided by the total number
of sequences analyzed multiplied by 100. To visualize the mutations
present at the target loci, clones representing individual somatic
or sperm cells were displayed in a Scatter plot of Ct versus Melt
temperatures (see FIG. 10 panel d for example). In these graphs,
each E. Coli colony is represented by a data point (x, y), with x
representing its Ct and y representing its melt. Individual
colonies carrying identical sequences should display similar
melting temperature. Colonies showing variant melting temperature
were grown overnight and their plasmid extracted and purified
(MINIPREPARATION kit, QIAGEN). The region containing the TALENs
target site were then sequenced using selected primers for the kiss
and kissR regions, as indicated. To characterize mutations in F1
and F2 fish, the 442 bp and 702 bp amplicons containing the target
kiss1.1a and KissRE3 loci were purified on silica-membrane-based
spin column (QIAQUICK PCR PURIFICATION KIT, QIAGEN). The purified
PCR were directly sequenced using an internal primer (KissRF).
[0455] G. Founder Screen
[0456] Gametes were stripped from all putative founders and F1
embryos were produced from in vitro fertilization with gametes
collected from WT stock. 3 weeks post-fertilization, F1 progeny
were fin-clipped and held separately in individual jar. Fin DNA was
extracted as previously described (see Tissue collection and DNA
extraction section above) and adjusted to 1 ng/.mu.l using a
spectrophotometer NANODROP ND1000). In general, 10-20 juveniles
from each potential founder were screened by QPCR using the melt
analysis strategy described above. For sequence confirmation,
genomic DNAs from single embryo/juvenile were amplified and the PCR
product submitted to sequencing after purification.
[0457] Sequencing chromatography of PCR showing two simultaneous
reads are indicative of the presence of indels. The start of the
deletion or insertion typically begins when the sequence read
become divergent. The dual sequences are than carefully analyze to
detect unique nucleotide reads (see FIG. 12 panel a). The pattern
of unique nucleotide read is then analyzed against series of
artificial single read patterns generated from shifting the wild
type sequence over itself incrementally.
[0458] H. Mutagenic Potency of Engineered TALENs
[0459] Engineered TALENs and synthetic capped mRNA encoding each
heterodimeric TALENs together was injected at various
concentrations from 10 to 250 ng/.mu.1 into 1-cell stage tilapia
embryos. We then observed the injected embryos at 6 days post
fertilization (dpf). Embryos injected with less than 10 ng of
TALENs developed normally while a dose of 200 ng (Kiss1a) and 100
ng (KissRE3) generated up to 50% of dead or deformed embryos. Dose
of 250 ng for kiss1.1b and kissRE2 generated less the 30%
mortality. On day five, injected embryos were separated between
those that developed normally from those with morphological
deformities. To check for evidence of mutations, genomic DNA was
isolated from a pool of 3 deformed embryos for each TALENs treated
group and from 3 normal embryos from a non injected control group.
Genomic DNA was used for QPCR melt analysis of the target loci.
Asymmetric melt profile were found in the pool of embryos treated
with TALENs targeting the kiss1.1a and kissRE3 loci (data not
shown) but not in embryos treated with the other 2 TALENs
pairs.
[0460] To confirm the presence of mutation, 20-40 normally
developed juveniles in each group were assayed by QPCR melt
analysis. None of the fish injected with TALEN KissR-E2 and
Kiss1.1b mRNA produced variant melt suggesting that either no
mutation were created or that the mutation did not produce
detectable melt variation. Nevertheless, a total of 8 fish
producing variant melt profiles were found, 4 for each kiss1.1a and
KissRE3 loci (FIG. 10 panel a and panel b). To confirm that the
observed melt variation results from a mixture of wild-type and
NHEJ products with micro-insertion or deletion at the target site,
each target region (442 bp for Kiss and 702 bp for KissR) was
amplified in a PCR reaction. The resulting PCR fragments were
cloned into Topo TA vectors and transformant colonies screened by
direct real time-PCR. For each fish tested, between 14 and 21 E.
coli transformant colonies were hand-picked (randomly) and added
directly (without DNA purification) to the Q-PCR reaction
mixture.
[0461] Colonies carrying mutated alleles were identified by
comparison to the wild-type unmodified sequence. High frequencies
of colonies with variant melt profiles ranging from 50-91% were
detected (FIG. 10, panels c and d).
[0462] To characterize some of these lesions, the plasmid from
clones that produced variant amplicons was extracted and the PCR
insert was sequenced. Between 4 and 7 clones were sequenced for
each TALENs treated group and all but one carried mutated alleles.
A total of fourteen different somatic mutations in the kiss and
kissr genes were detected from all 8 TALENs treated fish (eight at
the Kiss1.1a loci and six at KissRE3 loci). Nine different
nucleotide deletions, two insertions, and three combinations of
nucleotide insertions and deletions were observed (FIG. 11 panels a
and b). A deletion/insertion of as little as 3 bp was detectable by
RT-PCR melt analysis. It was observed that TALENs induced mutation
occurs multiple times in an RNA treated fish resulting in mosaic
somatic mutations (see table below).
[0463] It was found that more than 95% of the sequences from
colonies showing melt variation carry a mutation indicating that
DNA mutation rate can be approximated by measuring the frequency of
clones producing variant melt. Thus, the rate of mutation was
calculated to be between 35% and 91% depending on the fish. This
result indicates the highly efficient introduction of targeted
indels at the expected genomic locations.
[0464] The table, Summary of the results of somatic mutation
screen, shows results for TALENs-injected tilapia. The second
column describes the mutant sequences identified in somatic cells,
including the sizes of the indels (+, insertion; -, deletion) and
the resulting protein sequence modification are shown inside the
parentheses. In the last column, the estimated rate of somatic
mutation for each fish was calculated from the frequency of
colonies producing variant melting temperature.
TABLE-US-00016 TABLE Summary of the results of somatic mutation
screen % of mosaic somatic mutations (n = total number of Fish
colonies reference Mutation type screened) Kiss17 +10nt(frame
shift/stop); +4nt (frame shift/stop); 73% (n = 22) .DELTA.12nt
(-4AA) and .DELTA.18nt (-6AA) Kiss19 .DELTA.12nt (-4AA) 48% (n =
21) Kiss20 .DELTA.16nt (frame shift/stop); .DELTA.12nt (-4AA) 91%
(n = 23) Kiss41 .DELTA.4nt (frame shift/stop); .DELTA.12nt (-4AA
and F > C); 85% (n = 14) .DELTA.12nt (-4AA) RE3-1 .DELTA.10nt
(frame shift/stop); .DELTA.7nt (frame shift/stop) 35% (n = 21)
RE3-4 .DELTA.3nt (frame shift/stop); .DELTA.26nt (frame shift/stop)
85% (n = 14) RE3-6 .DELTA.5nt (frame shift/stop); .DELTA.14nt
(frame shift/stop) 63% (n = 16) RE3-11 .DELTA.7nt (frame
shift/stop) 66% (n = 21)
[0465] I. Sequence Analysis of TALENs Mutations
[0466] Of the different types of nucleotide mutation, five and six
caused a frameshift leading to the generation of premature stop
codons in the kiss and kissr gene respectively. Also, there was a
high frequency of 12 nt deletions at the Kiss1.1a loci which
occurred independently in all 4 TALENs treated fish. This mutation
result in the loss of 4 amino acids (AA).
[0467] F0 TALENs-mutated tilapia were raised to sexual maturity and
their sexes were determined. To show thatr TALENs treated fish can
induce heritable mutations; genomic DNA was extracted from the
semen's of each spermiating animals and screened. The frequency of
sperm carrying mutation was determined by the frequency of clones
showing variant melt profiles as previously described. To
characterize the sperm associated lesions, the plasmids from
colonies with variant melt was extracted and sequenced. Germline
mutation frequency ranging from 50% to 91% was observed. Sequences
revealed the existence of multiple indels in each fish
germline.
TABLE-US-00017 TABLE Sequencing % of mosaic somatic mutations (n =
total Male Fish number of colonies reference Mutation type
screened) Kiss17 .DELTA.12nt (-4AA) and .DELTA.18nt (-6AA) 50% (n =
20) Kiss19 .DELTA.12nt (-4AA); +3nt (+1AA) 65% (n = 30) Kiss20
.DELTA.16nt (frame shift/stop); 91% (n = 23) .DELTA.12nt (-4AA)
RE3-4 Not sequenced 88% (n = 18) RE3-6 Not sequenced
[0468] J. Analysis of Germ Line Mutations at the Kiss and kissR
Loci.
[0469] To further demonstrate that Kiss and kissR TALENs
effectively induced mutation in the germ line, the 8 founders were
intercrossed with wild-type stocks. All 8 TALENs treated fish were
fertile and produced viable clutches of embryos. These progeny were
raised and screened for the presence of mutated alleles. All 8
founders could transmit heritable mutations. The analysis first
showed that the fraction of progeny carrying putative mutation
ranged between 16% and 90% as gauged by QPCR melt profile analysis
of F1 fin-DNA extracts. As expected, there was a positive
correlation between the extent of mosaicism in the TALENs treated
parent and the frequency of progeny carrying a mutation. Analysis
of selected gene sequences producing deformed melt profile all
revealed a range of induced indel mutations, some of which were
previously found in somatic tissue of the founders (FIG. 12 panel
b). Furthermore, sequencing of F1 fish producing wild type melt all
revealed wild type sequences. More than one type of heritable
mutation from a single founder was often observed, suggesting that
those mutations occurred independently in different germ cells
within the same animal. Inherited mutations included deletions
ranging in size from 3 to 18 bp (FIG. 12 panel b). In the progeny
of all 4 kiss mutant founders, the only inherited mutations were
deletions of 12 nt and 18 nt which resulted in the loss of four and
six AA. Although, those deletions did not result in frameshift
mutations they remove either one or three AA at the most C-terminal
region of the kiss-10 peptide (FIG. 12 panel c). Because this core
sequence was found essential and sufficient for the activation of
the kissR signaling pathway throughout vertebrates, those mutations
would produce a loss of function phenotype. Also identified was a
frame shift mutation at the kissRE3 loci which was not previously
isolated in the founder. All frameshift mutations resulted in a
premature stop codon removing between 172 AA and up to 215 AA
(.+-.7 nt, FIG. 12 panel c) from the C-terminal portion of the
KissR protein. These mutations, which remove as much as 57% of the
protein sequence, will inactivate the gene function. All kiss and
kissr mutations identified among the juveniles F1 offspring were
viable in the heterozygous state.
TABLE-US-00018 TABLE Summary of founder screening results. In the
last column of each table, the numbers of embryos carrying indel
mutations are shown outside of the parentheses, and the sizes of
the indels are shown inside the parentheses. % F1 with putative
Fish mutations #F1 refer- (n = total sequenced # of ence number of
(Variant + mutants (sex) F1 screened) WT melt) identified Mutation
type Kiss17 66% (n = 30) 13 + 2 13 7 {.DELTA.12nt (-4AA)} and ( ) 6
{.DELTA.18nt (-6AA)} Kiss19 49% (n = 37) 10 + 2 10 10 {.DELTA.12nt
(-4AA)} ( ) Kiss20 73% (n = 29) 12 + 2 12 12{.DELTA.12nt (-4AA)} (
) Kiss41 16% (n = 38) 6 + 2 6 6{.DELTA.12nt (-4AA)} ( ) % F1
carrying putative mutations #F1 Fish (n = total sequenced # of
refer- number of (Variant + mutants ence F1 screened) WT melt)
identified Mutation type RE3-1 29% (n = 44) 19 + 2 19 10{.DELTA.3nt
(-1AA, R > Q); ( ) 8{.DELTA.11nt (frame shift/stop)}; 1
{.DELTA.8nt, (frame shift/stop)} RE3-4 90% (n = 22) 10 + 2 10
9{.DELTA.9nt (-3AA)}; ( ) 1{.DELTA.5nt, (frame shift/stop)} RE3-6 (
) RE3-11 63% (n = 35) 11 + 2 11 10{.DELTA.7nt (frame shift/stop); (
) 1{.DELTA.5nt (frame shift/stop)} +, insertion; -, deletion.
[0470] K. F1 and F2 generations
[0471] F1 heterozygous mutants showed no morphological defect as
they continued to develop, and all differentiated into fertile
adult of both sex. The absence of a reproductive phenotype in
sexually mature F1 generation is not unexpected given the presence
of a wild type allele of each targeted gene in all somatic cells of
selected mutant. The characterization of an inactivation phenotype
is only possible in the F2 generation in fish carrying the
associated loss-of-function mutation in the homozygous (or compound
heterozygous) state. To generate homozygous mutation, sperm and
eggs collected from F1 heterozygous mutant were used to produce F2
generations.
Example 52: Introgression of the Bovine Polled Allele into Horned
Cells by TALEN Stimulated HR
[0472] The polled allele schematic is shown in FIG. 61. Four TALEN
pairs were designed to cut 3' of the region duplicated in polled
(FIG. 61). The target sequences of the TALENs are shown in FIG. 61B
(HP1.1 left and right (SEQ ID NOs: 240 and 347); HP1.2 left and
right (SEQ ID NOS: 348 and 149); HP1.3 left and right (SEQ ID NOS:
150 and 151); HP1.4 left and right (SEQ ID NOS: 152 and 153). The
TALEN sequences are provided as follows (HP1.1 left and right (SEQ
ID NOs: 460 and 461); HP1.2 left and right (SEQ ID NOS: 462 and
463); HP1.3 left and right (SEQ ID NOS: 464 and 465); HP1.4 left
and right (SEQ ID NOS: 466 and 467). Horned Holstein fibroblasts
were transfected with mRNA encoding the TALEN pairs and analyzed
for activity 3 days post transfection. Surveyor assay revealed
activity of each TALEN pair (FIG. 61). Peak activity was observed
with HP1.3 and thus was chosen for subsequent experiments. Horned
Holstein primary fibroblasts were transfected with 2 micrograms of
HP1.3 TALEN mRNA along with ssDNA repair templates at the indicated
quantities and treatments (FIG. 64). One of the repair templates is
shown schematically in FIG. 62a (1594 bp template, SEQ ID NO: 381)
and is a contiguous sequence from Angus genomic DNA containing a
duplication of 212 bp that replaces a 10 bp deletion relative to
the horned allele. The 212 bp duplication is depicted by arrows in
both FIGS. 61a and 62a, the deletion of 10 bp is depicted by a
short arrow in FIG. 61a. The 5' homology arm can be defined as the
3' section of the 1594 bp template beginning immediately after the
212 bp duplication (a total of 555 bp). Hence 1594 subtract 827
subtract 555=212, the length of the inserted sequence/duplication
that comprises the Celtic polled allele. Being identical to the
exogenous Angus allele, the TALENs can no longer effectively cleave
the polled allel due to separation by about 212 bp because of the
212 duplication. Populations of cells three days post transfection
were analyzed for conversion to polled by PCR. Coating of the
repair template with NLS-RecA-Gal4 (Liao and Essner 2011) had a
significant effect on the frequency of polled conversion (FIG. 64
panels b and c). Polled conversion was also apparent in individual
colonies (FIG. 63).
[0473] Methods: Approximately 600,000 cells were transfected with
the NEON transfection system under the following parameters (1
pulse; 1800 v; 20 ms width). Each transfection consisted to two
micrograms of TALEN mRNA along with the indicated repair template.
Repair template was coated with Gal4:RecA by the following method.
Five hundred nanograms (3 ul total) of repair template PCR product
was incubated for 10 min at 95.degree. C. and placed on ice for 2
minutes prior to addition of 0.8 ul of buffer [100 mM Tris OAc, pH
7.5; 500 mM NaOAc; 10 mM DTT; 10 mM Mg(OAc)2], 0.6 ul 16.2 mM ATPyS
(Sigma) and 1,250 ng of NLS-RecA-Gal4 in a total reaction volume of
8 ul. This reaction was then incubated at 37.degree. C. for 30
minutes and placed on ice. The entire volume was used in a single
transfection. Cells were cultured and analyzed using methods
described in Carlson, Tan et al. 2012. The 591 bp HDR template was
used.
Example 53
[0474] Cells made by, or embryos modified by, the methods described
herein to introgress polled alleles are cloned and/or placed in
surrogate females, gestated, and born as live animals comprising
the POLLED allele. Whole live animals made from the cells of
Example 22B are shown in FIG. 68. The animals shown do not have
horns and are healthy animals that are Holsteins with a
non-meiotically introgressed pollele allele that replaces the
cognate portion of the native horned allele in Holstein cells. The
conversion is confirmed by PCR as shown in FIG. 62B.
Example 54
[0475] Porcine cells were modified with CRISPR/Cas9 nuclease to
knockout the KISS1 gene (SEQ ID NO: 374) in porcine cells by
homology dependent repair (HDR) using sgRNA ssKiss1 c.2.9 (SEQ ID
NO: 391). FIG. 73 shows the CRISPR/Cas9 target sequence, ssKiss1
Exon 2 (SEQ ID NO: 389), and the repair template, ssKISS1 Ex2.9
(SEQ ID NO: 393) designed to be inserted by HDR within ssKiss1 Exon
2. The alteration effectively creates a premature termination codon
followed by a HindIII restriction site for restriction fragment
length polymorphism (RFLP) genotyping (SEQ ID NO: 394). As a
control, a repair template containing a cut blocking mutation,
ssKiss1c.2.9 Blocking HDR (SEQ ID NO: 390) was co-injected with the
ssKiss1 Ex2.9 to increase the chance of heterozygous knockout
offspring versus homozygous knockout offspring. FIG. 74 shows the
CRISPR/Cas9 target sequence, ssKiss1 Exon 2, and the repair
template ssKiss1c.2.9 Blocking HDR designed to be inserted by HDR
within ssKiss1 Exon 2. FIG. 75 shows the results of RFLP analysis
of porcine cells injected with the ssKiss1c.2.9 Blocking HDR
oligonucleotide, generating a AcuI restriction site.
Example 55
[0476] Male pig fibroblasts were either transfected (+, transf.) or
non-transfected controls (C, untransf.). Cells were transfected
with a combination of IDT Alt-R crRNA:Tracer RNA complex,
Cas9=Alt-R HiFi Cas9 nuclease (protein) and ssKiss1 c.2.9 HD3 HDR
(SEQ ID NO: 394). FIG. 76, panel A show RFLP analysis results 3
days after transfection. Female pig fibroblasts were transfected
with IDT Alt-R crRNA:Tracer RNA complex, Cas9=Alt-R HiFi Cas9
nuclease (protein) with and without the ssKiss1 c.2.9 HD3 HDR
template. FIG. 76, panel B shows RFLP analysis results 3 days after
transfection. Cells from these populations were plated at low
densitity for isolation of single cell derived colonies (next
slide) and evaluated for editing. Select homozygous HDR clones were
confirmed by Sanger Sequencing and used for cloning founder
animals. FIG. 77 shows RFLP analysis results of individual colonies
propagated from the transfected populations, resulting in three
outcomes: Mutant RFLP (2), Heterozygous RFLP (3), or wild type (WT)
RFLP(1). FIG. 78 shows the results of Sanger Sequencing of RFLP
positive colonies.
Example 56
[0477] Transfection of pig fibroblasts to knockout Kiss 1 by HDR.
The injected zygotes were injected with 25 ng/.mu.l gRNA; 50
ng/.mu.l Cas9; 33.3 ng/.mu.l HD3 HDR; 66.7 ng/.mu.l Blocking HDR.
There were a total of 24 blastocysts resulting from injection. 18
of the 24 samples were subjected to whole genome amplification, PCR
over the target site, and Sanger sequencing. Amplicons were
sequenced using Sanger sequencing followed by analysis using ICE
software, Synthego. 61% of the blastocysts were wild type (WT), 39%
had a mutation within >10% of the allele. HDR was successful in
one blasocyst, sequencing data show that it was repaired with the
Blocking Oligo and was mono-allelic. FIG. 79 shows the results,
.about.22% of injected zygotes were heterozygous, meaning that they
were 31-60% mutant cells.
Example 57
[0478] Transfection of pig fibroblasts to knockout Kiss1 by HDR.
Similar to Example 56, zygotes were injected with 25 ng/.mu.l gRNA;
25 ng/.mu.l Cas9; 26.7 ng/.mu.l HD3 HDR; 53.3 ng/.mu.l Blocking
HDR. There were a total of 14 blastocysts resulting from injection.
11 of the 14 samples were subjected to whole genome amplification,
PCR over the target site, and Sanger sequencing. 36.4% were wild
type and the rest had biallelic mutation or monoallelic mutation.
Five embryos had HDR events. One embryo was mono-allelic for the
HD3 HDR, one embryo was mono-allelic for both HDR templates (HD3
HDR and Blocking HDR) and three embryos were positive for Blocking
HDR (one of which was bi-allelic). FIG. 80 shows the results. The
embryos were implated in a sow, resulting in a brood of piglets.
Nineteen piglets were born and two were born stillborn.
Example 58
[0479] Cells can made by, or embryos modified by, the methods
described in Example 51 to knockout KISS 1 in bovine cells (SEQ ID
NO: 375).
TABLE-US-00019 TABLE 8 TALEN to Figure mapping Table 8: TALEN to
Figure mapping. Target Repair TALENs HDR FIG. identified Animal
Gene type form Cell type TALEN ID template Samples (n=) 3B no
Bovine ACAN NHEJ mRNA Embryo btACAN12 -- 6 3C no Porcine p65 NHEJ
mRNA Embryo ssP65_11-1 -- 14 4A yes Bovine ACAN NHEJ mRNA Embryo
btACAN12 -- 4 4B yes Porcine p65 NHEJ mRNA Embryo ssP65_11-1 -- 17
5B no Porcine DMD NHEJ Plasmid Fibroblast ssDMDE7.1 -- Population
no Bovine ACAN NHEJ Plasmid Fibroblast btACAN12 -- Population 5C no
Porcine DMD NHEJ Plasmid Fibroblast ssDMDE7 -- Population no
Porcine LDLR NHEJ Plasmid Fibroblast ssLDLR4.1 -- Population no
Bovine PRNP NHEJ Plasmid Fibroblast btPRNP3.1 -- Population no
Porcine GDF8 NHEJ Plasmid Fibroblast ssGDF83.2 -- Population 6 yes
Bovine ACAN NHEJ Plasmid Fibroblast btACAN12 -- 12 7B, C No Bovine
GDF8 NHEJ Plasmid Fibroblast btGDF83.1 -- Population No Bovine ACAN
NHEJ Plasmid Fibroblast btACAN12 -- Population No Porcine DMD NHEJ
Plasmid Fibroblast ssDMDE7.1 -- Population No Porcine DMD NHEJ
Plasmid Fibroblast ssDMDE6 -- Population No Porcine LDLR NHEJ
Plasmid Fibroblast ssLDLR2.1 -- Population 8A yes Porcine LDLR NHEJ
Plasmid Fibroblast ssLDLR2.1 -- 5 8B yes-8A Porcine LDLR NHEJ
Plasmid Fibroblast ssLDLR2.1 -- 5 9A yes Porcine DMD NHEJ Plasmid
Fibroblast ssDMDE7.1 -- 8 9B yes Porcine LDLR NHEJ Plasmid
Fibroblast ssLDLR2.1 -- 10 10 yes Porcine DMD NHEJ/ Plasmid
Fibroblast ssDMDE6 -- Population large deletion yes Porcine DMD
NHEJ/ Plasmid Fibroblast ssDMDE7.1 -- Population large deletion 11
yes Porcine DMD NHEJ/ Plasmid Fibroblast ssDMDE6 -- 14 large
deletion yes Porcine DMD NHEJ/ Plasmid Fibroblast ssDMDE7.1 -- Same
As large Above deletion 12 yes Porcine DMD NHEJ/ Plasmid Fibroblast
ssDMDE6 -- 8 inversion yes Porcine DMD NHEJ/ Plasmid Fibroblast
ssDMDE7.1 -- Same As inversion Above 13 yes Bovine GDF8 HDR Plasmid
Fibroblast btGDF83.1 dsDNA- Population 1623 bp (BB-HDR) 14 yes FIG.
13 Bovine GDF8 HDR Plasmid Fibroblast btGDF83.1 dsDNA- 4 1623 bp
(BB-HDR) 15 yes Porcine LDLR HDR Plasmid Fibroblast ssLDLR4.2
dsDNA, Population LdIrE4N- stop 16 Yes. FIG. 15 Porcine LDLR HDR
Plasmid Fibroblast ssLDLR4.2 dsDNA, 8 LdIrE4N- stop 18 Yes Bovine
GDF8 HDR Plasmid Fibroblasts btGDF83.1 AAV-1623 Population bp (BB-
HDR) 19 Yes Bovine GDF8 HDR Plasmid Fibroblasts btGDF83.1 Oligos;
BB- Population HDR sense, BB-HDR antisense 20A Yes- 4B Porcine p65
NHEJ mRNA Fibroblasts ssP65_11-1 -- Population or Modified mRNA 20B
Yes-9A Porcine DMD NHEJ mRNA Fibroblast ssDMDE7.1 -- Population or
Modified mRNA 21 Yes-13 Bovine GDF8 HDR Plasmid Fibroblasts
btGDF83.1 Oligos; BB- Population or HDR sense and colonies mRNA 72
22 Yes Bovine GDF8 HDR mRNA Fibroblasts btGDF83.6 Oligos; seq
Population ID 135 23 Yes Bovine GDF8 HDR mRNA Fibroblasts btGDF83.6
Oligos; seq Population ID 135 24 No Porcine GDF8 HDR mRNA
Fibroblasts ssGDF83.6 Oligos; Seq Population ID 146 25 Yes Porcine
LDLR NHEJ mRNA Fibroblast ssLDLR2.1 Oligos; Seq Population ID 137
and colonies 184 26 Yes-9A Porcine DMD NHEJ Plasmid Germline
ssDMDE7.1 -- Population or stem cells mRNA 27A Yes Chicken DDX4
NHEJ Plasmid DF1 cells ggVASA1.1 -- Population VASA Yes Chicken
DDX4 NHEJ Plasmid DF1 cells ggVASA7.1 -- Population VASA 27C Yes
Chicken DDX4 HDR Plasmid Primordial ggVASA1.1 dsDNA- Population
VASA germ cells Donor targeting vector "Population" = to targeted
modification of 1,000-20,000 cells in the experimental group
TABLE-US-00020 TABLE 9 TALEN to Table mapping Table 9: TALEN to
Table mapping. Target Repair TALENs HDR Samples Table identified
Animal Gene type form Cell type TALEN ID template (n=) 1 Yes-FIG.
8A Porcine LDLR NHEJ Plasmid Fibroblast ssLDLR2.1 -- 275 Yes- FIG.
15 Porcine LDLR NHEJ Plasmid Fibroblast ssLDLR4.2 -- 95 Yes- FIG.
10 Porcine DMD NHEJ Plasmid Fibroblast ssDMDE6 -- 35 Yes-FIG. 9A
Porcine DMD NHEJ Plasmid Fibroblast ssDMDE7.1 -- 70 no Porcine
GHRHR NHEJ Plasmid Fibroblast ssGHRHR2.3 43 Yes- FIG. 6 Bovine ACAN
NHEJ Plasmid Fibroblast btACAN12 -- 35 Yes- FIG. 13 Bovine GDF8
NHEJ Plasmid Fibroblast btGDF83.1 -- 29 2 no Bovine ACAN NHEJ mRNA
Embryo btACAN11 -- 154 Yes- FIG. 6 Bovine ACAN NHEJ mRNA Embryo
btACAN12 -- 227 no Bovine PRNP NHEJ mRNA Embryo btPRNP3.2 -- 115
Yes- FIG. 13 Bovine GDF8 NHEJ mRNA Embryo btGDF83.1 -- 115 3 Yes-
FIG. 13 Bovine GDF8 NHEJ mRNA Embryo btGDF83.1 -- 2 embryos 4 yes
Porcine LDLR NHEJ Plasmid Pig tail ssLDLR2.1 -- 22 biopsy 5 Rows
1-12 -- same as Table 1. no Porcine GHRHR NHEJ mRNA Fibroblast
ssGHRHR2.3 38 Yes- FIG. 8A Porcine LDLR NHEJ mRNA Fibroblast
ssLDLR2.1 -- 166 Yes- FIG. 13 Bovine GDF8 NHEJ mRNA Fibroblast
btGDF83.1 -- 86
TABLE-US-00021 TABLE 10 TALEN RVD Codes Table 10: TALEN RVD codes
TALEN RVD 5' TALEN RVD 3' Target TALEN ID (Left) (Right) Sequence
btACAN12 HD HD NG NG NG HD NN HD NG HD HD NG SEQ ID NO: l HD NG HD
HD NI NN HD NG NN NG NG NN NN NN NI NG HD HD HD NG NG HD NG HD HD
NG HD NI NN NG btGDF83.1 NN NG NN NI NG NN NG HD NI NI NI NI SEQ ID
NO: 116 NI NI HD NI HD NG NG HD HD NI HD NI HD HD NI HD NI NN NN NG
NG NI NN NI NI NI NG HD NG NN btGDF83.2 NN NG NN NI NG NN NG HD NI
NI NI NI NI NI HD NI HD NG NG HD HD NI HD NI HD HD NI HD NI NN NN
NG NG NI NN NI NI NI NG HD NG NN btPRNP3.1 NN HD NI NI NN NI NI NG
HD NN NN HD NI NN HD NN NI HD NG HD HD HD HD HD HD NI NI NI NI HD
HD NI NN NG HD NG ssDMDE6 HD NG NI NG NI HD NI NN NG NG NG NN SEQ
ID NO: 91 HD NG NI NN NN NG NG NG NN HD NI NI HD NI NI NI NI NI NG
HD HD NI NN HD NG HD NI NG ssDMDE7 HD NN HD HD NI NI HD HD HD NI NI
NI NN NG NI NG HD NI NI NG NN HD NI HD NN NG NG NI NN NN NG NI NI
HD HD NG HD NI NG ssDMDE7.1 NN NN NI NI HD NI HD HD NI NN NG NI SEQ
ID NO: 55 NG NN HD NI NG NG NN NG NG NG HD NG HD NI NI HD NI NG HD
NG NI NG NN HD HD NG ssLDLR2.1 HD NG HD HD NG NI HD NN NN NI HD HD
SEQ ID NO: 39 HD NI NI NN NG NN HD NN NG HD HD NG NN NI NG NG NG NG
NN HD NI HD NG ssLDLR4.1 HD HD NI HD NG HD HD NN NG HD NI NN HD NI
NN HD NG NN NI HD NG NG NN NG NN HD NN HD NG HD HD NG NG NN HD NI
NN NG ssGDF83.2 HD NG NI NI HD NG HD NG NG NG NG NN NN NG NN NN NI
NG NN NN NG NN HD NI NG NG NG NN NI NI NI NG NI NI NG NN HD NG
ssLDLR4.2 HD HD NI NN NG NN HD NI NN NN NI NG HD NI NI HD NI NN HD
NI HD HD NI NG HD NG HD HD NI HD HD NI HD NI NN NN HD NG HD HD
ssP65_11-1 NN HD HD HD HD HD NI NG NI NN HD HD SEQ ID NO: 7 HD HD
NI HD NI HD NG HD NI NN NN NN NI NN HD NG NG NI HD NG btGDF83.6 NN
HD NG HD NG NN NI NG NN NI NN NN SEQ ID NO: 135 NN NI NN NI NI NG
NI NG NI HD NG NG NN NG NG NG SSGDF83.6 NI HD NG NN HD NG NN NG NN
NI NN NN HD NG NN NN NI NN NN NG NI NG NG NG NI NN NG NG NG NN NG
ggVASA1.1 NN HD NG NI NI HD HD HD NG HD HD NG NN NG NN HD NG HD HD
HD NI NG NI NN HD NG NN NN NG HD HD NN NI NI NG HD NG ggVASA7.1 NI
NG NI NG HD NG NN HD NG NN NG NN NI NI NI NI HD NG HD NG NG HD NG
NN NN NN NI NG HD NI HD NG ssGHRHR2.3 HD HD HD HD NG NN HD HD HD HD
HD NG HD HD HD NN NN HD HD NI HD HD NG NN NG NG NG HD NG NG NN HD
NG HD NG btACAN11 NN HD NI NI NG HD NN NG NI NN NN HD HD HD NI NN
NN HD NI NI NN NG NG HD NG NG HD NI HD HD HD HD NI NG NG HD NN NG
NG HD NN NG btPNRP3.2 HD NI NI NG NN NN NN HD NI NN HD NI NI NI HD
NI NI NI NN HD NG HD HD NG HD HD HD NI NN NG NN HD HD NI HD NI NI
NI NG NN HD NG NG ssP65_11-1 NN HD HD HD HD HD NI NG NI NN HD HD HD
HD NI HD NI HD NG HD NI NN NN NN NI NN HD NG NG NI HD NG btGDF83.6
NN HD NG HD NG NN NI NG NN NI NN NN NN NI NN NI NI NG NI NG NI HD
NG NG NI NG NG NG ssGDF83.6 NI HD NG NN HD NG NN NG NN NI NN NN HD
NG NN NN NI NN NN NG NI NG NG NG NI NN NG NG NG NN NG ggVASA1.1 NN
HD NG NI NI HD HD HD NG HD HD NG NN NG NN HD NG HD HD HD NI NG NI
NN HD NG NN NN NG HD HD NN NI NI NG HD NG ggVASA7.1 NI NG NI NG HD
NG NN HD NG NN NG NN NI NI NI NI HD NG HD NG NG HD NG NN NN NN NI
NG HD NI HD NG ssGHRHR2.3 HD HD HD HD NG NN HD HD HD HD HD NG HD HD
HD NN NN HD HD NI HD HD NG NN NG NG NG HD NG NG NN HD NG ss HD NG
btPNRP3.2 HD NI NI NG NN NN NN HD NI NN HD NI NI NI HD NI NI NI NN
HD NG HD HD NG HD HD HD NI NN NG NN HD HD NI HD NI NI NI NG NN HD
NG NG ssDAZL3.1 NN NN NI NG NN NI HD NG NG NG NG NI NI NI HD HD NN
NI HD NG NN NI NI HD NI NI NG NG HD NI NG NI NG ssTp53 NN NN HD NI
HD HD HD NI NG NN NG NI HD NN NG NN NG HD HD NG HD NG NN NI HD NN
HD NN HD HD NG NG ssAPC14.2 NN NN NI NI NN NI NN NI HD HD HD NI NI
NN NG NI NG HD NN NI NI NG NG NG NI NN HD HD NI NG HD NG NN NG
ssKISSR NN HD NG HD NG NI NN HD NI HD NI NG HD NG HD NG NI HD NN NI
NI NN NG HD HD HD HD NN HD HD HD NI ssIL2RG2.1 HD HD HD NI NI NI HD
HD NI NI NN NG NN NN NG NG HD NI NN HD NI NI NG NG NN NG NN NG NG
NG HD NI NG NN NG NI HD NG btGDF83.6 NN HD NG HD NG NN NI NG NN NI
NN NN NN NI NN NI NI NG NI NG NI HD NG NG NI NG NG NG ssRAG2.1 NI
HD HD NG NG HD HD NG NI NI NN HD HD NG HD HD NG HD NG NN HD NG NG
NG NG HD HD NN HD NG NG NN NI NI NG btGGTA9.1 HD NG NN HD NN HD NN
NG HD HD NG NN NG HD HD NG NG HD HD HD NI HD HD NG NI NI NI NN NG
HD NG NG HD NG Kiss1.1a NI HD NI NI HD HD NN NG NI NI NI NG
(Tilapia) HD NG HD NG HD NI NN NG NI NN HD HD NN HD HD NG NG NI NG
NG NN NG Kis1.1b HD NN HD NG NG NG NN NN HD NG HD NG (tilapia) NN
NN NN NI NI NI NG NG NG NI NI HD HD NN HD NG NI HD NI NN HD NG HD
NG NI NI NG ssKISSR3.2 NN HD NG HD NG NI NN HD NI HD NI NG HD NG HD
NG NI HD NN NI NI NN NG HD HD HD HD NN HD HD HD NI ssEIF4GI14.1 HD
HD NN NG HD HD NG NN NN NN NN NN NG NG NG NN HD HD HD HD HD NI HD
NN NI NI HD HD NG NG NN NG NG NN HD NG btHP1.1 NN NI NN NI NG NI NN
NI NI NI NI NN NN NG NG NG NG HD NI NN NI NN NG NG NG NG NN NN NG
NG NG NN NI NG HD NG NI NI NI btHP1.2 NI NN NG NG NG NG NN NI NI NI
NI NN HD NG NG NN NN NG NI NN NI NN NG NG NI NN NN NG NG NN NI NG
HD NG NI btHP1.3 NG NG NG HD NG NG NN NI NI NI NI NN NN NN NG NI NN
NN NI NN NI NN NG NG HD NG NN NG NG NN NI NG btHP1.4 NG HD NG NG NN
NN NN NI NI NI NI NN NG NI NN NN HD NG NI NN NI NN NG NG NN NN NG
NG NG NN btPRLR9.1 NN NN HD HD NN NN NG NI NI NI NN HD (SLICK HD NI
HD HD NI HD NI NG NN NG NG NN TRAIT) NI NN HD HD NN NG HD NG NN NG
caCLPG1.1 NN NI NN NI NN HD NN NI HD NI NN NN NN HD NI NN NN NI NG
NN NN NG HD HD NI NG HD HD NI HD NI NN HD HD caCLPG1.1a Same as
above NI NI HD NI NN NN NG NN NN NG HD HD HD NI NN HD HD caCLPG1.1b
Same as above NI NG HD NI NN NN NG NN NN NG HD HD HD NI NN HD HD
caCLPG1.1c Same as above NI NG NI NI NN NN NG NN NN NG HD HD HD NI
NN HD HD btDGAT14.2 NN NN HD NI NN NN NI NN HD NG HD NI NG NI NI NN
NN HD HD NN NN NG NN HD NN NN HD HD NN HD NG btDGAT14.4 HD NN HD NI
NN NN Same as above NG NI NI NN NN HD NN NN HD HD btDGAT14.5 NN NN
NI NI NN NN Same as above NG NI NI NN NN HD NN NN HD HD btDGAT14.6
NN NN HD NI HD NN Same as above NG NI NI NN NN HD NN NN HD HD
TABLE-US-00022 TABLE 13 TALEN Sequences TALEN ID Left SEQ ID NO:
Right SEQ ID NO: ACAN11 + 263 399 ACAN11 + 231 400 ACAN12 + 231 401
402 ACAN12 + 63 403 404 DMDE7 + 63 406 407 DMDE7.1 + 231 408 409
DMDE7.1 + 63 410 411 DMDE7 + 231 412 413 LDLR 4.1 + 231 414 415
LDLR 4.1 + 63 416 417 btPRNP3.1 + 231 418 419 btPRNP3.1 + 63 420
421 ssGDF83.2 + 231 422 423 ssGDF83.2 + 63 424 425 btGDF8 (also 428
431 btGDF83.1) + 63 btGDF8(also 520 521 btGDF83.1) + 231 DMDE6 +
231 434 437
TABLE-US-00023 TABLE 14 full plasmid sequence-pT3Ts-GoldyTALEN (+63
scaffold) TALEN ID Left SEQ ID NO: Right SEQ ID NO: LDLR2.1 + 63
438 439 ssP65_11-1 440 441 btGDF83.6 + 63 442 443 ssGDF83.6 + 63
444 445 ggVASA1.1 446 447 ggVASA7.1 448 449 btPNRP3.2 450 451
ssTp53 452 453 ssKISS 454 455 KISS1.1a (Tilapia) 456 457 KISS1.1 b
(Tilapia) 458 459 btHP1.1 460 461 btHP1.2 462 463 btHP1.3 464 465
btHP1.4 466 467 btPRLR9.1 (Slick trait) 468 469 caCLPG 1.1 470 471
caCLPG 1.1a 472 473 caCLPG1.1b 474 475 caCLPG1.1 c 476 477 ssGRHRH
2.3 + 63 478 479 ssDAZLe 3.1 + 63 480 481 ssAPC14.2 + 63 482 483
ssIL2RG 2.1 + 63 484 485 btGDF83.6 + 63 486 487 ssRAG2.1 + 63 488
489 btGGTA 9.1 + 63 490 491 ssKISSR3.2 + 63 492 493 ssEIF4GI 14.1 +
63 494 495 btDGAT14.2 + 63 496 497 btDGAT14.4 + 63 498 btDGAT14.5 +
63 499 btDGAT14.6 + 63 500
REFERENCES
[0480] Patent applications, patents, publications, and journal
articles set forth herein are hereby incorporated herein by
reference for all purposes; in case of conflict, the specification
is controlling. A. M. Geurts, et al., Knockout rats via embryo
microinjection of zinc-finger nucleases, 325 Science (2009). [0481]
B. Reiss, et al., RecA protein stimulates homologous recombination
in plants, 93 Proc Natl Acad Sci USA (1996). [0482] B. Reiss, et
al., RecA stimulates sister chromatid exchange and the fidelity of
double-strand break repair, but not gene targeting, in plants
transformed by Agrobacterium, 97 Proc Natl Acad Sci USA (2000).
[0483] C. Mussolino, et al., A novel TALE nuclease scaffold enables
high genome editing activity in combination with low toxicity,
Nucleic Acids Res (2011). [0484] Carlson et al., (2013) "Efficeint
nonmeiotic allele introgression in livestock using custom
endonukeases." Proceedings of the National Academy of Sciences.
[0485] Carlson, D. F., W. Tan, et al. (2012). "Efficient
TALEN-mediated gene knockout in livestock." Proceedings of the
National Academy of Sciences. [0486] D. A. McGrew & K. L.
Knight, Molecular design and functional organization of the RecA
protein, 38 Crit Rev Biochem Mol Biol (2003). [0487] D. F. Carlson,
et al., Strategies for selection marker free swine transgenesis
using the Sleeping Beauty transposon system, 20 Transgenic Res
(2011). [0488] D. J. Blake, et al., Function and genetics of
dystrophin and dystrophin-related proteins in muscle, 82 Physiol
Rev (2002). [0489] D. Y. Guschin, et al., A rapid and general assay
for monitoring endogenous gene modification, 649 Methods Mol Biol
(2010). [0490] E. E. Perez, et al., Establishment of HIV-1
resistance in CD4+ T cells by genome editing using zinc-finger
nucleases, 26 Nat Biotechnol (2008). [0491] H. J. Lee, et al.,
Targeted chromosomal deletions in human cells using zinc finger
nucleases, 20 Genome Res (2010). [0492] H. J. Kim, et al., Targeted
genome editing in human cells with zinc finger nucleases
constructed via modular assembly, 19 Genome Res. (2009). [0493]
I.D. Carbery, et al., Targeted genome modification in mice using
zinc-finger nucleases, 186 Genetics (2010). [0494] J. C. Miller, et
al., A TALE nuclease architecture for efficient genome editing, 29
Nature Biotech. (2011). [0495] L. Grobet, et al., A deletion in the
bovine myostatin gene causes the double-muscled phenotype in
cattle, 17 Nat Genet (1997). [0496] L. Tesson, et al., Knockout
rats generated by embryo microinjection of TALENs, 29 Nat
Biotechnol (2011). [0497] Liao, H. K. and J. J. Essner (2011). "Use
of RecA fusion proteins to induce genomic modifications in
zebrafish." Nucleic acids research 39(10): 4166-4179. [0498] M.
Christian, et al., Targeting DNA double-strand breaks with TAL
effector nucleases, 186 Genetics (2010). [0499] M. M. Cox,
Recombinational DNA repair in bacteria and the RecA protein, 63
Prog Nucleic Acid Res Mol Biol (1999). [0500] Medugorac, I., D.
Seichter, et al. (2012). "Bovine polledness--an autosomal dominant
trait with allelic heterogeneity." PloS one 7(6): e39477. [0501] N.
Takahashi & I. B. Dawid, Characterization of zebrafish Rad52
and replication protein A for oligonucleotide-mediated mutagenesis,
33 Nucleic Acids Res (2005). [0502] O. G. Shcherbakova, et al.,
Overexpression of bacterial RecA protein stimulates homologous
recombination in somatic mammalian cells, 459 Mutat Res (2000).
[0503] R. J. Yanez & A. C. Porter, Gene targeting is enhanced
in human cells overexpressing hRAD51, 6 Gene Ther (1999). [0504] R.
Kambadur, et al., Mutations in myostatin (GDF8) in double-muscled
Belgian Blue and Piedmontese cattle, 7 Genome Res (1997). [0505] T.
Cermak, et al., Efficient design and assembly of custom TALEN and
other TAL effector-based constructs for DNA targeting, (in press)
Nucl. Acids Res. (2011). [0506] T. Mashimo, et al., Generation of
knockout rats with X-linked severe combined immunodeficiency
(X-SCID) using zinc-finger nucleases, 5 PLoS One (2010). [0507] Y.
Doyon, et al., Transient cold shock enhances zinc-finger
nuclease-mediated gene disruption, 7 Nat Methods (2010). [0508] Z.
Cui, et al., RecA-mediated, targeted mutagenesis in zebrafish, 5
Mar Biotechnol (NY) (2003).
[0509] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
now occur to those skilled in the art without departing from the
invention. It should be understood that various alternatives to the
embodiments of the invention described herein may be employed in
practicing the invention. It is intended that the following claims
define the scope of the invention and that methods and structures
within the scope of these claims and their equivalents be covered
thereby.
TABLE-US-00024 Lengthy table referenced here
US20210185990A1-20210624-T00001 Please refer to the end of the
specification for access instructions.
TABLE-US-LTS-00001 LENGTHY TABLES The patent application contains a
lengthy table section. A copy of the table is available in
electronic form from the USPTO web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210185990A1).
An electronic copy of the table will also be available from the
USPTO upon request and payment of the fee set forth in 37 CFR
1.19(b)(3).
Sequence CWU 0 SQTB SEQUENCE LISTING The patent application
contains a lengthy "Sequence Listing" section. A copy of the
"Sequence Listing" is available in electronic form from the USPTO
web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210185990A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
0 SQTB SEQUENCE LISTING The patent application contains a lengthy
"Sequence Listing" section. A copy of the "Sequence Listing" is
available in electronic form from the USPTO web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210185990A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
* * * * *
References